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ABSTRACT 
Introduction 
Research suggests that patients with head and neck cancer from poorer backgrounds are more 
likely to have recurrences or die earlier than similar patients from affluent backgrounds. Survival 
is influenced by tumour characteristics on presentation and a range of individual factors such as 
socioeconomic status and comorbidity. Deprived patients of more advanced age have a higher 
likelihood of having comorbidity; this may be due to high-risk lifestyle behaviours such as 
smoking and drinking. Therefore, it seems reasonable to assume that survival will be lower in 
these deprived patients which can be attributed to comorbidity compared to index diseases such 
as the head and neck cancer itself. 
Survival rates for head and neck cancer patients are approximately 50% in the first five years in 
Scotland. This is dependent on a range of individual and tumour-related factors such as head and 
neck cancer sub-type and stage at diagnosis. The risk of head and neck cancer developing in 
deprived patients has been likened to that of developing head and neck cancer in heavy smokers. 
While the relationship between deprivation and comorbidity in head and neck cancer has been 
established, how both factors affect survival is yet to be explored. Reviewing these two factors 
individually has demonstrated the need to assess how both interact with each other in 
determining clinical presentation and survival. 
Aim 
The aims of this thesis are:- 
• To investigate the roles and interrelationship between comorbidity and deprivation on 
the survival of HNC patients. 
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•  To investigate whether there are differences in HNC presentation based on comorbidity 
and deprivation. 
• To ascertain whether patients from deprived backgrounds with comorbidity present with 
more advanced cancers. 
Methods 
In order to answer the research questions, this project began by describing the index disease, 
HNC and how comorbidity and deprivation are placed within the epidemiology of this disease 
using systematic review methods. The rationale for embarking upon this study was highlighted. 
Data linkage of administrative datasets 
We used anonymised patient data that was accessed through an encrypted repository held by 
the Health Informatics Centre. The data that was used in the retrospective cohort analysis was 
obtained from a prospective dataset collected by the Fife Head and Neck cancer Specialist Nurse 
(Fife data) and a retrospective case note review from the Tayside oncology records held by the 
Ear Nose and Throat Department and the Oral and Maxillofacial Surgery team. Thereafter we 
matched the patient data with that from routine medical datasets such the Scottish Morbidity 
Records, SMR01- inpatient discharges and SMR06 – Cancer Registry data. We conducted survival 
analysis methods with the intent of assessing the impact of both comorbidity and deprivation in 
determining survival. 
Results 
The systematic review found that worsening levels of comorbidity were linked to reduced 
survival whereas patients with low incomes and poor educational attainment also had poor 
survival outcomes. Being young and having severe comorbidity appeared to also be associated 
with poorer survival. In the retrospective cohort analysis, the level of association between risk of 
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death with comorbidity and deprivation could not be clearly ascertained in the patients from Fife. 
The Tayside data to a larger extent supported the systematic review findings particularly for the 
comorbidity measures with clearly defined measures of association for the Scottish Index of 
Multiple Deprivation income and education domains. 
Conclusions 
This thesis was able to use evidence triangulation by way of a systematic review of the literature 
followed by a retrospective cohort analysis to investigate what influence on prognosis both 
comorbidity and deprivation posed in patients with head and neck cancer. There was 
substantiation of both factors interacting with head and neck cancer to cause a significantly 
reduced impact on survival. The inherent difficulties of measuring socioeconomic status and 
comorbidity encountered in this thesis may go some way towards illustrating the complexity and 
multifaceted nature of both comorbidity and socioeconomic status; particularly the quite 
complex interplay between socioeconomic status, comorbidity, stage at diagnosis, and access to 
care in head and neck cancer, and these factors’ ultimate impact on survival.  
We found that socioeconomic status i.e. deprivation, comorbidity, stage at diagnosis, access to 
care, and survival are all potentially causally related. Future work directed at using administrative 
data linked to medical records would not be sufficient; there is need for epidemiological and 
clinical studies to unravel the survival disadvantage. To this end clinical cohorts could be nested 
within larger registry based studies which would allow for uniform interventions based on clinical 
practice guidelines, uniform SES measurement and ascertainment of comorbidity using a head 
and neck cancer comorbidity index, i.e. the Washington University Head and Neck Cancer Index. 
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C h a p t e r  1  
1.1. Head and Neck Cancer: An Introduction 
1.1.1 Chapter Outline 
This chapter will give the reader the background to the problem of head and neck cancer (HNC) in 
the population. HNC is a term used to define a distinct group of cancers occurring within the head 
and neck region. The statistics from the UK and globally show an unequal survival burden in 
people from deprived backgrounds compared to those from affluent backgrounds. Another 
important determinant of HNC presentation and survival that will be discussed is the issue of 
comorbidity.  
The relationship between HNC incidence and survival based on comorbidity and socioeconomic 
status (SES) will be explained. HNC is a disease mainly diagnosed in the elderly, and as 
comorbidities occur more frequently in older people hence it is expected that with advancing age 
comes the increased chance of an elderly person having some concurrent chronic medical 
conditions.  
Comorbidity refers to a chronic illness that occurs alongside and usually independent of the 
disease under study (1), in this case HNC. It is apparent that having one or more of these pre-
existing diseases may affect the severity of the cancer thereby reducing the likelihood of a 
favourable outcome. In the case of SES, HNC is normally associated with chronic exposures such 
as high smoking rates and excess alcohol consumption, with both risk factors noted to have 
higher prevalence in low SES (deprived) groups which may explain the higher HNC incidence in 
this group. Therefore HNC is compounded by comorbidity and the social patterning of this 
disease predominantly in deprived groups requires further exploration. The chapter will outline 
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the focus and aims of the project. It will also provide definitions of what is and is not included 
within the definitions of SES and comorbidity. This chapter will also provide the reader with an 
understanding of why the subject was chosen and considered important enough to merit this 
thesis. 
1.2. Head and neck cancer 
HNC is the collective term that defines neoplasms (cancerous tumours) that derive from a 
distinct group of primary sites within the head and neck area. (2, 3) There are more than 50 
epidemiological and clinical disease entities within the head and neck area and as there are more 
than 30 different sites within the head and neck where this form of cancer can develop, it is 
important to understand the exact anatomic location of these sites as depicted in Figure 1 below. 
 the pharynx, with its three component parts namely: nasopharynx, hypopharynx and 
oropharynx; larynx; 
 lip and oral cavity i.e. gum, tongue, floor of mouth, hard palate;  
 paranasal sinuses and nasal cavity;  
 and the salivary glands. (4, 5)  
There are more than 50 epidemiological and clinical disease entities within the head and neck 
area and as there are more than 30 different sites within the head and neck where this form of 
cancer can develop, it is important to understand the exact anatomic location of these sites as 
depicted in Figure 1 below. 
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Figure 1 HNC sites 
 
Source: National Cancer Institute (6) 
As a result of the possible misinterpretation of HNC due to case mix differences, this report will 
use the following ICD-10 codes to refer to HNC, Codes C00.0 to C32.9. (7) It is important to note 
that cancers that occur within the thyroid, brain, ear or eye are not included in the definition of 
HNC used in this thesis. Most HNCs (90%) are carcinomas, in particular squamous cell carcinomas 
as most types of HNC occur in epithelial tissue. (8) 
Incidence of HNC increases with age with the majority of cases in Europe occurring in those aged 
over 50 years, (9) as people who live longer are more likely to develop HNC. (10) With the global 
projections of an increase in the elderly population due to increased life expectancy, this will 
become an increasing problem for Scotland as HNC services will experience the effects of this 
demographic shift. Smoking cessation has had an impact on incidence however human papilloma 
virus positive (HPV+) cancers are on the rise especially in the younger population. (11) An ageing 
population represents an increase in comorbidities as these occur more frequently in the elderly. 
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Age introduces the probability of an excess burden of disease therefore it is necessary to factor 
comorbidity status into therapeutic interventions to minimise adverse treatment effects such as 
drug interactions or polypharmacy, (12-14) and additionally, increasing comorbidity has also been 
associated with a higher incidence of postoperative complications. (15) Incidentally HNC 
treatments are noted to be invasive which introduces an elevated risk of post procedural 
complications which also amplifies the risk of death. Careful planning and clinical decision making 
may not eradicate the risks posed by drug interactions and may have a detrimental effect on the 
survival of the patient. It remains unclear whether the elderly benefit from these invasive 
interventions or whether treatment selection based on patient factors favours better 
outcomes.(15-18)  
1.2.2. HNC Incidence 
HNC is the 6th most common site of cancer in the world (19-21) and has been found to be the 6th 
leading cause of cancer deaths globally. (19) It is listed as the 10th most commonly occurring 
cancer in Scotland (Table 1).  
Table 1 HNC incidence in Scotland 
HNC (C00-C14, C30-C32) Number 10 year change P value 
All persons 1 278 +11.5% P<0.0001 
Males 869 +6.8% P=0.0628 
Females 409 +25.4% P=0.0001 
Source: ISD Scotland (22) 
In 2010, 3% of all malignancies within the UK were attributed to cancer of the head and neck, with 
the majority of cases being recorded in people aged 50 and over.(23) The most common site for 
HNC in the UK is the mouth i.e. oral cavity, with evidence of site specific cancers having different 
rates, e.g. laryngeal cancer accounts for 2400 cases per year), nasal cavity and paranasal sinus 
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cancer 440 cases, while nasopharyngeal and salivary gland cancers are very rare forms of HNC. 
The sex ratio of males to females has decreased from 5:1, 50 years ago to 2:1, with males bearing 
the larger burden of disease. Although incidence of this form of cancer increases with age, 
MacFarlane et al found a high incidence of cancer of the tongue in young Scottish males in the 
late 1980s. (24) 
Global incidence rates are increasing; in the UK this equates to approximately 8000 cases per 
year. Approximately 90% of cases arise in over 50s with male to female ratio for oral cavity and 
laryngeal cancer at 2:1 and 5:1 respectively. (25) The incident cases for Scotland are approximately 
1000 each year which are the highest rates for HNC within the UK. (26) There is compelling 
epidemiological evidence of HNC increasing with age but there is an emerging trend of younger 
people being increasingly diagnosed with this oropharyngeal cancers, with clear evidence that 
these cases are linked to the human papillomavirus (HPV). (27) HPV-related HNCs have important 
clinical and prognostic differences compared to those typically associated with tobacco and 
alcohol use. (28-32) 
1.2.3. Risk factors 
The chronic exposures of tobacco (smoking) and alcohol are the most important risk factors for 
HNC especially for oral cavity, oropharynx, hypopharynx and larynx cancer subtypes accounting 
for approximately 75% of these cancers.(33) These two risk factors are known to have a 
multiplicative effect dependent on the level of consumption and especially more so in the 
presence of poor oral hygiene. (34) This multiplicative causal association has been estimated to 
increase risk to as high as over 35 times in heavy smokers who drink heavily when compared to 
those that neither smoke nor drink.(33, 35) More recent risk modelling has placed the risk of 
tobacco smoking alone to between 3 and 9-fold while both tobacco and alcohol have been 
predicted to increase risk by up to 100-fold. (36) According to findings from the National Cancer 
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Institute, 85% of HNCs are attributable to tobacco use, while others have placed this estimate to 
be as much as 90%.(6, 25) A common aspect is that the amount smoked has a reciprocal elevation 
to risk of developing HNC i.e. previous research has noted that the dose response relationship 
increases from 5 to 25 fold when comparing smokers to non-smokers. (37, 38) In addition, pipe or 
cigar smoking have been found to greatly elevate the risk of developing this cancer.(39) 
Chewing tobacco and betel nut has also been indicated in the causal pathway as both substances 
have carcinogenic properties. Studies of incidence of oral cancers in the UK show a higher HNC 
incidence in Chinese and South Asians which has been attributed to prevalence of betel liquid and 
areca nut chewing. (40, 41) Cannabis was also implicated  in the aetiology of HNC (42) but there is 
little evidence of this with only one other research paper identifying a statistically significant 
causal relationship despite cannabis having similar carcinogenic properties to tobacco.(43) The 
International Agency for Research on Cancer (IARC) conducted a review of the link between 
cannabis and oral cancers and did not find a causal link, however cannabis use and the number of 
oral sexual partners as causal factors are being explored further.(44, 45) Socioeconomic 
differences in lifestyle also contribute to the incidence of HNC e.g. a diet low in fruit and 
vegetables has been identified as a risk factor for HNC, as it has been found that such a diet is 
usually associated with patients from deprived backgrounds who have excessive alcohol and 
heavy smoking habits which in turn increases the risk of HNC. (46, 47)  
There is evidence that demonstrates that HNC occurs in people who never smoked nor drank, 
with 20% of cases falling into this category. (48) These cases are attributed to HIV, HPV, Plummer-
Vinson syndrome or Paterson-Brown Kelly syndrome in the United Kingdom, Epstein-Barr virus, 
occupational exposure, poor oral hygiene, immune-suppression from post-transplant therapy 
and Fanconi anaemia. (6, 49) 
There has been a notable shift in the epidemiology of HNC due to an association between human 
papillomavirus (HPV) and HNC. (27, 50-52) Approximately 25% (53) of HNC cases are caused by 
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HPV with the majority of these cases arising in the oropharynx. 85% of HNCs are caused by 
tobacco use while alcohol increases the risk, while 50% of oropharyngeal cancers are due to HPV 
positivity. In the last 20 years there has been a clear increase in HPV+ HNC with the predominant 
subsite being the oropharynx. (54, 55) (55, 56) (57) The risk profile of the HPV+ HNC patient is 
that of a younger adult with limited or no heavy smoking or drinking habits which is an atypical  
presentation to that of an elderly male, heavy smoker and drinker.(58) The strains that have been 
implicated in HPV-positive HNC are types 8, 16, 33 and 35 with up to 90% of HPV-positive HNC 
being caused by type 16. The most important risk factor is the total number of lifetime sexual 
partners particularly oral sex partners. An interesting fact is that when comparing cancers of the 
head and neck is that the HPV -positive cases have better outcomes.(27, 42, 59-63) Research has 
found that, HPV-positive cancers have an 85% to 90% disease-free survival rate over five years. 
(64)This has been put down to the better responses to chemo-radiation, but the exact 
mechanism that accords better prognosis is not fully understood and requires further 
investigation.(52, 65-69) Scheich speculated that improved outcomes may be due to DNA 
variations between HPV-positive and HPV-negative cancers which make HPV-positive tumours 
more favourable to treatment.(27) Poor prognosis in HPV-negative HNC incident cases may be 
due to late presentation with metastatic disease apportioning the poor five-year survival rates of 
approximately 40-50%.  
1.2.4. Diagnosis and Symptoms 
HNC signs and symptoms are usually picked up by a dentist during a routine dental check-up or 
when the patient visits their GP with a specific complaint. It is common that symptoms do not 
automatically indicate cancer but vary from, difficulty or pain when chewing or swallowing, 
trouble with speaking or breathing, a non-healing mouth ulcer, persistent throat or ear pain, a 
swelling or lump in the mouth or neck. Less commonly there may be unexplained changes in the 
lining of the mouth or on the tongue, which can be white patches (leukoplakia) or red patches 
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(erythroplakia) – these are usually painless but can sometimes be sore and may bleed. (5) The 
symptoms of HNC are especially insidious as they are similar to the symptoms of minor ailments 
which may explain why early diagnosis may be missed due to this clinical manifestation. Once 
HNC is suspected, the patient is usually referred to a local hospital where their case is reviewed 
by either an Oral/Maxillofacial surgeon or alternatively the Ear Nose and throat (ENT) specialist, 
an otolaryngologist and diagnosed. 
1.2.5. Prognosis 
The prognosis for HNC varies greatly by TNM stage at diagnosis, i.e. size of the tumour, extent of 
lymph node involvement and the presence /absence of metastatic disease. The actual site and 
nodal status are also important determinants of outcome. All these disease characteristics have a 
significant role in establishing survival but nodal status is vital as nodal disease is associated with 
poor prognosis. 5 year survival rates for HNC are between 60% and 90% in the UK and figures for 
median survival are less than 3 months for advanced disease without treatment while the 
Scottish Cancer Intelligence Unit, found that relative survival; was poorest among the most 
deprived areas. (4, 70)  
There appears to be an association between where one lives and survival following a diagnosis of 
cancer, also known as the “postcode lottery of care” which states that depending on where an 
individual lives, determines what treatment that individual gets and whether that individual 
subsequently survives. It was noted in the 1990s, that regional variations existed for cancer 
survival but the exact reasons for this variation were unclear, although the clinical course of the 
disease could explain some of these differences. (71) The typical HNC patient as defined by Hall et 
al (58) can unwittingly reduce long term survival prospects based on that individual’s personal 
characteristics: 
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 Being male aged 65+, 
 being deprived, 
 previous occupational exposure, e.g. exposure to dust, chemicals, fumes etc.’ 
 have a history of excess smoking and alcohol intake, 
 have low awareness of severity of symptoms, 
 presenting with an advanced tumour (s). 
This clustering of disadvantage makes it less likely for the typical patient to have a good 
prognosis especially as males are considered as hard to reach due their poor help-seeking 
behaviours (72). As evidenced by Hart et al (73), poor people are more likely to die from cancer 
compared to the rich, while Bungay (74), found that patients of similar socio-demographic 
backgrounds to the typical head and neck patient were likely to have more aggressive cancers 
due to poor diet and risky lifestyle behaviours.  
1.2.6. Determinants of HNC prognosis 
In HNC cases the outcomes for individual patients are also determined by the presence of 
comorbidities, while late presentation equates to more extensive treatments that result in 
significant disease burden and less positive outcomes.(46) Although treatments aim to eradicate 
the disease while maintaining function, there may be various physiological changes to structures 
that were affected by the cancer and the multitude of treatment modalities used. This can result 
in a loss of the ability to speak, swallow, and eat, breath, and work and comfortably carry out 
social interactions. Although the cancer may be gone, the loss of basic functioning abilities to 
communicate has a profound psychological impact on the patient. It is common for these 
patients to feel lonely and unable to communicate effectively with family and/or peers and can 
end up with a diagnosis of depression. Most individuals lose their livelihoods and all these factors 
contribute greatly to diminishing that individual’s quality of life. Logeman (75) recommended a 
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holistic care approach to the treatment and after care of HNC patients, taking into account other 
factors such as the social, lifestyle and environmental influences which encompasses theories 
such as the determinants of health model (Figure 2). (76)  
Figure 2 Determinants of health 
 
Source Dahlgren and Whitehead (76) 
On the age spectrum, although mortality has decreased in those aged 75 years and under, the 
same cannot be said for the older HNC patients. (77-80) It appears that oncologists are reluctant 
to offer more invasive treatments. These inequalities in therapeutic intervention choices pose 
serious challenges to the effective reduction of mortality. Foot and Harrison identified four key 
categories of cancer survival determinants which are equally applicable to HNC (Figure 3). 
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Figure 3 Possible drivers for international variation in cancer survival 
 
Adapted from Foot and Harrison (81) 
The aetiology of HNC makes comorbidity common and as the typical patient is elderly this makes 
the presence of concurrent chronic conditions more numerous. As highlighted by Boeje et al (11) 
the changing world demographics mean more diagnoses of HNC will occur with more patients 
having comorbidities which means comorbidity status has an importance in relation to 
prognostication. As elderly patients are not included in clinical trials, the changes in life 
expectancy patterns means further study of the impact of comorbidity on survival is required to 
assess whether comorbidity accords greater survival disadvantage HNC patients. 
1.3. Comorbidity Status 
The term comorbidity was introduced to medicine by Feinstein to denote those cases in which, “a 
distinct additional clinical entity,” occurred during the clinical course of a patient having an index 
disease. (1) Medical Subject Headings (MeSH) defines comorbidity as a complication i.e. a 
condition that existed prior to the index disease ensues. From this definition it appears as though 
the sequence by which comorbidities appear may have important connotations for the prognosis 
of HNC as the index disease. Comorbidity is useful in clarifying the total burden of disease and the 
Stage at diagnosis 
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implications of the comorbidity on the individual(82) but it is not to be mistaken for other 
constructs of coexistent disease as depicted in Figure 4. 
Figure 4 Constructs of comorbidity 
 
Source: Adapted from Valderas et al (82) by Safarti (83) 
As described by Sarfati, “this diagram shows the close relationship between comorbidity and 
multimorbidity, with the difference being that comorbidity is measured in relation to a primary 
index disease, whilst multimorbidity is a total measure of all diseases occurring concurrently in an 
individual”. (83) It is important to clarify the difference between comorbidity and multimorbidity 
as they have been considered as meaning the same thing. Comorbidity refers to the presence of 
condition(s) or disease that precedes the index/primary disease that is under study. 
Multimorbidity differs as it is an aggregation of the index disease and any concurrent medical 
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conditions i.e. comorbidities. The two terms are interrelated because one cannot exist without 
the other as comorbidity is an additional clinical entity that arises in the presence of a primary 
disease. The total disease burden of the comorbidity alongside the primary disease results in 
multimorbidity. In this thesis we did not look at multimorbidity as it was not a prognostic factor 
that we sought to investigate. In this model it is clear that patient complexity is compounded by 
other factors within the patient’s environment such as socioeconomic position, i.e. SES. 
As the natural course of the disease and its corresponding intervention(s) can influence the 
course of the second or even third disease, comorbidity has a direct impact on the single disease 
approaches of conventional oncology. Within this thesis HNC is the index disease as it is the 
disease that has prompted the episode of care under study while comorbidity will be defined as a 
disease(s) that: 
a) occurred prior to the cancer, and 
b) occurred as a result of the cancer treatment. 
Comorbidity in cancer is the presence of one or more medical ailments occurring concurrently 
alongside the primary tumour. This comorbidity has the potential to significantly affect prognosis 
in HNC patients, and is contributed to by tobacco, and alcohol misuse which are significant 
aetiological agents in HNC carcinogenesis. There is a pathophysiological explanation for 
comorbidity; it is a natural process in the natural course of a disease, e.g. diabetes mellitus and 
cardiovascular disease. (84) It is essential to highlight that comorbidity is not a complication in 
this instance that occurs as a side effect of cancer treatment. Instead it is a pre-existing or 
secondary disease that is entirely independent of the cancer (index disease) diagnosis.  
Comorbidity should not be confused with multi-morbidity which is the total sum of the existence 
of two or more pre-existing medical conditions in a patient without the specification of an index 
disease as depicted in Figure 4. It is known that as the risk factors for HNC are similar to those 
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causing pulmonary, respiratory and hepatic disease, hence it is highly likely that a HNC patient will 
have a condition that pre-exists HNC.  
Also as already established, cancer occurs more commonly in advanced ages, hence it is likely 
that these patients will have an underlying illness (comorbidity) as chronological age is not 
always a good indicator of health status. However there is risk of unintentional bias here, a 
phenomenon known as the Berkson’s fallacy, as disease clusters are more likely in health seeking 
patients than in the general population. (85) Therefore patients that are under medical care for a 
chronic disease are more likely to get a diagnosis of other diseases than people who do not 
receive such care. Comorbidity poses significant implications to the management of cancer 
patients as it may cause these patients to be more prone to acute illness episodes with high 
likelihood of presenting an atypical clinical picture to the responsible health professionals. (86) 
1.3.1. Comorbidity measurement 
It is unclear how to consistently measure the existence of comorbidity in cancer patients and 
evaluate its impact on survival, but some measures for aggregating comorbid disease have been 
developed. The two types of comorbidity indices defined by Hall (87) rely on: 
1. Primary data collected by physicians or nurses or through medical record review 
2. Secondary data that is derived from healthcare databases 
Comorbidity was brought to the fore in cancer prognosis research to investigate the benefits of 
modifications to treatment approaches in light of the presence of comorbidity.(88) To gain a 
fuller understanding of how comorbidity affects and contributes to a cancer patient’s burden of 
disease, it is necessary to use a measure of the comorbidity, to allow assessment of a patient’s 
combined burden of illness. Using these indices in cancer research gives a clear illustration of the 
prognostic implications of comorbidity. The most widely used comorbidity assessment tools have 
been condensed into Table 2 as highlighted by Paleri and colleagues (89) although the Adult 
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Comorbidity Evaluation 27 (ACE 27) and the Charlson Index are the most commonly used indices 
to quantify comorbidity within HNC oncology. 
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Table 2 Comorbidity indices 
Source: Adapted from Paleri et al (89)
               INDEX NAME         INDEX CHARACTERISTICS 
Adult Comorbidity Evaluation 27 (ACE 27)                  Includes 27 different comorbid ailments from different organ systems 
                  Each ailment graded into a three-category severity system (mild, moderate, severe) 
 Overall comorbidity score assigned according to the highest single scoring ailment, except when two or 
more grade 2 ailments are present. In this situation, the score is designated grade 3 
Charlson Comorbidity index (CCI) Developed from a study of causes of 1-year mortality in a cohort of 559 patients. Validated on a further 
sample of 685 patients 
A weighted index with 19 comorbid conditions that take into account the number and the seriousness of 
comorbid disease 
  Classifies patients into four grades based on comorbid disease 
Elixhauser Comorbidity Index (ECI)  Developed using administrative data from a state-wide California inpatient database 
It is a list of 30 comorbidities relying on the ICD-9-CM coding manual that are significantly associated with 
in-hospital mortality and includes both acute and chronic conditions 
Head and Neck Cancer (HNCA) Index  Refinement of the CI by selecting and weighting prevalent comorbid conditions in the HNC population 
       A weighted index with eight comorbid conditions 
       An adjusted relative risk for each condition used as a weight 
Alcohol–Tobacco-Related Comorbidities Index                  Simple count of 11 conditions that are related to alcohol and tobacco consumption with no weighting  
(ATC)                                                                                                          Range of scores from 0 to 11 
National Cancer Institute (NCI) Comorbidity  Comorbid conditions selected according to the leading  cause of chronic disease present in the population 
Index                       24 Comorbidities, score calculated by summing all conditions present 
       Two levels of comorbidity burden assigned based on scores 
Washington University Head and Neck                    Summative scale with a list of seven weighted items 
Comorbidity Index (WUHNCI)                                                           Comorbidity score calculated as the sum of weights of each of the comorbidities present 
                                       Validated on colon cancer population 
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Oncologists are faced with patients with multiple health and social care needs and ignoring these 
factors may have detrimental effects on prognosis. Unfortunately prescribing guidelines do not 
always cater for complex patient related factors such as comorbidity and there is a paucity of 
evidence indicating how polypharmacy affects elderly cancer patients. Older patients have a 
disproportionate burden of disease and this depicted clearly by the rates of HNC incidence in the 
elderly compared to younger age groups. These rates show that HNC  cancer is more common in 
people aged 50 years and older, which corresponds with Extermann’s assertion that, "time to 
accumulate mutations and epigenetic modifications, oxidative damage, modifications of the 
immune system and decreased cell repair mechanisms have all been hypothesized.” (90) 
One could argue that screening is the cause of this artefact but as screening is only provided in 
colorectal, breast and cervical cancers, this does not explain these findings. Therefore the 
opinion that cancer occurs more frequently as one gets older is accurate. Despite the existence 
of known oncologic treatment regimens for HNC; these have to be tailored to each individual 
patient as pre-existing medical conditions have to be factored into the therapeutic approach. 
Comorbidity can be defined as a serious medical condition that is not linked to primary disease 
under study but affects a major organ system such metabolic or cardiovascular. (91)  
Of interest when reviewing comorbidity in cancer patients is the comorbidity that precedes the 
diagnosis of cancer. This is of more importance as cancer treatment regimens have to be 
adjusted for the pre-existing chronic illness due to the risk of polypharmacy. (12-14, 92) 
Polypharmacy has been defined as the practice of over prescribing or duplicating similar drug 
types to the same patient. (12) This is a very likely scenario in HNC care as the majority of patients 
are elderly and likely to have concurrent health problems; this is the reason they have more 
prescriptions per head than any other group. (13) It is noteworthy that as comorbidities usually 
precede HNC by between five and 15 years, the challenge of polypharmacy is inherently complex. 
(93)  
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Oncologists face the test of attempting to treat a cancer in the presence of a comorbidity while 
navigating the risk of medicines interacting and causing more harm to the patient. These possible 
interactions can cause further morbidity through pharmacokinetics as this process is impaired in 
the aged due to age related factors such as delayed stomach emptying and reduced body fat 
ratio. Reduction in body mass index is particularly important in HNC as the effects of treatment 
can cause dramatic weight loss thereby affecting pharmacokinetics. Aging is also affected by 
pharmacodynamics (what a drug does to a body) through side effects of the drug, medicine 
toxicity and potential drug interactions which may cause iatrogenesis, site of action and response 
of the body to drugs. Drugs to treat comorbid disease may have implications on how cancer is 
treated and probability of disease recurrence. (11, 94-96) 
An essential aspect of personalised medicine involves developing an understanding of how host 
attributes such as age, sex and comorbidity status can affect cancer biology, treatment tolerance 
and efficacy. Holistic assessment of physiological functioning as an essential aspect of oncology 
has been poorly researched as older cancer patients are underrepresented in clinical trials. (97) 
Therefore it is unclear how being older and having comorbidity affects drug interactions and 
resultantly treatment outcomes. Comorbid illness and its treatment may interact with cancer 
treatment approaches therefore health related quality of life is important in determining survival. 
(90) 
Among HNC patients finding complex patients is a common phenomenon as the age (being 
elderly) and having comorbidity makes it more challenging. (98) Other environmental and social 
factors are known attributes that contribute to this complexity. This makes clinical decision 
making and resultant treatment plans remarkably complicated. Current clinical practice 
guidelines do not take comorbidity into account. As described by Sarfati (83) much of the 
research and planning relating to cancer and cancer care assumes a single disease paradigm 
despite overwhelming evidence that comorbidity affects treatments, increases hospital 
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admissions, reduces quality of life and raises the risk of death, ‘[a]although patients with more 
than one diagnosed disease are frequently encountered in modern medical practice, the inter-
relationships and effects of multiple diseases have not received suitable taxonomic attention in 
clinical science.” (1) Despite this being pointed out all those years ago, comorbidity is considered 
more as a confounder in most primary research papers rather than a prognostic factor in its own 
right alongside other factors such as age, sex, and SES. Notwithstanding this approach of 
treating comorbidity as a confounder, some researchers have identified its prognostic 
importance which has led to the development of clinically-based comorbidity indices to assess 
the role of comorbidity in outcomes for patients. 
The Charlson Comorbidity Index (CCI) (99) although widely used has some limitations. It was 
developed in 1987 which may account for the reason why it focuses on some conditions that do 
not have a direct impact on survival. Also some conditions such as AIDS are rarely encountered as 
patients can live with HIV for decades without developing AIDS. It does not consider the relative 
importance of a multiplicative effect of multiple conditions but instead treats all conditions as 
having an additive impact on survival. (100) The National Institute on Aging (NIA) Geriatrics and 
Clinical Gerontology Program (101) convened a taskforce on comorbidity which determined that 
there was no single measure that could ascertain comorbidity adequately. In her review of 
comorbidity instruments, Sarfati (102) found that there was no gold standard for risk adjustment 
of comorbidity. 
An alternative method is the systems approach that depends on models involving varying 
numbers of individual conditions such as the Elixhauser comorbidity index (ECI) developed by 
Elixhauser et al (103) in 1998. Valderas et al (82) in their review of comorbidity highlighted patient 
complexity (98, 104);which encompasses all the health determinants (Figure 5). Complexity has 
the potential to expand the idea of comorbidity further by considering the influence of all these 
other factors which may influence patient outcomes.  
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Figure 5 Patient complexity 
 
 
As described by Sarfati (105), “the concept of complexity reflects the intricate interactions 
between a multitude of factors that impact on care and outcomes at the individual level”. 
Comorbidity is common, particularly in the older population and HNC is a disease that occurs 
commonly in older people, hence the unravelling of the prognostic impact of comorbidity is of 
importance.  
Despite awareness of the challenge posed by comorbidity, not enough is being done to address 
this issue in all cancer patients and particularly in this case; HNC patients. There is currently no 
widely accepted conceptualisation that portrays the numerous influences that together make a 
patient complex. 
1.4 Socioeconomic status (SES) 
It is well known from population studies of life expectancy that people from poorer (deprived) 
backgrounds die younger and this group tends to have a higher proportion of disease compared 
to their affluent counterparts. A social gradient of health status and social class was first 
observed in the census of 1851 and this situation has not changed. As pointed out by Deaton, 
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“mortality and morbidity rates are inversely related to many correlates of SES such as income, 
wealth, education, or social class.”(106) As a concept, SES in itself has not been consistently 
defined nor has it been consistently measured. (107) SES, has been defined as a function of 
income, education and occupation, although it is not the cause of cancer or poor outcomes, but it 
is a marker for underlying physical and social factors that cause disease, disease recurrence and 
reduced survival. (108) SES can be identified as an individual’s relative position on the social 
hierarchy.  
It is important to study the impact of low SES (deprivation) in cancer as there is a plethora of 
evidence demonstrating the effect of SES on cancer incidence and mortality. A working definition 
for deprivation describes it as, “a demonstrable disadvantage to others and consists of material 
disadvantage, diet, income, housing etc. and social disadvantage such as, relationships in family 
life, work and the community”.(109) In Scotland, Conway et al (110) were able to ascertain the 
widening socioeconomic inequalities in oral cancer incidence over a 30 year period. Similar 
findings were noted by other research teams for laryngeal, oropharyngeal and oral cavity 
cancers. It is expected that if inequalities in HNC incidence exist, there would be corresponding 
disparities in HNC survival based on socioeconomic factors. 
There are various types of cancer that have a common contributing cause at the individual level 
such as tobacco smoking which is a known antecedent for cancers of the lung, breast and head 
and neck, but there may also be common socioeconomic causes at the population level i.e. due 
to social and cultural norms that influence behaviour. This complex mosaic of risk and 
predisposition to cancer is adequately depicted in the figure below (Figure 6) which 
demonstrates how difficult it is to decipher how patient characteristics such as socioeconomic 
deprivation can influence the incidence and outcome of cancer.  
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Figure 6 How socio-demographic factors lead to poor outcomes in cancer 
 
Adapted from Munro (111)  
Socioeconomic factors are closely linked to the main risk factors of cancer as poor people are 
more likely to participate in risky lifestyle behaviours e.g. sedentary lifestyle, poor diet, have 
obesity and excessive alcohol intake. Deprived groups have been found to be less likely to attend 
for screening meaning they are unlikely to have early identification of a cancer which has 
consequences on survival. (112) As previously described, HNC is a disease mostly associated with 
increasing age. Evidence abounds on how deprivation and increasing age are most strongly and 
consistently associated with premature death. 
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It is well established that health follows a social gradient, as health improves with increasing 
socioeconomic position, (113) but in spite of the relationship between poor survival and 
socioeconomic deprivation, this particular problem has been difficult to address. Numerous 
attempts to assess the effect of SES on cancer survival have been conducted however 
researchers have been unable to conclude how low SES had a detrimental effect on survival due 
to a lack of consistent measurement of SES. (114-116) It is important to combat this SES-related 
unequal morbidity and mortality burden in order to make realistic gains on cancer survival in 
Scotland in comparison with England.  
A complete understanding of what contribution deprivation makes to poor survival data is 
necessary in establishing what is causing these inequalities in cancer survival. It is widely 
accepted that low SES patients generally have poor health status and experience higher 
incidence and mortality compared to people from other SES groups. Evidence is available that 
demonstrates how socioeconomic factors contribute to prognosis, as research in the 1980s 
concluded that poorer survival in deprived groups were indicative of the lack of awareness and 
understanding of the dangers of cancer. (117) 
Socioeconomic factors are especially important to study as they have essential contributory 
effects to cancer incidence and survival. Most cancers are known to be caused by exposure to 
avoidable carcinogenic agents such as tobacco, alcohol and infection and e.g. evidence shows 
that smoking related cancers are highest in deprived groups. Krieger gave the definition that, 
“social inequalities… in health refer to health disparities, within and between countries, that are 
judged to be unfair, unjust, avoidable, and unnecessary and that systematically burden 
populations rendered vulnerable by underlying social structures and political, economic, and legal 
institutions.”(118)   
The Black and Acheson Reports illustrated how poverty is linked to ill health which explains how 
cancer patients share this vulnerability, as research has focused on survival disparities and the 
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practical means to tackle this issue as reduction of health inequalities is a key priority. (119, 120) 
For example, the introduction of the Scottish bowel cancer screening program aimed to reduce 
premature cancer mortality by 20%, but this is not enough, other prognostic variables such as SES 
and its effect should be considered. A major concern for health professional studying inequalities 
in health is that although the rates of relative survival are improving across the board, 
socioeconomic inequalities are increasing. Lower survival rates have been described in deprived 
groups and this gap had been widening since 1986 especially in women.(121)  
It was established that low SES has an equivalent risk to well established aetiological behaviours 
such as tobacco use in the development of oral cancer.(122) The role of tobacco and alcohol in 
the development of oral cancer is well established but increased use of tobacco and alcohol in 
individuals with low SES as a coping mechanism for dealing with poverty further implicates the 
role of deprivation in the aetiology of the disease. However it remains unclear whether it is the 
deprivation or increased exposure to known carcinogens that increases the risk. (123) There is a 
definite difference in incidence of cancer by SES for all cancers except breast and prostate which 
show an inverse relationship.  
1.4.2. SES measurement 
SES has been measured using a variety of indices. Indices of deprivation identify areas of multiple 
deprivations at the small area level. Deprivation measures have been used to assess and monitor 
inequalities in health which is useful in developing more targeted policies and more informed 
fund allocation. This is essential in order to understand the drivers behind geographical variations 
in illness and how this illness determines patient outcomes. Deprivation or low SES is usually 
measured at the individual level using information such as education, occupation and income. 
Unfortunately not all this information is usually available hence measurement at the geographical 
level was introduced to counter this shortcoming.  
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Initially the Carstairs and Morris Index (124) was used as an area based (postcode sector level) 
measure of deprivation following development using the 1981 census data to measure SES on 
four variables namely, overcrowding, male unemployment, low social class and ownership of a  
car. Categories are 1 for most affluent to 7 for the most deprived. The Scottish Index of Multiple 
Deprivation (SIMD) is similar to the aforementioned index as it looks at health inequalities across 
Scotland using small area concentrations (data zones) of multiple deprivations consistently. (125) 
The SIMD 2009 version is an improvement of earlier versions of SIMD 2004 and SIMD 2006. It 
now provides a relative measure of area concentrations of deprivation combining 38 indicators 
across seven domains which are; income health, employment, education, housing, crime and 
geographical access data.  
The improvements made in methods of aggregating SES, means that analysis of the relationship 
between SES and HNC survival will elicit more meaningful data. There has been an association 
found between low income and poor levels of education with shorter cancer survival times 
compared to those with higher incomes and better educational attainment.(126) Carstairs and 
Morris found that variations in morbidity and mortality from specific diseases were linked to area 
level of deprivation in Scotland. (127) Comparison with England did not elicit any similarities so it 
is unlikely that poverty alone was contributing to this variation that coined the term “the Scottish 
effect”. From this, it appears as though the excess burden of poor survival can be explained to 
some extent by deprivation. Therefore deprivation is an important prognostic factor in patients 
with cancer. From this it is clear that Scotland has a problem of widening health inequalities 
especially as a significant population live in deprived communities. 
1.5.1. Comorbidity and SES in HNC 
Cancer has socioeconomic implications, with higher incidence in and poor prognosis in the 
deprived groups. It is possible that deprived people are more prone to less favourable outcomes 
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due to poor dietary habits and lifestyle practices such as smoking and drinking to excess. From 
this, it is apparent that socioeconomic factors are just as important as behavioural risk factors, as 
stated by Broder, “poverty is a carcinogen”.(128) Woods et al found that risk of cancer related 
death was increased up to 1.5 times in deprived versus affluent groups.(129) It is essential to 
study socioeconomic differences in cancer survival data as this may explain the differences in the 
diagnosis and treatment of HNC, as an IARC review showed an association between survival 
outcomes and SES. (130) Intertwined in this is that cancer outcome was determined by cancer 
stage at diagnosis with deprived groups more likely to have poorer outcomes compared to 
affluent comparisons. Numerous research studies have found the link between SES or 
deprivation and poorer health outcomes, (119, 131) and it is fair to say this is the same when 
addressing cancer survival outcomes. 
This issue is of particular importance in Scotland as described by the then Chief Medical Officer 
that, “with deprivation comes a higher burden of disease, poorer uptake of services and worse 
outcomes of care”.(132) Unemployment is a key element of the socioeconomic determinants of 
health as unemployed males have been shown to have an excess cancer mortality of 25% 
compared to employed men. Excess cancer deaths were found to be 70% higher in men and 41% 
higher in women when comparing most deprived backgrounds to least deprived. (133) 
It has been established that people from deprived backgrounds have an unequal burden of 
mortality. (19, 134) Incidence of HNC is also very high in this group but it is unclear whether this 
difference is due to the differential distribution of cancer related risk factors. (135) There is an 
uneven distribution of high-risk behaviours and poor lifestyle choices amongst deprived groups, 
which may explain the variation in HNC incidence. This clustering of disease spells an almost 
inevitable outcome of poor survival rates in patients of deprived backgrounds. It is not clear why 
despite all the medical advances, there continue to be inequalities in health determinable by 
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deprivation status. As described by Tudor-Hart, “the availability of good medical care tends to 
vary inversely with the need for it in the population served. (136) 
The literature demonstrates that survival decreases with age. This may be due to older people 
having a higher frequency of comorbidity resulting in late presentation of late stage cancers 
which generally causes less favourable outcomes. SES has also been implicated in determining 
poor survival. It is possible that social class differences are caused by cancer stage at 
presentation for diagnosis. (137) There have been notable gains in survival statistics in affluent 
groups which may explain why deprived people have less favourable outcomes. Several studies 
have demonstrated the link between poor survival and the presence of comorbidities specifically 
for HNC. (138-140) It remains unclear why survival disparities exist between socioeconomic 
groups but Woods et al (129) have implicated differences in comorbidity status, access to 
treatment, and treatment choices, stage of disease at diagnosis and tumour biology. Although 
the effect of comorbidity and SES has been addressed individually, no studies have been 
identified that consider the combined effect of comorbidity and deprivation on HNC survival. 
As stated by Valderas et al, “a relatively new concept that is emerging is how influences such a 
patient’s SES, behavioural and cultural influences can contribute to the physiological complexity 
of a cancer diagnosis occurring in the presence of a comorbid disease”. (82) It is worthy to note 
that the relationship between deprivation and health status (comorbidity) is not fully understood 
despite the common place nature of both deprivation and concurrent chronic disease.(141) This 
illustrates the complex and intertwined nature of morbidity within the backdrop of other non-
health related characteristics which was highlighted earlier. (111) 
Richards reported that there had been a notable change in survival rates in the UK between 
deprived and affluent groups and although improvements are being observed in both groups, in 
order to explain the survival disparities, it appears now that, “clinicians attribute the deprivation 
gap to comorbidity”. (142) Based on this assertion, it makes sense to review what contribution 
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socioeconomic deprivation makes to the survival outcomes of HNC patients. Additionally, the 
cancer community can no longer continue to ignore the obvious prognostic importance of these 
factors. The continued focus on the description of the tumour while ignoring suitable 
descriptions of the cancer patient weakens the scientific accuracy of the cancer staging system 
and ultimately the humanistic care of patients.(143) 
1.5.2 Why study comorbidity and deprivation? 
Comorbidity may produce or exacerbate inequities in health outcomes between population 
groups with evidence internationally for the role of comorbidity in social class inequalities. (144, 
145) Deprived patients have higher prevalence of comorbidity, and are more likely to have 
multiple, complex comorbidity than their more affluent counterparts. (139, 146-152) HNC and the 
comorbidities normally found in HNC patients share many common risk factors. These include 
age, smoking, and alcohol abuse which are all risk factors for a range of common non-cancer 
conditions including diabetes, hypertension, respiratory, cardiovascular and peripheral vascular 
disease and liver disease, and are also risk factors for HNC. (153, 154) 13 studies (11, 89, 143, 148, 
155-163) all examined the prognostic importance of comorbidity. These studies were able to 
demonstrate that comorbidity is a predictor of survival in HNC. Diagnosis of HNC occurs in the 5th 
to 7th decade of life which means that a patient will usually have comorbidity. The presence of 
comorbidity was found to affect treatment selection, which in turn, may have an impact on 
survival. (11, 16, 155, 164)  
Although chronological age was not identified as an indicator of frailty, it does have an influence 
on treatment choices. (11) Apart from having comorbid disease and being elderly, an HNC patient 
has other vulnerabilities. The issue of chronological age compared to biological age has to be 
taken into consideration alongside other patient factors such as deprivation. A patterning of 
social inequality in a Danish cohort found an inverse relationship between HNC incidence and 
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social position (SES) with evidence of lower survival rates in the socioeconomically 
disadvantaged, i.e. the deprived (165) with confirmation of these findings in a later study. (11) 
There have been various theories developed to explain the reason for these disparities but 
despite adjusting for factors such as tumour biology, tumour stage at diagnosis, amongst others 
the survival differences between socioeconomic groups have prevailed. (129) There are different 
ways of assessing social contributors to health across the developmental spectrum, with risky 
behaviours such as smoking and drinking being major causes of ill health in adulthood compared 
to long-term exposure (e.g. to viral infections) in childhood. (166) Of note, the main antecedents 
of HNC are smoking and drinking to excess, which also follow a social patterning as the most 
deprived are more likely to drink and smoke more heavily than their affluent counterparts.(167-
169) In this instance it is unclear whether deprivation is the risk factor (128) or whether the social 
norms of high-risk lifestyle behaviours of deprived groups are to blame. 
Concurrent medical conditions (comorbidities) accumulate and complicate an HNC patient’s 
health status even as SES can compound this disadvantage leading to poor survival. As Boeje et al 
(11) advocated further scrutiny of how patient related factors impact prognosis; this thesis will 
explore this complexity presented by patients with head and neck diagnosis who have co-
occurring disease and the interplay of SES on survival. Comorbidity is common among people 
with HNC, due to the aetiology and epidemiology of this form of cancer. Comorbidity has an 
impact on HNC outcomes, and its impact is in part, modifiable. The same cannot be said for SES 
which as a social construct is beyond the control of the patient. The interest lies in identifying the 
role of comorbid conditions specifically in relation to treatment and survival for cancer. 
The gap in the literature that is the focus of this project is that despite numerous research studies 
on how either comorbidity or SES affect survival in patients diagnosed with HNC, before now 
there have been no previous attempts to investigate whether both factors were interrelated in 
determining survival. The survival disadvantage that is predetermined in the presence of 
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deprivation and severe comorbidity in patients face in comparison to their counterparts has 
never been investigated. It was unknown if this disproportionate mortality experience could be 
due to both factors as most studies only used comorbidity as a predictor as they adjusted for SES 
as it was considered a confounder. It was decided to establish whether deprivation did have a 
confounding effect in analyses of comorbidity or whether deprivation and comorbidity had 
measurable effects as prognostic factors. In addition it was essential to assess whether the 
prognostic association changed when the factors were assessed independently or in 
combination. The decision was made to focus on comorbidities in isolation from or ahead of 
other patient factors (age, gender, smoking, alcohol, behaviours), tumour factors (site and 
stage), and treatment factors on HNC survival because the systematic review research question 
had to specific and concise in order to formulate a sound literature search that obtained the most 
relevant research papers. Research has shown that the TNM classification is no longer enough to 
predict prognosis hence the need to focus on the patient related factors such as comorbidity and 
SES amongst others. In addition, the effect modification properties of the variables such age, 
smoking and alcohol status was taken into consideration which is why these factors were 
included in the retrospective cohort analysis. It appears that there is a case-mix difference in HNC 
where important factors such as HNC sub-type, treatment effects, comorbidity and deprivation 
all have a significant impact on survival. 
1.6. Aims and objectives 
Aim: The project will investigate the roles and interrelationships of comorbidity and deprivation 
on HNC survival. The project will investigate (a) what effect SES and comorbidity have on survival 
in HNC patients, b) whether there are differences in the presentation of HNC based on the levels 
of comorbidity and deprivation; a key secondary question is whether patients with lower SES 
present with more advanced cancer compared to their counterparts. In addition, a broad set of 
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secondary questions will ascertain whether there were differences in the prevalence of the HNC 
subtypes by SES in the Fife and Tayside communities. 
1.7. Chapter summary 
This chapter explained what HNC is and also what comorbidity and SES are as factors that 
influence survival. Measurement methods of these two concepts were discussed and a rationale 
for why these two factors needed to be evaluated within the context of HNC survival. The aims 
and objectives were set out for this project. The next chapter will report on a systematic review 
of the literature as a follow up to the introduction given in Chapter 1. The systematic review will 
appraises the evidence on the impact that comorbidity and deprivation have on survival in 
patients with HNC. 
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C h a p t e r  2  
2.1. Systematic review 
2.1.1. Chapter outline 
This chapter will describe in detail how a systematic review of the literature investigating the 
effect of SES (deprivation) and comorbidity on survival was performed. A summary of the 
findings from the narrative synthesis and meta-analysis of included studies will be given along. 
The overall survival estimates will be given in terms of the risk of death that both comorbidity 
and SES place either as independent prognostic factors or in combination. The chapter will 
conclude with how the systematic review of the literature recommended and influenced the 
development of future work. 
2.2. Systematic review background 
HNC is the collective term for cancers that occur in specific parts of the head and neck region. 
They usually (90% approximately) begin in the squamous cells that line the moist, mucosal 
surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). 
These squamous cell cancers are often referred to as squamous cell carcinomas of the head and 
neck. HNCs can also begin in the salivary glands, but as this form of HNC is relatively rare within 
the UK. Although these cancers are different, their treatments are similar so it makes sense to 
group them especially as the multidisciplinary teams (MDTs) which handle treatment follow set 
guidelines on treatment of HNC e.g. Scottish Intercollegiate Guidelines Network (SIGN) which are 
used in Scotland. Another issue that makes the grouping of HNCs easier is that they all share 
largely similar risk factors i.e. alcohol and smoking are all confirmed as aetiological factors with a 
multiplicative and additive risk for HNC based on degree of exposure. Although use of the 
collective term for HNCs is common there are inherent shortfalls due to peculiarities of the 
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specific HNC subtypes. This is especially the case for cancers that occur at the back of the tongue 
and in the tonsils (cancers of the oropharynx) have become more common over the last 2 
decades. These cancers are mainly attributable to infection with a type of virus called human 
papilloma virus in particular type 16 (HPV 16). The main cause of HPV infection is that the virus 
spreads to the mouth and throat through oral sex, with a corresponding increase of risk of 
infection based the number of oral sex partners, although this trend is more evident in younger 
patients who tend to be from affluent backgrounds. (27, 50) Another type of HNC is that of the 
outer lip which is caused by exposure to sunlight particularly those who work outdoors (1in 3). So 
for the purposes of the systematic review, the collective term of HNC was used with a plan to 
assess the prognostic impact of each individual cancer in the cohort analysis.  
In the UK, as in most other countries, HNC is more common in males than females, although this 
trend appears to be changing in Scotland due to the time lag of excessive smoking in females 
(note the similarity to lung cancer statistics). (170) Older adults are more prone to additional 
chronic diseases and these can exacerbate or be exacerbated by cancer which is especially 
pertinent here as cancer, like other chronic diseases, is largely related to advancing chronological 
age hence the relatively more common HNC diagnoses in Scotland as the fifth highest incident 
cancer as Scotland has an ageing population. (171) The typical HNC patient is usually male, older, 
and likely to have multiple comorbidities. (172, 173) It is believed that being older accords a 
greater likelihood of cancer diagnosis as  increasing age equates to an increasing vulnerability to 
age related health problems such as heart disease, hypertension, diabetes, arthritis and COPD i.e. 
comorbidities which compound the prognosis of HNC. (146, 174) 
Concurrently, within the UK there is a distinct north-south gradient of cancer morbidity with rates 
higher in the north (Scotland) than Wales and England to the south. (175) Although this 
phenomenon has been observed for a number of decades, the exact cause has not been 
34  
 
identified. Some researchers have pointed towards the influence of socioeconomic deprivation 
but this may not be the sole determinant for this inequality. (128, 176)  
The relationship between age, chronic disease and cancer can be compounded further by 
disparities such as SES. Health inequalities remain an important public health issue in cancer care 
within the UK. In reviewing the issue of inequalities in health, the contribution of poverty to ill 
health had been identified in the 1940s but the medical profession had no control over this social 
aspect of disease manifestation. (177) Notably this relationship has prevailed with worse 
outcomes of disease occurring more commonly in the worse off (deprived) within society. 
However with the continued advances in personalised medicine it is important to understand 
how socioeconomic status affects survival outcomes in order to adjust for this when devising 
treatment approaches within HNC oncology. 
Socioeconomic, environmental, cultural, biological/genetic and behavioural factors all have an 
impact on survival. (98) The ability to assess prognostic factors in patients is an important aspect 
of cancer treatment and control .(178) Although there have been advances in the care and 
treatment of HNC, there remains evidence of survival disparities between and within 
populations, as seen in Table 3. 
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Table 3 Scottish HNC incidence and mortality by SES 
 INCIDENCE MORTALITY 
SIMD 2009 
deprivation 
quintile 
Number of 
registration
s 
EASR - Lower 95% 
CI 
- Upper 95% CI Number of 
death 
registrations 
EASR - Lower 95% 
CI 
- Upper 95% 
CI 
5=Least 
deprived 
632 9.5 8.8 10.3 190 2.7 2.3 3.1 
4 814 12.1 11.2 12.9 240 3.3 2.9 3.8 
3 1,009 15.2 14.2 16.1 336 4.7 4.2 5.2 
2 1,335 21.4 20.2 22.6 469 7.1 6.4 7.7 
1=Most 
deprived 
1,571 28.8 27.4 30.3 618 10.8 9.9 11.7 
Test for trend 
(Poisson 
regression) 
<0.0001    <0.0001    
Sources: Scottish Cancer Registry, ISD (incidence); National Records of Scotland (NRS) (mortality and 
populations) 
    
Notes:         
1.  Rates are calculated using the populations in 2009.       
2.  Cancer registration is a dynamic process: the data presented here may differ from other published data relating to the same 
time period. 
    
3.  Confidence intervals for age-standardised rates (EASR) have been calculated using a formula which works 
only  
     
when numbers are sufficiently large.  They are therefore set to 'not applicable' in the event of there being 50 cases or less.     
4.  For analyses using SIMD 2009: ISD have changed their labelling and now label the categories as 1=most deprived to 5=least 
deprived.   
   
Our policy of population-weighting the quintiles remain unchanged, so the datazones contained within each quintile will differ slightly to those presented in Scottish 
Government releases. 
EASR: age-standardised incidence rate per 100,000 person-years at risk (European standard population)       
Source: ISD Scotland (26)
36  
 
This makes the case for a shift in focus from the use of time proven prognostic factors such as 
the TNM classification alone. Research conducted has demonstrated the prognostic importance 
of social health determinants. (166, 179-182) The stage at diagnosis is an important prognostic 
factor as the earlier the diagnosis, the better the outlook. There is evidence of a social gradient in 
HNC as deprivation is associated with late stage HNC, which could be due to delayed 
presentation due to poor health awareness levels and high exposure to risk factors such as 
smoking and drinking. (108, 116, 130, 135, 183-186) Although these characteristics are important, it 
is also imperative to account for the general health status of the patient, including the degree to 
which comorbidity influences the intervention of choice, the risk of complications and the 
outcomes of treatment. (187)  
Comorbidity is the simultaneous existence of several diseases, and can be prognostic or 
therapeutic. Therapeutic comorbidity pertains to the clinical course of cancer which can be 
altered by drug interaction and/or polypharmacy. This is the case in laryngeal cancer where COPD 
as the co-existing illness results in treatments that have to be administered differently because 
these patients tend to receive radiotherapy rather than chemotherapy to reduce the risk of 
toxicity of medications.(188)  
Prognostic comorbidity is how comorbid disease/diseases affect survival. This is due to the how 
co-existing illnesses can potentially alter both the efficacy of therapies and the course of the 
primary disease, thereby contributing to premature death. In other words, it can pre-exist HNC 
(particularly in older people) or it can develop during the clinical course of the index disease.(1, 
143, 147, 150) Comorbidity occurs more frequently in the elderly who are more prone to 
developing cancer, therefore posing considerable challenge to treatment selection.  Additionally, 
survival outcomes are wholly dependent on how well both the cancer and the comorbid 
disease(s) are managed. (189) The field of prognostication of disease now focuses on the 
important role of comorbidity and not only on the conventional TNM (tumour-node-metastasis) 
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classification as comorbidity has been found to have a negative effect on outcomes, whether 
tumour or treatment related. Previously this relationship was put down to confounding, but after 
controlling for common confounders such as age, gender and race, tumour stage and site, the 
relationship has remained significant, demonstrating that comorbidity is an important prognostic 
attribute of cancer. (178, 189)  Physiologic burden of chronic disease and cancer equate to poor 
outcomes as it is believed that the clinical course of HNC can be altered by comorbid disease as 
this form of cancer affects older patients who are more likely to have coexisting disease. (90, 156, 
190-193) 
Overall it is important to assess how these patient factors; comorbidity and socioeconomic 
deprivation affect outcomes in HNC patients because: 
 Deprivation may be described as both a risk and prognostic factor for HNC, 
 Comorbidity has been posited as a confounder and prognostic factor  in HNC 
Therefore these two patient factors should be considered in HNC survival. 
2.2.1. Literature scoping 
Prior to the main review, a scoping search of the literature was done with the aim of determining 
the existence of a systematic review on this subject. This scoping exercise also helped to clarify 
what literature was available pertaining to comorbidity and deprivation in HNC outcomes. A 
preliminary search of databases such as the Cochrane Library, Intute, MEDLINE, CINAHL, Centre 
for Reviews and Disseminations (York CRD) and Health Technology Assessments was made to 
identify whether a systematic review of this topic had been previously conducted. There was one 
study reported as a systematic review of socioeconomic status and cancer (194); however after 
mapping of the evidence and critical appraisal of the paper, it was found to be methodologically 
flawed . This review did not search all possible sources for relevant primary studies while the 
included studies were not quality assessed hence there was no way of reproducing any aspects 
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of the research. (195-197) There was no evidence of similar research being previously conducted 
within the HNC field, however a similar study reviewing the survival of patients from deprived 
backgrounds with comorbid disease had been carried out in colorectal cancer. (145) 
2.2.2. Systematic review rationale 
Despite the plethora of evidence relating to factors determining survival in HNC, there is an 
overwhelming lack of evidence of the systematic appraisal of the evidence demonstrating how 
comorbidity and SES together impact survival outcomes. HNC although the 6th most common 
incident cancer in the world, (20) has survival estimates of approximately 60% (97) which have 
only experienced marginal improvement in the last three decades. HNC is a potentially life 
threatening diagnosis and as such it is imperative to evaluate the influence of any factors that 
may reduce the risk of death in affected patients. As mentioned previously there is very little 
research around the role of comorbidity and SES in determining the survival of HNC patients. 
Focusing on these prognostic factors is imperative to as there have been very little increase in 
survival figures. The evidence base to determine the effect of both factors on outcomes is either 
incomplete or unavailable.  
HNCs are often associated with older age, low SES and high levels of comorbidity. In spite of this 
knowledge, the relationship between SES and comorbidity and how they combine to impact on 
survival is unclear. The systematic review investigating the extent to which comorbidity and SES 
are associated with survival in patients with HNC was conducted in order to help clarify this issue. 
A systematic review was chosen as it is the best research method to elicit and summarise all 
existing primary research on the issue under study.  
A few studies have been conducted that have focused on either comorbidity or SES but 
interestingly all these studies have largely been heterogeneous in their findings. A single paper 
39  
 
(145) that attempted to address the systematic review aim was not on HNC and failed to identify 
the effect of either factor independently or in combination.  
A systematic review of this topic was felt to be appropriate due to the considerable lack of 
research in this area. It is quite clear that if any review studies do exist, these are as yet 
unpublished or have not been evaluated rigorously or been validated as providing robust 
evidence of prognostic effect. Therefore, this review hopes to draw on an unexplored area in 
HNC survival.  
A systematic review is justifiable here as it can help to propose a future research agenda as the 
way forward in HNC prognostication as the current route appears unclear. Recent 
epidemiological shifts such as the increase in HPV-positive HNCs have shown improved survival 
but patients with HPV-negative HNCs remain at a marked disadvantage with little chance for 
improved outcomes as the mechanism explaining the prognostic impact of comorbidity and SES 
remains unclear. It is hoped that this review will successfully integrate a meta-analytic approach 
alongside the narrative synthesis in order to develop an evidence base to better inform health 
policy and practice around HNC oncology.  
HNCs are often associated with older age, low SES and high levels of comorbidity. In spite of this 
knowledge, the relationship between SES and comorbidity and how they combine to impact on 
survival is unclear; hence we conducted a systematic review investigating the extent to which 
comorbidity and SES are associated with survival in patients with HNC. 
The main aim of this review is to consider the extent to which comorbidity and SES affect survival 
in HNC patients. Of particular importance is the comorbidity that pre-exists HNC and that directly 
occurring as a consequence of HNC. In terms of SES this refers specifically to the socioeconomic 
level of those diagnosed with any form of HNC. SES can take the form of individual, household or 
neighbourhood (small area statistics) where available. There is a rationale for a systematic review 
in this instance as there is a substantive question about the individual roles and whether an 
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interrelationship between comorbidity and deprivation exists. Several primary studies do exist, 
all pointing to the detrimental effects of both factors; however, an analysis of how both affect 
survival has not been evaluated prior to this review. This review will endeavour to pull together 
all the available research in this area of HNC and make meaningful conclusions about comorbidity 
and deprivation and their relative contribution to survival.  
2.3. Systematic review aim 
The aim of this review was  
 To assess how the relationship and interrelationships of comorbidity and deprivation 
affected survival in patients diagnosed with HNC. 
2.3. Hypothesis 
The working hypothesis of the systematic review is that comorbidity and deprivation individually 
or in combination increase the risk of premature death in patients with HNC. The review seeks to 
understand the influence each factor’s contribution to survival for HNC patients. We believe that 
these two factors work together to reduce chances of survival. 
2.4. Methods overview 
The application of the Centre for Reviews and Dissemination systematic review guidance aided 
the research approach to this systematic review; reducing bias, providing an audit trail and 
making certain that the methods used were explicit and systematic, with some elements such as 
the search strategy reproducible. The reporting of this review follows the instructions defined in 
the Meta-analysis and Systematic Reviews of Observational Studies in Epidemiology (MOOSE) 
guidelines (198) which are shown in Appendix 1. 
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The review encompassed 4 stages: 
1. A reproducible literature search to locate relevant studies 
2. The application of the inclusion/exclusion criteria to select studies to include in the 
review. 
3. Methodological quality assessment and data extraction 
4. Synthesis of systematic review findings 
2.4.1. Inclusion criteria 
To reduce publication bias, (199) this review considered all published sources without restrictions 
to geographical setting. The following criteria were used to assess studies for inclusion: 
 Location- unrestricted 
 Language- English or where translation was possible 
 Time frame- no restrictions 
 Population- patients diagnosed with any form of HNC 
 Outcome of interest- survival 
 Study type- Primary research assessing contribution of comorbidity and/or deprivation 
2.4.2. Exclusion criteria 
This review excluded the following: 
 Survival studies of skin cancers of the head and neck, 
 Studies of survival outcomes in other cancers found in the head and neck area but not 
covered by the definition of HNC given previously,  
 Studies involving expert opinions, editorials, commentaries and secondary research 
papers,  
42  
 
 Studies written in any languages where translation was unavailable. 
 Studies focusing on racial disparities 
 Studies of incidence rates of head and neck cancers (HNC) were excluded because as 
they did not report survival outcomes for those with the disease.  
 Studies that focussed on cancer in general but without specific reference to HNC and 
those that focused on HNC definition grouped to include oesophageal cancer or thyroid 
cancer were also excluded.  
 Case control studies were also excluded from this review as they do not have high 
generalisability although their internal validity is quite high. They tend to be more useful 
in determining diagnosis and also because they use ‘outcome selective sampling’. (200-
202) Also the other limitations of case control studies include the risk that selection of 
cases and controls may be biased such that groups differ systematically in unknown 
ways. (203, 204) One might argue that the trade off between cohort and case control 
studies may be limited as the accuracy of cohort studies is dependent on the accurate 
collection of medical records. Nevertheless, cohort studies were included as they provide 
the strongest evidence for observational studies of prognosis. (205) 
2.4.3. Application of the inclusion/exclusion criteria 
Based on the stepwise approach to systematic reviews, the inclusion and exclusion criteria were 
applied to all the studies retrieved from the systematic literature search. Data arising from the 
review were used to make evidence-based recommendations regarding the prognostic 
importance of comorbidity and socioeconomic deprivation in the survival of patients diagnosed 
with HNC.  
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2.4.4. Outcome of interest 
This review was conceptualised to investigate survival in patients with head and neck cancer with 
survival classified as a single outcome measure, namely death. Death from all causes is an 
objective measure of outcome and it was used here to consider the following outcomes: 
 Disease free survival 
 Overall survival  
 Disease (tumour) specific survival 
 Death (mortality) 
The outcome measures used, as reported in the studies, should also meet the criteria of 
reliability, validity and feasibility. 
2.4.5. Protocol deviations 
The protocol was followed as much as possible in terms of the research question that needed to 
be answered. At the beginning of the project, the area of research was meant to be in four 
cancers; breast, head and neck, prostate and colorectal. While trying to devise the literature 
search, the principal investigator realised that focusing on HNC would give a clear and concise 
assessment of the relative contributions of comorbidity and deprivation in determining patient 
survival. Preliminary searches for each cancer had given the principal investigator a preview into 
the size of the workload and as colorectal cancer had previously been researched with same 
objective, it would be difficult to justify redoing the retrospective data analysis after the 
systematic review. As very little was known the combined effect of deprivation and comorbidity 
in head and neck cancer and as it became clear early on during the literature search that there 
was a paucity of studies focusing on both prognostic factors and their influence on survival in 
head and neck cancer, this focus on head and neck cancer was justified. Following discussion 
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with the principal investigator’s supervisors, it was agreed that HNC would be the focus the 
ensuing work. Unfortunately due to unforeseen circumstances the protocol was not registered. 
2.4.6. Search outline 
The aim of this research was to obtain all the relevant observational studies that focused on the 
effect of deprivation and/or comorbidity on survival. In order to devise a systematic and 
reproducible literature search, a formative search of the literature was done in MEDLINE 
followed by analysis of the text words contained in the title and abstract as well as index terms of 
an article pertinent to this review (206) From this pilot search, search terms were developed for 
the systematic literature searching. The search terms were identified using a variety of sources, 
including an examination of previous systematic reviews of a similar topic, brainstorming and an 
examination of database thesauruses and this resulted in a final list of free-text search terms.  
A detailed text and MeSH heading search strategy was carried out after consultation with a 
medical librarian and a colleague who specializes in systematic reviews (see Appendix 3 for 
details of the search strategies). The search strategy involved a systematic and reproducible 
search from various peer reviewed data sources to identify published literature based on the 
inclusion and exclusion criteria. To increase the sensitivity and specificity of the records obtained, 
the researcher consulted the university librarian and also used other research experts for advice 
on the search strategy. As a result the search strategy used relied heavily on free text wording to 
improve the specificity of the search. Survival was chosen as the outcome of interest, rather than 
recurrence; as the date of death is more likely to be measured accurately and the results for 
survival are easier to interpret than those for recurrence.  
From this initial search, a systematic search strategy was constructed in MEDLINE from the list of 
key words and index terms to retrieve articles to consider for the inclusion in the systematic 
review. A final extensive search using all identified keywords and index terms was then used to 
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devise adapted search strategies for different bibliographic databases and sources adding in 
relevant thesaurus terms specific to each database. The search terms used were designed to 
identify studies that indexed or pertained to (i) Head and neck cancer (HNC), (ii) survival 
analysis/prognosis and (iii) socioeconomic status (deprivation) and/or comorbidity status, or their 
synonyms. The search strategy included key terms for cancer (neoplasms OR cancer OR tumour), 
AND comorbidity (additional disease OR coexisting disease OR additional morbidity), AND 
survival or prognosis (survival analysis OR survival rate OR proportional hazards model OR 
survival OR prognosis).  
All search terms were ‘exploded’ in conjunction with using a keyword search. It was anticipated 
that most of the identified studies would be cohort studies; however, all observational study 
designs were eligible. The databases included were 
 EMBASE (1980–Feb. 2012), updated to January 2015 
 MEDLINE (1966–Feb. 2012),  updated to January 2015 
 LILACS (1975–Feb. 2012),  
 CINAHL (2012), updated to January 2015 
 SciELO (up to Feb 2012) and  
 ISI Web of Science (1980–Feb. 2012), updated to January 2015 
All search strategies (original and updated) are presented in the Appendix. The search included 
an iterative process to refine the search strategy through testing of several search terms and 
incorporation of new search terms as new relevant citations were identified. An attempt to use 
optimum search strategies of studies of prognosis devised by Wilczynsk and Haynes for use in 
both EMBASE and MEDLINE proved to be poor at obtaining relevant studies. (207, 208)  
To ensure the search strategy for this review was systematic and sensitive enough to pick up all 
the relevant studies, a further citation search was done from the reference list and bibliographies 
of all identified reports and articles that were retrieved from the searches detailed previously. 
The reference lists of all papers and relevant reviews identified were assessed for any additional 
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papers meeting the inclusion criteria. The electronic sources listed above were searched for all 
relevant studies regardless of the studies’ publication status, (in press, published, unpublished 
and in progress). An initial updated search was conducted again between January and February 
2012 and redone in January 2015 in order to obtain any other publications that may have been 
missed in the initial search. A systematic search of the literature was done for English, Spanish 
and Portuguese-language studies that reported survival of patients with a diagnosis of HNC. 
Language was extended beyond the English language as translation facilities were accessible for 
Spanish, Portuguese, Polish and German languages. In the end only Spanish and Portuguese 
papers were included as they met the inclusion criteria. 
A further cited reference search was conducted in Web of Science on the relevant papers and 
used the "related articles feature" in SciVerse Science Direct. After reviewing the "related 
articles" and "cited reference" search results and finding only 22 potentially eligible articles 
shown in Appendix 4, this part of the search process was concluded. The review process required 
many methodological decisions not fully anticipated in the initial protocol. These included issues 
regarding inclusion criteria and study eligibility based on methodological quality.  
2.4.7. Filtering and article selection 
All references identified were loaded onto Endnote. This reference management software was 
used to track and maintain an audit trail of all studies as they passed through the review process. 
The first reviewer (EM) conducted an initial filtering of all references in order to exclude obvious 
irrelevant references and duplicates located in the database searches. The excluded references 
were checked by a thesis supervisor (CM) in the group to ensure no relevant references had been 
excluded at this point.  
The titles and abstracts for these citations were then independently examined by the author 
(EM) and her supervisor (CM) with a third reviewer (MW) consulted where there was 
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disagreement, which additionally helped to ensure consensus was reached. The full text paper 
was retrieved if the abstract mentioned all of the following  
(i) patients with HNC;  
(ii) overall survival, HNC-specific survival or recurrence;   
(iii) comorbidity or SES. 
The initial search identified 2067 potentially eligible studies but on further review these were 
reduced to 1174 using the following methods: 
 Title and abstract review 
 Full text of paper review 
An updated search was conducted in January 2015 and 4 papers (209-212) focusing on SES were 
identified and 3 papers (213-215) on comorbidity. 
The full outline of how the search was initially conducted in order to obtain the final sample of 
papers is depicted in the flow chart; the new papers from the systematic review updated 
literature search are in italics. 
48  
 
Figure 7 Flowchart of included studies 
 
Adapted from the PRISMA flow diagram (216)  
Footnote explaining PRISMA 
Potentially relevant studies screened for 
retrieval (n=2 067) + (n=27) 
MEDLINE = 1285 
EMBASE = 262 
CINAHL = 161 
Web of science = 470 
Updated = 17 
 
Studies excluded (n=1204 duplicates) 
 
 
Studies retrieved for more detailed 
evaluation (n=1 174) + (n=17) 
Potentially appropriate studies to 
be included in the narrative 
synthesis (n=214) + (n=7) 
Studies reviewed for inclusion in narrative 
synthesis (n=98) + (n=7) 
Studies obtained from citations (n= 22) 
Studies with usable information 
(n=63) + (n=9) 
Updated to 72 included studies 
Studies excluded, with reasons (n=960 
irrelevant) + (n=10) 
 
Studies excluded, with reasons (n=5 case control 
study-bias prone) 
(n= 10 restricted to race) 
(n=6 HPV studies) 
(n=1 irrelevant systematic review) 
(n=71 irrelevant) 
(n=23 not on prognostic factors) 
(n=5 unable to obtain full paper) 
 
 
Studies withdrawn, by type, with reasons 
(n= 3 unable to obtain full text) 
(n= 31 irrelevant) 
Definition of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)  
PRISMA is an evidence-based minimum set of items for reporting in systematic reviews and 
meta-analyses. The flow diagram depicts the flow of information through the different phases 
of a systematic review. It maps out the number of records identified, included and excluded, 
and the reasons for exclusions 
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2.5.1. Development of the methodological quality assessment tool 
There is increasing volume of literature that focuses on prognosis in head and neck cancer. 
Despite these advances in this field, there has not been a corresponding plethora of literature on 
methods to assess the quality of prognosis studies. Although guidelines exist that explain 
reporting of observational studies (STROBE, REMARK, MOOSE), as yet there does not appear to 
be any guidance on how to conduct a systematic review of prognosis studies. Systematic reviews 
of prognostic studies are very complex to undertake as the methods for this have not been 
standardised unlike those for therapeutics or diagnostic reviews, as stated by Altman (202) and 
confirmed during the conduct of this review.  
There are no established criteria for assessing the quality of survival studies, therefore the author 
initially set out to use the McMaster University Effective Public Health Practice Project Quality 
Assessment Tool for Quantitative Studies. Quite quickly the author realised that this tool was not 
fit for purpose as it was more geared towards intervention studies. Therefore a search of the 
literature was conducted to investigate whether a pre-existing quality assessment tool for 
observational studies could be located. Originally a prognostic quality assessment tool developed 
by the University of Montreal (217) was considered for use but this was found to be more suitable 
for a professional measuring prognostic likelihood for a specific patient.  
A search of the literature on critical appraisal pointed to two tools that were potentially eligible 
for use either based on their own merit or with minor adjustments. (218) Both these tools proved 
inadequate to provide complete and concise critical appraisal and quality assessment of the 
included studies. (219, 220) Due to the difficulties faced in obtaining a validated quality 
assessment tool on evaluation studies, following discussions between the review team members, 
the decision was made to devise a tool for use in this review. An initial draft was based on work 
conducted by different researchers, and adapted into a tool. (202, 217, 221, 222) A pilot quality 
assessment of 20 papers was conducted by the author (EM) and the third reviewer (MW). The 
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purpose of this was to assess whether the quality assessment process was free from bias and 
fairly amenable to a systematic approach, while assessing the validity of each article, and 
determining its importance within the context of this review. This pilot quality assessment found 
a lot of inconsistencies as all the studies reviewed rated as strong although both researchers 
acknowledged that using basic critical appraisal skills, some of these studies had methodological 
flaws, hence a ‘strong’ quality rating was inaccurate. 
The methodological quality assessment tool was revised using more rigorous research evidence. 
(202, 203, 223) Also to minimize the possibility of different interpretations of each appraisal 
question, a dictionary of the meaning of each question was devised to make this tool useful and 
adaptable for future projects. 
Two reviewers, the author (EM) and the second supervisor (EW) independently assessed each 
study then discussed their ratings together. Any disagreements were discussed and resolved by 
consensus agreement and final discussion with the thesis supervisor (CM) as the third reviewer.  
2.5.2. Assessment of study eligibility 
Reviewers (EM, CM, and MW) were not blinded to the included studies identified for full 
evaluation in the screening process. Two reviewers, (EM and CM) independently assessed all 
studies identified for inclusion and resolved disagreements by discussion. For papers deemed 
eligible, the author and third reviewer (MW) with access to the full paper reviewed the eligibility 
decision. For the systematic review update EM had sole input to conducting the study eligibility 
exercise. 
Key of systematic review team 
1st reviewer – Author (EM) 
2nd reviewer – Thesis supervisor (CM) 
3rd reviewer – Collaborator (MW) 
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2.5.3. Data abstraction 
The principal researcher alongside three reviewers independently assessed the quality of 
included studies and abstracted data from all eligible studies; they resolved disagreements 
through discussion. Information relevant to the methodological quality of the studies included 
the study design, the populations selected (criteria inclusion in the primary study and the degree 
to which the studied population was representative of the wider universe of patients with the 
diagnosis), measurement of outcome (that is, the extent to which the outcome measures were 
defined similarly, and monitored similarly), loss to follow-up, and the extent of risk adjustment 
for confounders that might affect prognosis. Other data obtained during data abstraction 
included the country in which the study was conducted, the period of observation, the number of 
participants, and the main outcomes. Studies were classified as being of high, moderate or low 
quality according to the criteria used in the quality assessment tool developed by the lead 
investigator using data from other studies. 
2.5.4. Data extraction strategy 
Data from the final sample of the studies meeting the inclusion criteria was extracted and 
summarized in data abstraction forms, see Appendix. For the quantitative studies the data 
collected for extraction included the following: 
 Details of the publication (study author, country, year) 
 Number of study participants 
 Tumour site 
 Prognostic factor and measurement method (of comorbidity/SES) 
 Data analysis method 
 Survival analysis reported/endpoints considered: (median, overall, 3 or 5-year survival.) 
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 Adjustment for confounding 
 Methodological quality rating 
2.6. Review findings 
Due to the diversity of the sources of evidence used in this review, it was felt that attempting a 
meta-analysis of both comorbidity and SES studies would be problematic. This was mainly due to 
the heterogeneity of the study measures used as the comorbidity was measured using different 
indices e.g. ACE-27, CCI, WUHNCI, Kaplan Feinstein, etc. Similarly, SES was quantified differently 
using individual/household income, education and using aggregate measures such Index of 
Multiple Deprivation etc. The following reasons also posed uncertainties in the use of meta-
analysis to summarise review findings: - 
 Inadequate reporting of methods used- some authors did not explain in adequate detail 
 Different measurement techniques were used- comorbidity and SES measured differently 
 Variation in methods of analysis- some used Cox regression, life table method and Gray’s 
test etc. 
A formal meta-analysis of all studies was not attempted due to variations in study populations, 
and SES markers used. However, a meta-analysis was done for the comorbidity studies grouped 
by comorbidity index which resulted in separate analyses for ACE-27 and Charlson Comorbidity 
Index (CCI) studies. All the other studies’ findings were presented in narrative format. 
Based on these findings, both the meta-analytic and narrative synthesis were the most 
appropriate methods to report the results of this review. 
This review grouped included studies into two separate entities namely:  
i. Comorbidity studies using both meta-analysis and narrative synthesis where appropriate  
ii. Socioeconomic studies – narrative synthesis only. 
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In essence two parallel reviews were conducted simultaneously in order to answer the research 
question. Following the concurrent synthesis of findings for both arms of the review, a final 
synthesis was devised to bring together the emergent themes in the results.  
The aim was to integrate the findings of the two syntheses to investigate the prognostic impact 
of both SES and comorbidity in HNC survival. 
2.6.1. Results from search strategies 
The systematic search of the literature identified 124 potentially relevant studies that had 
information on HNC alongside estimates of survival. Of these nine studies were rejected as they 
focused solely on race.(224-233) One of these studies by Gourin et al (226) was restricted to 
treatment selection rather than survival hence it was excluded. Similarly a study was rejected as it 
focused on treatment choice in the elderly accounting for comorbidity. (234) Specifically a paper 
by Sethi et al did not meet the inclusion criteria as it reviewed compliance with treatment, (235), 
Six papers did not meet the inclusion criteria as they examined the influence of human papilloma 
virus positive (HPV+) status which is not a relevant prognostic factor based on the specified 
definition of this review. This is because HPV is not a comorbidity but rather a risk factor for 
oropharyngeal cancers.(60, 63, 69, 236-238) Five papers that were case control studies which 
were excluded due to risk of systematic bias and imprecise measurements in part due to 
selection and information bias as well as confounding.(239-243) 
The paper by Menvielle et al (244) was rejected as the defined HNC used in this paper included 
oesophageal cancer which does not conform to the HNC definition used in this review. Moles et 
al (245) focused on the increased socioeconomic gradient in oral and pharyngeal cancer but did 
not elaborate on survival, therefore it was excluded from the systematic review. Several other 
studies in much the same way were rejected for not reporting survival estimates (246-249). 
Twenty-three papers did not focus on how comorbidity and/or socioeconomic status contributed 
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to prognosis hence these papers were excluded from the analysis. (164, 248, 250-270) (164, 248, 
250-270) 
The paper by Antunes et al (271) was rejected as it was a comparison of Brazil vs. Spain without 
any reference to how comorbidity and/or deprivation were linked to survival. Another paper was 
excluded as only the abstract was available and did not provide adequate information for 
detailed evaluation (272). Four papers were excluded due to failure to obtain full text.(273-276) 
Six papers did not focus specifically on HNC hence did not meet inclusion parameters. (277-282) A 
paper was also excluded from the analysis for focusing on comorbidity (myocardial infarction) 
occurring after HNC diagnosis.(283) Six papers did not focus on survival outcomes (prognosis) 
hence they were discarded from the analysis, (15, 253, 284-288) while a paper on delayed 
diagnosis was excluded as it did not focus on survival. (289) 
The study by Alho et al, (156)was rejected as it reported on the same cohort as the more recent 
paper by Teppo et al (290) which was included. Similar inclusion was made of the paper by 
Grignon et al (291) while the later one (292) was discarded as it looked at first year trends of the 
earlier studies. One study was described as a survival study but on closer inspection it did not 
meet the inclusion as it was a survival trend analysis of England and Wales, rather than a cohort 
study. Two papers did not have sufficient data to allow complete evaluation.(293, 294) Quality of 
life is a function of survivorship rather than survival hence studies that looked at this were also 
ruled out.(122, 295, 296) 
Second primary cancers are not a comorbidity hence papers focusing on this did not fulfil the 
inclusion criteria. (297, 298) Papers that centred on comparison of comorbidity indices without 
reference to survival were also rejected.(148, 163, 299-301) Two studies did not meet the inclusion 
criteria as they were reviews rather than primary studies, (302, 303) while another was also 
excluded as it was a systematic review of the literature, (304) and yet another was a 
commentary. (305) Casasola et al’s (306) epidemiological paper and Piccirillo’s editorial were 
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deemed irrelevant because they did not give data on survival.(139) Two papers were rejected as 
they did not evaluate survival despite the influence of comorbidity from depression and Fanconi’s 
anaemia respectively. (307, 308) Another paper by an anonymous research team was rejected 
due to issues of relevance to the research question.(94) From the cited reference only two 
papers (309, 310) and the remaining 20 studies (69, 163, 225, 237, 240, 257, 258, 260, 261, 280, 281, 
311-318) were excluded from the analysis. 
From the systematic review update the following articles were rejected following full text review, 
(231, 302, 319-324) 
2.7.1. Narrative synthesis methods 
Narrative synthesis methods were employed to organise findings to provide an initial 
descriptions of patterns emerging across the included studies. (325) This was done using the 
following sequence with the comorbidity data presented as an example of the narrative 
synthesis process: 
 Textual descriptions: a short ‘story’ with key messages, significant information that acts 
as a ‘viewing platform’.  
- Age and disease stage 
- Severe comorbidity and disease stage 
- Presence of comorbidity 
- Diabetes as a comorbidity 
- Late diagnosis and severe comorbidity 
- Comorbidity increasing risk of death over time 
- Severe comorbidity and adjustment for confounding 
- Alcohol as a comorbidity 
- Advanced disease and severe comorbidity 
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- Age and comorbidity 
- Older age groups 
- Comorbidity severity 
- Late diagnosis and severe comorbidity 
- COPD in laryngeal cancer 
- Comorbidity severity and survival 
 Ordering/grouping: finding shared features and clustering studies along those lines 
Presence of comorbidity 
Comorbidity increases risk of death over time 
Advanced disease and severe comorbidity 
1. Comorbidity severity  Late diagnosis and comorbidity severity 
Severe comorbidity and adjustment for 
confounding 
Comorbidity severity and survival 
Cardiovascular comorbidity 
2. Type of comorbidity  COPD 
Alcohol 
Diabetes 
      Age and comorbidity 
3. Age related comorbidity  Older age groups 
 Common rubric: Using a common framework to allocate material from multiple studies.  
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1. Severity of comorbidity increases risk of death 
2. Types of comorbidity and effect on mortality 
3. Age and comorbidity have an effect on risk of death 
2.7.2. The chosen approach 
The studies included in this systematic review all underwent quality assessment and critical 
appraisal with ratings of strong, moderate and weak given on the basis of methodological 
quality. Various measures were used in the SES studies ranging from validated indices of 
deprivation, education, health insurance status, occupation and income.  Due to the variety of 
evidence of survival predicted by socioeconomic status all the study findings will be reported 
regardless of their overall quality rating.  
2.7.3. Meta-analytic methods 
In head and neck cancer (HNC) a cure may not be possible, but it is hoped that taking account of 
a patient’s general health status may increase the duration of survival.  
The rationale for not incorporating the studies that quoted their cohort’s survival using odds 
ratios (OR) and relative risks (RR) is that they measure only the number of events and take no 
account of when they occur are and therefore these methods are not entirely appropriate for 
analysing time-to-event outcomes. (326) Time-to-event data are most appropriately analysed 
using hazard ratios (HRs), which take into account of the number of events including when each 
event occurred they also take account of censored patients (the time until last follow-up for each 
patient who has not experienced an event). The studies that did not use the necessary statistics 
to allow estimation of the HRs will be discussed later in a narrative summary of results. 
The statistical methods used here are based on methods described by Tierney et al (326) when 
HR and their confidence intervals are given. The following equation is used: 
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                                             .  
The methods described by Sutton and colleagues (327) to approximate the hazard ratio as the 
effect size was used alongside the inverse variance method to conduct the meta-analysis.  
The meta-analysis was conducted using Microsoft Excel 2007 to calculate standard errors as well 
upper and lower confidence limits of these. This data were inputted in to survival analysis 
package (328) within the R statistical software using the meta-analysis program to conduct the 
statistical methods. 
Effect size estimates were grouped into sets according to comorbidity severity. Each study could 
contribute only one effect size per point in time. If a study had multiple comorbidity effect sizes, 
these were included in separate analyses dependent on comorbidity classification to represent 
the study effect on a particular comorbidity level. The variability of effect sizes was assessed 
using the Q statistic to test for heterogeneity. The Q statistic has an approximate chi-square 
distribution with k-1 degrees of freedom in which k represents the number of effect size 
estimates. 
A significant Q rejects the null hypothesis of homogeneity and supports the search for possible 
moderating variables. The fixed effect model is thereby used to examine systematic influence of 
moderating variables and overall effect size estimates. The use of the random effects model was 
selected over the fixed effects model as it was assumed that sources of variance associated with 
distribution of effect sizes were likely to be randomly distributed. As defined by Hedges, (329) 
the study sample is presumed to be literally a sample from a hypothetical population or collection 
of studies. Another benefit is that generalisations from findings of random effects model can be 
applied to a large variety of situations not reflecting similar considerations to those of the studies 
used in the meta-analysis. 
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2.7.4. Findings 
63 studies were eligible for inclusion in the review as detailed in the study flow chart. This 
increased to 72 studies once the systematic review was updated. The studies were from diverse 
geographic regions with the majority of papers coming from the USA. They focused on a variety 
of HNC subtypes and were mostly retrospective in design; see the data abstraction table in the 
Appendix. 
2.7.5. Results of the meta-analysis  
Adult Comorbidity Evaluation-27  
Mild decompensation vs. no comorbidity 
Seven studies were identified to investigate the likelihood of death due to mild comorbidity, 
which is defined as ACE-27 group 1 or mild decompensation. Of these, four studies crossed the 
line of no effect however the other three demonstrate a statistically significant increase in risk of 
death. From the results depicted in the forest plot, it shows that mild comorbidity has an effect 
on survival. The risk of death does not cross the line of no effect, hence showing the prognostic 
impact of comorbidity. The Q statistic of 15.2 with p value: 0.018 shows there is some 
heterogeneity between the studies, while the random effects model shows a clear increased risk 
of death with a hazard ratio of approximately 0.3. 
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Table 4 Risk of death in Mild decompensation vs. no comorbidity (ACE-27 1) 
Study Name Effect estimate 95% CI %W(fixed) %W(random) 
Datema (330)      0.042 [0.1285; 0.2125]      44.08      22.57 
Yung (150)        0.956  [0.0917; 1.8203]      1.72 4.72        
Piccirillo (147) 0. 030 [0.2209; 0.2809]      20.36 19.15 
Terhaard (331)    0.405  [0.0816; 0.7284]      12.25 16.15       
Sanabria (155)    0.372  [0.1396; 0.8836]      4.90       10.15 
Ledeboer (332)   0.105  [0.4911; 0.2811]      8.60      13.83 
Homma (160)     0.588  [0.1901; 0.9859]       8.10       13.43 
                                                       95%CI                    z-score                              p value 
Fixed effect model   0.1474  [0.0342; 0.2607]  2.5528     0.0107 
Random effects model 0.2280  [0.0209; 0.4351]  2.1577      0.031  
Quantifying heterogeneity: tau^2 = 0.0419; H = 1.59 [1.05; 2.41]; I^2 = 60.5% [9.5%; 82.8%] 
Test of heterogeneity:     Q: 15.2     d.f.: 6 p.value: 0.0187 
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Moderate decompensation vs. no comorbidity (ACE 27 2) 
This forest plot (Figure 9) demonstrates an exponential increase in risk of death for patients with 
moderate comorbidity. Only two studies show no effect but the pooled hazard of death has 
increased to approximately 0.5. Heterogeneity is evident with Q of 29.99, df: 7 and p value of 
<0.0001. Both the fixed and random effects models show similar point estimates but the 
influence of smaller studies such as Yung et al, (150) Tanvetyanon et al (333) and Soares et al 
(334) have pulled the effect size to the right. The wider confidence interval shows wider 
variability in the results of the pooled studies within the random effects model. This model shows 
that moderate comorbidity reduces survival. 
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Figure 8 Mild decompensation vs. no comorbidity (ACE-27 1) 
62  
 
Table 5 Moderate decompensation vs. no comorbidity (ACE 27 2) 
Study name Effect estimate 95% CI %W (fixed) %W (random) 
Datema (330) 0.321   [0.1407; 0.5013]     43.84      17.70 
Yung (150) 1.030 [0.1617; 1.8983]     1.89 7.09 
Piccirillo (147) 0.652   [0.4031; 0.9009]      23.00 16.68 
Terhaard (331) 0.531   [0.1645; 0.8975]      10.61 14.61 
Sanabria (155) 0.083   [0.6004; 0.4344]   5.32 11.89 
Ledeboer (332) 0.357   [0.7510; 0.0370] 9.18       14.11 
Tanvetyanon (333) 0.986   [0.4098; 1.5622] 4.29       10.91 
Soares (334) 0.916   [0.0399; 1.7921] 1.86        7.01 
                                          95%-CI        z    p.value 
Fixed effect model    0.3887   [0.2693; 0.5080]  6.3805   < 0.0001 
Random effects model  0.4277   [0.1358; 0.7197]  2.8714     0.0041 
Quantifying heterogeneity: tau^2 = 0.1169; H = 2.07 [1.47; 2.92]; I^2 = 76.7% [53.5%; 88.3%] 
Test of heterogeneity:      Q: 29.99 d.f.: 7 p.value: < 0.0001 
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Figure 9 Moderate decompensation vs. no comorbidity (ACE-27 2) 
 
Severe decompensation vs. No comorbidity (ACE-27 3) 
This figure shows that severe comorbidity accords a corresponding increase in risk of death 
compared to nil comorbidity. There is no evidence of heterogeneity between all the studies in the 
meta-analysis as Q: 13.29 d.f.: 7 p.value: 0.0652. There is also no difference between the random 
and fixed effects models. The risk of death which had experienced a steady increase by 
comorbidity severity for both mild and moderate comorbidity levels continued to increase with 
risk of death pooled estimate of approximately 0.8, demonstrating a significant reduction in 
survival for patients with severe comorbidity compared to those without comorbidity. 
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Figure 9 Moderate decompensation vs. no comorbidity (ACE-27 2) 
64  
 
Table 6 Severe decompensation vs. no comorbidity (ACE-27 3) 
Study Name   Effect estimate 95%-CI %W(fixed) %W(random) 
Datema (330)     0.802   [0.5492; 1.0548]      39.69      22.39 
Yung (150) 1.902   [0.9906; 2.8134] 3.05        5.87 
Piccirillo (147) 0.908   [0.5709; 1.2451]      22.33 18.93       
Terhaard (331) 0.993   [0.4227; 1.5633]     7.80 11.42 
Sanabria (155) 0.247   [0.3998; 0.8938]       6.07 9.73 
Ledeboer (332) 0.588   [0.0706; 1.1054]       9.48 12.81 
Grignon (291) 0.215   [0.4318; 0.8618]       6.07 9.73 
Ramakrishnan (162) 0.593   [0.0851; 1.2711]       5.52 9.12  
                                         95%-CI        z    p.value 
Fixed effect model   0.7731   [0.6138; 0.9324]  9.5123   < 0.0001 
Random effects model 0.7509  0.5039; 0.9978]  5.9596   < 0.0001 
Quantifying heterogeneity: tau^2 = 0.0543; H = 1.38 [1; 2.07]; I^2 = 47.3% [0%; 76.6%] 
Test of heterogeneity:      Q: 13.29 d.f.: 7 p.value: 0.0652 
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Figure 10 Severe decompensation vs. no comorbidity (ACE-27 3) 
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Figure 10 Severe decompensation vs. no comorbidity (ACE-27 3) 
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Charlson Comorbidity Index 
Mild/moderate comorbidity vs. no comorbidity (CCI 1) 
Only one study (290) did not show a statistically significant relationship with risk of death from 
comorbidity measured by the Charlson Comorbidity Index. The remaining 3 studies clearly 
indicate decreased survival prospects for patients with mild or moderate comorbidity. The Q 
statistic of 6.29, with df: 3 and p.value of 0.0982 is not significant hence the random shows there 
may be some variation due to study sample size.  
Table 7 Mild/Moderate comorbidity vs. No comorbidity (CCI 1) 
Study Name   Effect estimate 95%-CI %W(fixed) %W(random) 
Tanvetyanon (333) 0.829   [0.2939; 1.3641]   2.98       16.69 
Teppo (290) 0.105   [0.9576; 0.7476] 1.17        8.19 
Reid (335) 0.285   [0.1870; 0.3830] 88.91       47.99 
Hall (294) 0.531   [0.1802; 0.8818] 6.94       27.13 
                                         95%-CI        z    p.value 
Fixed effect model   0.3137   [0.2213; 0.4061]  6.6541   < 0.0001 
Random effects model 0.4106   [0.1445; 0.6767]  3.0240    0.0025 
Quantifying heterogeneity: tau^2 = 0.0359; H = 1.45 [1; 2.52]; I^2 = 52.3% [0%; 84.2%] 
Test of heterogeneity:     Q: 6.29 d.f.: 3 p.value: 0.0982 
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Figure 11 Mild/moderate vs. no comorbidity (CCI 1) 
 
Severe comorbidity vs. no comorbidity (CCI ≥2) 
A notable increase in risk of death is observable for severe comorbidity than no comorbidity. This 
hazard has increased to approximately 0.7. One of the larger studies (336) shows no effect but all 
the other studies show a statistically significant relationship between comorbidity level and 
likelihood of death. The test of heterogeneity shows a: 71.79 d.f.: 8 p.value: < 0.0001, showing 
that there is random variation between the studies included in this meta-analysis. These studies 
suggest potential decreases in  survival due to comorbidity severity. 
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Figure 11 Mild/moderate vs. no comorbidity (CCI 1) 
68  
 
Table 8 Severe comorbidity vs. No comorbidity (CCI 2) 
Study name    Effect estimate 95%-CI %W(fixed) %W(random) 
Teppo (290) 1.723   [0.8391; 2.6069]       0.58        5.56 
Singh (163) 0.854   [0.2092; 1.4988]       1.08        8.04 
Liu (337) 0.993   [0.5402; 1.4458]   2.20 10.82 
Reid(335) 0.604 [0.492; 0.7157]      36.10 15.81 
Sabin (276) 0.451   [0.1668; 0.7352]       5.58 13.59 
Hall (294) 1.037   [0.5725; 1.5015]   2.09 10.63 
Gimeno-Hernandez (338) 1.338 [0.3071; 2.3689]       0.42        4.50 
Ghobadi (336) 0.104   [0.0077; 0.2157]      36.10     15.81   
Mell (339) 0.215   [0.0464; 0.3836]      15.86              15.23 
                                         95%-CI         z    p.value 
Fixed effect model    0.3832   [0.3160; 0.4503]  11.1883   < 0.0001 
Random effects model 0.6484  [0.3915; 0.9052]   4.9473   < 0.0001 
Quantifying heterogeneity: tau^2 = 0.1054; H = 3 [2.3; 3.91]; I^2 = 88.9% [81.1%; 93.4%] 
Test of heterogeneity:      Q: 71.79 d.f.: 8 p.value: < 0.0001 
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Figure 12 Severe comorbidity vs. No comorbidity (CCI 2) 
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2.8.3. Narrative synthesis 
Comorbidity and SES  
The literature searches detailed in Appendix A2 yielded 72 studies for inclusion in the review. Of 
these, three studies used both comorbidity and SES, 25 studies were on SES and the remaining 44 
were on comorbidity. The reporting format for this section of the review will commence with the 
studies that focused on both factors under review followed by comorbidity and SES studies. 
Only three studies from the USA and The Netherlands were found to report on both comorbidity 
and SES. (335, 340, 341) The findings of the first of these studies by Gourin et al, (340) were 
deemed incomplete as no data was provided on survival based solely on the prognostic factors of 
interest, i.e. comorbidity and SES. The researchers focused on comparing patient survival by 
stratifying both prognostic factors by race. They were able to show the disparities in survival, 
notably that black patients had poorer prognosis at 29.3% compared to 54.7% (p<0.0001) for 
whites. Although there was no evidence for variation in comorbidity status by race, advanced 
comorbidity levels appeared to be indicative of poor survival for all patients with a disease 
specific survival (DSS) hazard ratio of 1.436 (p=0.0005), while overall survival had a hazard of 
1.482 for (p<0.0001). (340)  
Another study from the USA found that with each incremental level of comorbidity, the hazard of 
survival also decreased.(335) However, after accounting for other factors such as age, the 
prognostic impact of comorbidity was reduced. This team of researchers also investigated the 
effect of SES on outcomes measured by household wealth, but this did not demonstrate an 
association with survival.  
The study by Allareddy et al (341) found evidence to demonstrate that comorbid disease was 
linked to reduced survival measured using in hospital mortality and this relationship remained 
significant even after controlling for confounders. Likewise patients who were on Medicaid or 
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were uninsured had worse survival when weighed against privately insured patients. The severity 
of comorbidity appeared to be associated with a corresponding risk of poor survival, with 
advanced comorbidity increasing risk by up to 2 times than that of a patient with none/mild 
comorbidity.  
Comorbidity only 
Heterogeneous measurement of comorbidity meant 44 studies were not included in a meta-
analysis. Notably Gimeno-Hernadez et al (342) found that disease stage has a significant impact 
on survival. They found that having advanced comorbidity with stage 1 or stage 2 disease 
increased the hazard ratio to 4.68 compared to only 2.08 in patients with stage 3 or 4 disease 
without comorbidity. One study adjusted for age, disease stage and comorbidity with a resultant 
hazard of death attributable to comorbidity status of 3.91. (160) These findings were similar to 
those of other studies which found a similar consistent trend of a 2-fold increase in risk of death.  
Evidently comorbidity has a higher prognostic impact in the initial stages of disease unlike in 
more advanced disease stages when risk of mortality is unchanged. (343) In tandem with these 
findings, survival advantage was noted to change dependent on the presence of one or more 
comorbidities compared to none at all. Overall survival was noted to reduce from 26.3% for 
patients without comorbidity to 11.8% in patients with three comorbidities. (343) Singh et al also 
found that when comparing patients with mild versus those with severe comorbidity, the median 
survival intervals were different at 13.7 months and 57.6 months respectively. (163) 
The severity of comorbidity was associated with reduced survival in a number of studies. (343) 
(344) (148) (187) (159, 161, 291, 332, 345) (160, 346) (18) (347-349) A 2 fold risk of death was 
apparent in patients with severe comorbidity, with Paleri et al noting that patients without 
comorbidity had median survival of 58.6months with a mortality rate of 11.1%. (299) Comorbidity 
and advanced disease resulted in poor survival with median survival at 12.3 months for the high 
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comorbidity group compared to 38.7 months for patients classed as having mild comorbidity. 
(160) Leitner et al reviewed deaths at 6 months, 1 year and 5 years after diagnosis, and 
comorbidity was noted to affect survival within the first year with rates of death starting at 2% 
and increasing to 6% by the end of the 5 year period. (345) It was apparent that comorbidity 
severity had a direct effect on survival as each incremental level of comorbidity contributed a 25%- 
35% increase in mortality risk at five years. (159, 291)  
A recurring theme was that high comorbidity levels had a demonstrable impact on survival. 
Sanabria et al (346) found that after controlling for confounding, the hazard of death increased 
by 72% for ACE-27 ≥2 comorbidity group which is illustrative of the independent predictive 
importance in HNC survival for patients with severe comorbidity. These results corresponded 
with the later empirical findings of Ledeboer et al who recorded an 80% increase in hazard in 
patients with severe comorbidity (ACE-27 score 3) compared to those without comorbidity. (332) 
Additionally Sanabria et al had in their earlier study, noted that comorbidity severity contributed 
to reduced survival , but an alternative view by Sabin et al (155) had classified age as a comorbid 
condition which had reduced the relative risk of death from 1.5 to 1.36 however there were no 
other studies to support these results. 
Age appeared to have a more pronounced effect on survival in the presence of comorbidity. Mell 
et al (339) found that comorbidity had a prognostic effect in older patients which is indicative of 
the nature of competing mortality (comorbidity) which can contribute to increased number of 
deaths attributable to cancer i.e. the index disease. Ramakrishnan et al (162) also pointed out that 
age and comorbidity in combination did not have an effect on prognosis but comorbidity had an 
individual effect that contributed to a high hazard of death with a RR=1.81. All in all increased 
symptomatology i.e. comorbidity and cancer combined to reduce survival. (140) 
The severity of comorbidity was noted to have a prognostic impact on survival as Datema et al 
(344) established marked differences in the impact of comorbidity severity on prognosis, e.g. two 
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year survival probability in comorbidity grade 1 versus nil comorbidity was 67% and 75% 
respectively. Overall comorbidity severity was found to translate to a 2-fold risk of death and 
comorbidity type such as substance misuse posed the highest prognostic importance with grade 
3 hazard of death at RR=3.2 compared to 1.9 for grade 1. These figures were much higher than 
cardiovascular and respiratory comorbidity which had hazards of 1.8 and 1.7 respectively. Zhang 
et al (349) were able to demonstrate statistically significant incremental increases in risk of death 
with corresponding increase in comorbidity severity with HR of 3.6 (p<0.001) for CCI ≥3. 
In the presence of a specified comorbidity, in this case COPD in laryngeal cancer, more premature 
morbidity as a result of this co-existing disease was noted in patients aged ≥65 years with a 2-fold 
risk of death compared to patients aged 35-64 years. (350) Cardiovascular comorbidity was noted 
to significantly decrease survival while patients with two or more comorbidities had an elevated 
risk of premature death. (351) Notably alcohol was denoted in the causal pathway of HNC and in 
patients with alcohol-related health problems and alcoholism as a comorbidity, risk of death was 
increased 2-fold. (310) Diabetes mellitus in nasopharyngeal cancer patients was found to account 
for a lower disease free survival rates accounting for a 30% decrease in survival for diabetics 
compared to non-diabetics. These survival differences were especially apparent two years post-
HNC diagnosis with a marked decline in survival for the diabetic group. (352) Comparable 
increases in risk were demonstrated in a similar study on diabetic comorbidity, with risk of death 
increasing to 2.22 (p=0.008). (347) 
Late presentation appeared to increase the likelihood of premature death alongside severe 
comorbid disease equated to poorer survival with the relative risk of death increasing 5-fold in 
patients with advanced comorbidity, 3-fold in professional diagnostic delay and almost four times 
in patients with advanced clinical disease staging. Piccirillo et al found a strong dose response 
relationship between comorbidity severity and survival. (148) Similar findings by Montero et al 
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found that this translated to a twofold increase in risk of death from the highest comorbidity 
level compared to the lowest. (187) 
Comorbidity was a good prognostic indicator as patients with mild/moderate comorbidity 
measured using the ACE-27 index classed as grade ≤2 had survival rates of 64% survival versus 29% 
in grade 3 patients. (96) Comparable findings by Chen et al (161) found a higher risk of mortality 
was evident in patients with moderate/severe comorbidity compared to those with mild/none 
with 5 year survival rates at 21.8% and 46.3% respectively. The study by Yang et al (348) revealed 
that lower comorbidity levels were also linked to better survival as 5 year OS decreased from 77% 
for CCI 0 to 40% for CCI ≥6 (p<0.001). 
The odds of death in patients with comorbid disease was found to be OR=2.1 indicating a 
doubling in the risk of death in comparison to patients without comorbidity. Ramroth et al (214) 
noted an incremental decrease in 5 year overall survival (OS) and disease free survival (DFS) 
within their cohort with figures ranging from 73.4% to 52.1% (OS) and from 85.4% to 74.5% (DFS) 
for patients without comorbidity compared to those with severe comorbidity. 
Despite this overwhelming evidence pointing to the negative effect of comorbidity on survival, 
one study by Sadat et al (215) was unable to reach similar conclusions. They found no statistical 
difference in survival for the presence of comorbidity, HR of 0.13 (p=0.48), although this finding 
may be explained by the lack of an instrument to measure comorbidity. Comparable findings 
from Peters et al (213) were noted using the ACE-27 index but this relationship disappeared once 
risk status was categorised dependent on presence of comorbidity and its corresponding severity 
with odds ratios (OR) ranging from 0.323 for mild decompensation to 0.435 for severe 
comorbidity (p<0.001). 
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Socioeconomic status studies 
A meta-analysis was not attempted due to the heterogeneity of SES measurement. These studies 
will be reported as groups so that those looking at similar SES domains can be compared. This 
was done as SES in this review encompasses a variety of domains namely, education, age, indices 
of deprivation, household income, neighbourhood income, small area statistics, occupation and 
health insurance. The Carstairs index was used in four studies (309, 353-355). Disparities between 
affluent and deprived patients were evident and nasopharyngeal and UADT cancers poor survival 
was increased in deprived patients (354, 355), i.e. living in a deprived area is equal to an to 25% 
increase of risk of death in UADT cancers and deprived equated to a 24% higher likelihood of 
death from any cause (355).  
Age appeared to play a role with Paterson et al (353) noting no survival differences between 
deprived and affluent patients in the younger age group (0-39 years). However those aged 40-59 
years had survival rates of 59.5% for affluent patients vs. 52.4% for the deprived. In the 60-79 year 
age group relative survival rate were of 51.1% and 42% for affluent and deprived respectively. 
These results for the 40-59 years and 60-79 years age groups were showed a statistically 
significant linear relationship with p<0.001 for both age groups. (353) The more advanced the 
age, the lower the survival at five years, with rates of 76% for <50 years, 67% for 50-59 years, 56% 
for 60-69 years and 35% ≥ 70years (p=0.01). (356) There were significant differences in survival 
using the standardised rate ratios (SRR) between the most deprived and the most affluent 
groups. A notable pattern of reduced survival from most affluent to most deprived group was 
shown in males for mouth cancer but this was not so clear for either females or for tongue 
cancer in both sexes. (167). A comparable and more pronounced trend was shown in mouth 
cancer in males with SRRs increasing from 61 to 152 (p<0.005) for most affluent and most 
deprived respectively between 1986 and 1991. (167) Younger patients aged 0-44 years from 
deprived backgrounds were found to have a reduced likelihood of survival with HR=2.12 
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compared to less affluent patients HR = 1.19. (357) This result was highly statistically significant 
p=0.002. There were less clear patterns of risk for those aged ≥ 45 years with more affluent 
patients having a risk of 1.85 compared to 1.98 for less affluent patients. (357) 
Continuing with age, Chang et al (210) found that deprived patients aged <65 years had worse 
survival compared to their over 65 less deprived opposite numbers (p<0.001). Even after 
adjustment using multivariate analysis, this survival relationship remained significant with 
increased survival rates of between 0.5 and 0.7 for those aged >65 years. The odds of lower 
survival experiences increased to approximately 1.5 and 1.7 for those aged less than 65 from 
disadvantaged neighbourhoods after adjustment for treatment modalities and hospital choice. 
(210)  
Affluence was found to raise survival by 43% in NPC patients (p<0.001). (354) This was similar to 
findings for UADT cancers which showed that deprivation resulted in a premature reduction in 
survival of 41% for larynx cancer, 31% for pharynx and 28% for mouth cancers which compared to 
affluent patients. (355) Five year overall survival (OS) figures showed differences between social 
strata with affluence having OS of 53.9% in contrast to 42.3% in the deprived for oral cavity cancer 
while figures for larynx cancer were 68.4% in the affluent and 59.1% in the deprived. (309) 
Area level SES measures generally found that more advanced disease was more common in 
patients from deprived backgrounds, (108, 358) and an inverse relationship between SES and 
survival. (108, 123, 167, 357-360) Material deprivation in females was implicated as the cause for 
poor survival in mouth cancer patients. (167) HNC was found to occur more commonly in the 
poor. (167, 357-360) Only glottis cancer was found to occur more commonly in older well-off 
patients (108), while there was no difference in the proportion of patients with disease in the 
study by Warnakulasuriya et al (357). Robertson et al (358) found that despite the negative 
survival experiences across the socioeconomic strata much of this effect was diluted by the 
confounding effect of performance status. The hazard ratio in univariate analysis was 1.33 but 
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was reduced to 0.93 (p=0.04) after controlling for sex, stage, site, performance status, alcohol 
and tumour differentiation. 
Level of income was associated with improved survival from 3-23%, (108) with the relative risk 
(RR) with each incremental level of income from 1.47 for ≤ 20 000 to 1.07 for incomes between > 
40 000 and ≤ 50 000. (359) Relative survival in the most deprived quintile was 2.75 for death from 
glottic cancer although supraglottic cancers did not show an association between income and 
survival. (108) However one study (361) found that family income as a measure of SES was not 
related to survival (p=0.05). Low neighbourhood SES was found to be linked to low disease 
specific survival (DSS), in cancers of the oral cavity, oropharynx, hypopharynx/larynx and 
nasopharynx. (362) 
Evidence of a linear gradient in survival between income groups was evident as Rachet et al (363) 
found a reduction in survival of 17% for deprived groups compared to less deprived groups. Using 
neighbourhood income, Chu et al (364) found poorer survival for those from lower income 
groups. Jovanovic-Andersen et al (365) found evidence of similar gradients in survival based on 
SES which was akin to the findings of Boyd et al (209) who noted that for glottic cancer, relative 
risk (RR) was higher for the low SES groups . Comparable findings were noted for patients 
among oropharyngeal cancer patients from highly deprived neighbourhoods relative to less 
deprived neighbourhoods with poorer overall survival with a hazard ratio of 1.59. (366)  
Income quintiles based on median household income were noted to give reliable estimates of 
mortality risk as survival from HNC decreased by 7.4% and 13.7% for Ontario, Canada and the USA 
respectively between quintiles 1 and 5. (209) Survival was also noted to decrease by income 
quintile in the same study. Lee et al (211) noted that low individual SES corresponded to poor 
prognosis with statistically significant (p<0.001) differences for 2 year OS. At the individual level 
the OS went from 0.59 for low SES patients compared to 0.74 for higher SES patients. For 
neighbourhood level SES the OS was 0.59 weighed against 0.70 for low versus higher SES groups. 
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Specific to the United States, insurance status was also found to have an impact on survival with 
privately insured patients having better survival. (367) The odds of presenting with advanced 
tumours were high for patients on Medicaid or uninsured and they were also more likely to 
present with nodal disease with larynx cancer having odds of worst overall survival at 6.97 for 
advanced stage and 4.18 for nodal disease. (367) 
A number of studies, (360, 368, 369) demonstrated a link between education and survival, and 
this link remained after controlling for the confounding effect of gender. (369) An association 
between education and survival was shown in larynx cancer particularly in males with evidence 
that this form of HNC had a better prognostic outlook, (370) although improved survival in larynx 
cancer was not confirmed elsewhere in this review. Evidence of high social inequality amongst 
men for cancers of the larynx, mouth and pharynx were observed in Spain between the years 
2001 to 2003. (369) 
Being educated to a higher level was linked to improved survival, whereby post secondary 
educated p16-positive oropharyngeal cancer (OPC) patients had a hazard of death of 0.93 
(p=0.03). The survival estimates in oral cavity cancer showed a hazard of 0.95 but this was not 
statistically significant but may have clinical relevance. (360) The odds of survival for 
college/technical school level patients versus education less than college level showed poor 
survival with a risk of 1.30 (p=0.0056). (368) The higher the educational attainment, the better 
the chance of survival with case fatality ratios improving from 1.12 for middle school level to 0.78 
and 0.70 (p=0.401) for high school and university educated respectively for mouth and pharynx 
cancer, although no clear relationship was evident for larynx cancer. (370) 
Differences in survival by education level were shown for both sexes. Uneducated males had 
decreased survival with an increased risk of death of 24% compared to 14.8% for university 
educated counterparts, with rates in females in corresponding categories at 33% and 9.7% 
respectively. (369) This survival trend was also evident in mouth and pharynx cancer, although 
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trends in females were more stable. (371) Males had consistently worse survival at 1 year, 3 years 
and 5 years (p=0.05) compared to females (356) and being educated better than elementary 
school level was associated with improved survival with a 30% reduction in risk. (356) Occupation 
was a significant predictor of survival. (356, 371, 372) Professional/managerial level patients were 
generally found to have better survival in one of the three studies (356), which found that this 
group had a reduced likelihood of death of 20%. The findings of Wong et al (372) were less 
definitive with five year survival in the unskilled group at 70.57% which was marginally better than 
that of the professional/managerial group with a rate of 65.56% (log rank Χ2= 10.74, p=0.005), 
with this result remaining significant after adjusting for stage. Unemployment decreased the 
prospects of survival in patients with nasopharyngeal cancer (NPC) as the risk of death increased 
to 3.71 (p=0.01) (360). 
2.9. Discussion 
The literature search identified three studies that fulfilled the inclusion criteria fully and sixty-nine 
studies that attempted one or the other aspects of the research question. Sample sizes varied 
between studies and aims of the studies were equally heterogeneous. HNC is a particularly 
challenging area of cancer care and treatment due to the debilitating effects of both the disease 
process itself and the treatments (therapies) used. The heterogeneity of the subtypes of HNC 
may not make for easy comparison e.g. comorbidity in oral cancer cannot have the same 
prognostic impact as comorbidity in cancer of the parotid gland or a mixed HNC population. In 
addition there have been changes in treatment guidelines with both chemotherapy and 
radiotherapy now used in combination to ensure successful intervention. (373) These treatments 
have their associated effects notwithstanding the exacerbation of these treatment effects from 
patient related factors such as comorbidities, functioning status and concomitant risky 
behaviours such as smoking and drinking (which affect treatment efficacy). (180) 
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The poor survival in patients with comorbidities indicates both an additive and multiplicative 
relationship due to the multi-factorial pathology presented when HNC occurs alongside other 
medical conditions. The level of complexity poses key challenges to professionals as special 
attention should be paid to the possibility of treatment interactions due to the clustering of 
illness as well as the cumulative effects of both the index disease and comorbidity. (98) 
Comorbidity indices offer some method of assessment although there is variation in the 
information collected and how comorbidity severity is aggregated. Emphasis is placed on life 
threatening disease due their effects on survival outcomes e.g. arrhythmias and congestive heart 
failure (heart disease), chronic obstructive pulmonary disease, insulin dependent diabetes, liver 
disease, renal disease and gastrointestinal ailments. This was confirmed in a retrospective 
analysis of 1904 patients in the USA (374) when researchers found that comorbidities had an 
important and negative impact on survival, however this study was not included in this review as 
it did not give data on survival rates. 
Although SES has been measured differently in the studies included in this review, there is a clear 
association with survival. Other SES factors that influenced early identification of cancer 
symptoms and resultantly cancer stage at diagnosis include level of education and income. Both 
these factors are associated with a lack of awareness of symptoms. (375, 376) Consequently this 
impacts survival prospects as late symptom identification leads to late presentation and 
consequently late diagnosis with more advanced tumours. (184, 377)  
As described by Louwman et al (135), this analysis cannot decipher whether these survival 
differences are due to variation in exposure to risk factors as good education does not always 
equate to a good income. Education has been shown to have a protective effect (378) as it is has 
been demonstrated that well educated patients are more likely to notice any changes to their 
health status which may result in earlier diagnosis of localised disease which can result in the 
better survival outcomes. Hart et al posited the view that poor patients were more likely to die 
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from cancer than the rich, which has been shown in this review. (73) Although it is not clear 
whether this was due to late presentation or excessive exposure to poor lifestyle behaviours 
such as alcohol consumption, poor diet and tobacco smoking. (74) These patients from deprived 
backgrounds may be more vulnerable due to poorer health but knowledge of health promoting 
behaviours was lacking which may be responsible for the disparities found in this study. The 
socioeconomic difference in survival is explained by the excess mortality that is seen in this group 
and evidenced in this review. 
Consideration should be to the contribution of other mitigating factors are involved in 
determining survival by SES. These may include factors such as: 
 Medical  
o primary care,  
o speciality care,  
o access/use of services,  
o dental health services, 
o  emergency services  
 Behavioural 
o smoking,  
o drinking 
o health seeking behaviour 
o public health  
o symptom awareness/screening.  
SES has been shown to have influence on the incidence of head and neck cancer but the exact 
types of social disparities that encompass SES had not been fully explored in SES prior to this 
review. As most HNC patients present with advanced disease, (172) prognostic factors such as 
comorbidity and SES negatively compound survival. This accumulation of competing disease has 
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a definitive effect on survival increasing risk of death by at least 1.5times when comparing 
patients with and without comorbidity, with worse outcomes for comorbidity severity. (139, 147, 
153) The use of chemotherapy and loco regional treatment has been shown to demonstrate a 
survival advantage of 4% over 5 years but due to complications such as comorbidity, 
chemotherapy cannot always be used which nullifies the survival benefit. (379) It is apparent 
here that the more comorbidities a patient has, and the more severe the comorbidities are, the 
worse the survival prospects. (99, 153, 380) Diabetes has been shown to negatively impact 
survival which corresponds with evidence from Meyerhadt et al who found similar evidence in 
patients with colon cancer although in their case there was a clear biological interaction 
responsible for the reduction in disease free survival. (381)  
Since the landmark study by Kogevinas et al (382),followed up by the HN5000 paper it has been 
clear that socioeconomic gradients in cancer survival exist and have widened considerably in the 
last two to three decades. This is especially relevant to HNC as data shows that although year on 
year survival is improving, there are marked disparities in survival between deprived and affluent 
patients. A review of the two prognostic factors namely deprivation and comorbidity in HNC has 
not been attempted previously. Woods et al (129) previously reviewed the origins of 
socioeconomic inequalities in cancer which provided useful background information as it was 
deemed ineligible for inclusion into the review. Also work conducted by Munro et al (145) 
brought these two issues to prominence.  
HNC is a cancer commonly occurring in the elderly, (65+) and it has been found to frequently 
occur in patients from deprived backgrounds hence the need to examine the prognostic role and 
contribution of both these factors in relation to HNC. There is a higher prevalence of underlying 
modifiable risk factors in lower SES groups which may point to the health inequalities apparent in 
HNC. It is clear from the evidence demonstrated here that if patients improve their lifestyle by 
reducing excessive drinking and smoking, this may influence survivorship in those that do 
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develop the disease, whilst also minimising the risk of developing a second malignancy if 
aetiological risk factors are not modified, or even the recurrence of the index cancer. (383) 
The influence of HPV has to be considered as so far the literature shows that although HPV 
strains 16 and 18 are responsible for oropharyngeal cancer, (42, 55, 59, 60, 231, 384, 385) they 
have also been shown to have a protective effect with better survival for HPV-positive patients 
compared to HPV-negative patients. (386) It is not clear whether a socioeconomic effect is at 
play here, or whether HPV-positive HNCs have a social patterning as the deprived are diagnosed 
more frequently with HPV-negative cancers.  
2.9.1. Strengths and Limitations of the review 
Information used for the purpose of this review was obtained from research studies that used 
disparate methods, data collection and analysis. Some studies used different summary statistics 
such as cause specific survival and overall survival or both while others failed to report 
adequately to formulate meaningful conclusions.  
The publication languages used were limited meaning that other potentially useful studies may 
have been overlooked, although efforts were made to identify studies from languages other than 
English and to translate them. Although the principal researcher used reproducible methods, the 
quality assessment tool was neither validated nor published and hence may be prone to non-
systematic bias. Also the rating of assessment questions using an adjectival scale was purely 
subjective posing another methodological flaw. Although this was controlled for by using three 
other reviewers for the quality assessment process, there remains a residual risk of bias. 
As regards the prognostic importance of comorbidity, although this review has found that it does 
affect survival, it has not clarified exactly whether this relates to specific individual comorbid 
diseases or number of comorbidities. The only way to definitively assess comorbidity would be to 
do so with individual patient data in separate cohorts, but this was not feasible hence blanket 
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assumptions of prognostication had to be made at the expense of more accurate but impractical 
measurements. 
HNC refers to tumours derived from a distinct group of primary sites, while the studies used for 
this review considered all HNCs; it is possible that due to aggregation of tumour sites, there was 
dilution of the effect of both comorbidity and SES on outcomes. This is because HNCs such as 
laryngeal cancer have better overall survival than hypopharyngeal cancer; hence the direction of 
the effect of these two prognostic factors may not be as clear as expected. (387) 
Also the variability in the sample sizes of the primary studies introduced heterogeneity into the 
review which may affect the overall estimates of survival. The only way to overcome this in future 
may be to use data from cancer registries that includes information on comorbidity status; on a 
single HNC to get more accurate survival estimates. Alongside this is the issue of the settings of 
the studies, as different countries or even regions within countries have different data collection 
methods. This is evidenced by the different data presented in the studies included in this review. 
There is a higher prevalence of underlying modifiable risk factors in lower SES groups (388) and 
the higher SES groups for HPV+ HNC (389), which may point to the health inequalities apparent in 
HNC. This may be due to the fact that HPV+ cancers are rarely clear cut and are independent of 
smoking and alcohol in their aetiology. Additionally, these HPV+ HNCs occur in younger patients 
who are known to have high number of oral sex partners which may point to the other forms of 
HNC occurring in older patients. The evidence suggests that improvements in health behaviours 
should theoretically reduce the incidence of HNC, improve outcomes and reduce the risk of 
developing a second malignancy.  
There is evidence from the literature that there is a complexity in the relationship between health 
behaviour effects on HPV+ HNC and SES, (388) (384) hence improving health behaviours may not 
be enough. Patients from low SES backgrounds and those with comorbid disease may benefit 
from risk stratified care; therefore it is imperative that the systematic assessment and recording 
85  
 
of comorbidity status becomes standard practice; so that the influence of comorbidity is 
acknowledged making opportunities for further investigation easier. It may help for patients to 
improve their lifestyle by reducing excessive drinking and smoking, this may influence 
survivorship in those that do develop HPV-negative disease, as the findings of the HPV-related 
HNCs show that HPV reduces the risk of progression or recurrence of HNC and improves 
outcomes. (29, 30, 50, 59, 67, 68, 390-397)  
It would have been ideal to conduct a focused review using the three studies; however this was 
not possible due to disparate findings between them. The Danish study (365) found that with 
each incremental level of comorbidity, the hazard of dying increased but the effect of SES, 
measured by social class did not demonstrate an association with survival. Of the other two 
American studies, the first showed that patients with comorbidity and classified as self-pay/no 
charge/others had greater odds of dying compared to those with private insurance (P<0.02). 
(340) The second study reported advanced comorbidity was indicative of poor survival for all 
patients with statistically significant hazard ratios of 1.436 (p=0.0005) for HNC-specific survival 
and 1.482 for overall survival (p<0.0001). (341) Although there was evidence demonstrating that 
comorbidity was linked to poor prognosis even after controlling for confounders; and that 
patients who were uninsured or on Medicaid had worse survival when compared to privately 
insured patients, the results were not generalisable. No meaningful assertions could be made 
based on two studies from the same country as measurement methods for SES are different 
therefore I could not make meaningful conclusions from these studies. In essence despite the 
findings of the three studies being useful in informing practice, the extent to which research 
findings can be applied to settings other than that in which they were originally tested was 
limited hence the decision to include the studies that focused on either comorbidity or SES. 
This review aimed to ascertain the prognostic importance of both comorbidity and SES in HNC 
patients. The heterogenous measurement of both factors made the generalisability of findings 
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difficult. Although some efforts at minimising this were made through use of statistical 
aggregation through the meta-analysis, this had to be broken down to separate analyses for the 
two comorbidity indices, ACE-27 and CCI. The main shortcoming from relying on data from 
comorbidity indices is that although these indices are efficient at collecting comorbidity 
information, they have inherent biases emanating from the limited number of conditions that are 
used to calculate comorbidity. It was unclear whether the comorbidities focused on within the 
different indices had prognostic importance in HNC therefore validity of these meta-analysis and 
narrative synthesis findings was limited. 
It would seem that in addition to the systematic review and meta-analysis, which uses combined 
statistical effects, then furthermore a future method would be  to conduct a descriptive review 
of what is known about comorbidity and SES within the context of HNC in a cohort of patients to 
attempt to untangle the complexity of these two prognostic factors using one of  the  theories 
about health and health behaviour such as the salutogenic model, particularly of relevance being 
the concept of sense of coherence discovered by Antonovsky (398) which is a way of 
distinguishing those external factors that all combine in a multiplicative manner to cause 
premature death. This would be a worth investigating within the context of HNC due to the 
specific challenges of the patient complexity posed by the additional prognostic factors of 
comorbidity and SES play a significant role in determining survival outcomes.  
Taking an additional approach to the statistical systematic review by using the prospective 
cohort analysis would also enhance findings. This method is ideal in that it would utilise patient 
factors elicited using the salutogenic sense of coherence alongside the HNC diagnosis which 
would go a long way in allowing researchers to get a better understanding of the complex 
interplay between SES and comorbidity in determining HNC survival. 
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2.10. Conclusions  
The evidence presented in this review demonstrates that comorbidity and deprivation are 
associated with poor survival in HNC patients although exactly how both factors contribute to 
this could not be definitively elicited. Of particular importance are that severity of comorbidity 
and greater numbers of comorbid illnesses are indicative of poor prognosis. SES as determined 
by low income or low educational attainment was also implicated as being associated with poor 
survival for patients in these categories. This matches the social patterning of the main 
aetiological risk factors, smoking and alcohol drinking; behaviours which have been 
demonstrated to cause and contribute to HNC. Although it was difficult to conduct a direct 
comparison between studies, this review has added rich data to the complexity of the clinical 
picture presented by patients with HNC. Ensuring better survival of patients with HNC is not 
dependent solely on choice of treatment but other factors such as comorbidity and deprivation 
have to be taken into account. 
2.11. Chapter summary 
This chapter described the systematic review process from the literature search, article review 
and retrieval of full text. Once relevant articles were selected as per the inclusion criteria, these 
were read, assessed for methodological quality and their data abstracted. An analysis of the 
included studies was carried with narrative synthesis of all SES studies and those comorbidity 
studies that had heterogenous measurement methods. A meta-analysis of the comorbidity 
studies also found an association between comorbidity severity and reduced survival. The 
comorbidity and SES studies found that worsening severity of comorbidity and low SES were 
linked to poor survival. Better educational attainment and high incomes were linked to improved 
survival. The next chapter will describe in detail how the methodological quality assessment tool 
that was used to appraise the quality of the included studies was developed, including the 
literature review used to devise the initial draft. A description of the pilot testing of the quality 
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assessment tool and the ensuing refinement that was conducted until a final quality assessment 
tool for prognosis studies was completed. 
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C h a p t e r  3  
3.1. Developing a methodological quality assessment tool 
3.1.1. Chapter outline 
This chapter introduces the development of the quality assessment (QA) tool which the 
systematic review reported in the chapter 2 required to conduct an assessment of the 
methodological quality of studies identified as relevant for inclusion. The principal aim of this 
chapter was to develop and validate a tool as a proposed gold standard approach for the 
methodological assessment of survival studies for use in the systematic review. As the critical 
appraisal and assessment of methodological rigour was found to pose a major challenge for the 
observational studies on survival such as the cohort studies that were identified in the systematic 
review process. As the methodological (QA) of such studies was an essential component of this 
review process, this led to the development of the first iteration of a (QA) tool. Following pilot 
testing and assessment of content and face validity, a modified version of the tool for survival 
studies to assess the quality of observational survival studies which paid particular attention to 
study design, adjustment for censoring and multivariate analysis. This tool was used to quality 
assess the included observational studies to be used within the systematic review. It introduced 
the pre-existing empirical evidence of assessing methodological rigour i.e. checklists and research 
studies and will provide a rationale for the creation of the QA tool. 
3.1.2. Recap of the systematic review process 
A systematic review has been defined as a review of the literature that focuses on answering a 
research question by identifying, appraising, and synthesizing all available relevant evidence.(195) 
It is important that the research evidence used is both relevant and trustworthy. (399) Tools 
evaluating the quality of primary research evidence for systematic reviews have been formulated 
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which employ critical appraisal and trustworthiness rating methods. Although quality assessment 
(QA) in systematic reviews was pioneered in randomised controlled studies, (RCTs) (400) it was 
asserted that, “assessing methodological quality is considered essential in deciding what 
investigations should be included in research syntheses and in detecting potential sources of bias 
in results.”(401, 402) Therefore it has become good practice to assess quality in both 
experimental and observational study designs. 
3.2. Background 
There is an increasing volume of literature that focuses on determinants of survival outcomes but 
despite the number of such studies being published, there has not been a corresponding 
plethora of literature on methods to assess the quality of survival studies. Although guidelines 
exist that explain methods for the reporting of observational studies such as STrengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) (403) and Meta-analysis of 
observational studies in epidemiology MOOSE (198), there as yet does not appear to be guidance 
on the conduct of QA and  the corresponding QA tools for use in a systematic review of survival 
studies.  
A synthesis of robust empirical evidence is required in order to carry out systematic reviews of 
survival studies efficiently, using critical appraisal and the assessment of susceptibility to bias of 
the medical literature. (218, 400, 404) Survival studies are especially problematic as there is no 
gold standard or routinely used tools to assess the validity of said survival studies to warrant their 
inclusion in systematic reviews. (202) Overlooking the potential methodological flaws of included 
primary survival studies reduces both the internal and external validity of a systematic review; as 
this may introduce bias into the study resulting in flawed findings. (405) Systematic reviews of 
survival studies are generally quite complex to undertake as the methods are not as yet 
standardised unlike in the case of therapeutic and diagnostic reviews.  
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As different methodological components such as quality of reporting and potential bias all 
contribute to the quality of a systematic review, (406) it is essential that all these components 
that could lead to these shortcoming are accounted for by use of a QA tool. Survival studies of 
prognostic variables are essentially different from other observational studies as they determine 
how influential a prognostic factor is in determining the survival prospects of the target 
population. Survival studies allow for the calculation of time to event data using various statistics 
such as life tables, Kaplan-Meier, Log rank test and Cox Proportional Hazards Regression. The 
unique features of survival studies mean that the criteria required for QA of these studies differ 
significantly from those required for studies on evaluations of interventions. There is also a need 
for QA using a standardized approach rather than through use of an adapted tool which can 
introduce a biased assessment of quality, (407) as the tool is not meant to critically appraise 
survival studies.  
3.3.1. Initial approach to Quality Assessment 
As discussed in Chapter 2, the McMaster University Effective Public Health Practice Project 
Quality Assessment Tool for Quantitative Studies was not fit for purpose as it was more geared 
towards intervention studies. Another QA tool developed by the University of Montreal (217) was 
considered  more suitable for a clinician.  Especially of note is the observation that there is no 
identified ‘gold standard validated tool for reviewing the quality of survival studies. (196, 408, 
409) Consideration of a review of the literature on critical appraisal pointed to two tools that 
were potentially eligible for use either based on their own merit or with minor adjustments. (218) 
It is important to emphasise that the word ‘quality’ that is used to define critical appraisal and 
assessment of methodological quality, does not refer to the quality of reporting but rather the 
methods utilised within the conduct and analysis of research to make certain that the research 
study is free of bias. (218) 
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In spite of the modest number of tools developed for performing the assessment of 
observational studies, specific ones concentrating on prognosis were found to be unsuitable. 
(219, 405, 410-412) Although the checklists for the assessment of prognosis exist, (217, 219, 411) 
none of these tools have been systematically developed for use in systematic reviews of survival 
studies. Also they have not been validated despite similarities regarding the items they assess. It 
would appear that use of any of these would be dependent on researcher preference rather than 
one specific being classified as superior or more relevant. Unfortunately there was no evidence 
of, “analytical evaluations of the quality of the study” as described by Katrak et al, (413) i.e. these 
tools should have been published to demonstrate the empirical basis of their validity but this was 
not the case.  
One potentially useful critical appraisal tool (411) was found by Sanderson et al in their review of 
critical appraisal instruments. (218) However, this tool proved inadequate in providing a complete 
and concise critical appraisal and QA of the included studies. (217, 219, 220) Assessing the quality 
of evidence from survival studies requires a tool that is specific to this purpose. The aim of this 
project was to develop and evaluate an evidence based QA tool to be used for the 
methodological assessment of survival studies included in a systematic review. 
At this point it is important to clarify why this study is not developing a QA tool for prognosis 
studies instead it is focused on survival studies. Prognostic studies were defined by Carneiro (410) 
as, “cohort studies based on groups of subjects exposed to a suspected causative factor, but 
without evidence of disease, which have prospective comparison with an disease-free  group, but  
without exposure to the cause), or case control studies (in which patients with a particular 
disease are compared to subjects without the disease to determine possible links between the 
exposure to a given factor and the appearance of the disease).” This project defines survival 
studies as observational studies that assess the effect of two factors; comorbidity and SES on 
survival or risk of mortality. The similarities within the critical appraisal approach is in the 
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assessment of methodological validity, however  the remaining evaluation of how the clinical 
study affects the prognosis of an individual is not covered within the context of the survival 
studies. 
3.3.2. Research objective 
Aim: To devise a QA tool of observational (survival) studies for use in a systematic review on the 
effect of comorbidity and SES on HNC survival. 
3.4.1. Literature search 
The following search terms were initially used:  
 study quality assessment;  
 critical appraisal,  
 quality appraisal checklist,  
 methodological quality assessment;  
 and evaluation of study quality. 
Where possible, all terms were obtained from title, abstract, keyword, full text, with truncation 
used where possible to capture variation in the terminology, spellings etc. Due to the poor 
specificity and sensitivity of these search terms, the search was modified to use the search 
below: 
1. Quality assessment$    35 779 
2. Methodological quality    21 879 
3. Quality appraisal    1 190 
4. Quality rating     2 425 
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5. Critical appraisal    19 049 
6. Susceptibility to bias    431 
7. Quality appraisal tool$    61 
8. Quality appraisal checklist   18 
9. Critical appraisal checklist   100 
10. Critical appraisal tool    196 
11. Quality assessment tool   858 
12. /OR 1-11      73 936 
13. Prognosis stud$    4 425 
14. Survival stud$     23 085 
15. Studies of prognosis    1 433 
16. 13 OR 14 OR 15     400 
17. Remove duplicates    318 
From this initial search strategy; a search which was conducted in MEDLINE via Ovid, EMBASE, 
Journals@Ovid Full text, and NHS Scotland Journals@Ovid from inception till March 2012.  
3.4.2. Inclusion criteria 
Articles were included if they made reference to a tool that described methods for assessing 
quality of observational studies on survival or prognosis. Abstracts were scrutinized for suitability 
before obtaining the full text of all relevant articles. Seven articles were found to be relevant to 
studies of prognosis. (202, 203, 221, 223, 410, 412, 414) There was no date limit on the search. One 
researcher (EM) conducted the literature search, titles and abstracts of all articles were assessed 
for inclusion/exclusion by two independent reviewers (EM and CM) and consensus for inclusion 
was reached through discussion. Articles were retrieved in full text for inclusion in the study. 
Published articles were included if they provided evidence of measurement and/or practical 
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properties for multi-item quality assessment tools assessing survival or prognosis in patients with 
chronic disease. 
3.4.3. Specific inclusion criteria for generic and disease-specific tools 
 The instrument had to be patient-reported 
 Published evidence of measurement reliability, validity or responsiveness following 
completion in a specified patient population 
 The instrument had to be recommended for use with patients with chronic disease 
 The instrument provided English-language versions for use among adult patients 
regardless of geographic setting. 
 Evidence available from English language publications, and quality tool evaluations 
conducted in populations within UK, South and North America. 
3.4.4. Exclusion criteria 
 Quality assessment instruments that were not published in full, or were not in English, 
were excluded.  
 Tools that were used for appraisal of diagnostic instruments and interventions were also 
excluded. Clinician-assessed tools which have narrowly focused or vague questions.  
 Single-item tools to be excluded as well as tools without empirical evidence of 
measurement properties. 
3.5.1. Developing a methodological quality assessment tool 
Although survival is a specific field within medicine, tools to assess quality in this area should not 
be restricted to design specific tools. It was decided that a more generic tool would be ideal as 
study designs usually utilised in survival studies are prospective and retrospective. (415, 416) Due 
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to the difficulties faced in obtaining a validated quality assessment tool on survival studies, 
following discussions between the review team (EM and FM), the decision was made to devise a 
tool for use in this review. In developing the tool, special attention was paid to criteria developed 
by Clarke and Oxman (417) with the criteria of particular interest indicated with an asterisk (*).  
1. Study aims and objectives * 
2. Methodology used 
3. Sample selection * 
4. Methods of randomisation and allocation blinding 
5. Attrition * 
6. Blinding 
7. Outcome measurement characteristics * 
8. Intervention or exposure details 
9. Method of data analyses * 
10. Potential sources of bias * 
11. Issues of external validity 
An initial draft of the QA tool was based on empirical work conducted by different researchers, 
(202, 217, 221, 222) and adapted into a tool. Right from the outset, it was determined that both 
prospective and retrospective studies would be assessed as part of the review, despite 
retrospective studies having an inherent bias compared to their prospective counterparts. 
Prospective studies are more advantageous as they utilise an inception cohort i.e. a consecutive 
group of patients at a similar well defined disease stage, but these types of studies are not always 
used. (204) Similarly case control studies were deemed unsuitable as they are prone to many 
biases as treatment effects are underestimated due to poor matching on factors related to 
allocation of intervention. (200, 418) Also the differences between cases and controls may 
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introduce non-systematic bias (203) while the use of retrospective studies is especially fraught 
with problems as accuracy of these is reliant on medical records. (204) 
The principle characteristics of a robust quality assessment tool devised by the The Evidence for 
Policy and Practice Information (EPPI) Project were also considered in the QA tool formulation 
process. (419) 
A- Trustworthiness of results judged by quality of a study within the accepted norms of 
methodological quality, 
B- Appropriateness of study design for addressing the methodological relevance to the 
research question, 
C- Appropriateness of focus of the research for answering the research question, 
D- Judgement of overall weight of evidence based on A-C. 
All these characteristics are integral parts of evidence based practice. (205) To minimise 
confusion or misinterpretation, it was decided to provide guidance of what to do with the results, 
(217, 411, 412) i.e. whether the QA tool would use a scoring system and an overall score with 
ratings to explain the overall methodological quality of the QA tool. Discussion resulted in the 
team deciding on the use of adjectival scores and/or weighting of results (420). The chosen 
adjectives were ‘yes’, ‘no’, ‘partly’ and ‘unclear’. Weighting in quality appraisal is purely arbitrary 
and subjective hence this method was discarded before it could be explored further. (421) 
However the use of adjectival scores was considered with the caveat that it would encompass 
the consensus approach whereby the review of quality ratings was performed by 2 or more 
investigators.  
From this discussion it was accepted that the aforementioned may not be enough to fully take 
into account possible shortcomings in the quality assessment tool development process. It was 
therefore decided to use the approach suggested by Streiner and Norman. (420) This was 
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adapted using evidence from research, (202-204, 223) to develop the tool. This used the following 
stages of development: 
1. Devising the questions 
2. Question/item selection 
3. Assessment of face validity 
4. Pilot testing of item reliability, consistency and construct validity 
5. Generation of the modified tool 
1. Devising the questions 
The quality assessment tool was devised for use in systematic reviews of survival studies and it 
was not intended to be restricted by type of survival. It was intended to provide a consistent and 
reliable way of conducting the quality appraisal of survival studies. It had to be equally able to 
allow for different raters to reach similar rating scores for the same study. Another prerequisite 
was for the tool to be clear and concise allowing brief but simultaneously accurate objective 
quality assessment of primary studies of survival. The quality ratings were ‘strong’, ‘moderate’ 
and ‘weak ‘with scores of ‘3’, ‘2’, ‘1’ and ‘0’ dependent on the assessment question rating of ‘yes’, 
‘no’, ‘unclear’, and ‘can’t tell’ respectively. This was the simplest form of objective assessment 
and studies scoring the maximum score of 24 having the highest rating. 
A review of quality assessment tools conducted by Sanderson et al (218) only found two studies 
that were mentioned as quality assessment tools of prognosis. (217, 411) Neither of these tools 
demonstrated how quality could be incorporated into a systematic review. The incorporation of a 
adjectival scale (420), i.e. “…to give the rater a clear, unequivocal conception of the continuum 
along which he is to evaluate objects…” (420) in order to distinguish between high and low 
quality studies. In spite of the evidence against the use of quality scores, (422) this tool used 
quality scoring as a feature as all studies in the systematic review were reported on whether their 
rating showed high/low quality. This was a convenient way to include measures of quality in a 
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systematic review. Whiting et al (406) in their systematic review did not recommend the use of 
quality scores. However, as reviews of primary survival studies are usually of poor quality, (418, 
423) it was decided that use of quality scoring in this review would enhance the reliability of 
summary measures to be used in both the narrative synthesis and meta-analysis. This method 
resulted in a tool that could be adapted for use in other systematic reviews of survival as a 
criterion for inclusion of primary studies. It was also possible to use the quality criteria for the 
narrative discussion of findings which can be presented in summary tables. 
2. Question selection 
This was conducted initially using questions taken from the tools developed by the universities at 
McMaster (424)and Montreal (217), as well as the Health Evidence Bulletin in Wales. (219) Items 
were also modified using review articles(202, 223) which incorporated items similar to those 
detailed in the tools used by the author alongside evidence from research articles by Marx and 
Marx (221), Laupacis et al(203), Carneiro (410), and Darzins and Smith. (412) This was condensed 
into 14 questions as per the tool below. 
3. Initial assessment of face validity 
All the items for possible inclusion were presented to a research interest group (membership is 
listed in table 10). The aims of the tool within the context of a systematic review were explained 
as were the methods for developing the quality assessment questions. Comments and 
suggestions for modifications to the tool were encouraged.  
b) Face validity Round 2 
The results of the research interest group meeting were used to modify the tool from initially one 
with 14 questions reduced to 8 questions. Thereafter the tool was pilot tested on 30 studies (see 
Table 11). Following this it was found that the tool had a bias towards rating all studies as strong 
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despite methodological weaknesses in both the conduct and the reporting of the pilot studies 
using basic critical appraisal skills. (196) 
4. Content validation 
This process was used to fine tune items for inclusion in the quality assessment (QA) tool. 
Evidence from Centre for Evidence based Medicine (411) and NICE (425) were used to refine the 
tool appropriately. This was done to improve the consistency and reliability of the tool so that if 
QA was carried out by more than one researcher, there would be good consensus on the quality 
ratings. 
The completed tool was presented to a group of research experts for discussion and peer review 
group membership is presented in Table 10. The experts were asked to make judgements on the 
specified quality appraisal questions part of the instrument to measure the methodological 
quality of survival studies. Ideally the group of experts for validity assessment have been made 
up of experts from the field of cancer survival, but it was felt that researchers with experience of 
conducting systematic reviews and also other forms of primary research would afford the best 
objective approach to assess the appropriateness of the content of the QA tool.  
Table 9 Research Interest Group Membership  
Initials and Designation 
CM – Thesis Supervisor FS – Thesis Supervisor 
ST – Clinical Trials Unit Coordinator BG – Professor of Primary Care 
AG – Research Fellow BS – Professor of Population Science 
DM – Discovery Fellow DM – Senior Clinical Research Fellow 
JB – Research Nurse NT – Research Fellow 
PD – Professor of Biostatistics and 
Epidemiology 
SG – Lecturer in Medical Anthropology 
VS – Clinical Academic Fellow PD – Lead for Quality Improvement 
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Content validity of the tool appeared acceptable but issues such as the number of questions 
(content analysis) and time it may take to complete the tool were highlighted as initial 
drawbacks. The tool was reworked until the version dated 27 March 2012 was completed and a 
pilot QA of the 30 papers was conducted by the principal researcher (EM) (initially). The purpose 
of this was to assess whether the QA process was free from bias and fairly amenable to a 
systematic review approach, while assessing the internal and external validity of each article, and 
determining its importance within the context of this review.  
3.5.2. Iterations of pilot QA compared to later QA 
All the studies in the pilot quality assessment were assessed using the QA tool and data was 
extracted onto a form detailing the results for each study (see Table 11). The information 
presented by the study authors was taken at face value and used to assign a response to each of 
the fourteen assessment questions.  
The QA process did not only demonstrate an inherent bias towards rating most papers as strong 
quality during the first pilot assessment, there were some outliers that were considered weak or 
moderate even though the way the research was conducted and reported merited a much higher 
quality rating. The two pilot processes are depicted in Table 10 showing the variations in 
methodological quality between the assessment tools. 
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Table 10 Comparison of QA between the MQA and Modified MQA for Survival Studies 
Study information MQA score and rating Modified MQA score and rating 
*Anandan et al(354) 24/28       Strong 13/24      Moderate 
*Andersen et al(365) 25/28       Strong 16/24      Moderate 
Arbes et al(311) 27/28       Strong 23/24      Strong 
Booth et al(426) 18/28       Moderate 17/24      Moderate 
Castro et al(427) 27/28       Strong 20/24      Strong 
Chen et al(161) 25/28       Strong 19/24      Strong 
*Chu et al(360) 8/28         Weak 23/24      Strong 
*Chu et al(362) 26/28       Strong 17/24      Moderate 
Coleman et al(309) 17/28       Moderate 16/24      Moderate 
Datema et al(330) 27/28       Strong 21/24      Strong 
*de Cassia Braga Ribiero et 
al(140) 
24/28       Strong 15/24      Moderate 
de Graeff et al(361) 26/28       Strong 22/24      Strong 
*Hathaway et al(428) 26/28       Strong 11/24      Weak 
*Konski et al(368) 28/28       Strong 16/24      Moderate 
Kwok et al(367) 27/28       Strong 23/24      Strong  
Liu et al(337) 28/28       Strong 23/24      Strong 
Mackillop et al(359) 23/28       Strong 19/24      Strong 
Mell et al(339) 28/28       Strong 21/24      Strong 
*Menvielle et al(371) 21/28       Strong 15/24      Moderate 
Piccirillo et al(148) 27/28       Strong 20/24      Strong 
*Puigpinos et al(369) 17/28       Moderate 23/24      Strong 
Rosso  et al(370) 20/28       Strong 18/24      Strong 
Soares et al(334) 23/28       Strong 22/24      Strong 
Tanvetyanon et al(333) 24/28       Strong 22/24      Strong 
Teppo et al(290) 24/28       Strong 21/24      Strong 
Terhaard et al(331) 28/28       Strong 22/24      Strong 
Warnakulasuriya et al(357) 27/28       Strong 22/24      Strong 
Wong et al(372) 27/28       Strong 22/24      Strong 
*Woodard et al (351) 21/28       Strong 16/24      Moderate 
Yung et al(150) 28/28       Strong 19/24      Strong 
*Indicates studies that showed a discrepancy in the quality ratings after the QA tool modification. 
A paper examining the impact of socioeconomic status (SES) on survival (360) was found to be 
‘weak’ although critical appraisal showed that this paper had reported robust research methods. 
This paper made the principal researcher question whether the quality assessment tool was 
asking the right questions to ascertain methodological quality. These questions appeared to be 
restricted to risk of bias assessment which mainly led to appraisal of internal validity of the 
studies without any regard as to how their internal validity measured up. A similar pattern was 
noted for eight other papers. (140, 351, 354, 362, 365, 368, 371, 428)  
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The first version of the QA tool appeared to focus more on the strength of the inference one may 
draw from the study findings. There was no scope as to how statistical conclusions of the study 
gave validity to the findings reported by the authors. This is an area that the principal researcher 
felt required to be addressed within the quality appraisal process. It was also important to focus 
on whether incompleteness in reporting had an influence on the analysis and interpretation of 
results. Therefore, the principal researcher following discussion with the thesis supervisor (CM) 
decided that it was essential to include this aspect of methodological quality within a modified 
tool.  
Another shortcoming of the initial QA tool is that it was open to subjective interpretation as 
shown by variation on the results of the pilot appraisal as shown in Table 11. This is despite the 
pilot assessment was conducted by one person only. In reviewing the tool, it was decided that 
using a guide as to the interpretation of each question’s meaning and the information sought 
would be the ideal approach to minimize bias and subjective variability of findings. This resulted 
in the QA process being handled by three separate individuals, EM (principal researcher), CM 
(thesis supervisor) and FM (fellow research student). 
3.6.1. Results 
The literature review found that a variety of sources existed for potential items to use in a quality 
rating tool for systematic reviews of survival studies. (202-204, 223)  
3.6.2. The tool 
The modified quality assessment tool for survival studies has a list of 8 questions which have the 
following answers “yes”, “no”, “partly”, “can’t tell”. The tool is presented in the appendix, while 
a detailed description of each quality appraisal question and what each question is meant to elicit 
is also included. 
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The methodological quality assessment tool was revised using more rigorous research evidence. 
(202, 203, 223, 411) until a final version (16 May 2012) was completed. Again this tool was 
presented to a research group for face and content validity. The group of research colleagues 
were consulted, as a part of the content validity assessment, to identify areas of omission and to 
suggest areas for improvement or modification. The comments were extremely encouraging 
with earlier shortcomings no longer an issue. Also to minimize the possibility of different 
interpretations of each appraisal question, a dictionary of the meaning of each question was 
devised to make this tool useful and adaptable for future projects. The subjective perceptions 
(face validity) of the panel of experts concluded that the tool was appropriate for measuring the 
quality of primary studies in a review of observational (survival) studies. A comparative pilot 
assessment was conducted and is depicted in Table 10. 
Two reviewers, the researcher and a colleague with some research experience independently 
assessed each study then discussed their ratings together. Any disagreements were discussed 
and resolved by consensus agreement and final discussion with the dissertation supervisor as the 
third reviewer. Appendix A4 details the final tool with the corresponding guidance.  
3.7. Discussion 
This literature review produced an evidence based tool for the quality assessment of primary 
research on survival for use in systematic reviews. It is a simple but concise tool consisting of 
eight questions. It also includes a methods guide or dictionary to explain what each question 
relates to. It also includes an overall quality score which is useful for meta-analysis as any studies 
that were rated as “weak” can be excluded. 
The face and content validity methods were used to formulate the final tool in conjunction with 
input from the group of researchers. The pilot testing of the tool both at inception and for the 
final draft was utilised to highlight any inconsistencies or biases in the type of questions used to 
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assess methodological quality. This resulted in a tool with strengths but in spite of this there are 
some limitations to it. The quality scores do not provide an objective assessment of the quality of 
a primary research study. (429) The choice for the methods of grading or calculating quality is 
purely arbitrary and as no weighting was allocated to be indicative of the relative importance of 
individual quality appraisal questions over others. (422) Despite these shortcomings this tool is 
robust as it is evidenced from the literature on how to use articles of prognosis (survival), and has 
been systematically developed using these same sources.  
Although the review of the literature had found a few tools that appeared to have fulfilled some 
of the criteria which this study had sought to develop as part of the methods for the assessment 
of methodological quality of prognosis studies. Like the tools by the University of Montreal (217, 
412), prognosis was addressed in the context of the clinical relevance of on an individual patient. 
As a result, the tool developed for this systematic review is a far superior approach as it can be 
applied to the clinical studies to assess whether both their conduct and results both possess a 
high quality in terms of internal and external validity.  
3.8. Conclusions 
According to our knowledge this is the first attempt at condensing all the guidance on critical 
appraisal of survival studies into a meaningful tool providing both direction and a way to assess 
the methodological quality of survival studies. This tool acts as a generic starting point for quality 
assessment of primary survival studies without being limited by study design or setting. The 
versatility of this methodological quality assessment tool means it could be used to do quality 
assessment of papers focused on other diseases. It is easily adaptable to any condition as the 
quality assessment questions help to identify methodological rigour in a primary research paper. 
This tool will help assess the methodological soundness of methods used in a primary study but 
this has to be approached with caution as poor reporting does not always equate to poorly 
conducted studies. It is envisaged that the development of the MOOSE guidelines (198) has 
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contributed to the improvement in the quality of reporting of observational research such as 
studies of survival. This should diminish the likelihood of well conducted but poorly reported 
studies being published in future. The development of this tool should hopefully enhance the 
standards of systematic reviews of primary survival studies. 
3.9. Chapter summary 
This chapter discussed the process used to devise a QA tool. This tool would be used to evaluate 
whether studies that were selected for inclusion in the systematic review used sound 
methodology. The literature searches and selection of articles that focused on survival 
(prognosis) was conducted with the final resulting from an amalgamation of key questions from 
various sources. The process of face and content validation as well as the pilot QA was conducted 
in order to refine the tool and ensue it was fit for purpose. The final tool was devised and used to 
appraise the methodological soundness of the 70 articles that were included in the systematic 
review presented in Chapter 2. The next chapter will describe the data linkage methods used to 
prepare administrative health data for use in the retrospective study on the survival outcomes of 
HNC patients from Tayside and Fife based on their comorbidity status and SES. As described in 
the systematic review (Chapter 2) an ideal follow up to this work was to attempt to validate the 
systematic review findings in a cohort of HNC patients. In order to conduct this analysis of the 
retrospective data, HNC patient data from Fife and Tayside which was available for this project 
had to be linked with routinely collected administrative data. This next chapter will describe the 
process of obtaining the patient data and preparing the data for analysis and linking it in order to 
verify whether the systematic review results were generalisable. 
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C h a p t e r  4  
4.1. Data linkage methods 
4.1.1. Chapter Outline 
This chapter will describe the methods used to link administrative health data sources into a 
meaningful dataset of HNC patients from Fife and Tayside. It gives a comprehensive description 
of the routine health datasets that are used in Scotland. This includes the hospital data, death 
statistics and cancer registry information on HNC diagnosis. A definition of the procedures for 
obtaining these data, cleaning and the methods of linking them into a dataset will be given. The 
number and how any inconsistencies and duplicates were removed will be defined, alongside the 
process of assigning comorbidity status using the selected indices and the matching of variables 
will also be described. The data linkage of routinely collected data and patient data to create a 
single record with all important variables such as age, gender, HNC type, disease stage, TNM, 
summary scores for ECI and CCI, as well as Scottish SIMD quintiles, and income and education 
domains will be conducted in preparation for statistical analysis of these data. 
4.2. Routine healthcare datasets 
Scotland has high quality routine healthcare data which have been collected over the last 40 
years in mostly an electronic format and provide opportunities for record linkage. National 
Scottish datasets are maintained by Information Services Division (ISD) Scotland of the National 
Health Service (NHS). These data are collected from the point of birth until death using a unique 
patient identifier which the individual uses throughout the life course. 
The unique patient identifier is known as the Community Health Index (CHI) number (430)which 
is a unique ten character identification number that has been in use in Tayside since the late 80s 
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and throughout Scotland over the last decade. It is made up of six digits from the date of birth 
(DOB); the next two digits are a unique identifier with the ninth digit representing gender, with 
an even number for females and an odd number for males. The tenth digit is a check sum for 
validation purposes.  
A community prescribing database of prescriptions issued within the community is also kept. The 
information used in this database is obtained through GP issued prescriptions which are filled at a 
local pharmacy by the patient. The script is forwarded to the ISD Pharmacy Practice Division with 
the same information forwarded to the Health Informatics Centre (HIC) (431) regarding any 
Tayside and Fife prescriptions which are then entered onto the database. This service has been in 
place since 1989 and became fully operational in 1992. 
The Scottish Morbidity Records (SMR) Database (432) covers all patients in Scotland, and 
relevant care episodes requiring admission to non-obstetric hospitals together with any cancer 
registration and corresponding death records. These records known as SMR are collected by 
local NHS Scotland Health Boards and collated at the ISD. This information is collected for 
planning, monitoring, costing and contracting of the health service. All SMR data for Tayside and 
Fife is available through HIC. 
4.2.1. Types of SMR that is to be used in this study: - 
 SMR01 (432)- admission to non-psychiatric care/non-obstetric hospital for inpatient stay 
or as a day case 
Three databases spanning three time periods 1980-1995 (ICD 9 codes), 1996-1997 (ICD9 and 10 
codes) and 1997 onwards (ICD 10 codes only). This study will use the SMR database from 1997 
onwards which includes patient identifiers such as CHI No, ICD-10 codes and admission hospital. 
The International Statistical Classification of Diseases and related health problems (ICD-10) is the 
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10th revision of a medical classification list compiled by the World Health Organisation (WHO). (7) 
The ICD-10 codes are used to classify diseases and other health problems. 
 SMR06 (432) or Cancer Registry 
These data have been collected since 1958 at regional centres and was changed to a single 
national disease registration in 1997. The SMR06 gives information on all cancers as well as 
benign brain and spinal cord tumours. The data collected from the following sources is used to 
create the SMR06 record:- 
1. SMR01,  
2. Pathology,  
3. Haematology,  
4. Oncology,  
5. Radiotherapy,  
6. Prospective cancer audits and  
7. General Registrar’s Office (GRO) Scotland death records.  
There is a legal obligation to record any death occurring within Scotland. This information is then 
collated by the GRO Scotland. (432) The cause of death has to be included as per the medical 
death certificate and this information has been mandatory since 2000. HIC has access to this 
death data with the CHI number being manually added based on name, date of birth and current 
address to allow data linkage. 
The Scottish index of Multiple Deprivation (SIMD) (433) is a measure of deprivation that identifies 
small area concentrations of multiple deprivation across all of Scotland. It was designed to 
capture many aspects of deprivation in individual domains such as employment, income, 
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education, health, access to services, crime and housing.  Previous measures of deprivation used 
measures that came from the Census (e.g. people not owning a car, overcrowded housing and so 
on) but this information went out of date quite quickly.  The advantage of the SIMD is that it uses 
small units of geography that can be aggregated up into larger areas e.g. councils, CHPs, health 
boards. It ranks the 6,505 datazones in Scotland from 1 being most deprived to 6,505 being the 
least deprived and it does this for each domain as well as giving an overall ranking which is a 
weighted sum of the seven domain scores. (433) The SIMD is aggregated into quintiles and 
deciles. The quintiles split the datazones into 5 groups, each containing 20% of Scotland’s 
datazones, while deciles split the datazones into 10 groups, which each contain 10% of Scotland’s 
datazones. The main disadvantage from use of the SIMD is that it is based on a patient’s 
postcode 
There are issues around the use of routinely collected data with evidence of both advantages and 
disadvantages. 
4.2.2. Strengths and limitations of routine data 
The strong points of routinely collected data include- 
 These data are readily available 
 Usually at low cost 
 Useful for establishing baseline characteristics 
 Useful in identification of cases for a case-control study 
 Aid in the generation of aetiological hypothesis 
 Help to derive the expected number of cases in a cohort study 
 Useful as a source of ascertaining outcome in a cohort study 
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 Useful for examining disease trends over time and place 
In terms of weaknesses, generally these data are prone to bias, measurement error and 
incompleteness as well as the following characteristics: 
 not always up-to-date (dependent on when collected) 
 lack of completeness (except census) 
 some variables of interest may not be collected 
4.2.3. Access to routine datasets 
This was sought through submission of requests in the form of a study protocol and data analysis 
plan to the following two sources: 
1. The NHS Tayside and NHS Fife Caldicott Guardians and their respective Research and 
Development Departments (R&D)to allow use of anonymised patient data for research 
purposes 
2. The HIC data protection officer who ensures that all necessary permissions are in place 
and that data that is generated is anonymised before it is released for use by the 
researcher. The data are accessed only through a restricted database called a safe haven 
which is operated by HIC. The Scottish Government has defined a safe haven as, “a 
secure physical location that embraces standards of operation that ensure that 
confidential personal information is handled safely with appropriate levels of electronic 
security. It contains a computer but has no external devices with removal of any 
information from the safe haven strictly controlled by the HIC team. 
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4.3. Identifying the cohort 
Once approval (See Appendix) was obtained from the relevant Caldicott Guardians, R&D 
departments and HIC, the data was forwarded to the principal researcher. The cohort was 
identified from two main sources: Fife patients were identified from records kept by the Head 
and Neck Cancer Nurse Specialist who had kept a record of all incident cancers that occurred 
since inception of her post in 1989. This resulted in Fife patients being identified as any individual 
with a diagnosis of HNC based on clinic notes, or who had a hospital discharge record (SMR01) 
with a code for HNC; or any individual with a HNC record (SMR06) in the Cancer registry who was 
a Fife resident; or anyone with a cause of death code of HNC in the GRO death records system. 
Tayside patients were initially identified using a retrospective case note review of all HNC incident 
cases from the Tayside area from 1997 onwards. These patients were identified as HNC cases 
based on diagnostic records from Oral/Maxillofacial, Ear, Nose and Throat (ENT) and dentistry. 
This also encompassed patients with a hospital discharge record (SMR01) of HNC, or any Tayside 
resident whose Cancer registry record (SMR06) was coded for HNC, as well as anyone with a 
cause of death within the GRO death records coded as HNC. 
All the additional data (SMR01 and SMR06) were requested from the HIC Data Protection Officer 
and matched to the unique patient identifier (PROCHI) and added to the project population. 
As part of the information governance approval required for this project, HIC provided patient 
data that was anonymised meaning that there was no identifiable information within the dataset. 
The data was made available through the Safe Haven which is a secure access portal 
administered by the HIC team at University of Dundee. Safe haven access was obtained through 
submission and approval of a protocol and data analysis plan to the HIC. 
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4.4. Data linkage  
Although the data for the Fife and Tayside HNC datasets were collected for research purposes, 
these were independent operations. Due to inconsistencies in the level of detail collected for the 
key variables; careful thought and planning was required to merge the data with the other 
routine data sources in order to create a meaningful HNC patient cohort. The analysis of the 
Tayside and Fife data was conducted separately as Tayside had small patient numbers while Fife 
had a larger cohort but with missing information, although combining the two cohorts would 
help elicit more meaningful results which would have greater validity and generalisability. 
To ascertain that all the patients in both the Fife and Tayside cohorts had a diagnosis of HNC, 
diagnostic codes relating to HNC from the International Classification of Diseases 10th edition 
(ICD-10) (7) were cross matched against the SMR06 (432) Cancer Registry codes for both cohorts. 
The SMR01 (432) data was used to highlight any hospital discharges for concomitant disease 
other than the index disease, HNC. The diagnosis code was matched to key comorbidity 
conditions listed in the two indices of interest, the Charlson Comorbidity Index (99) and the 
Elixhauser Comorbidity Index (ECI). (103) 
4.4.1. Data extraction 
The anonymised dataset was allocated a unique identifier known as PROCHI to each patient 
record. The list of PROCHIs for both Fife and Tayside were matched against hospital discharge 
and cancer registry data. The GRO death records were used to identify any deaths and any 
corresponding causes of death for the specific individuals within the cohort. All the data i.e. 
SMR01, SMR06 and GRO death information were linked to make an individual patient record 
alongside other demographic information available in the amalgamated Fife and Tayside cohort. 
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4.4.2. Data cleaning overview 
This process of data cleaning or data cleansing was carried out to aid the elimination of errors 
and improve the consistency of data found in the databases. The type of inconsistencies and 
errors that need to be dealt with include but are not limited to record duplication, incomplete or 
inaccurate entries. A process of record linkage was conducted, “a solution to the problem of 
recognizing those records in two files which represent identical persons, objects, or events (said 
to be matched).” (434) Therefore the information was closely reviewed for its quality and 
reliability with any inconsistencies, errors or inaccuracies addressed to improve data quality. 
(435) The classification of data quality problems in data sources (436) process is illustrated 
below. 
Data quality problems 
Multi- Source Problems 
 
  Schema level   Instance level 
(Heterogeneous data models and Schema designs)  (Overlapping, contradicting and inconsistent data) 
-Naming conflicts      -Inconsistent aggregating 
-Structural conflicts     -Inconsistent timing 
4.4.3 Data Cleaning Process 
As determined by Maletic and Marcus (435) and Van den Broeck et al (437), there are three 
phases to the data cleansing process namely:  
1) Definition and determination of error types through manual inspection of the data 
(screening), 
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2) Search and identification of error instances using verification to ensure that accurate 
error identification occurs (diagnosing),  
3) Correction uncovered errors through data transformation (editing suspected 
abnormalities). 
This process was conducted within Microsoft Access 2007 which allowed the researcher to 
manipulate the data while making the necessary adjustments and improvements. The data 
cleansing approach involved is depicted in the following diagram 
Figure 12 Data cleaning approach 
Source: Van den Broeck et al (437) 
4.4.4. Data inconsistencies 
Predefined queries were used to identify duplicate records. Three main datasets were initially 
identified as containing the pertinent data for the Fife cohort namely: all patients, episodes, and 
appointments. Due to the large volume of inconsistent data such as date of diagnosis and/or 
referral, diagnosis, and duration of appointments, the HNC Nurse Specialist who had collated all 
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the individual patient data assisted in clarifying any errors. Following this multiple entries for the 
same patient were removed as in most instances, a recurrence of HNC was recorded as a new 
cancer. Other inconsistencies that were apparent within the data were dealt with using the 
following methods: 
a) Where there was evidence of 3 or more records for one patient, these records were 
reviewed. As all records had some useable information; the decision was made to merge 
them into 1 record i.e. row shift.  
b) There were instances of duplicate patient records with the only variation being the date 
of diagnosis. The earliest date of diagnosis was taken while other dates were 
disregarded.  
c) Duplicate records with identical information were also found and an arbitrary decision to 
keep only one such record was made using the first record as the default record for 
retention. 
In order to reduce data inconsistencies a key review process of renaming variables was 
conducted to ensure consistent variable matching across the two datasets. Some data cleaning 
occurred during the analysis process as the importance of some variables only became apparent 
at this stage. Column shift was also evident as data from one column was entered onto an 
adjacent column. Descriptive statistics using frequencies specifically to elicit maximum and 
minimum values for variables such as age to ensure that the data made sense. Final logic checks 
were also conducted to ensure that the data made sense. This was done using the baseline 
patient files and the routine data was then linked to this.  
Once it was verified through individual record checking that data appeared to be clean, the 
dataset was truncated into a summarised version with only key variables of interest to the 
analysis. This reduced the cohort variables from 125 to 23 which was a more manageable number 
thereby also minimising potential errors in the subsequent analyses.  
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The research question sought to investigate whether deprived patients with comorbidities 
presented with advanced and experienced higher than average mortality risk. It was therefore 
necessary to conduct risk stratification based on the key explanatory variables, comorbidity and 
SES. The process of assigning relevant values for the two prognostic factors was the next stage 
of preparing the data for analysis. 
4.5. Identification of explanatory variables 
The cohort eligibility criteria were defined as any patient residing in Fife or Tayside with a 
diagnosis of HNC, regardless of clinical staging of the disease. There were no restrictions placed 
based on gender, race, and length of survival or age. The definition of the cohort will report 
results of the Fife patients, followed by the Tayside patients. Finally the analysis will describe the 
combined cohort of the Fife and Tayside patients in full detailing the pertinent demographic 
characteristics as well as any survival analysis and multiple imputation results obtained.  
4.5.3. Other important variables 
Age was also considered to be of particular importance in the context of HNC survival as 
empirical evidence has shown that the typical HNC patient is older, aged 50+ and presents with 
more advanced disease (58) therefore it was crucial to assess the influence of age. To simplify 
matters, age was divided into categories as follows: ≤40 years; 41-50 years; 51-60 years; 61-70 
years and 71+. As HNC occurs predominantly in males with the ratio for incidence standing at 2:1 
compared to female, gender was also considered an important explanatory variable. Likewise 
tumour characteristics have been known to affect prognosis therefore it was important to assess 
whether disease staging had an influence on survival. Unfortunately not all patients had stage of 
disease recorded which was particularly the case for patients from the Fife cohort. 
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4.5.4 Assigning comorbidity 
In order to conduct the analysis adequately, the pre-existing conditions, or comorbidities for all 
the patients in the cohort had to be systematically stratified using the following method:  
(1) The conditions, (if present) that each patient had were matched to the conditions for 
each of the two comorbidity indices, 
(2) The comorbidity information was summarised into a score which amalgamated all the 
relevant conditions, 
(3) In the case of the Charlson Comorbidity Index (CCI), this also included the addition of age 
related information to provide an age related comorbidity score. 
The comorbidity data was presented as ICD-10 codes which were then translated into the 
relevant conditions based on previous work. (438-441) 
4.5.5. Measures of comorbidity used  
Comorbidity is known to affect the detection of disease, treatment options and prognosis; 
additionally it has known to be the cause and consequence of the index disease. In HNC most of 
the comorbidities share the same risk factors as the cancer itself; therefore comorbidity can act 
as an effect modifier compromising the internal and external validity of any study findings.  
The choice of comorbidity measure was based on a number of decisions. The CCI was deemed 
ideal in conducting the analysis of the Fife and Tayside patient data as the findings from the 
systematic review pointed to the utility of both the ACE-27 and CCI to measure comorbidity. 
Initially it was envisaged that both indices would be used for the subsequent analyses. The ACE-
27 index requires measurements such as blood pressure, creatinine levels, FEV1, alongside 
treatments such as blood transfusions of ≥6 units of blood, and diabetes medications, etc. As this 
information was not available, it was necessary to select an alternative comorbidity index to 
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provide meaningful comparison to the CCI. After reviewing indices used within HNC research, the 
index chosen was the van Walraven’s modification of the Elixhauser index (ECI) as it provides a 
recent risk-adjustment model in comparison to the CCI. This scoring system for calculating ECI 
was selected for its superior ability to discriminate in-hospital mortality. Prior to settling on using 
the ECI and CCI, the principal investigator considered other comorbidity indices such as those 
mentioned within Chapter 1. The National Cancer Institute Index was not suitable because it 
considers ten coexisting conditions without providing the severity of these conditions. The 
Alcohol and Tobacco-related comorbidities index was too restrictive as it focuses only on 
comorbidities related to smoking and drinking and does not consider any other age-related 
conditions. The Washington University Head and Neck Cancer Index is derived from the ACE-27 
therefore data collection would have been difficult due to the limitations pointed out with the 
ACE-27 index. 
4.5.6. Comorbidity indices 
The findings from the systematic review pointed to the usefulness of both the ACE-27 and CCI to 
measure comorbidity, hence both indices would have been ideal to use in the ensuing analyses 
The modified CCI (442) was selected over the initial version of the CCI (99) as it includes age to 
calculate a composite comorbidity score (see below). This was of particular importance in this 
study as age has significant influence both within the incidence and prognosis of HNC.  
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Figure 13 Age related CCI 
 
The rationale for use of the modified CCI (442) which incorporates age, was supported by its 
reputation as one of the most commonly used indices. The CCI was developed for the express 
purpose of prospectively predicting 1 year mortality among 600 patients with cardiovascular 
disease. As it has been used extensively in the field of cancer care and also in the systematic 
review (see Chapter 2), it was deemed an ideal comorbidity measure for use in this study. 
The index chosen to compare against the CCI was the van Walraven (441) modification of the 
Elixhauser index (ECI). The original Elixhauser index (103) had been used extensively, but van 
Walraven et al modified it to calculate a single numeric score to summarise disease burden 
thereby representing comorbidity classification. The original Elixhauser Index provides a more 
recent risk-adjustment model in comparison to the CCI. It uses 30 conditions and also includes 
weight loss and obesity which are not included in the CCI. The ECI has been validated in other 
cancers namely, colorectal, (443, 444) cervical, (445) prostate, (446) oesophageal, lung, bladder, 
121  
 
pancreatic, colon and gastric. (447) van Walraven et al (441) developed their index by modelling 
in-hospital mortality with in-patient admission data from Ottawa Hospital from 1996–2008. This 
scoring system for calculating ECI was selected for its superior ability to discriminate in-hospital 
mortality using 15 conditions which is better than using the 30 individual comorbidities without a 
summary score.  
Figure 14 Van Walraven's ECI 
 
The utility of the van Walraven method was confirmed for long-term cancer survival which is of 
relevance here as this is the main outcome measure of this study. (448) The scores according to 
the ECI method were categorized into the same groupings as to CCI to allow for comparison 
across the two comorbidity indices. As the classification of comorbidity varies depending on the 
index in use, the summary scores used in this project were not calculated through a simple count 
of conditions. The categories of mild and moderate comorbidity have different meanings 
dependent on the comorbidity measurement tool. A person's CCI summary score is the sum of 
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the weights assigned to each of the comorbid conditions alongside the age adjustment score. 
The assigned weights for each of the 19 conditions were derived from regression coefficients 
predicting survival in the initial development of the index. In the CCI, mild comorbidity refers to a 
score of 1, moderate comorbidity refers to a score of 2 and severe comorbidity is for an assigned 
score of 3 or more. (444) In the ACE-27 Index the assignment of comorbidity severity is based on 
the degree of organ decompensation and prognostic impact, i.e. the highest ranked single 
disease in different organ systems. A score of 1 meaning mild comorbidity is assigned when the 
comorbidities for a particular individual are all ranked as mild decompensation. Moderate 
comorbidity which is scored as 2 for condition causing mild decompensation but this only applies 
if only one condition is ranked as 2. If 2 or more conditions from different organ systems are 
found, then the comorbidity score is 3 meaning severe comorbidity. These categories indicate the 
overall prognostic impact which determines possible outcome taking into account the treatment 
selection and treatment management issues with the comorbidities and the index disease. 
4.5.7. Defining Important Comorbidities   
The entire burden of illness for a patient, as reflected in the information relevant to a 
hospitalization, can be divided into five separate concepts:   
1. The primary reason for hospitalization, as reflected in the principal diagnosis;   
2. The severity of the principal diagnosis;   
3. Complications that result from the process of care;   
4. Unimportant comorbidities or other conditions present on admission that have a trivial impact 
on resource use and outcomes; and   
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5. Important comorbidities or conditions present on admission that are not related directly to the 
main reason for hospitalization, but that increase the intensity of resources used or increase the 
likelihood of a poor outcome.   
To conceptually identify important comorbidities, we attempted to exclude information that 
relates to the other aspects of a patient's condition, concepts 1 through 4 above.  
4.6. Methods for variable matching 
Table 11 Variable matching methods 
Fife Tayside Matched variable 
Sex Gender Sex 
Age at time of presentation Calculated age Age 
Tumour  
Node                                 TNM 
Metastasis  
T 
N                                TNM  
M 
TNM 
Staging UICC stage Stage 
Diagnosis Site of primary disease HNC Type 
Diagnoses date Date of diagnostic histology Date of diagnosis 
Smoking History of smoking Smoking status 
Alcohol consumption History of drinking Alcohol 
4.6.1. Demographic characteristics 
The demographic attributes of the population included age, sex, education level and income level 
measured using the Scottish SIMD. The data did not contain any information on factors such as 
marital status, ethnicity or occupation.  
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4.6.2. Tumour characteristics 
Tumours were classified using the tumour-node-metastasis (TNM) system was adapted into 
stage according to the American Joint Committee on Cancer system as stages I, II, III and stage 
IV. (449) 
4.6.3. Assigning alcohol status 
Allocation of alcohol status was derived from guidance from the Institute of Alcohol studies 
which gave the calculated units of alcohol as follows: 
                                                  
    
                 
These units were calculated for each patient where the data were available and each patient was 
placed into types of drinker groupings (see Table 12). 
Table 12 Units and alcohol consumption guidelines 
Drinker type Men Women 
Units per day  Units per day 
Moderate < 21 <14 
Hazardous  21-50 14-35 
Harmful 50+ 35+ 
Source: Holmes et al (450) 
4.6.4. Assigning smoking status 
Smoking status was devised from reclassification of the smoking variable into 4 distinct 
categories based on methods developed by a team of pulmonologists led by Uzuner. (451)The 
categories were: 
1. Never smoked 
2. Ex smoker 
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3. Moderate smoker 
4. Heavy smoker 
Where smoking was defined through quantity of tobacco smoked, it was estimated that 50g of 
tobacco made approximately 100 roll up cigarettes using a generous allocation of tobacco. (451) 
This meant that a person smoking approximately 14 of these cigarettes per day was deemed a 
moderate smoker. If quantity such as 15-20 cigarettes was given than the highest number was 
taken meaning this individual was classified as a heavy smoker. Therefore anything more than 20 
cigarettes would be classified as a heavy smoker. This algorithm was deemed the most 
appropriate as it catered for patients with HNC.  
4.7. Data linkage 
Record linkage techniques have been used to enable researchers to identify and merge data 
regarding a single individual stored in different databases. Within this thesis record linkage 
followed the methods described by Bohensky et al (452) to find records within the datasets that 
were linked to the each individual patient across different data sources that were available from 
Fife and Tayside. Linkage was conducted via CHI seeding which has handled by the HIC data 
officer and then released to the principal investigator with corresponding unique PROCHI ID 
(which is a simulated CHI number used by HIC) for each patient in accordance with the data 
access protocols of anonymisation.  
The data linkage procedure used to identify explanatory variables is depicted in the flow chart 
below. 
126  
 
Flowchart of the data linkage process 
FIFE     TAYSIDE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Datasets for Fife 
Fife patients, Fife episodes 
Fife demography 
Datasets for Tayside 
Tayside case note review 
Tayside demography 
Single patients 
records n= 468 
Multiple patient 
records n=1183 
Data cleaning and 
removal of 
duplicates 
N= 876 single 
patient records 
Creation of alcohol and smoking status 
Linking of datasets matched by PROCHI with:  
1. SMR01 Hospital discharge records 
2. SMR06 Cancer Registry data 
3. GRO death data cut off date 31/12/2013 
4. SIMD data i.e. Scottish quintiles, income and education domains 
Conducting multiple imputation of missing data to allow robust analysis of datasets 
Define a Fife cohort of person level 
data with all demographic factors 
and predictors n=876 patients 
Define a Tayside cohort of person level 
data with all demographic factors and 
predictors n=468 patients 
Convert ICD-10 codes relevant to HNC from SMR01 
data. 
Aggregate multiple conditions and episodes to create 
person level data with comorbidity categories 
Convert ICD-10 codes relevant to HNC from 
SMR06 Cancer Registry data. 
Combined cohort derived 
from Fife and Tayside 
patients n=1384 
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4.8. Chapter summary 
This chapter explained the methods used to link the data to make up one composite dataset. The 
final variables and how the matching of variables was achieved were demonstrated. The data 
cleaning and linkage procedures were laid out. Assignment of key variable information such as 
alcohol and smoking status as well as comorbidity status were also explained. As the data was 
collected in different regions of Scotland, there is a high likelihood of a lack of consistent 
measurement of key variables e.g. TNM was recorded as the full values in Tayside and yet in Fife, 
all three values were recorded in individual columns. It was necessary to begin with this and then 
highlight proposed methods to analyse data such as survival analysis and any statistical methods 
for dealing with missing data. The next chapter will give an overview of the survival analysis 
proposed to deal with the linked health data for the Fife and Tayside cohorts of HNC patients. 
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C h a p t e r  5  
5.1. Cohort Analysis Methods 
5.1.1. Chapter Outline 
This chapter outlines the methods for the statistical analysis of the linked retrospective cohort 
data for Fife and Tayside. Description, definition of the cohort, assignment and calculation of 
variables such as HNC type and ECI measured comorbidity will be given.  The key variables of 
comorbidity and SES had to be adequately described for each patient as they are ultimately 
useful for assessing their prognostic impact. The primary and secondary outcome measures will 
be explained as well as how missing data will be accounted for using statistical methods. Analysis 
of survival will be conducted  using the Kaplan-Meier method and the log-rank test, with key 
explanatory variables analysed using multivariate survival analysis using the Cox proportional 
hazards regression model. The hazard ratios (HR) with their 95% confidence intervals (CI) will be 
reported to assess the corresponding survival estimates dependent on explanatory variables. 
5.2. Identifying the cohort 
In order to have access to patient data to conduct the analysis investigating the influence of both 
comorbidity and SES, approvals to conduct the research had to be obtained. These approvals 
were sought from the respective NHS Fife’s and NHS Tayside’s Caldicott Guardians as well as the 
custodian for the Fife data JP, the HNC Specialist Nurse. Ethical approval was not required for this 
project as the patient data was anonymised meaning that there was no identifiable information 
within the dataset. The data was made available through the Safe Haven which is a secure access 
portal administered by the HIC team at University of Dundee. In order to obtain Safe haven 
access, the PI had to submit a protocol and data analysis plan to the HIC. 
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The final patient cohort was derived from 2 sources; for Fife a database containing all known 
diagnoses of HNC was being prospectively compiled by the HNC Specialist Nurse. The second 
data source for Tayside patients was based on a retrospective case note review conducted by a 
research assistant. The source of these patient files were the following departments, Oral and 
Maxillofacial, Ear Nose and Throat, as well as Oncology at Ninewells Hospital in Dundee. To 
ascertain that all the patients in both the Fife and Tayside cohorts had a diagnosis of HNC, 
diagnostic codes relating to HNC from the International Statistical Classification of Diseases and 
Related Health Problems 10th edition (ICD-10) (7) were cross matched against the SMR06 Cancer 
Registry codes for both cohorts. We used a tool provided by MacMillan (5) to assign ICD-10 codes 
to the different HNC sub-sites. The head and neck three character ICD-10 site codes categorise 
the HNC to its point of origin within a specific structure such as the larynx or tonsils. These codes 
can be broken down into the specific location within the structure such as in malignant neoplasm 
of the gum. The corresponding code of C03 is subdivided into upper gum C03.0. The lower gum 
has an ICD-10 code of C03.1. There is also a subcategory .9 which is used when the sub site is not 
specified. From using coding methods as broken down into the steps similar to the preceding 
example, there were no major issues assigning the codes for the HNCs. Even though there has 
been some debate in the case of oropharyngeal cancer particularly for the area behind the 
wisdom teeth (called the retromolar trigone) which can be included as a part of the oral cavity. 
As it is often considered part of the oropharynx, it was included as part of the oropharyngeal 
subsite. The oropharynx is the part of the throat just behind the mouth. It begins where the 
cavity stops. It includes the base of the tongue (the back third of the tongue), the soft palate (the 
back part of the roof of the mouth), the tonsils, and the side and back wall of the throat. We 
were able to assign ICD-10 codes by specifying the exact structures of the oropharynx. 
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Figure 15 ICD-10 codes for HNC 
 
Adapted from Boing et al (453) 
The SMR01 data was used to highlight any hospital discharges for concomitant disease other 
than the index disease, HNC. The diagnosis code was matched to key comorbidity conditions 
listed in the two indices of interest, CCI and ECI. 
5.2.1. Variables under study  
Date of diagnosis was taken from that specified in the datasets provided for both geographic 
regions. If this was unavailable, the date identified in the cancer registry was taken as the 
diagnosis date. Notably the earliest diagnosis date was used if there were any disparities 
identified. The date of death was taken from the GRO deaths records data and used in place of 
the one already recorded within the initial dataset information due to the higher reliability of the 
GRO data.  
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5.2.2. Primary outcome measure  
All cause mortality was considered as the primary outcome of interest as it accounts for 
variations in the data available for all patients in the cohort. Date of death was obtained from 
GRO death records as this government source is a more robust source of information compared 
to data collected by an individual which are prone to non-systematic bias. 
5.2.3. Secondary outcome measures 
Cause specific survival was chosen as the a net survival measure representing cancer survival in 
the absence of other causes of death. It was deemed the most reliable method to estimate the 
probability of surviving HNC within the cohort under study. Patients with cause of death 
according to GRO data listed as HNC death were flagged while other cancers were censored. 
Disease free survival was measured as the amount of time that a person with HNC survived 
without known recurrence of the cancer. The duration before recurrence was calculated from 
initial diagnosis date to the date when recurrence of HNC was recorded. 
5.2.4. Characteristics of the cohort 
Age at diagnosis for each patient was calculated using date of birth from diagnosis date. This is 
the age used throughout the analysis. There were a small number of patients who did not have a 
date of birth and these were excluded from the analysis. Patients were allocated into age bands 
ranging from 0-19, 20-39, 40-59, 60-79, and 80-99 years. Comorbidity is an important prognostic 
factor with evidence from the principal researcher’s review found that the more severe the 
comorbidity level, the higher the likelihood of premature death in patients with HNC. (163, 299, 
330, 338, 343) In order to measure comorbidity within the cohort, the literature was reviewed 
and it was decided to employ the ECI and CCI comorbidity Indices. 
132  
 
de Groot et al pointed out that survival studies can also be complicated by comorbidity as it can 
either act as a confounder, threatening the internal validity, or as an effect modifier, threatening 
the internal and external validity of the study. (454) For that reason it was decided to employ an 
efficient method to measure comorbidity due to four important reasons, namely to be able to 
correct for confounding, and improve the internal validity of the study, to identify effect 
modification, while also facilitating the applicability of comorbidity as a predictor of outcome, 
and finally, a comprehensive comorbidity measure, including many co-occurring comorbid 
conditions in one valid variable, was required to enhance statistical efficiency. Despite numerous 
comorbidity measures in existence for use in HNC, there is no identified “gold standard” index 
available for measuring comorbidity. Due to this, the principal researcher decided to use two 
indices for comparison purposes the CCI and the ECI which have been shown to be both valid and 
reliable in comorbidity measurement in HNC. (333) Initially the intention had been to use the ACE-
27 index. The ACE-27 classifies comorbid conditions and ailments separately as no comorbidity, 
mild, moderate, and severe according to the degree of organ decompensation and prognostic 
impact. (148) These grades are then used to assign patients to their overall comorbidity, the 
overall ACE-27 ranking being equated to the highest ranked ailment. Patients with more than two 
moderate ailments in different organ systems are graded overall as severe. It is a modification of 
the Kaplan–Feinstein index (KFI) (455) and has been validated for head and neck cancer,1 
although its use has not been widely reported in patients with head and neck cancer in the 
United Kingdom.(299, 456) Despite the obvious advantages of using the ACE-27 index, this had to 
be shelved as this index requires access to patient records which was not possible at this stage of 
the research project. Comparison was carried out using both statistical tests to test which 
comorbidity measure was the best predictor of mortality. 
The Charlson Index (99) has been used extensively and has been identified as suitable for use in 
HNC studies. (89, 163, 337, 457) The 19 diseases included in the index have been selected and 
weighted on the basis of the strength of their association with mortality. A person’s Charlson 
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index is the sum of these weights. The index was first validated in a cohort of patients with 
breast cancer, with the weights derived from regression coefficients predicting survival.  
SES; in particular, income (108, 362)and education as the main domains within SIMD, were shown 
in an earlier systematic review by the principal researcher to affect survival prospects. (167, 309, 
355, 359) The marker for deprivation within this cohort was the SIMD specifically the income and 
education domains were included in the analysis. 
Tumour characteristics- TNM classification of cancers of the head and neck) are provided below, 
along with anatomic staging. This translated to tumour size, presence of regional node 
metastasis and any distant metastasis. The categories for each HNC type are listed in below. 
Table 13 Types of HNC 
HNC Types 
1. Hypopharyngeal cancer 
2. Laryngeal cancer 
3. Mouth (oral cavity) cancer 
4. Nasopharyngeal cancer 
5. Oropharyngeal cancer 
6. Paranasal sinus cancer 
7. Salivary gland cancer 
Source: Macmillan (5)  
5.2.5. Identifying cause of death 
In Scotland the death certificate lists the cause of death as follows: 
An immediate cause of death is given, and then a process of retracing the disease or condition 
that started the process is commenced. It identifies:  
 the disease or condition that led directly to the death;  
 any antecedent or intermediate causes of that disease or condition (i.e. which occurred 
earlier in the chain of events that led to the death); and, eventually, goes back to -  
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 the underlying cause of death which is defined in the ICD-10 (7)as: “(a) the disease or injury 
which initiated the chain of morbid events leading directly to death or (b) the circumstances 
of the accident or violence which produced the fatal injury". (458) 
In order to identify the immediate cause of death and any underlying causes, the ICD-10 codes 
will be retrieved and matched to the immediate cause of death and the specific underlying 
conditions.  
5.3.1. Statistical methods - Defining outcome measures 
Patient follow-up was until death or 31.12.2013 the date of the last records available for study. All 
other records were considered alive for the analysis unless their death was already recorded in 
the GRO death dataset. This meant that all events up to and including that date were considered 
for the analysis. For the purpose of this thesis it is important to highlight the primary and 
secondary outcome measures. The primary outcome of interest is death from all causes. All cause 
mortality is a robust method for measuring outcomes in cancer. To give the findings better 
generalisability, it was also determined that HNC specific survival would enhance study 
outcomes. Initially the PI had intended to measure recurrence free survival as a secondary 
outcome but due to the low incidence of recurrence within the cohort, this outcome will not be 
explored. The methods used to account for this are explained below. 
5.4. Multiple imputation methods 
Missing data poses serious challenges that have to be accounted for when dealing with 
multivariate data such as in this project. The missing values that are referred to in this project are 
the values that should have been present in the Fife and Tayside datasets but were either missing 
or absent. These data could have been missing for a variety of reasons such as: 
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a)  the person doing data entry was not trained and there was a possibility that data 
collection was not done systematically 
b) There may have been errors in data entry which led to missing values 
c) The Fife dataset was almost double that of Tayside which may have led to more errors 
due to data management shortcomings 
d) Some of the data was based on self response such as smoking and alcohol status 
allocation therefore some patients may have been unwilling to provide a response to 
questions  
e) The Fife data were collected prospectively; therefore it is possible that some patients 
died before all the relevant information could be collected. 
In order to estimate the missing values multiple imputation was used, which refers to the process 
of replacing the missing values with plausible answers. (459) In order to identify which of the key 
variables had missing values, frequency distributions were obtained for these variables namely 
HNC type age group, smoking and alcohol status, stage of disease, Scottish SIMD quintile, SIMD 
income and education domains as well as ECI and CCI classification. 
A missing values analysis showed that the information was missing at random as there was no 
evidence of a pattern of missingness in the data. (460). As a result the statistical approach taken 
was chained imputation as no assumptions were made about missingness or patterns of 
distribution of the variables. Chained imputation as defined by Woodward (459) is known as 
regression switching or sequential multiple imputations. It is an iterative process that is 
dependent on the type of data and uses a sequence of univariate imputations, e.g. binary variable 
imputations use logistic regression. 
The modeling procedures available in SPSS version 22 which was used to conduct the analysis 
resulted in 199 cases being excluded from the analysis. This loss of cases meant that out of the 
total cohort of 1344 patients, 14.8% was excluded due to missing data for any variable. In essence 
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only 1145 could potentially be included in the analysis. Had our sample been large, we may have 
been able to allow for these 199 cases to be excluded from the analysis but this was deemed 
unsuitable unless a missing value could ascertain the pattern of missingness of the data which 
might allow exclusion of those cases. 
The missing values analysis allowed us to determine whether the complete case analysis (list wise 
deletion) performed using SPSS was sufficient and relevant in this instance. We adopted a three 
stage approach as follows: 
 We sought to obtain a full description of the distribution the number of cases 
missing per variable 
 We sought to clarify the pattern of the missingness of the data specifically we 
considered the probability of missingness, i.e. where there certain cases in the 
cohort that were more likely to have missing values? 
 This information allowed us to make decisions on which approach we would from 
the available options of dropping those cases from the analysis, or using 
substitution methods i.e. single or multiple imputations to create values where 
these were missing. 
In order to make sound judgments on the data we also had to evaluate whether the patterns of 
missingness were  
1. Missing completely at random (MCAR) – the missing value neither depends on an 
observed value or one that has not been observed within the dataset. An example that 
would apply to this dataset is the disease staging was not recorded as the patient died 
before such information could be ascertained 
2. Missing at Random (MAR) Missing value (y) depends on x, but not y 
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Example: Respondents in service occupations less likely to report income 
Missing not at Random (NMAR) The probability of a missing value depends on the variable that is 
missing 
Example: Respondents with high income are less likely to report income 
As the patient sample was relatively small, a substitution method had to be used to allow for the 
retention of enough cases to have sufficient power with our study to detect any prognostic 
influence effects from the factors under study. The results of this analysis are presented in the 
results section, however as a result of these findings we had to use the multiple imputation 
method to substitute  
5.4.1. Rationale for using multiple imputations 
The missing data was especially apparent in the Fife cohort and as this contributed the largest 
number of patients. Multiple imputation models were created in order to estimate the values for 
the missing records. Using this method made it possible to account for missing data which meant 
that list-wise deletion of the large number of cases that had missing values was avoided which 
saved time. The major advantage for using multiple imputation methods is that once all missing 
values had been imputed, the data set was ready for analysis using standard techniques for 
complete data. 
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5.4.2. Multiple imputation process 
1. Impute data   2. Process data   3. Pool data 
 
 
 
 
 
 
 
 
 
5.5. Statistical methods for the survival analysis 
In order to ascertain time to the event of interest, death, survival analysis was deemed to be the 
preferred and logical method to conduct the analysis. In general the amount of data generated 
from merging the Fife and Tayside patient files, meant that a large number of variables were in 
the dataset. The next step was to provide the descriptive analysis of the population 
characteristics and any explanatory variables. This included an overview of the age and gender 
distribution of the cohort. The incidence of comorbidity and SES groupings within the cohort 
were also described. 
The analysis commenced with Kaplan Meier curves to examine the number of patients surviving 
without experiencing the event of interest, death. This was analysed using age, gender, HNC 
Data set with 
missing values 
Imputed datasets Analysis results of 
each dataset 
Final estimates 
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subtype, comorbidity, and SES. As tumour staging information was complete for only the Tayside 
portion of the cohort, the survival plots presented only apply to that population. The Kaplan 
Meier method was also selected as it allowed for comparison of survival between groups. The 
analysis the proceeded to Cox proportional hazards regression which allowed for the assessment 
of the individual effect of the same explanatory variables used in the Kaplan Meier survival 
analysis.  
The fit of the Cox Proportional hazards model to the study data were tested using two 
complementary methods: 
1. Area under curve or Receiver operating statistic (C-statistic) (461) is a method that has 
been used to evaluate the overall performance of the risk scoring system. It is an 
established measure of model discrimination for binary outcomes and works well when 
applied to survival data. Values for the C statistic range from 0.5 to 1.0. A value of 0.5 is 
indicative that the model is no better than chance at making a prediction of the model fit. 
A C-statistic that is higher than 0.7 is considered reasonable while 0.8 is considered 
strong. A value of 1.0 indicates that the model perfectly fits the data. 
2. Akaike information criterion (AIC) (462) is a framework that allows simultaneous 
estimation and selection. This statistic illustrates how well the Cox model conforms to the 
observed data in the cohort. The following criteria are used to determine the applicability 
of levels of the AIC. 
Table 14 AIC criteria 
AIC Level of empirical support for AIC 
0-2 Substantial 
4-7 Considerably less 
>10 Essentially less 
Source: Burnham and Anderson (463) 
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After reviewing the individual effect of each predictor variable, the PI was able to assess the 
combined effect of these variables in a single Cox regression to address the hypothesis that low 
SES and severe comorbidity are linked to poor survival. The final Cox model calculated the hazard 
or probability of death using the following equation: H (t) =H₀ (t) × exp (b1X1+b2X2=b3X3+.....bkXk). 
All the statistical analyses were conducted in SPSS version 22. 
5.6. Chapter Summary 
This chapter gave a synopsis of the planned statistical analysis highlighting both the descriptive 
statistics as well as the survival analysis methods. It also explains how the findings of the 
systematic review which were used in the analysis fed into the selection of predictors was 
described. In addition the methods for dealing with missing data were explained by the use of 
missing values analysis and multiple imputations. The results of the statistical analysis are 
presented in the next chapter.
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C h a p t e r  6  
6.1. Survival Analysis Results 
6.1.1. Chapter Outline 
This chapter will depict the findings from the analysis that was proposed in the preceding 
chapter. A description of the cohort attributes will be explained in relation to the outcomes of 
interest in this study. Survival analysis methods will be used to assess the prognostic contribution 
of both comorbidity, (defined using the CCI and ECI) and SES (using the Scottish SIMD quintiles 
and the income and education domains of the SIMD) will be presented in the order of the 
research questions and the hypothesis underpinning this study. The analysis was done initially by 
region to test the hypothesis and evaluate whether either region had data that corresponded or 
disputed the results of the systematic review. This was done using survival distributions and cross 
tabulation to assess whether there were associations between stage at presentation with SES 
and if comorbidity and SES were prognostic factor for survival. Due to missing data multiple 
imputations were used to account for missing data. The results of the two regions were 
compared and the final analyses looked at a combined cohort as the bigger numbers gave the 
study greater power. 
6.1.2. Introduction 
The cohort was initially made up of 1384 patients but this was reduced to 1344 due to removal of 
duplicate patient records and also some ineligible cancers (thyroid n=9, oesophagus n=2) that 
occur in the head and neck region but do not fall under the HNC definition used in this thesis. Out 
of the cohort of 1344 patients, 524 (39%) deaths had occurred by 31st December 2013. 
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6.1.3. Cohort definition 
The description of the entire cohort is displayed in Table 15 and the analysis by each individual 
sub-cohort and followed by the combined cohort results. 
Table 15 Full cohort characteristics 
Variable N % Variable n % 
 Sex   Comorbidity  
Female 429 31.9 Charlson comorbidity index 
Male 913 67.9 None 132 9.8 
Missing 2 0.1 Mild 28 2.1 
Age groups Moderate 244 18.1 
<40 years 20 1.5 Severe 745 55.4 
41-50 years 67 5.0 Missing 195 14.5 
51-60 years 231 17.2 Elixhauser comorbidity index 
61-70 years 382 28.4 None 856 63.7 
71+ years 517 38.5 Mild  148 11.0 
Types of HNC Moderate 127 9.4  
Mouth 260 29.7 Severe 19 1.4 
Laryngeal 233 29.6 Missing 194 14.4 
Oropharyngeal  112 12.8 Smoking status 
Hypopharyngeal  14 1.6 None smoker 214 15.9 
Paranasal sinus 20 2.3 Ex smoker 247 18.4 
Nasopharyngeal 15 1.7 Moderate  141 10.5 
Salivary gland  37 4.2 Heavy smoker 317 25.6 
Missing 185 21.1 Missing 425 31.6 
Stage Income quintiles 
Stage 0 54 4.0 Most deprived 154 11.4 
Stage 1 202 15.0 Quintile 2 112 12.8 
Stage 2 143 10.6 Quintile 3 135 15.4 
Stage 3 151 11.2 Quintile 4 202 23.1 
Stage 4 392 29.2 Least deprived 210 24.0 
Missing 402 29.9 Missing 132 15.1 
Scottish SIMD quintiles Education quintiles 
Most deprived 278 20.7 Most deprived 158 11.8 
Quintile 2 261 19.4 Quintile 2 206 15.3 
Quintile 3 228 17.0 Quintile 3 198 14.7 
Quintile 4 211 15.7 Quintile 4 283 21.1 
Least deprived 153 11.4 Least deprived 295 21.9 
Missing 213 15.8 Missing 202 15.0 
 Alcohol status     
None drinker 126 9.4    
Moderate drinker 253 18.8    
Harmful drinker 130 9.7    
Hazardous drinker 248 18.4    
Missing 587 43.7    
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The causes of the deaths that occurred within the cohort are tabulated below (Table 16). 
Table 16 Main cause of death in the cohort 
Main cause of death n % 
HNC  225 42.9 
Other tumours 123 23.5 
Circulatory system disorders 46 8.8 
Respiratory disorder 35 6.7 
Immune system disorders 30 5.7 
Central nervous system disorders 27 5.1 
Alcoholism 10 1.9 
Digestive disorders 8 1.5 
Missing cause of death 6 1.1 
Death from complications 4 0.8 
Accidental death 2 0.4 
Musco-skeletal disorders 2 0.4 
Total deaths 524 100.0 
 
As per Scottish death certification, we found that HNCs were the main cause of death accounting 
for 42.2% of deaths within the cohort, leaving 52.7% of the cohort alive after the end of 2013. For 
additional causes of death, the distribution of HNC types and their contribution to death is shown 
in figure 16. 
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Figure 16 HNC contributions to additional causes of death 
 
In order to describe the cohort further, a table on the distribution of the comorbidities by the 
specific comorbidity measure is presented. 
•Hypopharyngeal - 4 
•Laryngeal - 71 
•Mouth - 49 
•Nasopharyngeal - 13 
•Oropharyngeal - 65 
•Paranasal sinus - 8 
•Salivary gland - 8 
•Total = 218 deaths (41% of all deaths) 
1st 
additional 
cause of 
death 
•Hypopharyngeal - 1 
•Laryngeal - 27 
•Mouth - 11 
•Nasopharyngeal - 1 
•Oropharyngeal - 20 
•Paranasal sinus - 1 
•Salivary gland - 1 
•Total = 62 deaths (11.6% of all deaths) 
2nd 
additional 
cause of 
death 
•Mouth - 5 
•Oropharyngeal - 1  
•Paranasal sinus - 1 
•Total = 11 deaths (2.06% of all deaths) 
3rd 
additional 
cause of 
death 
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Table 17 Distribution of patients by comorbidity measure 
Charlson comorbidity index (CCI) n % Elixhauser comorbidity index (ECI) n % 
AIDS/HIV                                                                 0 0 Alcohol abuse                                                       75 5.6 
Cerebrovascular disease                                       0 0 Blood loss anaemia                                               0 0 
CHF                                                                            8 0.6 Cardiac arrhythmia                                              0 0 
Connective tissue disease                                     0 0 CHF                                                                          8 0.6 
CPD                                                                          101 7.5 Coagulopathy                                                       19 1.4 
Dementia                                                                  12 0.9 CPD                                                                        101 7.5 
Diabetes mellitus                                                  147 10.9 Complicated diabetes                                          2 0.1 
Diabetes with chronic complications                0 0 Complicated hypertension                                0 0 
Hemiplegia                                                                9 0.7 Deficiency anaemia                                              0 0 
Leukaemia                                                                 11 0.8 Depression                                                             3 0.2 
Lymphoma                                                                21 1.6 Drug abuse                                                            4 0.3 
Metastatic tumour                                                   0 0 Fluid & electrolyte disorders                           0 0 
Mild liver disease                                                     51 3.8 Hypothyroidism                                                   0 0 
Moderate to severe liver disease                           0 0 Liver disease                                                         58 4.3 
PVD                                                                             86 6.4 Lymphoma                                                             21 1.6 
Renal disease                                                              0 0 Metastatic cancer                                                 0 0 
Solid tumour                                                              0 0 Obesity                                                                   20 1.5 
Ulcer disease                                                              0 0 Other neurological disorders                             0 0 
   Paralysis                                                                   8 0.6 
   PVD                                                                         86 6.4 
   Psychoses                                                                3 0.2 
   Pulmonary circulation disorders                       0 0 
   Renal failure                                                           27 2.0 
   Rheumatoid arthritis                                           19 1.4 
   Solid tumour without metastasis                       0 0 
   Ulcer disease                                                            0 0 
   Uncomplicated hypertension                              0 0 
   Valvular disease                                                       0 0 
   Weight loss                                                             47 3.5 
   AIDS/HIV                                                                  0 0 
 
A total of 587 (43.7%) patients had CCI measured conditions. Diabetes mellitus 147 (10.9%), 
myocardial infarction 141 (10.5%), chronic obstructive pulmonary disease 101 (7.5%), peripheral 
vascular disease 86 (6.4%) and mild liver disease 51 (3.8%) were the most common comorbidities. 
The less common conditions included lymphoma 21 (1.6%) hemiplegia (1.0%), dementia (0.9%), 
leukaemia 11 (0.8%) and congestive heart failure (0.6%).  
For ECI there were a total of 285 (21%) comorbidities in the cohort. These were made up of 
alcohol abuse (5.6%), liver disease 58 (4.3%), weight loss 47 (3.5%), renal failure 27(2%), obesity 20 
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(1.5%), coagulopathy 19 (1.4%), rheumatoid arthritis 19 (1.4%), paralysis 8 (0.6%), drug abuse 4 
(0.3%), depression 3 (0.2%), psychoses 3 (0.2%), and diabetes with chronic complications 2 (0.1%). 
The distribution of comorbidity classification for these patients based on the comorbidity index is 
shown in Table 18 and 19. The no comorbidity and the mild comorbidity groups in the CCI were 
combined into one group due to very few numbers in both groups as this would have 
complicated the results of any subsequent analysis particularly the proportional hazards 
regressions. 
Table 18 CCI distribution by comorbidity classification 
Explanatory variable Frequency Percent 
None/Mild comorbidity 160 11.9 
Moderate comorbidity 244 18.2 
Severe comorbidity 745 55.4 
Total  1149 85.5 
System missing 195 14.5 
Total  1344 100.0 
 
Table 19 ECI distribution by comorbidity classification 
Explanatory variable Frequency Percent 
No comorbidity 856 63.7 
Mild comorbidity 148 11.0 
Moderate comorbidity 127 9.4 
Severe comorbidity 19 1.4 
Total  1150 85.6 
System missing 194 14.4 
Total  1344 100.0 
 
6.2.1. Fife cohort 
The Fife cohort had 844 patients who were included in the analysis, including 593 (67.7%) males 
and 281 females (32.1%), and the largest group of patients were aged over 71 years (42.2%). 
Patients aged ≤50 years made up only 5.2% of the cohort. 42.2% of the patients had a smoking 
status of heavy/ex/moderate, and 38.3% of patients represented the harmful and hazardous 
drinkers combined. The types of carcinoma included 29.7% mouth and 29.6% laryngeal cancer. 
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Most of the patients were in stage IV (24.2%) and 11.8% patients were in stage I. Over half of the 
patients had a CCI score of moderate or severe comorbidity with both categories making up 
28.3% and 35% respectively. The ECI score of no comorbidity had 62.1% share of the cohort while 
only 96 patients had moderate comorbidity and 12 patients had an ECI score of severe 
comorbidity.  
After conducting an analysis using cross tabulation to identify any patterns within the data, a 
trend for increasing severity of comorbidity was noted for age, see the cross tabulation of CCI 
and age. 
Table 20 Cross tabulation of Age and CCI 
Age CCI Total 
 None  Mild  Moderate  Severe   
<40 years 10 0 0 0 10 
41-50 years 12 18 4 2 36 
51-60 years 22 28 50 14 114 
61-70 years 29 6 137 49 221 
71+ years 59 11 57 242 369 
Total 132 63 248 307 750 
 
An association of comorbidity status having an increasing severity in relation to worsening 
disease stage was also confirmed. Using cross tabulation we found that more patients from 
lower SES backgrounds presented with advanced disease, see Table 21. 
Table 21 Cross tabulation of Disease stage by Income Quintile 
Income Quintiles  Stage Total 
 Stage 0 Stage I  Stage II  Stage III Stage IV   
Most deprived  2 12 9 4 17 44 
2 2 12 12 12 21 59 
3 1 14 8 15 43 81 
4 0 34 20 20 54 128 
Least deprived 4 22 19 28 65 138 
Total 9 94 68 79 200 450 
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6.2.2. Results of Kaplan-Meier Analysis in Fife dataset 
The survival distribution by age showed that the 71+ age group appeared to have a superior 
survival experience. The log rank test was used to test the null hypothesis using the χ 2 test and 
corresponding p value. Having inspected the cumulative survival plot (Figure 17) and reviewed 
the descriptive elements from our results using the Means and Medians for Survival Time output, 
we found that the age 71+ had better mean and median survival distributions with 3611.622 days 
compared to 3118.196 days for those aged 41-50 years. The log rank Chi-square (χ 2) test did not 
reach statistical significance with χ 2 of 1.702 and a p value of 0.790. 
Figure 17 Fife survival distributions by age 
 
Survival distribution based on gender also did not reach statistical significance with a χ 2 statistic 
of 1.129 and p=0.288. The Kaplan-Meier output did however show that males appeared to have 
better survival outcomes with mean survival rates of 3560.259 days as rates for females were 
lower at 3519.176 days, (Figure 18). 
149  
 
Figure 18 Fife survival distributions by gender 
 
Next we assessed the survival distributions of the type of HNC within the patient group (Figure 
19). We found that laryngeal cancer had the best overall mean and median survival times. In 
contrast patients who were diagnosed with cancers of the nasopharynx had the worst survival 
with mean survival time of 2346.202 days compared to 4165.917 days in laryngeal cancer. The log 
rank test did show a statistically significant difference in survival between the HNC Type groups 
with χ 2=17.510, p=0.008. 
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Figure 19 Survival distributions by HNC Type 
 
 
Disease stage was noted to have better survival distributions in patients with Stage 1 disease.  
Mean survival rates were compared and Stage 1 had the best survival at 3779.726 against the 
worst survival rate of 2835.671 in patients with Stage IV disease. This result was statistically 
significant with χ 2 test of 31.760 (p<0.0001). The Kaplan-Meier survival distribution is shown in 
the figure below. 
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Figure 20 Fife survival distributions by Disease stage 
 
The log rank test that was run to determine if there were differences in the survival distribution 
for the different types of alcohol status: none drinkers, moderate, harmful and hazardous  
drinkers (Figure 21) found the survival distributions for the groups did not achieve the statistically 
significant difference with a p<0.05 with, χ2= 7.306, p 0.063. Hazardous drinkers had the worst 
mean and median survival times with mean of 2842.768 days in comparison to moderate drinkers 
who had mean survival of 3266.742 days. 
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Figure 21 Survival distributions by Alcohol Status 
 
Cumulative survival for all smoking groups had evidence of statistical difference between groups 
with χ 2 of 17.866. These results were also shown to have reached statistical significance 
p<0.0001.  Mean survival distributions for smoking status (Figure 22) did not follow a linear 
pattern with the worst outcomes for moderate smokers with mean survival of 2915.017 days 
compared to 3643.577 days for non-smokers.  
 
153  
 
Figure 22 Fife survival distributions by Smoking Status 
 
We began evaluating the two prognostic factors under study. Comorbidity measured by CCI 
appeared to demonstrate a divergence in cumulative survival which was shown to have statistical 
significance between the comorbidity groups. Severe comorbidity had the worst cumulative 
survival at 3132.877 days and the no comorbidity group had the best survival at 4077.387 days.  
The χ2 statistic was 9.571 which was statistically significant with p=0.023.  
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Figure 23 Fife survival distributions by CCI 
 
In the ECI model, (Figure 24) the group without comorbidity appeared to have a much higher 
cumulative survival compared to the groups with comorbidity. Comparison between the groups 
showed that the mean survival time for the no comorbidity group was 3719.195 days with a 
decline to 2292.500 days for those with severe comorbidity levels.  
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Figure 24 Survival distributions by ECI 
 
Survival distributions classified by Scottish SIMD quintiles (Figure 25) were the next step and we 
found that the fifth quintile (least deprived) appeared to have a much higher survival with mean 
survival of 3573.006 days compared to the Quintile 4 with the worst mean survival time of 
2.994.637 days. The cumulative survival distribution reached statistical significance with a value 
of p=0.027 and χ 2 of 10.976.  
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Figure 25 Fife survival distributions by SIMD quintiles 
 
A log rank test was run to determine if there were differences in the survival distribution for the 
SIMD Education quintiles. The cumulative survival distribution (Figure 26) did not reach statistical 
significance with a value of 0.653 and χ 2 of 2.451.The fifth quintile (least well educated) appeared 
to have a much lower mean survival of 3190.224 days compared to Quintile 2 with 3797 days.   
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Figure 26 Survival distribution by Education quintile Fife 
 
Cumulative survival for all SIMD Income groups (Figure 27) did not reach statistical difference 
between the groups with χ 2 of 4.345 and a p value=0.361. In terms of the cumulative survival 
distribution of patients from Quintile 5 (lowest income group) appeared to have the lowest 
cumulative survival proportion 3164.602 days compared to Quintile 1 (highest income groups) 
who had cumulative survival of 3903.894 days.  
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Figure 27 Survival distribution by SIMD Income quintile Fife 
 
As the initial exploration of the data using Kaplan-Meier was complete, the next step was to 
conduct an analysis of time to death determined by the key predictors, comorbidity and SES. 
6.2.3. Cox proportional hazards regression - Fife dataset 
The Cox proportional hazards regression was used as it is the ideal method to estimate the 
relative risk of death within the cohort. The first model was an unadjusted Cox regression using 
just SES and comorbidity. The initial model fit was tested using the survival package in R to 
ensure the assumptions of the model had been met. This would allow for more precise estimates 
of prognostic effect of both comorbidity and SES. 
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Table 22 Initial Cox Model of SIMD and CCI 
Explanatory variables df Sig HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) 4 .029    
SIMD quintile 2  .211 .832 .625 1.109 
SIMD quintile 3  .539 .912 .680 1.123 
SIMD quintile 4  .217 1.231 .885 1.713 
Least deprived SIMD quintile  .019 .646 .449 .930 
CCI No comorbidity (Ref group) 3 .049    
CCI Mild comorbidity  .431 .829 .519 1.323 
CCI Moderate comorbidity  .574 .913 .664 1.255 
CCI Severe comorbidity  .151 1.233 .926 1.642 
 
The individual predictors of Scottish SIMD quintiles and CCI were placed in the model (Table 22), 
and they were unable to demonstrate a reduction in survival. We repeated the analysis 
substituting CCI with ECI score. For SIMD quintiles there appeared to be a protective effect for 
patients from Quintile 5 (Least deprived) as the hazard of 0.655 reached statistical significance 
with p=0.023. There was evidence of a doubling of the risk (HR=2.283, p=0.023) when comparing 
the survival of patients without comorbidity to those with severe comorbidity as measured using 
the ECI. We conducted the same analysis but this time we used SIMD Income and Education 
quintiles to approximate SES with CCI for comorbidity. This regression analysis found a marginally 
statistically significant reduction in survival for severe comorbidity with HR=1.3336, p=0.051 
(95%CI 0.999-1.787). When this analysis was repeated using ECI to measure comorbidity, there 
was a marked decrease in survival for severe comorbidity with HR=2.229 and this reached 
statistical significance with p=0.027 (95%CI 1.096-4.533).  
As a next step within the analysis, Cox Proportional Hazards Regression Model that adjusted for 
the following variables of interest age, sex, stage, smoking and alcohol status was conducted. 
The Cox model appeared to show that when compared to the most deprived group, patients 
from the least deprived quintile had an increase in survival with reduced risk of death of nearly 
30% but this result did not attain statistical significance. 
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A comparative model using the ECI instead of CCI demonstrated a survival effect for moderate 
comorbidity with a hazard ratio of 1.465 which reached statistical significance with p=0.046 (95% 
CI 1.007-2.131). Using income and education alongside CCI, we were unable to demonstrate an 
effect on survival as the results did not reach statistical significance. Another subsequent model 
using ECI for comorbidity status, and income and education for SES, did not find a survival effect. 
Moderate comorbidity did show promise but despite risk of death reaching marginal statistical 
significance with p=0.053 and HR=1.450, the null hypothesis could not be rejected as the 95% CI 
included 1. 
 
Our next attempt was to fit a model that adjusted for Scottish SIMD quintiles, CCI, HNC type, age 
and stage. This model did not appear to show an effect on survival as the 95% confidence 
intervals for the hazard ratios included 1. Replacing CCI with ECI did not show any effect (Table 
23), however moderate comorbidity showed a significant survival disadvantage as it nearly 
showed effect with HR=1.452, p=0.051 but the lower limit of the 95% CI was 0.999 which is less 
than 1 therefore the null hypothesis could not be rejected.  
Table 23 Cox Model HNC type, stage, age, + Scottish SIMD and ECI 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) 4 .209    
SIMD quintile 2  .213 .782 .531 1.151 
SIMD quintile 3  .662 .911 .602 1.380 
SIMD quintile 4  .251 1.311 .817 2.169 
Least deprived SIMD quintile  .208 .718 .428 1.203 
ECI No comorbidity (Ref group) 3 .268    
ECI Mild comorbidity  .783 1.005 .719 1.549 
ECI Moderate comorbidity  .051 1.452 .999 2.111 
ECI Severe comorbidity  .867 .905 .279 2.929 
 
Using CCI alongside the income and education quintiles  was able to demonstrate a statistically 
significant reduction of survival in the cohort but this was only apparent for patients with severe 
comorbidity compared to those without comorbidity, HR=1.744, p=0.045 (95%CI 1.013-3.005). 
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After repeating the analysis using a model that used ECI in the place of CCI, no effect on survival 
was observed. 
In the next proportional hazards regression model, we decided to drop age as a separate 
predictor from the analysis as it was possible there was some interaction with CCI as it was the 
age=related CCI that which used to calculate the summary comorbidity score. In spite of the 
changes, the new iteration did not show that either comorbidity or SES measured using the CCI 
and Scottish SIMD quintiles respectively were good predictors of survival as they continued to 
show no significant effect (Table 24).  
Table 24 Cox Model HNC type, Stage +Scottish SIMD +CCI 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) 4 .289    
SIMD quintile 2  .189 .772 .525 1.136 
SIMD quintile 3  .830 .956 .634 1.442 
SIMD quintile 4  .381 1.234 .771 1.973 
Least deprived SIMD quintile  .249 .739 .443 1.235 
CCI No comorbidity (Ref group) 3 .028    
CCI Mild comorbidity  .216 .622 .294 1.319 
CCI Moderate comorbidity  .942 .981 .595 1.619 
CCI Severe comorbidity  .192 1.366 .855 2.183 
 
Comparing the same variables and using ECI in place of CCI showed a measure of effect for ECI 
measured comorbidity, particularly moderate comorbidity, HR= 1.478 (p=0.040). Running a new 
Cox regression model that used SIMD income and education quintiles instead of SIMD quintiles 
alongside CCI could not demonstrate an effect on survival. However the one that substituted ECI 
for CCI and had SIMD income and education for SES, found an effect survival for patients with 
moderate comorbidity. Survival wamelike a hazard of 1.525 which reached statistical significance 
with p=0.031, (95%CI 1.039-2.239). Multivariate analysis adjusting for HNC type and disease stage 
did not demonstrate a survival effect for ECI measured comorbidity, although the hazard ratios 
increased from 0.610 for mild comorbidity to 1.374 for severe comorbidity. 
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We ran another Cox regression model and substituted SIMD income and education quintiles to 
take the place of SIMD and used the CCI score for comorbidity. The results were unable to 
demonstrate an effect on survival. After using ECI in place of CCI in a subsequent model, this 
showed an effect only for moderate comorbidity, with HR=1.560, p=0.023 (95%CI 1.064-2.288). In 
order to elicit whether comorbidity and SES were linked to survival in our cohort of patients we 
ran two regression models where comorbidity was measured using first the CCI and SES using 
the SIMD income and education quintiles. This analysis was able to demonstrate an increasing 
risk of death based on both SES and comorbidity (Table 25) as there was a two-fold increase in 
risk of death (p=0.040) when comparing severe comorbidity to not having any comorbidity. In 
terms of SES, there was a less clear measure of association for both SIMD income and education 
with death. 
Table 25 Cox Model of All variables + CCI + SIMD income and education 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
CCI No comorbidity (Ref group) 3 .024    
CCI Mild comorbidity  .867 .922 .358 2.378 
CCI Moderate comorbidity  .502 1.283 .620 2.654 
CCI Severe comorbidity  .040 2.117 1.037 4.325 
Lowest Income quintile (Ref group) 4 .901    
Income quintile 2  .421 .682 .268 1.733 
Income quintile 3  .590 .748 .260 2.151 
Income quintile 4  .445 .654 .220 1.945 
Highest  Income quintile  .656 .768 .240 2.457 
Most educated quintile (Ref group) 4 .446    
Education quintile 2  .376 1.511 .606 3.767 
Education quintile 3  .789 .879 .342 2.259 
Education quintile 4  .741 1.180 .443 3.145 
Least educated quintile   .674 .792 .267 2.349 
The same model using the ECI measured comorbidity had contrasting results to the CCI model as 
depicted in Table 27. In this model moderate comorbidity had a nearly two-fold higher risk of 
death than no comorbidity. This result was highly statistically significant with p=0.014. Level of 
income had a protective effect. In the education quintiles the analysis appeared to show that 
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patients from Quintile 2 had 1.3 times the risk of death compared to the least well educated 
group. 
Table 26 Cox Model of All variables + ECI + SIMD income and education 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
ECI No comorbidity (Ref group) 3 .053    
ECI Mild comorbidity  .951 .983 .560 1.723 
ECI Moderate comorbidity  .014 1.960 1.143 3.362 
ECI Severe comorbidity  .276 .439 .100 1.931 
Lowest Income quintile (Ref group) 4 .975    
Income quintile 2  .783 .875 .337 2.268 
Income quintile 3  .553 .716 .237 2.162 
Income quintile 4  .655 .773 .250 2.392 
Highest  Income quintile  .766 .835 .255 2.736 
Least educated quintile (Ref group) 4 .654    
Education quintile 2  .521 1.349 .540 3.371 
Education quintile 3  .755 .858 .329 2.239 
Education quintile 4  .753 1.176 .429 3.226 
Most educated quintile   .788 .859 .285 2.595 
 
A final model was run that adjusted for all the following predictor variables, smoking and alcohol 
status, HNC Type, stage, alongside the prognostic variables namely SIMD income and education 
quintiles as well as CCI and ECI. The rationale for the use of both the CCI and ECI in the model to 
check if there was an increase in the parameter estimates. This model showed that moderate and 
severe comorbidity measured using ECI were able to demonstrate a marked reduction in survival 
when compared against the no comorbidity category. The results of this analysis are shown in 
Table 27. Mild ECI comorbidity had a pronounced impact on survival although this result was 
marginally insignificant with risk of death 4 times that of patients without comorbidity, 
(HR=4.424, p=0.052). This pattern of poor survival prediction was also noted for ECI measured 
comorbidity severe comorbidity category which demonstrated a relative risk nearly 5.5 times that 
of patients without comorbidity, (HR=5.465 p=0.029). Comorbidity measured by CCI was shown 
to have no effect as all the hazard ratios were less than 1. 
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Table 27 Cox Model of All variables + SIMD Income, Education + ECI + CCI 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
ECI No comorbidity (Ref group) 3 .033    
ECI Mild comorbidity  .052 4.424 .988 19.810 
ECI Moderate comorbidity  .262 2.356 .527 10.527 
ECI Severe comorbidity  .029 5.465 1.190 25.086 
CCI No comorbidity (Ref group) 3 .002    
CCI Mild comorbidity  .008 .372 .180 .771 
CCI Moderate comorbidity  .009 .350 .158 .772 
CCI Severe comorbidity  .002 .461 .284 .748 
Lowest Income quintile (Ref group) 4 .763    
Income quintile 2  .556 1.400 .456 4.293 
Income quintile 3  .995 1.003 .397 2.535 
Income quintile 4  .422 .757 .383 1.495 
Highest  Income quintile  .831 .943 .552 1.611 
Most educated quintile (Ref group) 4 .354    
Education quintile 2  .886 1.079 .382 3.050 
Education quintile 3  .656 1.232 .493 3.078 
Education quintile 4  .642 .825 .367 1.855 
Least educated quintile   .133 1.505 .883 2.567 
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6.2.4. Results of Multiple Imputations in Fife dataset 
It was noted from this analysis that 586 patients representing 66.9% of the cohort would have 
been dropped from the analysis due to missing values. From this it was deemed necessary to 
conduct multiple imputation methods to fill in the missing values. Conditional imputation was 
employed and the output of the different analyses is presented. Linear dependency prevented 
the analysis of CCI and Scottish SIMD quintiles as predictors. An imputation model was run but 
this could not generate pooled data. Similar issues were observed for SIMD income and 
education quintiles when they were included in a multivariate model. 
A multiple imputation (MI) model of ECI and Income and Education domains was conducted. The 
pooled data showed a reduction in the standard errors compared to the original data. There did 
not appear to be any effect in predicting survival from the imputed variables to demonstrate an 
effect of comorbidity and SES on survival. Similar imputations were run for the rest of the 
analyses incorporating the different combinations of explanatory variables using either CCI or ECI 
for comorbidity and Scottish SIMD quintiles or income and education domain scores to 
approximate SES. The outputs for these analyses using the imputed data are depicted in the 
ensuing analyses. 
Table 28 Cox Model of Age, Smoking, Alcohol, Income, Education and ECI with MI data 
Explanatory variables Sig  HR 95% CI for HR 
Lower  Upper  
Income Quintile 2 .227 .198 1.339 .858 
3 .292 .278 1.373 .773 
4 .303 .305 1.365 .753 
Lowest Income quintile .315 .141 1.591 .858 
Education Quintile 2 .237 .646 1.115 .700 
3 .295 .845 .944 .525 
4 .311 .659 .871 .471 
Least educated Quintile .316 .843 .939 .504 
ECI Mild comorbidity .164 .413 1.144 .828 
ECI Moderate comorbidity .160 .959 .992 .724 
ECI Severe comorbidity .375 .023 2.353 1.128 
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A model that used age, smoking, alcohol, SIMD income and education quintiles and ECI did not 
demonstrate a clear increase in risk of death in the imputed data compared to the original data 
(Table 28), however this changed in the subsequent analysis model using imputed data, with 
evidence of a gradient in survival being particularly apparent for alcohol status, smoking status, 
ECI, income and education quintiles. There was no clear pattern of approximating survival for the 
predictors, age, smoking, alcohol, SIMD income and education quintiles and ECI within the model 
(Table 29) which was unexpected after the addition of stage to the same predictors as those in 
the previous model. 
Table 29 Cox Model of HNC Type, Income, and Education, stage, alcohol, smoking and 
ECI with MI data 
Explanatory variables Sig  HR 95% CI for HR 
Lower  Upper  
Education Quintile 2 .241 .702 1.097 .683 
3 .282 .853 1.054 .605 
4 .306 .905 .964 .527 
Least educated quintile .317 .792 1.087 .583 
Income Quintile 2 .235 .299 1.277 .805 
3 .321 .699 1.133 .598 
4 .352 .585 1.213 .598 
Lowest Income quintiles .345 .473 1.282 .648 
ECI Mild comorbidity .259 .081 1.571 .945 
ECI Moderate comorbidity .229 .178 1.364 .868 
ECI Severe comorbidity .171 .248 1.219 .871 
 
When analysing the original Fife data, we had conducted a multivariate Cox model with both 
comorbidity measures but excluding age. Therefore, we replicated this same step within the 
dataset with imputed values for the missing data. We wanted to investigate whether using both 
ECI and CCI (Table 31) alongside the other predictor variables would make a difference to the risk 
modelling conducted thus far as previous models that included CCI had been unable to estimate 
the magnitude and direction the of effect on survival due to issues of co-linearity and failure of 
coefficient convergence. We found that using both measures of comorbidity improved the risk 
attenuation in the entire model. 
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Table 30 Final Cox Model of HNC Type, education, income, age, stage, CCI with MI data 
Explanatory variables Sig  HR 95% CI for HR 
Lower  Upper  
Education Quintile 2 .244 .648 1.118 .692 
3 .285 .819 1.068 .609 
4 .312 .982 1.007 .544 
Least educated quintile .322 .714 1.125 .597 
CCI Mild comorbidity .277 .992 .997 .579 
CCI Moderate comorbidity .219 .824 1.050 .676 
CCI Severe comorbidity .200 .032 1.542 1.038 
Income Quintile 2 .238 .449 1.197 .751 
3 .330 .751 1.111 .574 
4 .358 .736 1.129 .549 
Lowest Income quintiles .359 .649 1.179 .577 
 
6.3.1. Tayside Cohort 
The Tayside cohort consisted of 468 patients who were included in the analysis, including 320 
males (68.4%) and 148 females (31.6%). The largest age group were patients were aged between 
61 and 70 years (34.4%), followed by those over 71 who made up 31.4% (n=147) of the cohort. 
Heavy smokers made up 34% of the cohort, and 23.3% of patients were classed as hazardous 
drinkers. The types of HNC subsite included 29.7% for mouth and 26.6% for laryngeal cancer. Most 
of the patients were in stage IV (38.5%) and 21.2% patients were in stage I with the rest distributed 
over the other disease stages. Over three quarters of the patients had a CCI score of moderate 
comorbidity or severe comorbidity with both categories making up 38.7% and 40.6% respectively. 
The ECI score of no comorbidity had a 66.7% share of the cohort while only 31 patients were 
classed as having moderate comorbidity and 7 patients had an ECI score of severe comorbidity.  
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6.3.2. Results of Kaplan-Meier Analysis in Tayside dataset 
The cumulative survival distributions were conducted for the Tayside cohort. The first variable to 
be evaluated was age, however prior to this we checked to see if there was a pattern in the 
distribution of ECI based on the patients’ ages, prior to conducting the Kaplan-Meier survival 
analysis.   
Table 31 Cross tabulation of Age and ECI  
  ECI Total 
  None Mild  Moderate Severe  
Age Group <40 years      
41-50 years 7 0 0 0 7 
51-60 years 24 0 0 0 24 
61-70 years 80 8 10 2 100 
71+ years 107 20 9 3 139 
Total  93 21 12 2 128 
 
It appeared that there were more patients in the no comorbidity category (Table 31). Of note was 
that for the mild and moderate categories there were more patients in these categories as the 
ages increased. In comparison the CCI and age cross tabulation (Table 32) was different as there 
were fewer patients in the no comorbidity and mild comorbidity categories. These two levels of 
comorbidity, i.e. none/mild were combined as they had only 28 (7=none, 21=mild) patients within 
them. 
Table 32 Cross tabulation of Age and CCI  
 CCI Total 
None/Mild Moderate Severe Missing 
Age Group <40 years 7 0 0 3 10 
41-50 years 20 2 2 7 31 
51-60 years 0 83 17 17 117 
61-70 years 0 96 43 22 161 
71+ years 0 0 128 19 147 
Total  27 181 190 68 466 
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In terms of the survival distribution by stage and Scottish SIMD, we found a trend that the 
majority (n=147) of patients had Stage IV disease with a larger proportion of these patients 
coming from quintiles 4 and 5 (Table 33). 
Table 33 Cross tabulation of Disease Stage and Scottish SIMD quintiles 
 Scottish SIMD Quintiles Total 
1 2 3 4 5 
Stage Stage 0 5 10 7 6 7 35 
Stage I 9 17 14 23 17 80 
Stage II 15 9 14 14 6 58 
Stage III 14 10 10 16 6 56 
Stage IV 32 25 24 46 20 147 
Total  75 71 69 105 56 376 
 
In terms of the distribution of disease stage by SIMD income quintiles, there appeared to be 
higher frequencies of stage IV disease in patients across all quintiles (Table 34).  
Table 34 Cross tabulation of Disease stage and Income quintiles 
 Scottish SIMD Income Quintiles Total 
1 2 3 4 5 
Stage Stage 0 5 10 5 6 10 36 
Stage I 16 20 15 21 14 86 
Stage II 11 6 14 16 13 60 
Stage III 8 17 7 8 17 57 
Stage IV 27 41 20 27 36 151 
Total  67 94 61 78 90 390 
 
When we reviewed stage and SIMD income domain scores (See Table 34), we found similar 
findings to that of the Scottish SIMD quintiles. Table 36 shows this to be the same for the cross 
tabulation of stage and SIMD education quintiles.  
Table 35 Cross tabulation of Disease stage by Education quintiles 
 Scottish SIMD Education Quintiles Total 
1 2 3 4 5 
Stage Stage 0 6 6 9 7 8 36 
Stage I 17 20 17 18 14 86 
Stage II 8 10 12 11 19 60 
Stage III 8 13 14 9 13 57 
Stage IV 21 45 24 31 30 151 
Total  60 94 76 76 84 390 
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The probability of surviving dependent on age was examined and older patients had higher risk 
of death compared to their younger counterparts as depicted in Figure 28. The majority of the 
patients died within the first five years and older patients aged 71 years and older appeared to 
have the worst survival (1339.626 days) as an age related gradient in survival is apparent from 41 
years onwards. The age group of those 41-50 years had better survival with 2248.349 days.  The 
age related survival distribution was highly statistically significant with evidence of differences 
between age groups defined by χ 2 of 33.032 (p<0.0001). 
Figure 28 Survival by Age group Tayside 
 
 
When considering survival based on gender (Figure 29), the log rank test did not find any 
statistically significant differences between the two groups, χ 2 = 0.047 (p=0.829) although the 
survival curve appeared to indicate that being males had better survival. The mean survival times 
supported these results as the mean survival times for males were marginally different to 
females at 1761.854 days compared to 1744.859 days respectively.  
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Figure 29 Survival by gender Tayside 
 
 
There were more male deaths 107 (22.8%) deaths compared to 49 (10.5%) in females over the 
same time period, but as the male to female ratio was approximately 2:1 these findings are not 
surprising.  
In terms of HNC type (Figure 30), the log rank test found statistically significant differences in the 
survival, with χ 2 = 16.987 with a p.value of 0.005. Hypopharyngeal cancer was noted to have the 
worst survival at 985.673 days compared to the other forms of HNC. The patients diagnosed with 
cancers of the nasopharynx had the best survival rates at 2020.625 days. 
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Figure 30 Survival distribution by HNC type Tayside 
 
Survival distributions by disease stage (Figure 31) appeared not to follow the expected pattern of 
worse outcomes for increasing severity of disease. Stage 1 patients appeared to survive longer 
than any other patient group. The group with the worst overall survival was stage 4 disease 
surviving up to a mean of 1429.393 days but there was little difference with Stage 0 patients. 
Stage 1 patients had the best mean survival rate of 2195.024 days. The log rank test had evidence 
of highly statistically significant differences between the groups with χ 2 of 44.977 and p<0.0001. 
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Figure 31 Survival by Disease stage Tayside 
 
A log rank test was run to determine if there were differences in the survival distribution for the 
different alcohol status groups. Hazardous drinkers appeared to have the worst survival with 
mean survival compared to the other groups with mean survival of 1735.148 days. The cumulative 
survival distribution for alcohol status did not reach statistical significance, χ 2 = 4.608, p=0.203 
(Figure 32), with moderate drinkers appearing to have much better survival compared to the 
other groups with a mean survival of 2014.195 days.  
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Figure 32 Survival by Alcohol status Tayside 
 
 
In terms of smoking status (Figure 33), non-smokers and ex-smokers had the superior outcomes 
compared to the other smoking groups. Mean survival rates were 1631.218 days for heavy 
smokers who had the worst cumulative survival and 2183.709 days for never smokers with the 
best outcomes. This survival distribution reached statistical significance with χ 2 test result of 
15.578 (p<0.001).  
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Figure 33 Survival by Smoking status Tayside 
 
Next we decided to test the survival distribution in terms of the survival as determined by 
comorbidity status measured using the CCI (Figure 34). We found that the survival experiences of 
the Tayside patients were difficult to unravel as a lot of events occurred across all comorbidity 
levels. The mean and median survival times showed that patients with moderate comorbidity had 
the best outcomes compared to severe comorbidity group with mean survival of 1932.934 days 
and 1448.493 days respectively. This cumulative survival analysis achieved statistical significance 
with χ 2 of 22.020, p<0.0001.  
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Figure 34 Survival by CCI Tayside 
 
When assessing the survival distribution of comorbidity using ECI (Figure 35) was taken into 
account to estimate the survival of patients in the cohort, severity of comorbidity was shown to 
be linked to poorer survival. A log rank test was run to determine whether there were differences 
in the survival distribution for ECI, and they were statistically significantly different with χ 2 score 
of 31.845 with a p value <0.0001. Patients classed as having severe comorbidity had a mean 
survival of 530 days while the best survival times were for patients without any comorbidity at 
1842.576 days. 
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Figure 35 Survival distribution by ECI Tayside 
 
Cumulative survival estimates were conducted based on SES using the SIMD quintiles (Figure 36) 
and it was apparent that an inverse relationship existed with quintile 1 patients having worse 
survival. The log rank test did not show evidence of statistically significant differences between 
groups, with χ 2 = 1.028 (p=0.906). We were however able to determine that patients from the 
most deprived category had lower survival (1590.289 days) and the least deprived fared better 
with a mean survival time of 1717.805 days. 
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Figure 36 Survival by Scottish SIMD quintile Tayside 
 
We assessed the cumulative survival distribution of SES measured using the SIMD Education 
quintiles (Figure 37). Although the model did not meet the statistical significance level with χ 2 = 
5.024 and p = 0.285, the Kaplan-Meier curves appeared to show that Quintile 4 had the worst 
overall survival while the most educated (Quintile 1) had better outcomes. This finding was 
confirmed by the mean survival times of 1491 days and 1833.497 days for Quintile 4 and Quintile 1 
respectively. 
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Figure 37 Survival by SIMD Education quintiles Tayside 
 
Using SIMD income domain scores (Figure 38); we were able to determine that quintile 3 had the 
best mean survival compared to lowest income quintile at 1567.818 days and 1965.660 days 
respectively. This result, however did not reach statistical significance as χ 2 test statistic of 7.046 
which had a p value of 0.133. 
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Figure 38 Survival by SIMD Income quintiles Tayside 
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6.3.3. Cox proportional hazards regression - Tayside 
As the Tayside cohort information was relatively complete in comparison to the Fife data, we 
began by analysing the relationship between the CCI and Scottish SIMD quintiles (Table 36). 
Survival estimates appeared to decrease with each incremental level of comorbidity with the 
hazard ratios going up to nearly three times the risk of death for patients without comorbidity or 
those with mild comorbidity. This result achieved statistical significance with p=0.015 but there is 
no clear pattern of survival based on Scottish SIMD quintiles. 
Table 36 Initial Cox Model of CCI and SIMD quintiles 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
CCI None/Mild (Ref group) 2 .000    
CCI Moderate  .500 1.341 .571 3.149 
CCI Severe  .015 2.821 1.226 6.486 
Most deprived SIMD quintile (Ref group) 4 .984    
Quintile 2  .943 .981 .588 1.637 
Quintile 3  .567 .855 .501 1.461 
Quintile 4   .844 .955 .600 1.519 
Least deprived SIMD quintile  .820 .937 .538 1.634 
 
Using the SIMD Income and Education domain quintiles in place of the Scottish SIMD quintiles 
(Table 37) showed a protective effect as the level of education was shown to increase survival 
when the most educated quintile was compared to the least educated quintile. The risk 
patterning in the income domain was less clear as Quintile 2 had a risk of HR=1.234 but this hazard 
ratio was not a good indicator of survival as the result did not reach statistical significance. As for 
the other variables in the model, these were shown to have an attenuation of risk corresponding 
to an increase in the hazard ratio to 2.7 times in patients with severe comorbidity compared to 
patients with mild or no comorbidity.  
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Table 37 Cox Model of SIMD income and education and CCI 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Highest Income quintile (Ref group) 4 .361    
Quintile 2  .470 1.234 .698 2.183 
Quintile 3  .252 .638 .296 1.377 
Quintile 4   .753 .875 .380 2.011 
Lowest Income quintile  .809 .896 .368 2.182 
Most educated quintile (Ref group) 4 .657    
Quintile 2  .691 1.129 .621 2.054 
Quintile 3  .297 1.471 .712 3.039 
Quintile 4   .139 1.909 .810 4.499 
Least educated quintile  .224 1.773 .704 4.465 
CCI None/Mild (Ref group) 2 .000    
CCI Moderate  .508 1.333 .569 3.125 
CCI Severe  .017 2.744 1.196 6.295 
 
In the next model (Table 38) we decided to investigate whether a model that incorporated all the 
variables (gender, HNC Type, smoking and alcohol status, disease stage) with SES measured by 
Scottish SIMD quintiles and comorbidity measured by CCI would be able to predict survival based 
on increasing levels of severity of comorbidity and decrease in SES. We found what appeared to 
be an effect on mortality risk, despite the results not reaching statistical significance. These 
results matched findings of the Kaplan-Meier survival curves which showed a trend of poorer 
survival estimates for patients from the low income backgrounds  
Table 38 Cox Model of SIMD quintiles, CCI + All variables 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) 4 .909    
Quintile 2  .354 1.383 .696 2.745 
Quintile 3  .701 1.166 .532 2.557 
Quintile 4   .872 1.054 .557 1.993 
Least deprived SIMD quintile  .644 1.202 .551 2.620 
CCI None/Mild (Ref group) 2 .004    
CCI Moderate  .423 .657 .235 1.837 
CCI Severe  .439 1.505 .535 4.230 
We took out the age and sex variables and reran the models but this time instead of SIMD 
quintiles we used SIMD income and education domains. We found that all the variables (Table 
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40) were showing evidence of worsening survival dependent on SES and for comorbidity; the 
higher comorbidity levels had worse survival outcomes.  
Table 39 Cox Model of CCI + SIMD Income and education + All variables 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Lowest Income quintile (Ref) 4 .412    
Quintile 2  .843 1.088 .473 2.502 
Quintile 3  .298 0.576 .204 1.629 
Quintile 4   .225 0.509 .171 1.514 
Highest Income quintile  .119 0.385 .116 1.278 
Most educated quintile 4 .250    
2  .748 1.156 .477 2.803 
3  .217 1.888 .688 5.179 
4  .037 3.369 1.076 10.549 
Least educated quintile  .087 3.006 .853 10.600 
CCI None/Mild (Ref) 2 .003    
CCI Moderate  .459 .685 .252 1.865 
CCI Severe  .359 1.582 .593 4.218 
 
Next we decided to change the dichotomised comorbidity categories (None/Mild comorbidity) 
into separate categories. Our analysis focused on the effect of both ECI and SIMD quintiles in a 
model (Table 40). Survival estimates using SIMD quintiles were not clear; however the risk of 
death was noted to increase by increasing severity of comorbidity with all comorbidity categories 
demonstrating a statistically significant impact on survival. Notably survival showed a marked 
reduction due to risk of death increasing from 1.7 (p<0.0001) to 4 times (p=0.001) for mild 
comorbidity and severe comorbidity respectively when compared to the no comorbidity group. 
Table 40 Cox Model of ECI and Scottish SIMD quintiles 
Explanatory variables Sig  HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) .826    
Quintile 2 .617 1.142 .679 1.919 
Quintile 3 .495 .828 .481 1.424 
Quintile 4   .835 .952 .597 1.517 
Least deprived SIMD quintile .809 1.072 .609 1.888 
ECI None (Ref group)  .000    
ECI Mild comorbidity .028 1.676 1.059 2.652 
ECI Moderate comorbidity  .000 2.941 1.801 4.802 
ECI Severe comorbidity .001 4.134 1.772 9.644 
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As the results we had gotten were quite similar to the systematic review findings and the Tayside 
survival distributions in the Kaplan-Meier curves, we thereafter decided to use the SIMD income 
and education quintiles as a more reliable marker for SES (Table 41) in place of the Scottish SIMD 
quintiles. We found that the hazard ratios had changed to demonstrate the survival effect of 
these variables. Income appeared to affect prognosis as it had a steady increase in risk although 
it is unclear why the patients in Quintile 2 had poor survival with a hazard ratio of 1.290. Although 
the hazard ratios for education did not attain statistical significance, education appeared to be 
clinically relevant as a pattern of risk is apparent with survival estimates decreasing. This is 
evident as hazard ratios increased from approximately 1.3 to 1.8 for the least educated compared 
to the well educated group. Only ECI was noted to show a consistently statistically significant 
increased risk of death based on presence and severity of comorbidity. Mild comorbidity was 
shown to predict lower survival by up 1.6 times compared to no comorbidity (p=0.033). The risk 
increased to 2.813 (p=0.000) for moderate comorbidity and 3.513 (p=0.003) for severe 
comorbidity. 
Table 41 Cox Model of SIMD income and education with ECI 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Lowest Income quintile (Ref group) 4 .605    
Quintile 2  .546 1.190 .677 2.092 
Quintile 3  .398 .718 .333 1.548 
Quintile 4   1.000 1.000 .437 2.288 
Highest Income quintile  .932 1.040 .424 2.549 
Most educated quintile (Ref group) 4 .695    
Quintile 2  .399 1.290 .713 2.335 
Quintile 3  .395 1.368 .665 2.813 
Quintile 4   .155 1.853 .791 4.341 
Least educated quintile  .355 1.549 .613 3.915 
ECI None (Ref group)  3 .000    
ECI Mild comorbidity  .033 1.636 1.039 2.576 
ECI Moderate comorbidity   .000 2.813 1.714 4.617 
ECI Severe comorbidity  .003 3.534 1.518 8.226 
 
After adding all the other predictors to the model (Table 42) we found that moderate 
comorbidity HR=3.658 (p=0.002) and severe comorbidity HR=4.236 (p=0.006) were good 
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predictors of survival in patients as the hazards increased from the previous model. Although 
Scottish SIMD quintiles gave the impression of being good indicators of survival, the relevant 
hazard ratios for these three variables did not reach statistical significance. 
Table 42 Cox Model of ECI, Scottish SIMD, Sex, Age, HNC Type and Stage 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Most deprived SIMD quintile (Ref group) 4 .689    
Quintile 2  .216 1.554 .773 3.124 
Quintile 3  .714 1.158 .529 2.536 
Quintile 4   .864 .942 .478 1.859 
Least deprived SIMD quintile  .871 1.070 .472 2.429 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .155 1.643 .828 3.260 
ECI Moderate comorbidity   .002 3.658 1.585 8.440 
ECI Severe comorbidity  .006 4.236 1.524 11.777 
 
A model that included all variables was carried out and certain categories within the explanatory 
variables were shown to be significantly associated with outcome. As the Tayside data was nearly 
complete we looked closely at the prognostic effect of variables such HNC Type, stage, smoking 
and alcohol status had in this cohort. In this model, laryngeal cancer was noted to affect survival 
as it had a protective effect with a HR of 0.436 which was statistically significant with a p value of 
0.007. In terms of smoking status only ex smokers had a 2 fold risk attenuation for suvival with 
HR of 2.316 p=0.017. For alcohol status only harmful drinking affected survival with HR of 1.499. 
This result was marginally statistically insignificant with p=0.051. When considering disease stage, 
Stage 1 disease had a survival effect as risk of death was 2 times higher than Stage 0)with 
HR=2.407, p=0.044. For comorbidity measured using ECI only mild comorbidity was shown to 
affect survival as it reached statistical significance with HR of 3.150 and p=0.002, demonstrating a 
3 fold risk of death for patients with mild comorbidity levels in comparison to their counterparts 
without comorbidity. 
The next step was to conduct the Cox regression using SIMD income and education quintiles as 
the measure of SES (Table 43). Laryngeal cancer continued to have better survival with HR=0.513 
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(p=0.026). In this model both moderate and heavy smokers had significant risk of death with HRs 
of 3.262 (p=0.039) and 3.642 (p=0.011) respectively. Education appeared to be closely linked to 
survival, in particular quintile 4 had a hazard of 3.667 with a significance level of p=0.026. 
Although quintile 5 (least educated) did not achieve statistical significance due to a high p value 
of 0.070, the HR of 3.292 is worth mentioning as it may be clinically relevant in predicting survival. 
From the results it would appear that survival worsened by educational attainment. Moderate 
comorbidity was shown to affect survival as there was a notable increase in the risk of death by 
up to 4 times with HR of 4.265 (p=0.001). Similarly severe comorbidity reduced survival even 
further as the risk of death increased to nearly 5 times with a hazard of 4.760 (p=0.003). 
Table 43 Cox Model of ECI + SIMD Income and education + All variables 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Lowest Income quintile (Ref group) 4 .477    
Quintile 2  .413 .699 .296 1.649 
Quintile 3  .252 .536 .184 1.560 
Quintile 4   .257 .530 .176 1.590 
Highest Income quintile  .068 .318 .093 1.087 
Most educated quintile (Ref group) 4 .175    
Quintile 2  .765 1.148 .464 2.840 
Quintile 3  .222 1.926 .673 5.508 
Quintile 4   .026 3.667 1.169 11.506 
Least educated quintile  .070 3.292 .906 11.964 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .102 1.773 .892 3.523 
ECI Moderate comorbidity   .001 4.265 1.755 10.364 
ECI Severe comorbidity  .003 4.760 1.712 13.236 
 
As the patterns of survival associated with income did not demonstrate a clear linear relationship 
for poor survival by income levels, we decided to combine the previous model with CCI. In the 
results of that Cox regression analysis, we noted that the inclusion of age in this model appeared 
to distort the size of the effect as the HRs for CCI categories were 0.000 which may have been 
due to summary CCI scores having been calculated inclusive of age. 
The next model we ran dropped the age variable as this was already incorporated in the 
calculation of the CCI scores and here again; we used both the CCI and ECI in the model to check 
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if there was an increase in the hazard ratios. The results of this analysis showed that laryngeal 
cancer was protective (HR=0.508 (p=0.023)). The other HNCs appeared to increase risk of death 
but those results did not reach statistical significance. Smoking status showed risk attenuation, 
especially for heavy smoking which reached statistical significance with HR of 3.123 (p=0.026). ECI 
measured comorbidity status was also linked to amplified risk with moderate comorbidity having 
HR=2.783 and p=0.021. Severe comorbidity had a HR of 3.343 and p of 0.024. Comorbidity 
measured using CCI did not show an effect as the parameter estimates did not achieve statistical 
significance and the 95%CI included 1. 
In a model that substituted Scottish SIMD quintiles with SIMD income and education domain 
quintiles, we noted that there was modification of risk estimates. Although most variables did 
show an increase by each incremental level, the results did not achieve statistical significance 
therefore a clear influence on survival was unclear. A constant protective effect for laryngeal 
cancer similar to that from previous models was confirmed here with HR 0.563 and p=0.049. 
Smoking status, specifically heavy smoking was associated with reduced survival, with a hazard 
of 3.558 (p=0.014). Comorbidity was also linked to poor survival, with moderate comorbidity 
having a HR of 2.794 (p=0.028) and severe comorbidity HR= 3.150 (p=0.030).  
We conducted another model where we analysed the influence of all predictors based on CCI. 
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Table 44 Cox Model of All variables ECI, CCI and SIMD income and education. 
Explanatory variables df Sig  HR 95% CI for HR 
Lower  Upper  
Lowest  Income quintile (Ref group) 4 .527    
Quintile 2  .958 .978 .428 2.234 
Quintile 3  .310 .584 .207 1.648 
Quintile 4   .198 .485 .161 1.459 
Highest Income quintile  .112 .377 .113 1.256 
Most educated quintile (Ref group) 4 .229    
Quintile 2  .936 1.038 .421 2.559 
Quintile 3  .353 1.631 .580 4.585 
Quintile 4   .044 3.283 1.033 10.436 
Least educated quintile  .124 2.733 .760 9.832 
CCI None/Mild (Ref group) 2 .121    
CCI Moderate  .356 .618 .222 1.718 
CCI Severe  .899 1.070 .377 3.038 
ECI None (Ref group)  3 .040    
ECI Mild comorbidity  .181 1.626 .798 3.314 
ECI Moderate comorbidity   .028 2.794 1.116 6.998 
ECI Severe comorbidity  .030 3.150 1.115 8.900 
 
Since some of the variables used to conduct the analysis had missing values, particularly the SES 
indicators, the decision was reached to conduct multiple imputations in order to improve the 
methodological rigour and validity of these findings. The results of the imputation analysis are 
presented in the next section. 
6.3.4. Results of Multiple Imputations in Tayside dataset 
The first model fitted with the imputed data was that for CCI and the SIMD income and education 
domains. The model had issues of constant dependence which meant that the income and 
education quintiles could not be modelled as categorical variables. The imputed data showed 
better prediction than the original data with worse risk of death for increased comorbidity. A 
model using the Scottish SIMD data as the SES measure and CCI was conducted (Table 45). The 
model was able to show that chance of survival decreased with each incremental level of 
comorbidity, and similarly for SES, worsening survival was noted for the less affluent SIMD 
quintiles.  
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Table 45 Cox Model of CCI, SIMD Income and Education with MI data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
CCI Moderate .436 .555 1.293 .550 3.041 
CCI Severe .425 .019 2.702 1.174 6.219 
Quintile 2 .257 .928 .977 .590 1.618 
Quintile 3 .284 .618 .868 .495 1.521 
Quintile 4  .236 .734 .923 .580 1.467 
Least deprived SIMD quintile .285 .673 .887 .507 1.551 
 
The next step was to attempt to run a Cox model with all the key variables using SIMD income 
and education domains as the SES measure. Table 48 shows the results of that analysis. HNC type 
was included as a continuous variable as linear dependence posed problems in the model. 
Notably only heavy smoking appeared to be linked to premature mortality in the pooled analysis. 
The imputations did not add anything new to the analysis as evidenced by the change between 
standard errors in the original and pooled data. 
Table 46 Cox Model of All variables, CCI+ SIMD Income and Education with MI data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
CCI Mild 1.622 .231 .139 .005 3.680 
CCI Moderate 1.624 .292 .177 .007 4.702 
CCI Severe 1.610 .112 .074 .003 1.887 
Education Quintiles .128 .217 1.172 .909 1.511 
Income Quintiles .113 .782 .969 .775 1.211 
 
In the analysis using ECI (Table 47) as the comorbidity measure, the hazards of death were more 
pronounced in this simple multivariate model which included Scottish SIMD quintiles and ECI 
only. The change in standard errors between the original and pooled data showed that the 
imputation did not fit the data well, therefore this model could not demonstrate survival 
influences of the prognostic factors.  
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Table 47 Cox Model of ECI and Scottish SIMD quintile with MI data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
ECI Mild comorbidity .245 .031 1.703 1.050 2.762 
ECI Moderate comorbidity  .287 .001 2.678 1.505 4.766 
ECI Severe comorbidity .430 .685 1.192 .501 2.837 
Quintile 2 .264 .842 1.054 .628 1.769 
Quintile 3 .272 .415 .801 .469 1.367 
Quintile 4  .238 .815 .946 .593 1.509 
Least deprived SIMD quintile .293 .957 .984 .554 1.749 
 
The same issue that was highlighted for the Fife data where co-linearity caused issues with 
getting reliable risk estimates for income quintiles was noted in this analysis; therefore further 
models that were run did not treat income or HNC Type as categorical variables. Table 48 
demonstrated a reduction in survival of up to 1.7 times (p=0.031) for mild comorbidity and nearly 
2.7 times (p=0.001) for moderate comorbidity. The other variables did not show a statistically 
significant risk of death. 
A proportional hazards model that used Scottish SIMD, ECI and the other key predictor variables 
showed the magnitude of the effect of adding in the imputed data. The analysis showed that 
most of the variables had a role in determining outcomes although it was less clear for Scottish 
SIMD (Table 48). Only moderate comorbidity was able to demonstrate risk of death with a hazard 
of 2.298 (p=0.006). 
Table 48 Cox Model of all variables including Scottish SIMD quintiles and ECI with MI 
data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
Quintile 2 .292 .662 1.137 .636 2.031 
Quintile 3 .284 .700 .896 .513 1.565 
Quintile 4  .244 .903 1.030 .638 1.664 
Least deprived SIMD quintile .314 .717 .892 .481 1.654 
ECI Mild comorbidity  .258 .295 1.311 .787 2.185 
ECI Moderate comorbidity  .296 .006 2.298 1.280 4.127 
ECI Severe comorbidity .425 .969 1.017 .435 2.375 
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An additional model that used all the same key variables and added in CCI as an additional 
comorbidity measure was run and the output is depicted in Table 49. As in previous models only 
moderate comorbidity in ECI showed an effect with HR=2.453 (p=0.002). Neither SIMD nor CCI 
were able to demonstrate an improvement in survival as their parameter estimates did not reach 
statistical significance and the 95% CIs included 1. 
Table 49 Cox Model of All variables with MI data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
Quintile 2 .274 .435 1.239 .723 2.124 
Quintile 3 .312 .799 .924 .498 1.713 
Quintile 4  .249 .974 .992 .608 1.617 
Least deprived SIMD quintile .310 .824 .933 .508 1.714 
ECI Mild comorbidity .266 .196 1.411 .836 2.383 
ECI Moderate comorbidity  .288 .002 2.453 1.396 4.313 
ECI Severe comorbidity .479 .187 1.895 .728 4.936 
CCI Mild  1.633 .275 .163 .006 4.568 
CCI Moderate 1.640 .274 .161 .006 4.596 
CCI Severe 1.598 .078 .056 .002 1.405 
 
This combined model (shown in Table 50) did not improve the prediction of survival when 
compared to an earlier model that used only the ECI (Table 47). When Scottish SIMD was 
substituted with SIMD income and education quintiles the likelihood of worsening survival was 
increased (Table 50). Only ECI measured moderate comorbidity had a statistically significant 
effect on survival prospects with HR=2.530, p=0.001. 
Table 50 Cox Model All variables, ECI, SIMD Income and Education with MI data 
Explanatory variables SE Sig  HR 95% CI for HR 
Lower  Upper  
Income Quintiles .123 .763 .964 .755 1.229 
Education Quintiles .135 .208 1.189 .906 1.560 
CCI Mild  1.687 .255 .141 .005 4.408 
CCI Moderate 1.712 .251 .134 .004 4.472 
CCI Severe 1.662 .082 .051 .002 1.480 
ECI Mild comorbidity .276 .206 1.421 .823 2.454 
ECI Moderate comorbidity  .277 .001 2.530 1.471 4.352 
ECI Severe comorbidity .504 .243 1.818 .655 5.051 
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6.4.1. Full cohort results 
We conducted a cross tabulation based on both comorbidity and SES to investigate whether 
there was an age associated pattern to comorbidity and whether there was a social patterning to 
stage of disease at diagnosis. We began with CCI and age. This showed that older patients had 
more severe comorbidity levels (see Table 51) 
Table 51 Cross tabulation of Age and CCI Full cohort 
 CCI Total 
None/Mild Moderate Severe 
Age Group <40 years 17 0 0 17 
41-50 years 32 20 8 60 
51-60 years 22 111 81 214 
61-70 years 29 102 229 360 
71+ years 59 11 427 497 
Total  159 244 745 1148 
 
The same effect was apparent for age and ECI as depicted in Table 52. 
Table 52 Cross tabulation of Age and ECI Full cohort 
Age Group  ECI Total 
 None Mild  Moderate Severe 
<40 years 16 1 0 0 17 
41-50 
years 
56 0 4 0 60 
51-60 
years 
169 16 24 5 214 
61-70 
years 
273 48 33 6 360 
71+ years 341 83 66 8 498 
Total  855 148 127 19 1149 
 
The influence of SES on disease stage was explored next using first Scottish SIMD quintiles which 
showed that more advanced disease occurred in patients from the most deprived quintiles as 
shown in Table 53. Across all quintiles, more patients presented with advanced disease and these 
results were similar for income and education domains, (See Tables 54 and 55). 
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Table 53 Cross tabulation of Disease Stage and Scottish SIMD quintiles Full cohort 
 Scottish SIMD quintiles Total 
1 2 3 4 5 
Stage Stage 0 7 11 9 8 9 44 
Stage I 30 52 31 36 25 174 
Stage II 35 27 23 25 16 126 
Stage III 44 28 29 22 13 136 
Stage IV 92 73 70 70 43 348 
Total  208 191 162 161 106 828 
 
Table 54 Cross tabulations of Disease stage and Income quintiles Full cohort 
 Scottish SIMD quintiles Total 
1 2 3 4 5 
Stage Stage 0 7 12 6 6 14 45 
Stage I 28 32 29 55 36 180 
Stage II 20 18 22 36 32 128 
Stage III 12 29 22 28 45 136 
Stage IV 44 62 63 81 101 351 
Total  111 153 142 206 228 840 
 
Table 55 Cross tabulations of Disease stage and Education quintiles Full cohort 
 Scottish SIMD quintiles Total 
1 2 3 4 5 
Stage Stage 0 7 8 11 10 9 45 
Stage I 29 28 37 49 37 180 
Stage II 15 21 25 26 41 128 
Stage III 16 21 29 31 39 136 
Stage IV 46 67 55 92 91 351 
Total  113 145 157 208 217 840 
 
6.4.2. Results of Kaplan-Meier Analysis in Full cohort dataset 
The probability of surviving dependent on age was examined and older patients had higher risk 
of poorer survival compared to their younger counterparts as depicted in Figure 39. The majority 
of the patients died within the first five years and older patients aged 41 -50 years appeared to 
have the worst survival which did not match up with the expected age related gradient in 
survival. The result was not statistically significant with evidence of differences between age 
groups defined by X2 =3.439 (p=0.487). 
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Figure 39 Survival distributions by Age group in Full cohort 
 
When considering survival based on gender (Figure 40), the log rank test did not find any 
significant differences between the two groups, X2 = 152.567 (p<0.0001) although the survival 
curve appeared to indicate that being female was linked to better survival. These findings should 
be treated with some caution as there were two missing cases within the analysis.  
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Figure 40 Survival by Gender in Full cohort 
 
 
There were 126 female deaths compared to 236 in males over the same time period, but as the 
male to female ratio was approximately 2:1 these findings are not surprising. In terms of sex, the 
log rank test did not find statistically significant differences in survival, with X2= 1.129 (p=0.288). In 
terms of HNC type, the log rank test for survival reached statistical significance with X2= 32.479 
(p<0.0001). 
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Figure 41 Survival by HNC type in Full cohort 
 
Figure 41 shows that laryngeal cancers had better mean survival times (3776.62) which were 
better than those for hypopharyngeal cancer which had median survival times of 1769.201. 
Survival distributions by disease stage appeared to follow the expected pattern of worse 
outcomes for advanced disease, as Stage 0 had better survival (Figure 42). 
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Figure 42 Survival distributions by Disease stage in Full cohort 
 
The log rank test for disease stage had evidence of statistically significant differences between 
the groups with X2 of 66.713 and p<0.0001 (Figure 42).  
In terms of alcohol status we found this variable reached statistical significance, X2= 11.168, 
p=0.004 (Figure 43), with none drinkers appearing to have better survival compared to the other 
groups.  
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Figure 43 Survival distributions by Alcohol status in Full cohort 
 
On considering smoking status, (Figure 44) we found that non-smokers had the superior 
outcomes compared to the other smoking groups. This survival distribution followed a gradient 
with heavy smokers having the poorest survival. This relationship was highly statistically 
significant with X2 test result of 20.848 (p<0.0001). Mean survival time comparisons between 
non-smokers and heavy smokers were 3748.161 and 2669.042 respectively. The mean survival 
time for heavy smoking group was significantly less than the overall survival time of 3143.295. 
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Figure 44 Survival distributions by Smoking status in Full cohort 
 
Survival estimates were conducted based on SES (Figure 45) at first using Scottish SIMD quintiles. 
It was apparent that an inverse relationship existed with lowest quintile patients having worse 
survival. The log rank test had evidence of statistically significant differences between groups.  It 
was apparent that patients from quintile 4 had worse chances of survival compared to their 
counterparts with X2 = 15.172 (p=0.004). Quintile 5 had better survival, (mean survival time of 
3179.25 compared to 2947.443 for overall survival time). 
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Figure 45 Survival distributions by Scottish SIMD quintile in Full cohort 
 
Due to the unexpected finding of the Scottish SIMD quintiles analysis, we conducted an analysis 
of the survival distribution using the income and education quintiles.  
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Figure 46 Survival distributions by SIMD Income quintiles in Full cohort 
 
The analysis of income quintiles (Figure 46) showed that the least deprived quintile had the worst 
outcomes, however this result did not reach statistical significance with X2 of 6.452 (p=0.168). 
SIMD education quintiles were not shown to be statistically significant (X2=3.053, p=0.549) and 
survival distribution between quintiles did not follow a predetermined relationship of worse 
survival in the most deprived. 
The survival distribution for comorbidity was the next variable to be assessed. The analysis using 
CCI (Figure 47) showed that the dichotomised none/mild comorbidity category had the better 
survival with mean survival time of 3957.734 days compared to 2918.699 days for severe 
comorbidity. This result was statistically significant p=0.047 and X2=6.135. 
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Figure 47 Survival distributions by CCI in Full cohort 
 
When comorbidity using ECI was used to estimate survival, severe comorbidity was shown to be 
linked to poor survival (Figure 48). The log rank test statistic had statistical significance with X2 
score of 16.559 (p=0.001) showing that there were differences in the survival distribution of ECI.  
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Figure 48 Survival distributions by ECI in Full cohort 
 
6.4.3. Cox proportional hazards regression analysis – Full Cohort 
As the independent analysis showed that most of the factors had some prognostic importance, 
Cox regression modelling was applied in order to find out which categories within the 
explanatory (predictor) variables had the ability to predict survival. Survival analysis of the cohort 
was conducted to estimate the prognostic impact of comorbidity and SES on time to the event of 
interest (death) of an individual.  
The outcomes for the individual Cox proportional hazards regression analysis for the predictor 
variables are shown in Tables 55 to 60. 
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Table 56 Initial Cox Model of CCI and Scottish SIMD quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
CCI None (Ref group) 3 .068    
CCI Mild  .101 1.319 .948 1.836 
CCI Moderate  .011 1.430 1.086 1.883 
CCI Severe  .188 1.204 .913 1.588 
Most deprived SIMD quintile (Ref group) 4 .005    
Quintile 2  .201 .849 .661 1.091 
Quintile 3  .329 .880 .680 1.138 
Quintile 4   .044 1.311 1.007 1.706 
Least deprived SIMD quintile  .062 .750 .555 1.014 
 
In Table 56, CCI did not display a consistent prognostic influence on survival although moderate 
comorbidity had a hazard of 1.43 which was significant with p=0.011. Scottish SIMD quintiles had 
similar results with only Quintile 4 achieving statistical significance with p=0.044 and hazard of 
death of 1.311. A subsequent model that used SIMD income and education domains in the place of 
the Scottish SIMD quintiles (Table 58) found that the two measures of SES although possessing 
hazard ratios that were greater than 1, the results were not statistically significant as they were 
greater than the p<0.05. The mild and moderate categories of CCI were noted to have reached 
statistical significance with HRs of 1.409 (p=0.042) and 1.509(p=0.004) respectively. 
Table 57 Cox Model of SIMD Income and Education Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Lowest Income quintile (Ref group) 4 .266    
Quintile 2  .119 1.319 .931 1.869 
Quintile 3  .912 1.026 .656 1.602 
Quintile 4   .427 1.218 .749 1.980 
Highest t Income quintile  .251 1.359 .805 2.293 
Most educated quintile (Ref group) 4 .693    
Quintile 2  .194 1.258 .890 1.780 
Quintile 3  .856 1.040 .681 1.589 
Quintile 4   .756 1.079 .667 1.747 
Least educated quintile  .882 1.040 .619 1.748 
CCI None (Ref group) 3 .030    
CCI Mild  .097 1.267 .958 1.675 
CCI Moderate  .042 1.409 1.012 1.961 
CCI Severe  .004 1.506 1.141 1.987 
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In Table 57, patients with oropharyngeal cancer were shown to have significantly better overall 
survival (HR=0.630, p=0.030). Smoking status showed that being a heavy smoker appeared to be 
associated with poor survival, with the risk of death to 4.263 p<0.0001. The two prognostic 
factors SES and comorbidity did not illustrate an effect on survival. 
Table 58 Cox Model of All variables, CCI + SIMD quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .230    
Laryngeal cancer  .132 .766 .541 1.084 
Oropharyngeal cancer  .030 .630 .415 .956 
Hypopharyngeal cancer  .740 .901 .486 1.669 
Paranasal sinus cancer  .709 1.222 .426 3.502 
Nasopharyngeal cancer  .464 .469 .062 3.553 
Salivary gland cancer   .467 1.377 .582 3.257 
None smoker (Ref group)  3 .000    
Ex smoker  .072 1.506 .964 2.350 
Moderate smoker  .464 1.163 .776 1.742 
Heavy smoker  .000 4.263 2.556 7.109 
Non-drinker (Ref group) 2 .147    
Moderate drinker  .856 1.038 .693 1.554 
Harmful drinker  .097 1.387 .942 2.041 
Stage 0 (Ref group) 4 .000    
Stage 1  .144 .445 .150 1.318 
Stage 2  .723 .825 .286 2.384 
Stage 3  .904 .936 .320 2.733 
Stage 4  .347 1.637 .586 4.576 
Most deprived SIMD quintile (Ref group) 4 .599    
Quintile 2  .769 .942 .635 1.400 
Quintile 3  .863 1.040 .668 1.617 
Quintile 4   .172 1.343 .880 2.050 
Least deprived SIMD quintile  .927 .977 .589 1.620 
CCI None (Ref group) 3 .025    
CCI Mild  .381 .753 .400 1.420 
CCI Moderate  .367 1.297 .737 2.282 
CCI Severe  .184 1.488 .828 2.676 
Female (Ref group) 1 .251    
Male  .116 .186 .023 1.518 
 
Another model was run comparing HNC types to mouth cancer and appeared to show that 
hypopharyngeal cancers had the worst survival HR=2.037, and this result reached statistical 
significance, p=0.018. Laryngeal cancer had the best survival estimates compared to mouth 
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cancer with HR=0.648 (p=0.015). There was evidence of an attenuation of risk in correspondence 
to the increase of smoking habits, with heavy smokers having up to 2 times an increased risk of 
death compared to ex-smokers who had 1.5 times the risk of death (Table 59). 
Table 59 Cox Model of HNC Type, smoking and alcohol status, Scottish SIMD and CCI 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .011    
Laryngeal cancer  .015 .648 .456 .919 
Oropharyngeal cancer  .972 .993 .665 1.483 
Hypopharyngeal cancer  .018 2.037 1.127 3.681 
Paranasal sinus cancer  .382 .662 .263 1.669 
Nasopharyngeal cancer  .790 .892 .384 2.071 
Salivary gland cancer   .151 1.857 .798 4.324 
None smoker (Ref group)  3 .045    
Ex smoker  .088 1.587 .934 2.696 
Moderate smoker  .046 1.759 1.010 3.064 
Heavy smoker  .006 2.041 1.231 3.383 
Non-drinker (Ref group) 2 .027    
Moderate drinker  .208 1.353 .845 2.166 
Harmful drinker  .015 1.833 1.126 2.983 
Most deprived SIMD quintile (Ref group) 4 .242    
Quintile 2  .079 .702 .473 1.042 
Quintile 3  .098 .698 .456 1.069 
Quintile 4   .894 1.029 .672 1.576 
Least deprived SIMD quintile  .445 .834 .523 1.329 
CCI None/Mild (Ref group) 2 .419    
CCI Moderate  .481 1.223 .698 2.142 
CCI Severe  .210 1.366 .838 2.227 
 
After replacing Scottish SIMD quintiles with SIMD income and education quintiles, (Table 60) the 
protective effect of oropharyngeal cancer remained significant. There was an improvement in 
prognosis with risk of death in heavy smokers to 3.605 with p<0.0001. 
 
 
 
207  
 
Table 60 Cox Model All variables, CCI + SIMD Income and Education Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .214    
Laryngeal cancer  .391 .858 .606 1.216 
Oropharyngeal cancer  .034 .634 .416 .965 
Hypopharyngeal cancer  .871 1.051 .575 1.922 
Paranasal sinus cancer  .654 1.273 .444 3.653 
Nasopharyngeal cancer  .318 .356 .047 2.697 
Salivary gland cancer  .401 1.450 .609 3.454 
None smoker (Ref group)  3 .000    
Ex smoker  .126 1.407 .909 2.179 
Moderate smoker  .636 1.105 .730 1.675 
Heavy smoker  .000 3.605 2.235 5.815 
Non-drinker (Ref group) 2 .335    
Moderate drinker  .971 1.007 .677 1.500 
Harmful drinker  .237 1.266 .856 1.871 
Stage 0 (Ref group) 4 .000    
Stage 1  .107 .409 .138 1.214 
Stage 2  .736 .833 .289 2.404 
Stage 3  .763 .848 .290 2.476 
Stage 4  .393 1.568 .558 4.405 
Lowest Income quintile (Ref group) 4 .730    
Quintile 2  .789 .922 .508 1.672 
Quintile 3  .261 .660 .320 1.363 
Quintile 4   .679 .856 .411 1.785 
Highest Income quintile  .678 .843 .377 1.886 
Most educated quintile (Ref group) 4 .344    
Quintile 2  .265 1.394 .777 2.500 
Quintile 3  .714 1.134 .580 2.216 
Quintile 4   .231 1.550 .756 3.177 
Least educated quintile  .818 1.098 .494 2.443 
Female (Ref group) 1 .218    
Male  .136 .205 .026 1.643 
 
After replacing CCI with ECI and retaining Scottish SIMD quintiles (Table 61), the Cox proportional 
hazards regression showed an reduction in survival for SIMD quintile 4, HR=1.347 (p=0.026). 
Severe comorbidity also had poor survival prospects with HR of 2.689 p<0.0001.  
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Table 61 Cox Model of Scottish SIMD and ECI Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Most deprived SIMD quintile (Ref group) 4 .004    
Quintile 2  .217 .854 .666 1.097 
Quintile 3  .468 .909 .703 1.176 
Quintile 4   .026 1.347 1.036 1.753 
Least deprived SIMD quintile  .094 .773 .571 1.045 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .109 1.220 .957 1.555 
ECI Moderate comorbidity   .073 1.258 .979 1.616 
ECI Severe comorbidity  .000 2.689 1.568 4.612 
 
After changing the Scottish SIMD quintiles and adding in SIMD income and education quintiles 
(Table 62), the statistical significance of the model was reduced. Only severe comorbidity 
reached statistical significance p<0.0001 with HR= 2.677 emphasising the poor survival prospects. 
Table 62 Cox Model of ECI +SIMD Income and education quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Lowest Income quintile (Ref group) 4 .327    
Quintile 2  .142 1.297 .917 1.834 
Quintile 3  .872 1.038 .662 1.627 
Quintile 4   .490 1.188 .728 1.939 
Highest Income quintile  .265 1.350 .797 2.287 
Most educated quintile (Ref group) 4 .724    
Quintile 2  .196 1.256 .889 1.773 
Quintile 3  .778 1.063 .693 1.631 
Quintile 4   .863 1.044 .642 1.697 
Least educated quintile  .849 1.052 .623 1.776 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .066 1.260 .985 1.613 
ECI Moderate comorbidity   .157 1.199 .933 1.542 
ECI Severe comorbidity  .000 2.677 1.562 4.588 
 
In the analysis presented in Table 63, we found that most of the variables were not significant 
with p>0.05. However both age and oropharyngeal cancers were noted to have protective 
effects on survival. Ex- smokers and heavy smokers were at high risk of poor survival with 
hazards of 1.667 (p=0.026) and HR= 4.229 (p<0.0001) respectively. Only moderate comorbidity 
was also shown to affect survival with HR=1.569 p=0.049. 
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Table 63 Cox Model All Variables, ECI and Scottish SIMD quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
None smoker (Ref group)  3 .084    
Ex smoker  .028 1.916 1.071 3.427 
Moderate smoker  .020 2.059 1.122 3.778 
Heavy smoker  .016 1.986 1.135 3.477 
Non-drinker (Ref group) 2 .240    
Moderate drinker  .274 1.348 .789 2.302 
Harmful drinker  .099 1.583 .917 2.732 
Stage 0 (Ref group) 4 .000    
Stage 1  .063 .303 .086 1.066 
Stage 2  .503 .659 .195 2.233 
Stage 3  .740 .814 .240 2.756 
Stage 4  .673 1.291 .394 4.227 
Most educated quintile (Ref group) 4 .337    
Quintile 2  .367 1.335 .713 2.499 
Quintile 3  .980 1.010 .478 2.132 
Quintile 4   .302 1.530 .683 3.427 
Least educated quintile  .158 1.882 .782 4.533 
ECI None (Ref group)  3 .138    
ECI Mild comorbidity  .439 1.185 .771 1.822 
ECI Moderate comorbidity   .049 1.569 1.002 2.457 
ECI Severe comorbidity  .143 1.846 .812 4.197 
Lowest Income quintile (Ref group) 4 .785    
Quintile 2  .753 .902 .476 1.711 
Quintile 3  .516 .768 .345 1.706 
Quintile 4   .563 .784 .344 1.789 
Highest Income quintile  .279 .612 .251 1.490 
 
In Table 63, age remained protective, while smoking status contributed to a reduction in survival 
in these patients. Ex smokers had HR=1.916 (p=0.028), moderate smokers, HR=2.059 (p=0.020) 
heavy smokers had HR= 1.459 (p=0.016). There was a stepwise linear gradient in survival for 
patients based on ECI comorbidity level, rising from hazards of 1.185 to as much as 1.846 although 
the results did not achieve statistical significance. As previous analyses had shown dependency 
between HNC type and Stage, we decided to remove stage from the model to see if there was 
any change in the hazard ratios. The results are shown in Table 64. 
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Table 64 Cox Model with key variables except Stage Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .036    
Laryngeal cancer  .024 .667 .469 .948 
Oropharyngeal cancer  .618 .901 .598 1.358 
Hypopharyngeal cancer  .033 1.914 1.053 3.480 
Paranasal sinus cancer  .483 .718 .285 1.811 
Nasopharyngeal cancer  .811 .901 .384 2.115 
Salivary gland cancer  .286 1.588 .679 3.711 
None smoker (Ref group)  3 .044    
Ex smoker  .057 1.677 .984 2.857 
Moderate smoker  .030 1.865 1.062 3.275 
Heavy smoker  .005 2.086 1.249 3.482 
Non-drinker (Ref group) 2 .036    
Moderate drinker  .105 1.487 .921 2.402 
Harmful drinker  .013 1.878 1.145 3.080 
Most educated quintile (Ref group) 4 .356    
Quintile 2  .158 1.546 .844 2.830 
Quintile 3  .647 1.176 .587 2.355 
Quintile 4   .159 1.755 .803 3.835 
Least educated quintile  .153 1.846 .796 4.278 
ECI None (Ref group)  3 .120    
ECI Mild comorbidity  .247 1.260 .852 1.865 
ECI Moderate comorbidity   .335 1.216 .817 1.812 
ECI Severe comorbidity  .031 2.258 1.075 4.740 
Lowest Income quintile (Ref group) 4 .700    
Quintile 2  .847 1.061 .581 1.939 
Quintile 3  .686 .853 .396 1.838 
Quintile 4   .339 .676 .303 1.510 
Highest Income quintile  .574 .783 .334 1.837 
 
The exclusion of Stage showed an increase in survival estimates but the two SES predictors were 
not significant. In terms of comorbidity, only severe comorbidity was linked to outcome with a 
hazard of 2.258 (p=0.031).  
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Table 65 Cox Model of All variables + ECI and Scottish SIMD quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .108    
Laryngeal cancer  .067 .719 .504 1.024 
Oropharyngeal cancer  .060 .668 .438 1.018 
Hypopharyngeal cancer  .962 1.015 .549 1.876 
Paranasal sinus cancer  .513 1.424 .494 4.106 
Nasopharyngeal cancer  .304 .347 .046 2.613 
Salivary gland cancer  .818 1.109 .457 2.691 
<40yrs (Ref group) 4 .000    
41-50yrs  .009 .193 .056 .662 
51-60yrs  .002 .182 .062 .537 
61-70yrs  .002 .177 .061 .516 
71+ yrs  .053 .354 .124 1.014 
None smoker (Ref group)  3 .000    
Ex smoker  .000 2.441 1.742 3.419 
Moderate smoker  .016 1.459 1.073 1.984 
Heavy smoker  .000 1.729 1.278 2.341 
Non-drinker (Ref group) 2 .132    
Moderate drinker  .126 1.244 .940 1.644 
Harmful drinker  .307 1.147 .881 1.493 
Stage 0 (Ref group) 4 .000    
Stage 1  .116 1.735 .874 3.448 
Stage 2  .057 1.788 .982 3.254 
Stage 3  .237 .743 .455 1.215 
Stage 4  .102 1.401 .936 2.098 
Most deprived SIMD quintile (Ref group) 4 .767    
Quintile 2  .949 .987 .661 1.474 
Quintile 3  .978 .994 .639 1.545 
Quintile 4   .486 1.165 .758 1.789 
Least deprived SIMD quintile  .390 .799 .478 1.334 
Female (Ref group) 1 .089    
Male  .060 .136 .017 1.084 
ECI None (Ref group)  3 .038    
ECI Mild comorbidity  .093 1.611 .924 2.808 
ECI Moderate comorbidity   .815 .943 .580 1.535 
ECI Severe comorbidity  .364 .828 .551 1.244 
 
In the model presented in Table 65, ex-smokers had reduced survival with HR=2.441 (p<0.0001), 
as did moderate smoking which had a hazard of 1.459 (p=0.016), while heavy smokers had nearly 
a 2-fold risk of death with HR=1.729 which was a highly significant evidence of poor survival with 
p<0.0001. Neither comorbidity nor SES was able to give evidence of an effect on survival in this 
model. 
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Table 66 Cox Model of All variables ECI+ SIMD Income and education Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .168    
Laryngeal cancer  .192 .790 .554 1.126 
Oropharyngeal cancer  .077 .680 .443 1.043 
Hypopharyngeal cancer  .971 .988 .532 1.838 
Paranasal sinus cancer  .347 1.664 .576 4.804 
Nasopharyngeal cancer  .264 .314 .041 2.398 
Salivary gland cancer   .837 1.100 .444 2.725 
None smoker (Ref group)  3 .000    
Ex smoker  .036 1.625 1.032 2.558 
Moderate smoker  .496 1.160 .756 1.781 
Heavy smoker  .000 4.546 2.754 7.503 
Non-drinker (Ref group) 2 .271    
Moderate drinker  .970 1.008 .670 1.516 
Harmful drinker  .205 1.297 .867 1.940 
Stage 0 (Ref group) 4 .000    
Stage 1  .151 .448 .149 1.342 
Stage 2  .867 .913 .314 2.653 
Stage 3  .952 .967 .328 2.856 
Stage 4  .309 1.718 .606 4.868 
Lowest Income quintile (Ref group) 4 .885    
Quintile 2  .620 .857 .467 1.575 
Quintile 3  .318 .686 .327 1.437 
Quintile 4   .479 .758 .353 1.630 
Highest Income quintile  .387 .691 .299 1.595 
Most educated quintile (Ref group) 4 .304    
Quintile 2  .358 1.327 .726 2.427 
Quintile 3  .504 1.264 .636 2.509 
Quintile 4   .094 1.882 .897 3.948 
Least educated quintile  .445 1.386 .600 3.201 
ECI None (Ref group)  3 .018    
ECI Mild comorbidity  .617 1.113 .733 1.690 
ECI Moderate comorbidity   .004 1.880 1.229 2.875 
ECI Severe comorbidity  .135 1.859 .825 4.190 
 
The analysis of survival concluded with a Cox model of all predictor variables and comorbidity 
measured by ECI, CCI and SES using Scottish SIMD income and education quintiles. The results are 
shown in Table 66 above. The same results were found with protective effects noted for 
laryngeal and oropharyngeal cancers as well as all age groups. A slight increase in survival 
estimates was noted for the variables with statistically significant categories. The risk for ex-
smokers increased to HR=1.625 p=0.036 and for heavy smokers the hazard went up to HR=4.546, 
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p<0.0001. In terms of comorbidity only moderate comorbidity had a statistically significant effect 
on survival with a hazard of 1.880 p=0.004. 
Table 67 Cox Model of All variables ECI, CCI +Scottish SIMD quintiles Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
Mouth cancer (Ref group) 6 .121    
Laryngeal cancer  .048 .697 .487 .996 
Oropharyngeal cancer  .046 .649 .424 .993 
Hypopharyngeal cancer  .833 .935 .502 1.742 
Paranasal sinus cancer  .466 1.481 .515 4.261 
Nasopharyngeal cancer  .451 .454 .058 3.536 
Salivary gland cancer   .808 1.116 .460 2.710 
None smoker (Ref group)  3 .000    
Ex smoker  .040 1.607 1.021 2.531 
Moderate smoker  .475 1.165 .767 1.769 
Heavy smoker  .000 4.147 2.443 7.038 
Non-drinker (Ref group) 2 .094    
Moderate drinker  .999 1.000 .663 1.508 
Harmful drinker  .089 1.413 .949 2.104 
Stage 0 (Ref group) 4 .000    
Stage 1  .176 .469 .157 1.403 
Stage 2  .778 .858 .295 2.493 
Stage 3  .975 .983 .333 2.896 
Stage 4  .287 1.759 .622 4.972 
Most deprived SIMD quintile (Ref group) 4 .811    
Quintile 2  .817 1.049 .699 1.575 
Quintile 3  .856 1.042 .668 1.625 
Quintile 4   .425 1.193 .774 1.838 
Least deprived SIMD quintile  .533 .845 .498 1.435 
CCI None (Ref group)  .313    
CCI Mild  .533 1.263 .607 2.630 
CCI Moderate  .133 1.669 .856 3.255 
CCI Severe   .367 1.401 .673 2.916 
ECI None (Ref group)   .072    
ECI Mild comorbidity  .622 1.120 .714 1.756 
ECI Moderate comorbidity   .011 1.778 1.139 2.774 
ECI Severe comorbidity  .235 1.688 .712 4.004 
 
As a comparator the analysis using CCI and ECI to classify comorbidity, was modified to include 
SIMD income and education quintiles for SES and all the other explanatory variables. The results 
are presented in the Table 67. ECI measured comorbidity demonstrated lower survival for 
patients with moderate comorbidity HR=1.778 (p=0.011). The results shown in Table 68 depict the 
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analysis for all the selected predictor variables when placed together in the multivariate 
proportional hazards regression analysis. Again moderate comorbidity is associated with poor 
survival with HR=1.886 (p=0.006). 
Table 68 Cox Model of All variables, ECI, CCI + SIMD Income and education Full cohort 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
None smoker (Ref group)  3 .000    
Ex smoker  .057 1.559 .988 2.461 
Moderate smoker  .556 1.138 .741 1.748 
Heavy smoker  .000 4.450 2.610 7.587 
Non-drinker (Ref group) 2 .185    
Moderate drinker  .868 1.035 .686 1.562 
Harmful drinker  .129 1.370 .912 2.059 
Stage 0 (Ref group) 4 .000    
Stage 1  .154 .450 .150 1.348 
Stage 2  .857 .907 .312 2.633 
Stage 3  .977 .984 .334 2.903 
Stage 4  .278 1.779 .629 5.033 
Lowest Income quintile (Ref group) 4 .883    
Quintile 2  .538 .826 .449 1.519 
Quintile 3  .358 .709 .341 1.475 
Quintile 4   .508 .772 .359 1.660 
Highest Income quintile  .357 .676 .294 1.555 
Most educated quintile (Ref group) 4 .358    
Quintile 2  .395 1.298 .712 2.365 
Quintile 3  .531 1.243 .629 2.458 
Quintile 4   .125 1.783 .851 3.737 
Least educated quintile  .537 1.302 .564 3.008 
CCI None (Ref group) 3 .298    
CCI Mild  .420 1.353 .649 2.822 
CCI Moderate  .096 1.763 .904 3.439 
CCI Severe  .245 1.544 .743 3.208 
ECI None (Ref group)  3 .037    
ECI Mild comorbidity  .646 1.112 .708 1.747 
ECI Moderate comorbidity   .006 1.886 1.205 2.952 
ECI Severe comorbidity  .198 1.765 .743 4.192 
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Table 69 Final Cox Model of HNC type, age, stage, Income, Education, alcohol, smoking 
and ECI 
Explanatory variables df Sig HR 95% CI for HR 
Lower Upper 
<40yrs (Ref group) 4 .204    
41-50yrs  .139 .148 .012 1.863 
51-60yrs  .276 .282 .029 2.757 
61-70yrs  .180 .205 .020 2.079 
71 +yrs  .448 .409 .041 4.117 
Non smoker (Ref group) 3 .003    
Ex smoker  .849 1.137 .305 4.231 
Moderate smoker  .299 2.061 .527 8.060 
Heavy smoker  .033 3.957 1.117 14.019 
Non-drinker (Ref group) 2 .861    
Moderate drinker  .786 .873 .326 2.338 
Harmful drinker  .935 1.044 .369 2.957 
Stage 0 (Ref group) 4 .008    
Stage 1  .340 3.630 .256 51.368 
Stage 2  .128 7.212 .567 91.697 
Stage 3  .043 13.312 1.085 163.300 
Stage 4  .032 16.217 1.263 208.237 
Lowest Income quintile (Ref group) 4 .289    
Quintile 2  .394 .646 .236 1.767 
Quintile 3  .227 .457 .128 1.629 
Quintile 4   .101 .337 .092 1.235 
Highest Income quintile  .030 .218 .055 .860 
Most educated quintile (Ref group) 4 .014    
Quintile 2  .427 1.528 .537 4.343 
Quintile 3  .009 6.304 1.583 25.105 
Quintile 4   .001 10.163 2.443 42.271 
Least educated quintile  .003 11.056 2.315 52.805 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .906 .937 .318 2.763 
ECI Moderate comorbidity   .120 2.361 .799 6.975 
ECI Severe comorbidity  .000 7.629 2.732 21.302 
 
The model presented in Table 69 was able to clearly demonstrate the survival estimates as well 
as risk attenuation for the explanatory variables within the analysis. Heavy smokers had nearly 4 
times an increased risk of death compared to non smokers (p=0.033). Patients with stage 3 
disease were 13 times more likely to die (p=0.043) compared to those with stage 0 disease. Stage 
4 patients were 16 times more likely (p=0.032) to experience reduced survival compared to stage 
0 patients. Lower levels of educational attainment was also linked to poor survival, as Quintile 3 
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had a hazard of 6.304 (p-0.009), Quintile 4 had 10 times the risk (p=0.001), while the least 
deprived quintile had HR=11.056 (p=0.003). Only severe comorbidity demonstrated an association 
with poor survival with HR=7.629 which was highly significant with p<0.0001. 
6.4.4. Multiple imputations of Full Cohort 
As mentioned previously there were instances of missing data particularly for the Fife portion of 
the cohort. This data had been called prospectively as part of the patient records kept by the 
HNC Nurse Specialist. There were occurrences of missing data in important explanatory variables 
such as smoking and alcohol status, HNC type, SIMD income and education quintiles, TNM 
staging and sex. It was not clear exactly why there were missing data; however the missing 
values analysis shown below highlights the rationale for multiple imputations. 
Figure 49 Missing values summary 
 
 
The initial Cox proportional hazards regression model (Table 70) of the imputed data used 
Scottish SIMD and CCI. The risk prediction was unclear for all predictors except for moderate 
comorbidity which did demonstrate an elevation in risk of poor survival; however that result did 
reach statistical significance. 
217  
 
Table 70 Initial Cox Model of Scottish SIMD quintiles and CCI with MI data 
Explanatory variables SE HR 95% CI for HR 
Lower Upper 
Quintile 2 .257 .977 .590 1.618 
Quintile 3 .284 .868 .495 1.521 
Quintile 4  .236 .923 .580 1.467 
Least deprived SIMD quintile .285 .887 .507 1.551 
CCI Mild  .436 1.293 .550 3.041 
CCI Moderate .425 2.702 1.174 6.219 
CCI Severe .535 .858 .301 2.447 
 
Although there were some differences, the model (Table 71) including ECI and Scottish SIMD 
quintiles did show higher risk of death dependent on level of comorbidity or SES. In this model 
only moderate comorbidity was shown to have an effect on survival with HR=2.678 p=0.001. 
Table 71 Cox Model of Scottish SIMD quintiles and ECI with MI data 
Explanatory variables SE HR 95% CI for HR 
Lower Upper 
Quintile 2 .264 .842 1.054 .628 
Quintile 3 .272 .415 .801 .469 
Quintile 4  .238 .815 .946 .593 
Least deprived SIMD quintile .293 .957 .984 .554 
ECI Mild comorbidity .245 .031 1.703 1.050 
ECI Moderate comorbidity  .287 .001 2.678 1.505 
ECI Severe comorbidity .430 .685 1.192 .501 
 
We then modified the analysis (Table 72) by adding all the other predictor variables to the 
analysis using Scottish SIMD quintiles and ECI comorbidity scores. This model showed an increase 
in risk of lower survival. Although there was no conclusive evidence for SES, we did nevertheless 
find that ECI moderate comorbidity was associated with poor survival with nearly with HR=2.298 
(p=0.006).  
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Table 72 Cox Model of all variables + Scottish SIMD and ECI with MI data 
Explanatory variables SE HR 95% CI for HR 
Lower Upper 
Quintile 2 .292 .662 1.137 .636 
Quintile 3 .284 .700 .896 .513 
Quintile 4  .244 .903 1.030 .638 
Least deprived SIMD quintile .314 .717 .892 .481 
Sex .184 .652 1.087 .757 
ECI Mild comorbidity .258 .295 1.311 .787 
ECI Moderate comorbidity  .296 .006 2.298 1.280 
ECI Severe comorbidity .430 .685 1.192 .501 
 
The earlier systematic review conducted as part of the thesis had found that income and 
education had a significant impact on survival. This finding was tested in the combined cohort 
using SIMD income and education quintiles with ECI as well as the other predictors (Table 73). We 
could not find an association with poor survival in this iteration. 
Table 73 Cox Model of all variables + Income, education quintiles and ECI with MI data 
Explanatory variables SE Sig HR 95% CI for HR 
Lower Upper 
Income Quintiles .128 .768 .963 .743 1.247 
Education Quintiles .146 .251 1.187 .879 1.603 
Sex .183 .718 1.068 .746 1.529 
ECI Mild comorbidity .267 .302 1.320 .775 2.248 
ECI Moderate comorbidity  .282 .002 2.397 1.376 4.173 
ECI Severe comorbidity .435 .979 1.012 .421 2.432 
 
In the next step we conducted the same analyses as before but this time we replaced ECI with 
CCI in order to see if this would provide a better model of predicting premature mortality. The 
outputs are depicted in the following 4 tables, (Table 74-77).  
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Table 74 Cox Model of income, education and CCI with MI data 
Explanatory variables SE Sig HR 95% CI for HR 
Lower Upper 
Original data Income Quintiles .108 .841 .841 .978 .791 
Education Quintile .114 .266 .266 1.134 .908 
CCI None/Mild (Ref)  .000 .000   
CCI Moderate .433 .549 .549 1.296 .555 
CCI Severe .422 .018 .018 2.714 1.187 
Pooled data Income Quintiles .112 .980 .980 1.003 .805 
Education Quintiles .120 .411 .411 1.104 .871 
CCI Mild  .433 .556 .556 1.290 .552 
CCI Moderate .422 .018 .018 2.705 1.774 
CCI Severe .531 .794 .794 .871 .308 
b. Constant or Linearly Dependent Covariates CCI (3) =0 
The analysis illustrated in Table 74 did not demonstrate a modification of the approximation of 
survival once the data imputations had been conducted. The original data showed a HR of 2.714 
(p=0.018) in the severe comorbidity group but this was no longer evident after the multiple 
imputations. 
Using SIMD income and education domains showed improved prediction of survival with higher 
hazard ratios noted within the model (Table 75). The CCI moderate comorbidity group showed an 
elevation in risk of death with HR=2.418 (p=0.043). 
Table 75 Cox Model of all variables, Income, education and CCI with MI data 
Explanatory variables SE Sig HR 95% CI for HR 
Lower Upper 
Income Quintiles .114 .878 .983 .784 1.232 
Education Quintiles .126 .440 1.103 .858 1.417 
CCI Mild  .445 .814 1.110 .464 2.655 
CCI Moderate .436 .043 2.418 1.029 5.683 
CCI Severe .540 .419 .647 .225 1.862 
b. Constant or Linearly Dependent Covariates Charlson(3) = 0 ; 
 
However in comparison, when assessing the prognostic impact of the predictor variables, ECI 
status and SES measured using the Scottish SIMD quintiles, there was evidence that both 
comorbidity and SES affected survival (Table 76). This model could not demonstrate the influence 
of either SES or comorbidity in determining survival within the cohort. 
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Table 76 Cox Model of all variables, Scottish SIMD and CCI with MI data 
Explanatory variables SE Sig HR 95% CI for HR 
Lower Upper 
Quintile 2 .273 .436 1.237 .724 2.114 
Quintile 3 .313 .979 .992 .533 1.847 
Quintile 4  .252 .867 1.043 .636 1.712 
Least deprived SIMD quintile .309 .626 .860 .469 1.576 
CCI Mild 1.613 .249 .151 .006 3.968 
CCI Moderate 1.609 .325 .201 .008 5.214 
CCI Severe 1.586 .114 .078 .003 1.883 
 
6.5. Key findings 
There were initial methodological challenges in conducting the survival analysis of the Fife and 
Tayside data due to missing data particularly in the Fife cohort. These data did not appear to 
follow any patterns of missingness i.e. the data were missing at random, therefore multiple 
imputations were used to fill in the missing values were conducted. The two regions showed an 
approximately 2:1 ratio of HNC occurrence in males compared to females. Most of the HNC cases 
occurred in patients aged 60 years and above with the majority of HNCs being laryngeal cancers. 
Cross tabulations of disease stage and SES showed that more advanced cancers were diagnosed 
in the lower SES (deprived groups).  
In the evaluation of cumulative survival distributions, there were contrasting findings by region 
particularly for age, HNC Type, smoking status, CCI, ECI, SIMD quintiles, as well as the income and 
education quintiles (Table 77).  
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Table 77 Comparison of survival between Fife and Tayside 
Explanatory 
variable 
Highest 
survival 
group (Fife) 
Mean 
survival 
time (Fife) 
Highest survival 
group (Tayside) 
Mean 
survival 
time 
(Tayside) 
 
Lowest mean 
survival group 
(Fife) 
Mean 
survival 
time (Fife) 
Lowest mean 
survival group 
(Tayside) 
Mean 
survival 
time 
(Tayside) 
Age  71+years  3611.622 41-50years 2248.349 41-50years 3118.196 71+years  1339.626 
Gender Males  3560.259 Males  1761.854 Females  3519.176 Females  1744.859 
HNC Type Laryngeal 
cancer 
4165.917 Nasopharyngeal 
cancer 
2020.625 Nasopharyngeal 
cancer 
2346.202 Hypopharyngeal 
cancer 
985.673 
Stage  Stage I 3779.726 Stage I 2195.024 Stage IV 2835.671 Stage IV 1429.393 
Alcohol 
status 
Moderate 
drinker 
3266.742 Moderate drinker 2014.195 Hazardous 
drinker 
2842.768 Hazardous 
drinker 
1735.148 
Smoking 
status 
Never 
smoked 
3643.577 Never smoked 2183.709 Moderate 
smoker 
2915.017 Heavy smoker 1631.218 
CCI No 
comorbidity  
4077.387 Moderate 
comorbidity 
1932.934 Severe 
comorbidity 
3132.877 Severe 
comorbidity 
1448.493 
ECI Moderate 
comorbidity 
3719.195 No comorbidity 1842.576 Severe 
comorbidity 
2292.500 Severe 
comorbidity 
 
530 
SIMD 
quintiles 
Least 
deprived 
3573.006 Least deprived 1717.805 Quintile 4 2994.637 Most deprived 1590.289 
SIMD 
education 
quintiles 
Quintile 2 3797.331 Most educated 1833.497 Least educated 3190.224 Quintile 4 1491 
SIMD Income 
quintiles 
Highest 
income 
3903.894 Quintile 3 1965.660 Lowest income 3164.602 Lowest income  1567.818 
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We found that survival distributions for age contrasted between the two regions as in Fife 
patients aged 71 years and older had better survival than their younger counterparts, and this 
same age group had the worst mean survival times in the Tayside cohort. Those age 41-50 years 
appeared to fare better in Tayside with the highest mean survival time, however this group had 
the worst survival amongst the Fife patients. These results were unexpected as the risk of death 
did not follow the expected age gradient in Fife although the reason for this difference was not 
immediately clear.  
There were regional variations for HNC Type as laryngeal cancer patients fared better than those 
diagnosed with nasopharyngeal cancer in Fife. In contrast, the Tayside patients diagnosed with 
nasopharyngeal cancer had best mean survival figures in comparison to other forms of HNC while 
those with cancer of the hypopharynx appeared to have the worst survival outcomes.  
For smoking status, we found the disparity in that moderate smokers from Fife experienced the 
lowest survival as did heavy smokers in the Tayside group. There were differences in outcomes 
based on CCI, with patients without comorbid disease having the best outcomes. This result was 
not similar to the outcome in Tayside where patients with moderate comorbidity had the better 
prognosis. In contrast for ECI measured comorbidity, it was the moderate comorbidity group that 
had better survival figures in the Fife cohort and in Tayside patients classified as having no 
comorbidity fared better than all other comorbidity categories. 
In terms of SES, we noted that differences between groups were also evident. For the SIMD 
quintiles we found that Fife patients from Quintile 4 had the worst outcomes as did the most 
deprived patients within the Tayside cohort. In Fife patients from Quintile 2 had the best mean 
survival time as did the Tayside patients from the most educated quintile. For the worst survival 
outcomes, in Fife patients from Quintile in Fife and the most educated Tayside had the best 
prognosis. For those with the worst mean survival, the least educated and those from Quintile 4 
from Fife and Tayside respectively were noted to have the lowest mean survival times. Prognosis 
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was favourable for Fife patients classified as highest income quintile while the Tayside patients 
from Quintile 3 had the best survival outcomes. 
The cumulative survival distributions were able to present evidence of factors such as the type of 
HNC, disease stage; alcohol intake and smoking are linked to survival in HNC. Empirical evidence 
has shown that laryngeal cancers have the best prognosis in HNC as they have high cure rates. 
(464, 465) However despite this Tayside appeared to buck this trend. The results for disease 
stage and alcohol status were unremarkable and similar to those confirmed elsewhere, i.e. 
patients with stage I disease have the better prognosis and those with stage IV have the highest 
risk of death. (267) (466) Moderate alcohol intake has long been linked with more favourable 
outcomes in cancer patients and this appeared to be the case for patients classified as moderate 
drinkers in both Fife and Tayside. (467-471) 
Smoking has been noted as a significant aetiological factor in HNC and the heavier the smoking, 
the higher the risk of poor HNC outcomes. In the Fife cohort the survival distributions showed 
that moderate smokers had the worst survival. This finding is contrary to the research findings 
that noted a dose-response relationship for smoking in HNC. (33, 77, 472-482) The SIMD income 
and education had a less clear pattern of survival distribution particularly for the education 
domain which showed that the Quintile 4 patients had the worst survival, meaning that the least 
educated had better mean survival times. It is not apparent why this particular group did not 
have the expected survival distribution of those with the lowest educational attainment having 
the worst prognosis, (126, 483-485) A finding that has been confirmed in oesophageal cancer. 
(486) 
The table (Table 78) depicts the variation in Cox proportional hazard regression analyses 
conducted on the two regions. These results show that the Tayside data was able to provide 
more reliable estimates of risk when compared to the Fife dataset. These effects were clearly 
demonstrated for smoking status which showed a clear statistically significant elevation in risk 
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for a corresponding increase in smoking levels; moderate smokers HR= 2.825 (p=0.051), heavy 
smokers HR= 3.885 (p=0.005).Only stage 4 disease showed a high risk of death, HR=2.659 
(p=0.049), as did severe comorbidity measured using the ECI with HR=3.052 (p=0.030). 
It would appear that multiple imputations in the Fife data did not enhance the predictive 
potential as the results were unable to show whether comorbidity or SES were linked to survival. 
This was unexpected as the initial analysis had shown that both prognostic factors affected 
survival. It is not clear why the imputed Fife data could not provide meaningful conclusions. 
Another issue worth pointing out is that the CCI was shown to have limited capacity for 
predicting survival as the hazard ratio did not achieve statistical significance. Initially there was 
evidence of confounding from age which makes sense as the CCI score incorporated age. In 
subsequent analyses age was dropped from the analysis; however this did not improve matters. 
On its own CCI measured comorbidity could not provide meaningful results but when combined 
with the ECI, an increase in the hazard was noted for ECI; therefore CCI appeared to amplify the 
effect of ECI. This may be due to the fact that ECI incorporates other conditions which are not 
included in the CCI.  
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Table 78 Risk of death comparison between Fife and Tayside 
Explanatory variables Sig 
(Tayside) 
HR (Tayside) 95% CI for HR 
Lower 
(Tayside) 
Upper 
(Tayside) 
Non-smoker (Ref) .774 (.021)    
Ex-smoker .605 (.120) .839 (2.172) .430 (.817) 1.635 (5.776) 
Moderate smoker .751 (.051) 1.119 (2.825) .560 (.993) 2.234 (8.033) 
Heavy smoker .807 (.005) .923 (3.885) .483 (1.502) 1.763 (10.045) 
Non-drinker (Ref) .292 (.387)    
Moderate drinker .463 (.109) .785 (.565) .411 (.281) 1.499 (1.135) 
Harmful drinker .731 (.650) 1.114 (.811) .602 (.328) 2.061 (2.004) 
Hazardous drinker .304 (.436) 1.340 (.741) .767 (.349) 2.340 (1.574) 
Stage 0 (Ref) .001 (.000)    
Stage 1 .320 (.411) .347 (.621) .043 (.200) 2.801 (1.932) 
Stage 2 .673 (.845) .640 (1.113) .080 (.381) 5.093 (3.256) 
Stage 3 .858 (.492) .827 (1.479) .104 (.484) 6.606 (4.522) 
Stage 4 .802 (.049) 1.298 
(2.659) 
.170 (1.006) 9.935 (7.031) 
Lowest Income quintile 
(Ref) 
.763 (.831)    
Quintile 2 .556 (.949) 1.400 (.973) .456 (.421) 4.293 (2.248) 
Quintile 3 .995 (.377) 1.003 (.626) .397 (.221) 2.535 (1.772) 
Quintile 4 .422 (.576) .757 (.733) .383 (.246) 1.495 (2.180) 
Highest Income quintile .831 (.364) .943 (.571) .552 (.170) 1.611 (1.917) 
Most Educated quintile 
(Ref) 
.354 (.477)    
Quintile 2 .886 (.949) 1.079 (.972) .382 (.399) 3.050 (2.364) 
Quintile 3 .656 (.368) 1.232 (1.600) .493 (.575) 3.078 (4.448) 
Quintile 4 .642 (.139) .825 (2.359) .367 (.758) 1.855 (7.346) 
Least Educated quintile .133 (.336) 1.505 (1.857) .883 (.527) 2.567 (6.540) 
ECI No comorbidity (Ref) .033 (.114)    
ECI Mild comorbidity .045 (.365) .532 (1.378) .288 (.689) .986 (2.758) 
ECI Moderate comorbidity .440 (.125) 1.235 (2.013) .723 (.823) 2.111 (4.923) 
ECI Severe comorbidity .052 (.030) .226 (3.052) .050 (1.112) 1.012 (8.376) 
CCI No comorbidity (Ref) .002 (.122)    
CCI Mild comorbidity .896 (.563) .939 (.747) .368 (.278) 2.401 (2.008) 
CCI Moderate comorbidity .551 (.630) 1.238 (1.284) .613 (.464) 2.500 (3.552) 
CCI Severe comorbidity .008 (.831) .943 (.571) .552 (.170) 1.611 (1.917) 
 
We found that comorbidity measures identified both alcohol and smoking related comorbidities 
namely, ECI found rates of 5.6% for alcohol abuse, 4.3% for liver disease, while CCI had 3.8% for 
mild liver disease, 10.5% for myocardial infarction and 6.4% for peripheral vascular disease. The 
presence of comorbidities may also be due to the relationship there a large proportion of the 
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cohort were as older patients, who tend to develop more chronic age related conditions. This 
assumption was substantiated through cross tabulations.  
In the combined model of the Fife and Tayside patients using all the explanatory variables, there 
was significant synergistic effect of both Elixhauser measured comorbidity and SIMD income and 
education measured SES in overall survival for HNC. Table 79 shows the multivariate model of the 
Full cohort and how smoking, alcohol and stage contributed to the analysis of survival. This 
model showed that both education and ECI measured comorbidity were associated with survival 
in the Full cohort. Smoking and alcohol consumption are important aetiological factors for HNC 
which have also been found to affect survival after diagnosis. (270, 310, 361, 392, 481, 487-492) 
Table 79 Cox model of Full cohort 
Explanatory variable df Sig HR Lower 
95%CI 
Upper 
95% CI 
Ex smoker  .849 1.137 .305 4.231 
Moderate smoker  .299 2.061 .527 8.060 
Heavy smoker  .033 3.957 1.117 14.019 
Non-drinker (Ref group) 2 .861    
Moderate drinker  .786 .873 .326 2.338 
Harmful drinker  .935 1.044 .369 2.957 
Stage 0 (Ref group) 4 .008    
Stage 1  .340 3.630 .256 51.368 
Stage 2  .128 7.212 .567 91.697 
Stage 3  .043 13.312 1.085 163.300 
Stage 4  .032 16.217 1.263 208.237 
Most educated quintile (Ref group) 4 .014    
Quintile 2  .427 1.528 .537 4.343 
Quintile 3  .009 6.304 1.583 25.105 
Quintile 4   .001 10.163 2.443 42.271 
Least educated quintile  .003 11.056 2.315 52.805 
ECI None (Ref group)  3 .001    
ECI Mild comorbidity  .906 .937 .318 2.763 
ECI Moderate comorbidity   .120 2.361 .799 6.975 
ECI Severe comorbidity  .000 7.629 2.732 21.302 
 
In the full cohort and in the individual predictor models, the effect of both comorbidity and SES 
did have an effect but this was amplified when all the other predictors (HNC type, smoking, 
alcohol, gender, stage and age) were added to the model. 
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In terms of smoking status and comorbidities, the survival analysis results presented in this 
chapter did show that patients classified as heavy smokers had more severe comorbidities. The 
Tayside data was able to give more clarity to the disproportionate risk of premature death posed 
by increasing severity levels of comorbidity. This was more apparent for comorbidity that was 
measured using the ECI in combination with Scottish SIMD income and education quintiles, as 
this more apparent for mild and severe comorbidity in proportional hazards modelling that 
adjusted for all the important explanatory variables i.e. HNC type, age, stage, smoking and 
alcohol status. Laryngeal and oropharyngeal cancers were shown to have the most favourable 
outcomes, while hypopharyngeal cancers were associated with higher likelihood of premature 
mortality. Heavy smoking was also linked to excess mortality while no relationship could be 
elicited for alcohol status.  
In this study, there were a higher number of men who were diagnosed with HNC, which 
represented an approximate 2:1 ratio of incidence in males compared to females. Evidence of a 
higher incidence of HNC from the 6th decade of life onwards for most of the patients was 
observed in this study. More HNC patients had advanced disease with a greater number coming 
from deprived backgrounds which would appear to be a substantiation of the theory of lower 
SES (deprivation) being associated with patients presenting with more advanced disease.  
HNC type was found to have a significant influence on survival. Nasopharyngeal cancers were 
noted to have a high risk of mortality compared to the other forms of HNC within the cohort. The 
increased hazard of death was particularly apparent for patients with severe comorbidity and 
from deprived backgrounds who were shown to have an elevated risk of death compared to 
patients who had no comorbidity and came from less deprived backgrounds. These findings are 
consistent with the initial hypothesis and a prior systematic review we found that the association 
between comorbidity, SES and overall survival was stronger for patients with severe comorbidity 
and from the most deprived quintiles. The simultaneous occurrence of comorbidity and HNC is 
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known to increase with age and with the typical HNC patient also coming from a deprived 
background, this clustering of disadvantage poses significant challenges to the clinical course of 
the disease and patient outcomes. Interestingly the systematic review reported in an earlier 
chapter of this thesis had noted that age and SES had an interaction but when this was tested 
using proportional hazards methods an increased risk was noted for younger patients although 
the relationship was less clear for SES.  
The influence of comorbidity was assessed using the ECI and this was found to be a better 
predictor of mortality compared to the CCI with AIC statistics of 6089.35 for ECI and 6089.769 for 
CCI. The rationale for selecting the ECI is had the smaller AIC which meant that ECI fit the cohort 
data better. The AIC score focuses on the strength of evidence, and gives a measure of 
uncertainty for each model. In contrast, conventional model selection approaches such as 
backward, forward, or stepwise selection procedures are generally based on hypothesis tests, 
where at a certain P -value, a variable is included or excluded. These techniques often yield 
different conclusions depending on the order in which the models are computed, whereas the 
AIC approach yields consistent results and is independent of the order in which the models are 
computed. ECI was chosen before CCI as it had more reliable estimates of survival based on the 
AIC which was greater for the former compared to the latter. The findings of this analysis are 
useful to frontline clinicians as they can use them to match patient characteristics within the 
context of HNC as closely as possible in order to ascertain the risk profile for each patient. This 
means that the clinical team have to collect comorbidity and SES data alongside other 
demographic variables upon the patient’s first presentation in order for the methods reported 
here to be useful in allowing them to conduct a more accurate prediction of survival.  
In addition to the statistical evidence advocating the use of the ECI to measure comorbidity 
within a cohort; a systematic review and comparative analysis (493) was able to demonstrate 
that among various comorbidity indices, ECI is a better predictor of survival when  compared to 
the CCI.  
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6.6. Chapter summary 
In this chapter the results of the survival analysis of the original data and the imputed data were 
presented. There were 1344 patients in a cohort that was derived from HNC patients residing in 
Fife and Tayside. 533 deaths were recorded and HNC accounted for 42% of these deaths. Methods 
to account for missing data were used in order to allow for more robust survival analysis. The key 
predictors were ECI measured comorbidity, stage, smoking status, SIMD income and education 
quintiles. We were able to demonstrate the importance and impact of both comorbidity and SES 
in survival and this was particularly the case in the Tayside cohort. Although the Fife data had 
more patient numbers, the datasets validity was reduced by missing data. Chapter 7 will discuss 
the key findings of this thesis. It will compare the results of Chapter 6 with other empirical 
findings. This chapter will analyse the methods used to answer the research questions and 
analyse the data in order to identify any strengths and weaknesses. 
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C h a p t e r  7  
7.1. Discussion 
7.1.1. Chapter Outline 
This chapter will bring together all the information presented in this thesis and  by evaluating the 
results presented in Chapter 6, discuss these within the context of their association with findings 
from the systematic review (Chapter 2). The contribution of the development of a QA tool 
(Chapter 3) will be examined alongside a discussion of whether the information presented in the 
thesis supported the hypothesis. The soundness of methods employed to conduct data linkage 
will also be under consideration. A debate on how the results were presented as well as how the 
results relate to the research questions will also be conducted. The strengths and weaknesses 
will be debated alongside the consideration of whether any inferences of the findings could be 
made in order to modify clinical practice. 
7.2. Discussion 
In order to answer the research questions, the principal investigator began by seeking empirical 
evidence of how both deprivation and comorbidity act or interact to affect HNC survival. This 
began with a systematic review which found that both these two factors appeared to affect 
survival. Increasing comorbidity and deprivation were associated with a greater risk of mortality 
for HNC patients. However almost all studies reported on one factor only, so there was limited 
evidence of the interplay between them. A key issue was how to critically appraise and assess the 
quality of the primary research studies reported in the systematic review of the literature. Due to 
the lack of a suitable existing tool, a methodological quality assessment tool was developed to 
appraise the studies included in the systematic review. In order to test whether the results from 
the review could be validated using a sample of patients from Scotland, a retrospective data 
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analysis of patients from Fife and Tayside was carried out. The analysis found a linear association 
between deprivation and comorbidity illustrating that patients from deprived backgrounds 
measured using SIMD and with severe comorbidity measured using the ECI rather than CCI had 
lower survival compared to their counterparts. The results for the Tayside cohort were largely 
similar results to those of the systematic review as the data was more complete. When the 
analysis used the combined data, surprisingly the findings were less clear for the SIMD domains 
of income, although education did appear to be linked to survival. 
The results of the survival analysis pointed to the key prognostic importance of both comorbidity 
and SES in determining the survival of patients diagnosed with HNC. It was clear that the ECI 
performed better than the CCI as the parameter estimates demonstrated a marked change when 
the ECI was introduced into the survival analysis. The Fife data had limited validity due to issues of 
missing data for the key predictors however this shortcoming was addressed through multiple 
imputation methods. The full cohort analysis was able to demonstrate the dose-response 
relationship of important predictors such as stage, smoking and alcohol in estimating survival as 
comorbidity and educational attainment were shown to have a significant impact on HNC 
survival.  
In terms of SES (using income and education domains), the survival analysis showed that patients 
from deprived backgrounds had lower survival. We were also able to demonstrate that deprived 
patients from both regions presented with more advanced tumours, while the type of cancer was 
also shown to have an important role in predicting survival with laryngeal cancers having better 
outcomes when compared to mouth cancers. These findings gave similar results to the 
systematic review with evidence of a declining survival gradient dependent on comorbidity 
severity and the SIMD also income and education particularly; having a detrimental effect on 
survival for those patients from low SES backgrounds.   
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Both the systematic review conducted at the beginning of this thesis and the analysis of a 
homogenous cohort of patients from Fife and Tayside assessed the prognostic capacity of two 
factors; comorbidity and SES. We were able to ascertain that comorbidity and SES are important 
prognostic factors in HNC. The Tayside data was more complete and therefore was able to 
demonstrate a strong dose response relationship for this association showing that both factors 
contribute a multiplicative risk of reduced survival prospects. The systematic review was able to 
confirm that increasing comorbidity was associated with worse survival and that low income and 
low educational attainment were also linked to poor survival outcomes. The retrospective cohort 
analysis found that only moderate and severe ECI measured comorbidity were independent risk 
factors for overall survival in multivariate analysis. The reduction in survival probability became 
more pronounced when CCI scores were used in the analysis in addition to ECI. Despite there 
being limited prognostic capacity of the CCI, the results obtained from both the systematic 
review and the cohort study point to the importance of these findings as well as their clinical 
implications.  
In terms of the measurement of SES, the initial approach of using Scottish SIMD deciles was 
found to be cumbersome. The Scottish SIMD quintiles were also considered, however as the 
systematic review had noted how both income and education were appropriate measures to 
approximate SES this was considered a superior method of classifying SES. In the retrospective 
cohort analysis, the SIMD findings were not as pronounced as those for the income and 
education domains therefore we have reported on these because they were found to be the best 
method of SES measurement. 
7.3. Comparison with the literature 
There is a plethora of evidence confirming a link between poor HNC survival, based on prognostic 
factors such as comorbidity and SES. The results presented in this thesis showed that severe 
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comorbidity had a significant impact on survival. The survival estimates based on comorbidity 
level and SES found in this study are broadly similar to findings from other studies. These studies 
showed a significant relationship between comorbidity severity and survival. (10, 139, 150, 156, 
160, 294, 494, 495) Datema et al (330) confirmed this by creating a risk model to predict survival 
for newly diagnosed HNCs. After adding comorbidity, a substantial comorbidity impact on overall 
survival was observed with the worst outcomes predicted for severe comorbidity. (496) Better 
survival was noted for mild or no comorbidity groups, (333, 497). Table 80 presents the Tayside 
cohort analysis results from this thesis in comparison to those of four studies that were included 
in the systematic review presented in Chapter 2. 
Table 80 Comparison between this study & systematic review studies 
Study author & 
country 
Type of HNC Measurement 
method 
Magnitude of effect (HR) 
This study Scotland  All HNCs 
except 
thyroid 
Comorbidity: ECI & 
CCI 
ECI None HR=1.0 
Mild HR=1.676 (CI 1.059;2.632) 
Moderate 2.941 (CI 1.801;4.802) 
Severe HR=4.134 (CI 1.712;9.644) 
CCI None/Mild HR=1.0 
Moderate HR=1.341 (CI 0.571;3.149) 
Severe HR=2.821 (CI 1.226;6.486) 
Teppo  
Finland 
Larynx, 
tongue and 
pharynx  
Comorbidity: CCI Low comorbidity HR=1.0 
Modest HR=0.9 (CI 0.4,2.2) 
High HR=5.6 (CI 2.3,13.5) p<.001 
Piccirillo USA Head and 
neck  
Comorbidity: ACE-27 
Index 
No comorbidity HR=1.00 
Mild HR=1.03 (CI 0.80,1.32) 
Moderate HR=1.92 (CI 1.50,2.47)  
Severe HR=2.48 (CI 1.77,3.47) p<.001 
Yung  
USA 2008 
Oral cavity, 
oropharynx 
and larynx  
Comorbidity: ACE-27 
Index 
None to mild 1.4 (CI 0.4-5.3) 
None to moderate 1.7 (CI 0.4-6.7) 
None to severe 3.4 (CI 1.1-10.1) 
Homma 
Japan 2009 
Hypopharynx Comorbidity None-Mild 1.80 (CI 1.21, 2.68) p=.0036 
Moderate-Severe 1 
 
We could not find any previous empirical investigating the same prognostic effect of comorbidity 
and SES in HNC. The only reviews we found were on comorbidity only (304) (11) and SES, (194) 
however the latter review had methodological flaws. (195-197) There was no evidence of similar 
research being previously conducted within the HNC field, however a similar study reviewing the 
survival of patients from deprived backgrounds with comorbid disease had been carried out in 
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colorectal cancer. (145) Therefore due to the paucity of research in this field of oncology, we 
embarked upon the SR and subsequent retrospective cohort analysis. 
Interestingly a recent systematic review by Boeje et al (11)showed that comorbidity is a strong 
predictor of survival confirming findings from Habbous et al (392)and Peters et al (10). These 
previous research studies point to the validity and applicability of our findings in the 
prognostication of HNC. Comorbidity is a common occurrence in HNC (258, 498) and severe 
comorbidities increase the risk of death as treatments have to be adapted meaning patients are 
at higher risk of death as confirmed elsewhere. (16, 499) This relationship between severity of 
comorbidities and outcome has been found in different cancer sites, including head and neck 
cancer, (138, 500) breast, (501, 502) ,prostate, (503, 504) and colon cancer,(100, 505) among 
others.  
The CCI has been validated to be applicable in the evaluation of head and neck cancer (163), 
however there has been one previous attempt to validate the ECI within HNC (506) although this 
has been conducted in other diseases. (441, 443, 446, 493, 507, 508) Our results revealed that CCI 
and ECI were useful prognostic indicators for comorbidity and should be widely applied in the 
evaluation of comorbidities. Previous researchers had shown that the ECI is a superior method of 
comorbidity measurement compared to the CCI. (441, 443, 444, 493, 507-511)This study was able 
to establish that the ECI was the best possible method for comorbidity measurement (Tables 39, 
43-46, 50-52, 54, 65-71, 73-75) after comparison of survival estimates between ECI and CCI, it was 
noted that the ECI used more conditions that impact HNC survival such as weight loss and 
therefore it was deemed that this index was able to provide more reliable estimates of risk.  
When considering the prognostic contribution of comorbidity using the ECI in the cohort analysis, 
there was evidence of an association between severe levels of comorbidity and an increase in risk 
of death from all causes. The ECI appeared to be superior in predicting mortality when compared 
against the CCI. In most of the models, the findings of the ECI achieved better statistical 
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significance while CCI did not. This supports research studies that have shown that the ECI 
performed better than CCI in other conditions such as colorectal cancer (443), orthopaedics 
(508), coronary artery bypass graft surgery (493), myocardial infarction (493, 507),  and 
stroke(493) among others in calculating risk of death. In terms of the impact of SES on survival, 
there was evidence showing that HNC survival was strongly correlated with SES as lower SES 
groups had higher incidence of mortality compared to higher SES groups. (108, 212, 360, 362, 363, 
372, 426, 512-514) 
According to our findings, smoking and alcohol status played an important role in the survival of 
HNC patients. It has been hypothesised that low SES (deprived) backgrounds may mediate poor 
lifestyle behaviours such as smoking and drinking. The lifestyle factors of smoking and alcohol 
status were both shown to be linked to increased mortality; and smoking especially had a 
statistically significant effect on survival and in this cohort there was a strong association 
between smoking status and SES with the low SES patients predominantly found in the heavy 
smoker group. It would appear from this data that both smoking and alcohol did not have an 
independent effect on survival as they are both closely linked to SES. There is evidence to show 
that smoking and alcohol may have amplified the effect of both prognostic factors as excessive 
smoking and high alcohol consumption have previously been identified as the main risk factors of 
HNC.(123, 179, 194, 306, 473, 491, 515, 516) (34, 477, 481, 489, 517-519)  
There is empirical evidence pointing to low SES being linked to a lack awareness of the symptoms 
of HNC (112, 520, 521) and that patients from deprived backgrounds tend to present with more 
advanced disease. (522-525) Conversely there is an emerging trend in HNC that has pointed to 
better overall survival for younger HNC patients due to their HNC being caused by HPV. (27, 31, 
32, 60, 526-528) Additionally age related complications that tend to occur at higher rates in older 
age groups have also been shown to contribute to these survival disparities. (495) (79, 256, 272, 
529) Our systematic review (Chapter 2) found that younger patients with severe comorbidity had 
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worse outcomes, but this finding was not evident in the analysis of the retrospective cohort. We 
did however find that death from all causes was higher due to comorbidities, a finding echoed in 
previous HNC studies, (17, 530, 531) and also in cancer of the prostate, (206, 446, 506, 532) lung 
cancer (533), colorectal cancer (534) (145), renal disease, (535) breast cancer, (536, 537) and non-
Hodgkin lymphoma. (538) 
This thesis has been able to investigate the prognostic influence of SES and has found survival 
disadvantage for patients from deprived backgrounds. Specifically, the individual SIMD domain 
scores for income and education which had been identified in the earlier systematic review as 
good predictors of mortality were also found to have clinical importance within the cohort under 
study. This supports existing empirical evidence that identified reduced survival probabilities for 
patients with severe comorbidity and low SES. In terms of SES, it’s influence has been confirmed 
in other cancer sites namely, oesophageal cancer (486, 539), prostate cancer (540), gastric 
cancer (541, 542), lung cancer and cancers of the upper aero-digestive tract (543), colorectal 
cancer (144) and breast cancer.(544) In spite of a disproportionate burden of disease being noted 
for males compared to females, (543), there was little evidence of a socioeconomic gradient to 
this. 
There is a strong gradient of increasing incidence with deprivation in tumours of the head and 
neck. (545) (110, 123, 183) This is particularly the case for cancers of the oral cavity (183, 545), 
oropharynx and larynx. (545) Cancer survival as determined by SES has received attention from 
researchers previously with SES defined using income level data or level of education while 
others have employed proxy measures such as occupation and particularly in America, health 
insurance status. (309, 540, 546) Patients of low SES and of more advanced age have a higher 
likelihood of having comorbidity. This may be due to risky lifestyle behaviours such as smoking 
and drinking. Brusselaers et al (486) found that higher education levels had improved survival 
compared to the less well educated in oesophageal cancer.  
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Although the individual SIMD domains did not consistently show evidence of statistical 
significance, the difference in survival probabilities between the groups show that income and 
education have prognostic importance and clinical relevance. This finding had been confirmed in 
the systematic review conducted prior to the retrospective data analysis. Patients from least 
deprived quintiles were noted to have better survival compared to their most deprived 
counterparts in the median survival distribution in Kaplan-Meier, univariate and multivariate 
analysis. In the Cox proportional hazards regression model, both comorbidity and low SES 
measured by SIMD income and education quintiles demonstrated increase in the risk of mortality. 
In terms of the influence of type of HNC on outcomes, this study had found that cancers of the 
nasopharynx had poor survival compared to cancers from other sites within the head and region. 
These study findings agree with empirical evidence that cancers of the oral cavity (mouth 
cancer), oropharynx and larynx have better outcomes. (149, 164, 262, 547) SES has previously 
been confirmed as a predictor of survival, something which this thesis has been able to 
corroborate.  
7.4. Strengths of the study 
This is the first attempt to systematically review and seek confirmation of systematic review 
findings by conducting a retrospective cohort evaluation of how both comorbidity and SES can 
affect survival. These findings suggest that people with severe comorbidity from low SES 
backgrounds have an excess risk of mortality and a significant attenuation in risk is apparent 
following adjustment for covariate variables. The systematic review provided a summary of the 
empirical evidence on this subject, while the cohort analysis was used to confirm whether the 
systematic review findings could occur in a cohort from two distinct geographic regions of 
Scotland.  
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The methodological QA tool was a key strength of this thesis as it is an excellent instrument 
which was validated as suitable for use with the cohort in the latter part of this thesis. The tool 
was developed to quality appraise survival studies which is very different from reporting 
checklists such as MOOSE. The tool helped to assess the adequacy of the methods used to 
conduct the primary study. This appraisal of study quality was then used to construct a quality 
score or rating of the methodological quality of each study. In contrast MOOSE is an example of 
study reporting guidelines which allow researchers to give clear and accurate accounts (full 
information) of the study methods and findings. It allows peer reviewers to assess the adequacy 
of reporting, allow assessment of risk of bias and is now considered as a key to the value of a 
research publication which further enhances the project as the systematic review used these 
guidelines to report the review results. This demonstrates a link between study reporting 
guidelines and their link to critical appraisal. Additionally, inclusion of studies into meta-analysis 
hinged on the quality of reporting and homogeneous measurement methods and by using the 
MOOSE guidelines to support the QA of included studies, this thesis was able to ensure that 
study methods showed relevance, reliability, validity and are reproducible where applicable i.e. in 
the retrospective cohort analysis. 
The methods used to create the patient cohort were ideal at selecting eligible HNC cases from 
the two geographic regions of interest. The sources of the linked health datasets were derived 
from sources within the NHS which provided a robust and valid patient pool. It is therefore likely 
that deaths of those patients who had migrated out of Fife or Tayside could be identified easily. 
These data corroborate earlier studies and clearly demonstrate the effect on survival of 
comorbidity and SES in HNC patients. The major strengths are that this is a much larger cohort 
than most previous studies with 1145 patients from two distinct geographic regions of Scotland. 
In addition, this thesis has been able to identify robust SES and comorbidity measures, which 
were tested during the data analysis and held up well as sound predictors of mortality risk.  
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A key strength from this study is that we used linked administrative health data in order to create 
the dataset we analysed. This method is a more robust technique of assessing comorbidity status 
in a cohort as compared to chart review. (438, 444, 548-550) This study had several strengths as 
we used two centres to assess the prognostic impact of comorbidity and SES. We had a diverse 
group of HNC patients of various ages, HNC subtypes and disease stage and were able to assess 
the prognostic influence of both factors. The findings presented here advocate the assessment 
of comorbidity and SES in planning treatments and management of HNC with the ultimate goal 
of improving survival outcomes.  
A key point to note is the differences in the cohort sizes which is unexpected as Tayside is a much 
bigger geographical area than Fife and has a larger population, so one would expect a much 
larger cohort. The Tayside cohort is much smaller than that from Fife because it was made up the 
data collected between the Oral/Maxillofacial, ENT and oncology teams at Ninewells Hospital. ISD 
Cancer Registry statistics show a higher incidence of HNC in Tayside, however as there had not 
been a formal process for prospective data collection between the teams mentioned peviously, 
the records are fewer. However despite this appearing to be a shortcoming the inclusion of the 
Fife data which the Head and Neck Cancer Nurse Specialist began collecting prospectively upon 
commencement of her post in the late 90s made the data reported here the largest retrospective 
cohort analysis of this kind in Scotland. The results from survival analysis largely correspond with 
data from the Cancer Registry, with factors such as SES, type of HNC, stage, TNM classification 
having an impact on survival. The data reported in this thesis are more robust than the cancer 
registry data as the data linkage with SMR01 made it possible to use more in depth data on HNC 
subsite, comorbidity and SES measured using the Scottish SIMD quintiles in addition to SIMD 
income and education domain scores. The analysis data unravelled the complex interplay 
between tumour and patient factors in determining survival in HNC. 
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We used composite scores for both Charlson and Elixhauser, a composite score is the summary 
score after adding the relevant weights for each comorbidity to get a final score that helps with 
predicting survival of patients. The rationale is that a composite score or summary score provides 
an attractive advantage by reducing the risk of over-fitting comorbidity data in small datasets and 
limiting calculation requirements in large datasets. The use of summary comorbidity scores for 
the evaluation of comorbidity status was a more efficient method for predicting patients’ survival 
than considering single comorbidities. This was a sound approach as the two indices were able 
to, “explore the comorbidity burden primarily by using a quantitative approach”, with the CCI 
and the ECI chosen to evaluate comorbidity severity by weighting the comorbid conditions to 
assess clinical impact. (444) 
The use of a diverse population including the geographic regions of Fife and Tayside to derive 
summary comorbidity scores represents another key strength of this study. Further, we used 
SMR01 data to refine patients’ comorbidity status and used validated comorbidity summary 
scores. (441, 442) This study is an original attempt to validate any Elixhauser summary score using 
Scottish data, while the use of multiple measures to provide a robust comparison of model 
performance was another strong point. 
CCI and ECI were used as the comparative comorbidity measures as they both allow for the use 
of a composite score of overall comorbidity classification. This is made up of the weighted score 
for each comorbid condition that has been identified as having an influence on the survival of 
cancer patients. The CCI has been validated to be applicable in the evaluation of head and neck 
cancer, (163) while there has been one previous attempt to validate the ECI within HNC (506) 
although this has been conducted in other diseases. (441, 443, 446, 493, 507, 508) The results 
revealed that CCI and ECI were useful indicators and should be widely applied in the evaluation of 
comorbidities. 
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Another main strength of this study is that we used evidence triangulation to measure SES, we 
used an area level measure, the Scottish SIMD quintiles and also the individual SIMD measures of 
income and education. Education was identified as a primary determinant for the development of 
cancers of the upper aerodigestive tract (551) therefore it would be logical that this factor would 
resultantly impact survival. (545). The chosen multiple imputation by chained equations method 
that was chosen uses conditional imputation models where one variable is imputed conditioning 
on other. This method may not be mutually consistent and consequently may not be reliable, 
(459) however, multiple imputation provides valid statistical inferences, because conducting the 
analysis with only complete cases would have biased the results of this study through the loss of 
a substantial number of cases from the analysis. (552)  
There are also additional strengths in the study. Information on comorbidity was based on high 
quality administrative, SMR01 data hence it did not depend on the accuracy of the clinicians 
involved which would have left the data prone to bias, misclassifications and coding errors. 
However since comorbidity was derived independently prior to data linkage with information on 
the patient data, the misclassification could not occur. The data was provided through the HIC 
data team who ensured that the anonymised data received by the research team was matched to 
the patients’ clinic data. It is unclear whether the HPV status of the patients in this cohort may 
have been useful as this information was not available due to lack of collection, but it could 
potentially have had important prognostic validity on the calculation of survival estimates. (42, 
60, 231, 553) 
To date, many studies have focused on cancer mortality; but in this instance this is the first time 
that a study has been carried out in Scotland, using data linkage of prognostic factors such as 
comorbidity and SES to estimate survival. Through the use of individual SIMD domains as well as 
an area based measure, we were able to conduct a comprehensive exploration of cancer survival 
risk  
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7.5. Weaknesses of the study 
Firstly this work relied on administrative data, which are never complete or detailed enough to 
provide a clinically precise method for identifying comorbidities. The most important 
shortcoming of administrative data as is the case for this study is that it is not possible to identify 
when a condition became apparent. Complete SMR01 information has the ability to identify the 
timing of diagnoses as a way to differentiate between complications and comorbidities, however 
as we did not use timing of comorbidities, it is possible that some of the conditions we used to 
calculate comorbidity scores were in actual fact complications. In mitigation as per Feinstein’s (1) 
definition of comorbidity we did not need to distinguish between either conditions present prior 
to or after the diagnosis of HNC. As there was no predetermined study commencement date 
given, there is a possibility of some case-mix differences due to treatment advances in HNC 
oncology, however the longer periods of follow up reported in the retrospective cohort analysis 
further enhances the long term prognostic risk prediction within this group of HNC patients. 
Although there was some potential of missing some comorbid conditions by using secondary 
care data, the use of the SMR data has been shown to be a key strength in recent papers. (548, 
554, 555) 
The focus for the systematic review was to determine how comorbidity and SES affected survival 
in combination. Only three studies were found that attempted to answer this question but in 
order to enhance the validity of the findings, studies that focused on both factors separately had 
to be included in the review. Unfortunately the comorbidity studies that were included in the 
systematic review did not report whether they treated SES as a confounder, therefore it is 
impossible to make any judgements on this, but it is possible that this may have affected the 
resultant pooled hazard ratio within the meta-analysis.  
Secondly, the influence of lifestyle factors such as smoking and alcohol consumption was taken 
into account in order to determine their influence on outcomes, and these showed that heavy 
243  
 
drinking and excessive smoking had a negative impact on survival. The data on smoking and 
alcohol was based on self-report by patients hence it is possible that there was reporting bias in 
this information. (556) Recurrence-free survival was a key outcome measure identified at the 
time of devising this study; however, it could not be measured. This is because recurrence of HNC 
could only be ascertained in a few cases therefore a subgroup analysis was not possible. As 
pointed out by Sharabiani et al (557), ‘risk adjustment modelling in comorbidity is essential’, 
however the missing data may have limited the capacity to conduct accurate and robust risk 
prediction in this study. Another shortcoming was the influence of treatment on outcomes which 
could not be determined due to missing and/or incomplete data. The inclusion of outcomes data 
based on treatment type stratified by comorbidity status and SES would have enhanced the 
validity of the retrospective analysis by providing evidence to refute or substantiate whether 
these two prognostic factors were taken into account when clinical interventions were selected.  
As the systematic review findings had shown that younger patients with severe comorbidity 
experienced premature mortality, the optimisation of survival based on the treatments selection 
would have shown whether older patients do indeed receive less invasive procedures while 
younger patients are given more aggressive treatments. As pointed out by Dronkers et al (558), 
patients are now partners in the clinical decision making process therefore an assessment of 
outcome based on chosen intervention requires a full understanding of not only the standard 
treatments, but also patient and clinician choice.  
The reasons for treatment choice could be manifold with the main one for less invasive 
interventions being the debilitating effects of some curative treatments such as laryngectomy. 
Therefore, in spite of the recognition that an analysis of the treatment modalities would have 
provided meaningful evidence on the variation in age-related survival rates, choice of HNC 
treatment modalities are not straightforward and as such in the absence of rationale for choice 
of treatment, the usefulness of this data is diminished. The retrospective design introduced 
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information bias as data was obtained from routinely collected and medical record review when 
adding a survey would have provided rich data which could then account for patients’ choice of 
treatment with the added benefit of checking whether their comorbidity and SES were linked. 
(16, 17, 499, 558-560) 
This thesis demonstrated the inherent pitfalls of linked administrative data for research 
purposes. This was particularly the case for the Fife data which had missing data which required 
complex methods of missing data analysis as it provided the most cases compared to Tayside. 
This study had the advantage of using complex statistical methods to account for missing data as 
without these 199 cases would have been lost from the analysis. These methods enhanced the 
power of the study unlike other techniques for dealing with missing data such as list-wise or pair-
wise deletion which would have reduced the statistical power of the study due to a reduction in 
patient numbers. The deleted may have held important information that could enhance the study 
findings and additionally the estimates would not be reliable as the data may have been missing 
completely at random. Multiple imputation methods have the added advantage that for each 
missing value the variability of the data is reduced and it also takes into account any variability 
due to sampling and variability due to the imputation itself. 
All cause mortality and HNC specific mortality were the only outcome measures reported as the 
GRO death certification laws mean that a main cause of death and contributing causes are also 
given. For that reason, in order to minimise errors only the data given as the main cause of death 
were used to assign death from all causes and death from HNC. This study measured survival 
based on comorbidity and SES though amalgamation of patient data collected through disparate 
methods. Ideally the case note review which worked so well for the Tayside data should have 
been applied to the Fife data to allow for good quality data. The survival analysis was unable to 
employ methods of comorbidity assessment used in the prior systematic review as the ACE-27 
index required more patient information that was readily available in the two data sources used. 
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The CCI and the ECI were used as the linked patient datasets had sufficient information to allow 
allocation of comorbidity status to each patient. CCI and ECI are two of the best known 
comorbidity indices, with the latter designed for use in databases. There is only partial overlap in 
the set of comorbidities that these two cover, and many diseases are not covered by either, 
which is why both were deemed ideal for this project. Although they were designed or at least 
suggested for general purpose use, there have been numerous attempts by researchers to adjust 
these indices for sets of diseases that are of particular importance to a specific patient group. 
(557)  A further drawback is that these indices were originally used to predict 1-year mortality 
(CCI) or length of stay, hospital charges, and in-hospital death (Elixhauser), whereas other 
outcomes such as 5 year or even longer-term survival which are of interest in this thesis would 
have been difficult to accurately predict. 
Ghali et al (561) refuted the utility of summary comorbidity indices such as CCI and ECI stating 
that the prognostic ability of summary measures created using one’s own data were superior to 
that of measures derived using published algorithms which they were able to prove within a 
sample of patients undergoing coronary artery bypass graft surgery. These findings were also 
confirmed by Schneeweiss and Maclure (562) in a cohort of patients receiving angiotensin-
converting enzyme inhibitors or calcium-channel blockers by suggesting that confounding which 
using CCI and ECI without deriving study specific weights would remain uncontrolled resulting in 
unreliable findings which was backed up by Hansen  who suggested that the summary measures, 
or prognostic scores as he terms them, be estimated using a researcher’s own data. In contrast 
Austin et al (448) presented the argument for, “the general theoretical justification for 
prognostic scores such as CCI by demonstrating that comorbidity summary measures can have 
properties similar to propensity scores thereby removing confounding in observational studies”. 
Another potential drawback of using linked health data rendered some planned analysis 
redundant due to missing data and incomplete information. The lack of consistency and accuracy 
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of key variable information such as gender, HNC sub type, age, status (i.e. dead or alive), smoking 
status and alcohol consumption meant that some key analyses could only be conducted after 
complex analysis, multiple imputation method. This reduced the generalisability of the study 
findings. These variables would have provided meaningful prognostic indicators for survival and 
disease recurrence.  
The prognostic utility of comorbidity on head and neck cancer may be determined by factors 
such as disease stage but this could not be elicited fully due to missing data. In spite of these 
limitations, this study was able to confirm that both comorbidity and SES independently and in 
combination affected the survival outcomes of HNC patients. As there is no scope for the 
prevention of comorbidity or deprivation in the context of HNC care and treatment, oncologists 
need to develop clinical practice guidelines (CPGs) that take account of these two factors as 
much as possible. It is acknowledged that clinical practice guidelines may not fully facilitate 
accurate decision making processes, due to the complexity of HNC patients who have 
comorbidities.  
One of the main limitations arising from this thesis is the feasibility of comorbidity data collection 
in creating the comorbidity summary score. It would have been ideal to extract the ICD-9 and 
ICD-10 codes into meaningful comorbidity conditions using predefined statistical data mining 
syntax, however there was no evidence of these being available for use in SPSS. This meant that 
manual methods of obtaining the relevant comorbidity conditions included in both the CCI and 
ECI. This method had potential shortcomings due to coding errors but this was minimised 
through the use of predetermined codes for comorbidity extraction. (438, 439)  
This thesis presents for the first time linkage of HNC incidence data from Fife and Tayside 
providing a large cohort and number of primary tumours followed up for several years. Finally, 
the confirmation of the HNC population through the cancer registry and SMR01 records 
demonstrates evidence of high data quality and information triangulation. 
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7.6. Implications 
This study confirmed the multiplicative prognostic importance of both comorbidity and SES. It is 
clear from the survival analysis that being deprived and having severe comorbidity increases the 
risk of mortality. As both factors are important determinants of HNC survival, it is imperative that 
oncologists mitigate for their effect not only on stage at diagnosis, but survival and subsequently 
long term quality of life. A clear management plan to optimise treatments needs to be tailored to 
each patient taking into account patient factors i.e. comorbidity and SES amongst the patient-
related factors and for the tumour factors such TNM and disease stage. As recommended by 
Sarfati (105) a risk profile of a patient is easily created by taking note of the patient and tumour 
factors, and although no specific tool was recommended ECI was retained due its superiority 
over the CCI. It is feasible that HNC patients can have proper risk stratified care based on their 
comorbidity status and SES as this will take account of the threat posed by these patient-related 
alongside tumour factors such as disease stage and type of HNC. (312, 563-565) 
Hence from the findings it may be possible to create a short comorbidity index that would focus 
on factors of which are known to predict outcome using the Elixhauser index and additional 
comorbidities such as smoking >20 cigarettes/day and level of education using a self-
administered questionnaire such as that proposed by Molto and Dougados (566). In case of 
issues around self-reporting bias, the healthcare staff could collect the comorbidity information 
although with workload pressure this may be difficult. It would be possible to overcome this 
challenge by creating a comorbidity index that would be easy to apply within the oncology 
setting. A short index (akin to the widely used Mini Mental state Exam) which includes a small 
number of comorbidities may work well and as pointed out by Marventano et al, (444) the 
proposed index should focus on conditions known to affect HNC so as to fully assess their impact 
on survival. If the data are available then using an already validated tool such as the WUHNCI to 
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measure comorbidity would also be a great method of collecting comorbidity data which feeds 
into the personalised medicine approach advocated in this study. 
It is acknowledged that the retrospective cohort study methods had a shortcoming, i.e. that the 
individual SES domains are based on area level SES measure (SIMD) hence these individual 
domains may not reflect individual SES accurately i.e. an ‘ecological fallacy’ may occur. SIMD uses 
ecological data this allows for the drawing of inferences which may not directly applicable to the 
individual, (567) Area rather than individual measures of SES such as SIMD are created for the 
smallest available administrative unit, out of necessity, are increasingly used worldwide to 
measure effects of SES on health outcomes and to plan services and may be used as surrogates 
for individual social indicators. This justifies the use of the SIMD rendering the results of this 
study clinically important and the chance of misclassification of SES very small. (282, 568-570) 
This is a novel presentation of time data linkage of administrative data on HNC incidence, 
comorbidity and SES which provided a large cohort, linked to SMR01, Cancer Registry and GRO 
death data.  
When interactions between age and SES that were found in an earlier systematic review were 
tested, only age, i.e. being younger was shown to increase the hazard of mortality. Our findings 
on the inter-relationship between area deprivation and education show the synergistic effect of 
area and individual SES measured by education and which is consistent with others focusing on 
cancer. Sharpe et al (543) reported an inter-relationship between area levels of deprivation and 
education which has congruence with our study. Given these cancers are largely driven by 
smoking and alcohol behaviours, which are both more prevalent among the more deprived 
implies that social and cultural aspects of SES are important in uptake and continuation of 
smoking and alcohol consumption. Education level captures the impact of socioeconomic and 
cultural circumstances at an early age when adopting the habits that predispose to the 
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development of HNC. In addition, the differences between the sexes in the smoking epidemic are 
likely to explain the mitigating effects identified.  
Cancer survival as determined by SES has received attention from researchers previously with 
SES defined using income level data or level of education while others have employed proxy 
measures such as occupation and particularly in America health insurance status. (309) (540, 546) 
Survival is influenced by a range of individual and tumour factors such as SES and comorbidity. 
Patients of low SES and of more advanced age have a higher likelihood of having comorbidity this 
may be due to risky lifestyle behaviours such as smoking and drinking. Brusselaers et al (486) 
found that higher education levels had improved survival compared to less well educated in 
oesophageal cancer. 
With the classic risk factors of alcohol and smoking in addition to HPV- related incidence, there is 
also the continuing shift in population structures with more people surviving longer, 
comorbidities are becoming more common alongside cancer. Also the number, type and severity 
of these coexistent diseases has been said to increase with age which consequently affects 
survival. (146) Yung et al (150) found that comorbidity had an independent prognostic effect on 
HNC survival and that relative risk of death increased two times due to advanced comorbidity. 
(380)  
Specific comorbidity such as cardiac, respiratory, cardiovascular, cerebro-vascular, dementia, 
renal, hepatic, weight/nutrition and previous surgery/radiotherapy/chemotherapy are of 
particular importance in HNC based on research conducted by Peake. (151) Therefore it is not 
difficult to assume that deaths will become more frequently attributed to comorbidity compared 
to index diseases such as HNC. The Scottish Head and Neck Cancer Audit found that deprivation 
survival relationship was largely explained by WHO performance status. However there are 
distinct conceptual differences between comorbidity and performance status. The WHO 
Performance status differs from comorbidity as it seeks to ascertain how well a patient is able to 
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carry out normal activities while living with cancer. It does not provide a method of measuring co-
existing conditions i.e. comorbidity. It is particularly useful for evaluating treatment response, 
whether and how the cancer is progressing, ascertaining the patient’s tolerance of cancer 
treatments through the assessment of physical health. It can also be used as a method for 
selecting clinical trial participants. The only similarity to comorbidity assessment is the ability to 
estimate prognosis. 
To date, many studies have focused on cancer mortality; here for the first time in Scotland, 
multiple individual SES metrics were used to explore HNC mortality risk. Comorbidity is frequent 
in HNC patients due to the aetiological factors, smoking and alcohol consumption which have a 
negative impact on survival, therefore assessment of comorbidity is of great importance, both in 
order to treat/optimize patient's health before treatment commences and also in order to be 
able to stratify/control for comorbidity in randomized trials for HNC therapeutic interventions. A 
key strength from this project is the methodological quality assessment tool as it carries a lot of 
potential for both use and application. It could be used to do quality assessment of papers 
focused on diseases other than HNC. It is easily adaptable to any condition as the quality 
assessment questions help to identify methodological rigour in a primary research paper that 
focuses on survival. The utility of application of this tool in other areas is immense as it really 
focuses on papers that investigate time to an event and an example could be weight 
management in renal disease. 
The accuracy of the information provided through the linkage of health data enabled the 
assessment of demographic patterns in the distribution of comorbidity and SES within the HNC 
population in Fife and Tayside. This information is critical for adaptation and enhancement of 
oncology services in order to mitigate the risk of poor outcomes in HNC patients. Creating 
collection of additional information on comorbidity that can be assessed by cancer registry staff 
(such as the incorporation of comorbidity advocated by the National Cancer Intelligence Network 
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(151, 152) will also be useful, as will information on how patients with HNC are clinically managed 
and the treatment adjustment dependent on patient factors and tumour characteristics. 
Collectively, these data will help clinicians and policymakers to identify any gaps in the care of 
patients with HNC, alongside comorbidity and low SES. This will mean that clinicians will be able 
to organise care delivery to optimally address identified gaps. 
The main issue that arose in this study is that patients need to have their individual circumstances 
addressed. It is necessary as part of the holistic approach to care and treatment of oncology 
patients in order to tailor the treatments based on both tumour and host factors. HNC patients 
who have severe comorbidity and are deprived have higher likelihood of premature mortality, 
but careful monitoring of the interplay between host and tumour factors may improve chances 
of survival, while reducing the likelihood of HNC recurrence. This study makes the case for proper 
assessment of the influence of comorbidity and SES on head and neck cancer prognosis.  
7.7. Chapter summary 
This chapter reviewed the results of the survival analysis and how these could be applied within 
clinical practice. The shortcomings and the strengths of the survival analysis were also discussed, 
and these results were placed within the context of congruence with prior work (the systematic 
review in Chapter 2) carried out as part of the thesis. The final chapter will explain what the 
findings of this thesis mean and give indication of further work that could be done to fully 
explore the implications of comorbidity and deprivation within HNC oncology. It will make sense 
of what the project found by comparing and contrasting the systematic review and the 
retrospective cohort study. It will review whether the research questions have been answered 
fully. Any shortcomings at this point will be highlighted and any directions for future work will be 
given. What this thesis adds to the body of evidence on the effect of comorbidity and deprivation 
on HNC survival will also be presented in Chapter 8.
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C h a p t e r  8  
8.1. Conclusions 
8.1.1. Chapter summary 
This chapter will provide a brief summary of the results of the thesis. The findings from both the 
systematic review and the data linkage study will be reviewed against the aims and objectives of 
the thesis. Any lessons that were learned during the conduct of this thesis will also be discussed. 
A discussion on the implications of the findings will be conducted as well as recommendations for 
future research studies that may contribute to unravelling the individual contribution of 
deprivation and comorbidity in HNC survival. This would allow for an enhanced understanding of 
whether this contribution is multiplicative or independent. In addition any recommendations on 
future research will be given, prior to a conclusion on the project results presented in this thesis. 
8.2. Summary of findings 
The poor survival of HNC patients who have comorbidities and from deprived backgrounds 
remains a major issue for clinicians working in this field of oncology. The work reported in this 
thesis used robust methods to explore whether comorbidity and deprivation had an influence on 
the stage at presentation and survival of patients with head and neck cancer.  
The original objectives for the project are depicted below: 
Aim: The project aimed to answer a number of specific research questions: 
1. To investigate the roles and interrelationship between comorbidity and deprivation on the 
survival of HNC patients. 
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2.  To investigate whether there are differences in HNC presentation based on comorbidity and 
deprivation. 
3. To ascertain whether patients from deprived backgrounds with comorbidity present with 
more advanced cancers. 
This thesis began with a systematic review to confirm whether there was prior empirical evidence 
that evaluated the effect of both comorbidity and SES in HNC patients. The systematic review 
found three studies that focused on both factors. All three found that severity of comorbidity 
was associated with poor survival, but in terms of SES only two out of three studies found a 
socioeconomic gradient for survival. Although there were heterogenous methods used in the 
measurement of either factor, the systematic review was able to establish a connection between 
both comorbidity and SES on survival in HNC. 
As a follow up to the systematic review, the next step was an examination of a cohort of patients 
with HNC to describe SES and comorbidity on diagnosis and any subsequent effect on mortality. 
This study provided evidence of mortality risk dependent on comorbidity measured using the ECI, 
and SES measured using the SIMD income and education domains.  
8.3. Reflection on this work 
It is apparent from the results presented in this thesis, that there is some interaction and 
influence of both comorbidity and SES on HNC outcomes. This thesis was able to triangulate the 
findings of the systematic review with those of the survival analysis using Cox proportional 
hazards regression methods. Income and education were found to have an impact on survival in 
the systematic review, and this relationship was confirmed in the survival analysis with definitive 
evidence of statistical significance. This makes the case for a shift in focus from the use of time 
proven prognostic factors such as the TNM classification alone. The research conducted here has 
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also demonstrated the prognostic importance of social health determinants such as SES within 
oncology. (166)  
Another point to note is that research has pointed to the importance of performance status as an 
additional marker for patient complexity. The WHO Performance status differs from comorbidity 
as it seeks to ascertain how well a patient is able to carry out normal activities while living with 
cancer. It does not provide a method of measuring co-existing conditions i.e. comorbidity but it is 
particularly useful for evaluating treatment response, whether and how HNC is progressing, 
ascertaining the patient’s tolerance of cancer treatments through the assessment of physical 
health. It can also be used as a method for selecting clinical trial participants. The only similarity 
to comorbidity assessment is the ability to estimate prognosis.  
This is of particular relevance as the Scottish Head and Neck Cancer Audit found that the 
deprivation survival relationship was largely explained by WHO performance status although this 
is not an objective of this project. In essence future work should also take the patient’s 
performance status alongside deprivation and comorbidity in order to have a complete 
understanding of the patient-related factors in order to conduct a thorough assessment and 
provide interventions that are personalised to each patient. 
This project has been able to identify the intrinsic complexities of relying on area measures of 
deprivation and counts of comorbidity. Nevertheless this study was able to mitigate for these in 
order to assess risk of mortality by using complementary measures of SES, i.e. SIMD alongside 
income and education domains and for comorbidity; by using two weighted indices of 
comorbidity measurement. This interlinking of comorbidity and SES poses particular challenges 
as there are changes in cancer risk due to aging populations which not only represents the 
complex, and multifaceted challenge of attempting to improve survival in HNC patients. This 
complexity will take time to lessen in the face of treatment advances and improved patient 
assessment and tailored treatment regimens. 
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In conclusion, the different and independent SES and comorbidity measures have been shown to 
be associated with worse outcomes in patients with HNC. Of interest is that the different 
measures of comorbidity (ECI and CCI) had different effects on survival with ECI being shown to 
be slightly better at calculating mortality risk. Additionally only the SIMD income and education 
domains had the superior ability in capturing hazards of death despite the SIMD quintiles and the 
income and education domains being based on the same area level measure of deprivation. The 
inherent difficulties of measuring SES and comorbidity accurately go some way towards a 
reflection of the complexity and multifaceted nature of both comorbidity and SES.  
8.4. Future work 
Although both the systematic review and the retrospective cohort study achieved their aims, 
there may be scope for further work in this area of prognostication. As described by Munro and 
Bentley (145) the interrelationships between comorbidity, deprivation and outcome in a group of 
patients are complex. There is the possibility that in order to investigate any interrelationship 
between comorbidity and deprivation it is helpful to have a cohort of patients in whom decisions 
concerning assessment and clinical management have been uniform and consistent over time. 
Using administrative data linked to medical records is not enough, there is need for 
epidemiological and clinical studies to unravel the survival disadvantage. To this end clinical 
cohorts could be nested within larger registry based studies. All patients can be assessed 
prospectively and their full clinical history and type of HNC and staging information confirmed 
through pathological examination entered into electronic patient records. The patients’ care 
would follow the Clinical Practice Guidelines (CPGs) recommended for HNC; however their 
unique comorbidities and SES would be taken into account. Comorbidity would ideally be 
assessed using the Washington University Head and Neck Cancer Index (WUHNCI) but as the ECI 
(441) has been used in this project, that alongside SES using the SIMD income and education 
domains would both be ideal as both methods have been validated in this thesis. If this work 
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could be done in the two regions of Fife and Tayside and expanded to other centres such as 
Edinburgh and Glasgow, this could provide validation of modification to HNC care and treatment 
with the objective of improving survival outcomes. In spite of healthcare advances, inequalities in 
health still exist and it is envisaged that factors like SES will continue to have a detrimental effect 
on survival. 
The project was unable to unravel how both deprivation and comorbidity interrelate. It was clear 
however, that this review could have elicited more meaningful findings, had the inclusion of a 
social cognition model been taken into account. The rationale for this is that this project relied on 
measures of comorbidity and deprivation which have a myriad of shortcomings. The fact that an 
individual is defined as being deprived using the SIMD domains does not reflect an HNC patient’s 
self perception of social standing. Social standing is not permanent as individual circumstances 
may change. SIMD uses census data which is only available every 10 years and therefore the SES 
of a particular individual may change during that time. In terms of comorbidity, there is some 
utility of summary comorbidity indices such as CCI and ECI but these indices do not include all 
additional conditions therefore bias is a possibility here. Comorbidity indices have utility as both 
clinical tools and for epidemiological and/or research studies as most can be easily or readily 
scored or computed within the clinic. With improved understanding of the mechanisms of 
comorbidity, the additional data will be useful within health services research particularly as part 
of a personalised holistic approach. The variability of comorbidity and deprivation shown here 
requires further exploration. This is best illustrated using the Salutogenic model (Figure 50) 
which considers the issue of health creation i.e. improved health suggesting a continuum of 
influences that are essential to individual health behaviours and other extrinsic factors that 
ultimately lead to death in HNC patients. 
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Figure 50 Salutogenic model 
 
The Salutogenic Model Adapted from International Public Health Partnership (571) 
This model shares similar factors to Dahlgren and Whitehead’s social determinants of health 
model (76) and provides a mechanism of unpacking the interwoven complexity of the elative 
contribution of comorbidity and deprivation in HNC presentation and survival. Figure 45 shows 
exactly where within the health continuum, comorbidity and SES are found. Granted the indices 
of comorbidity and SES have applications for the analysis of the data, but a fuller understanding 
of patient factors go a long way into the application of personalised treatment and care. This is 
where the Salutogenic model’s sense of coherence comes under consideration. If Figure 51 is 
used as an aid into developing an holistic approach to the HNC patient, this will contribute to the 
richness of the results from this data.
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Figure 51 Salutogenic model – Sense of Coherence 
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This model attempts to elicit what keep people healthy by asking a series of questions which all 
go towards the underlying question, ‘why do some people, despite stressful situations in their 
lives, manage to stay healthy and others do not?’ (572) This is especially important as not all the 
people who smoke and drink excessively are known to develop HNC despite both factors having 
a known multiplicative contribution to carcinogenesis. The sense of coherence is measured using 
An additional method to further validate this would be to use pharmacy based comorbidity 
evaluation methods such as that proposed by Sarfati et al (83) in order to explore the issue of 
polypharmacy and pharmacokinetics in determining how comorbidity treatments impact cancer 
therapies and efficacy of same.  
This thesis addressed the quite complex interplay between SES, comorbidity, stage at diagnosis, 
and access to care in head and neck cancer, and these factors’ ultimate impact on survival. We 
found that SES, comorbidity, stage at diagnosis, access to care, and survival are all potentially 
causally related. From the findings of this thesis, as future direction for this area of HNC 
prognostication we hypothesise the causal direction as: lower SES leads to poor access to 
healthcare, which in turn leads to both advanced stage at diagnosis as well as increased 
comorbidity, which then both impact survival; therefore it would make sense conduct 
prospective cohort analysis using the salutogenic model. This would consider how health beliefs 
such as perceived health in the salutogenic sense of coherence (398, 572) can contribute to 
determining outcomes alongside other external factors in HNC patients. This is of particular 
importance as the salutogenic theory has been described, ‘as a position on a health ease/dis-ease 
continuum and the movement in the direction towards the health end’. (572, 573) As shown in 
chapter 2the salutogenic model has a role to play in disentangling exactly how comorbidity and 
deprivation (low SES) contribute to poor survival outcomes in HNC patients. 
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8.5. Final thoughts 
In this thesis both comorbidity and SES were important indicators of survival in HNC. When 
assessing the influence of comorbidity and SES alongside other known prognostic factors such as 
smoking, alcohol, disease stage, HNC type and age, both factors were shown to have a significant 
independent effect on overall survival. As the world population ages there will be more elderly 
HNC patients and many of these will have comorbidity at the time of diagnosis. These results 
support the fact that comorbidities should be assessed in prognostic staging of patients and 
comorbidity should be treated in order to optimize and gain a survival benefit from treatment. 
There is evidence showing that comorbidity and SES are important factors influencing the 
survival of HNC patients in the developed world. However, to the best of our knowledge, no 
studies have reported the influence of comorbidities and deprivation on the prognosis of HNC in 
Scotland. The current study is the first to confirm that comorbidities and SES were both 
interrelated and independent factors affecting the prognosis of overall and disease free survival 
of patients with HNC. This study has been able to demonstrate that the value of comorbidity and 
SES in HNC survival was comparable to that of clinical stages. In conclusion, our findings suggest 
that administrative databases may be a useful tool for surveillance of the prognostic importance 
of comorbidity and SES. . However, it is striking that routinely collected administrative health 
data do not often include information on measures of comorbidity and SES. It appears as if it’s 
necessary to reconsider the potential benefits of tailoring treatment to the patient at the point of 
cancer care delivery. 
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A p p e n d i x  A 1  
Moose Guidelines Checklist 
Table 81 MOOSE Guidelines Checklist 
 Reported 
on page 
Comments 
Reporting of background should include 
Problem definition 32 Described in the background 
text 
Hypothesis statement 33  
Description of study outcomes 36  
Type of exposure or intervention used  
 
N/A 
Type of study designs used 34-35 Listed in inclusion/exclusion 
criteria 
Study population 34  
Reporting of search strategy should include 
Qualifications of searchers (e.g. librarians and investigators) 37 1st reviewer with checking by 
Librarian & Systematic 
reviewer 
Search strategy, including time period used in the synthesis 
and key words 
263-277 Appendix A3 
 
Effort to include all available studies, including contact with 
authors 
 Not conducted as adequate 
data available in primary 
studies 
Databases and registries searched 37 Cochrane Library, York CRD, 
Joanna Briggs Institute Library 
of Systematic Reviews, 
MEDLINE and the Database of 
Abstracts and Reviews of 
Effects 
Search software used, name and version, including special 
features used (e.g. explosion) 
264-278 MEDLINE,  
MeSH, explosion and keyword 
search, proximal and adjective 
search 
EMBASE, map terms key 
words and explosion 
ISI Web of Science – key 
words 
LILACS – key word search 
SciELO – key word search 
CINAHL – Medical headings, 
key word search 
Use of hand searching (e.g. reference lists of obtained 
articles) 
38 Described 
List of citations located and those excluded, including 
justification 
279 Appendix A4 
Method of addressing articles published in languages other 38 Translation available for 
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than English articles in Spanish, German, 
Portuguese and Polish  
Method of handling abstracts and unpublished studies  N/A 
Description of any contact with authors  None required as adequate 
data available 
Reporting of methods should include 
Description of relevance or appropriateness of studies 
assembled for assessing the hypothesis to be tested 
34-35 Inclusion/exclusion criteria 
Rationale for the selection and coding of data (e.g. sound 
clinical principles or convenience) 
43 Assessment of study eligibility 
Documentation of how data were classified and coded (e.g. 
multiple raters, blinding and interrater reliability) 
39 First 2 reviewers selected 
articles for inclusion. Lack of 
consensus resolved by 3rd 
reviewer 
Assessment of confounding (e.g. comparability of cases and 
controls in studies where appropriate) 
42-43 QA tool developed to account 
for this 
Assessment of study quality, including blinding of quality 
assessors, stratification or regression on possible predictors 
of study results 
42-43 QA tool developed to account 
for this 
Assessment of heterogeneity 48-49 Results grouped as 
comorbidity + SES, 
comorbidity only, SES only 
Description of statistical methods (e.g. complete description 
of fixed or random effects models, justification of whether 
the chosen models account for predictors of study results, 
dose-response models, or cumulative meta-analysis) in 
sufficient detail to be replicated 
50-51 Full description of meta-
analytic methods given 
Provision of appropriate tables and graphics 52-61 Parameter estimate tables and 
forest plots 
Reporting of results should include 
Graphic summarizing individual study estimates and overall 
estimate 
52-61  
Table giving descriptive information for each study included 292-314 Appendix A5 Data abstraction 
tables 
Results of sensitivity testing (e.g. subgroup analysis) 292-314 Appendix A5 Data abstraction 
tables 
Indication of statistical uncertainty of findings  N/A 
Reporting of discussion should include 
Quantitative assessment of bias (e.g. publication bias) 74  
Justification for exclusion (e.g. exclusion of non-English 
language citations) 
74  
Assessment of quality of included studies 42-43 QA tool developed for study 
Reporting of conclusions should include 
Consideration of alternative explanations for observed 
results 
 N/A 
Generalization of the conclusions (e.g. appropriate for the 
data presented and within the domain of the literature 
75  
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review) 
Guidelines for future research 75  
Disclosure of funding source   
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Background  
A global review of cancer has shown an inverse relationship between cancer incidence and 
survival and socioeconomic factors. Although this does not apply to all known cancer sites, the 
existing differences in survival are still a cause for concern. Previous reviews have also identified 
this association. 1; 2; 3 Another important determinant for cancer survival that has been identified is 
the presence of a pre-existing medical condition or comorbidity. Rosenbaum describes a 
comorbidities as, ‘chronic illnesses that exist simultaneously with and usually independent of 
another medical condition, in this case cancer’. 4 There is some evidence that having one or more 
of these pre-existing medical conditions may affect the impact and severity of the cancer thereby 
affecting outcomes/ prognosis. 5 
As pointed out by Yancik et al, cancer incidence increases exponentially with increasing age but 
this advancement in age also brings with it an increased susceptibility to health problems. 7. 
Although survival trends available from ISD Scotland 7 show large absolute increases for breast, 
colorectal and prostate cancer on an ecological level, it is unknown how these statistics relate to 
individual factors such as level of deprivation and comorbidity status. 
Towards a Healthier Scotland targeted the reduction of health inequalities as a key priority 
suggesting that research should focus on the causes of these inequalities and the practical means 
to tackle them. 8 The aim of the Scottish Executive at this time was to reduce cancer mortality by 
20% which was implemented through a colorectal demonstration project. Despite the advantages 
of screening such as early disease detection and treatment, screening is not the only solution to 
the significant, public health, medical and policy challenges of cancer. There are other important 
variables to consider such as deprivation (socioeconomic status) and comorbidity.  As the effect 
of comorbidity and social deprivation has not been extensively researched for the 4 cancers, 
namely head and neck, colorectal, breast and prostate; this systematic review will attempt to 
investigate this. 9; 10  
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From previous research it was identified that low socioeconomic status was linked to worse 
prognosis and that the same relationship existed for comorbidity and outcomes. What is as yet 
uncertain is whether being from a deprived background increases the likelihood of having one or 
more comorbidities or whether both deprivation and comorbidity have an independent effect on 
cancer outcomes. It will be interesting to measure this effect as either confounding or effect 
modification of one risk factor over another. 
Objectives 
The primary objective of this review is to establish what effect comorbidity and deprivation have 
on patient survival in 4 cancers namely, breast, colorectal, prostate and head and neck. The 
specific questions are: 
 Do comorbidities and socioeconomic status have an independent effect from each other 
on survival following cancer? 
 What is the prognosis of these patients dependent on cancer stage at presentation? 
Criteria for considering studies for this review 
Types of studies 
The review will consider studies that focus on the outcomes of patients diagnosed with any of 
the following cancers with concurrent comorbidities and socioeconomic status. Studies that 
compare cancer patients based on socioeconomic status and/or pre-existing medical conditions 
will also be considered. 
Studies reviewing other cancers apart from the 4 cancers under review will be excluded. In the 
absence of research studies, other forms of evidence such as text and opinion papers will be 
considered for inclusion in a narrative summary. 
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Types of participants 
The participants of interest are adult patients with a diagnosis of cancers of the breast, 
colorectal, head and neck or prostate gland. The age will be restricted to exclude patients with 
childhood cancers with no upper limit on the age as comorbidities are more likely to occur with 
more advanced age. Also it is envisaged that the impact of deprivation will be difficult to measure 
in a younger population bearing in mind that these cancers usually occur after the 5th decade of 
life. 
The outcome of interest  
This is the survival rates of cancer patients with pre-existing medical conditions from deprived 
backgrounds. This will be analysed based on all cause mortality versus cancer specific mortality to 
measure the true effect of these variables on survival. 
References: 
1. Macleod U, Ross S, Gillis C, McConnachie A, Twelves C, Watt GC. Socio-economic deprivation 
and stage of disease at presentation in women with breast cancer. Annals of Oncology 2000; 
11(1):105-7. 
2. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ, Scottish Cancer Therapy N. 
Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect 
on differences in survival. Journal of Epidemiology & Community Health 2001; 55(5):308-15. 
3. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and 
survival. J Natl Cancer Inst 2002; 94(7):490-6, 2002 Apr 3. 
4. Henley NC, Hole DJ, Kesson E, Burns HJ, George WD, Cooke TG, et al. Does deprivation affect 
breast cancer management? British Journal of Cancer 2005; 92(4):631-3. 
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5. Macleod U, Ross S, Twelves C, George WD, Gillis C, Watt GC. Primary and secondary care 
management of women with early breast cancer from affluent and deprived areas: retrospective 
review of hospital and general practice records. BMJ 2000; 320(7247):1442-5. 
6. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic 
diseases. Cancer 2000; 88(3):653-63. 
7. Houterman S, Janssen-Heijnen ML, Verheij CD, Louwman WJ, Vreugdenhil G, van der Sangen 
MJ, et al. Comorbidity has negligible impact on treatment and complications but influences 
survival in breast cancer patients. British Journal of Cancer 2004; 90(12):2332-7. 
8. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL, Jr. Prognostic importance of 
comorbidity in a hospital-based cancer registry. JAMA 2004; 291(20):2441-7. 
9. Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of 
illness for patients with breast cancer. Medical Care 2005; 43(2):132-40. 
10. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, 
Nieuwenhuijzen GA, et al. Less extensive treatment and inferior prognosis for breast cancer 
patient with comorbidity: a population-based study. European Journal of Cancer 2005; 41(5):779-
85. 
11. Munro AJ, Bentley AHM.  Deprivation, comorbidity and survival in a cohort of patients with 
colorectal cancer.  European Journal of Cancer Care 2004; 13: 254–262. 
12. Munro AJ. Deprivation and survival in patients with cancer: we know so much, but do so little.  
Lancet Oncology 2005; 6(12):912-913. 
13.  McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey T P. Cohort 
study examining tamoxifen adherence and its relationship to mortality in women with breast 
cancer. British Journal of Cancer 2008 99 1763-68. 
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14. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical 
review of available methods. Journal of Clinical Epidemiology 2003; 56(3):221-9. 
15. Perkins AJ, Kroenke K, Unutzer J, Katon W, Williams JW, Hope C, et al. Common comorbidity 
scales were similar in their ability to predict health care costs and mortality. Journal of Clinical 
Epidemiology 2004; 57(10):1040-8. 
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 
40(5):373-83. 
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative databases. Journal of Clinical Epidemiology 1992; 45(6):613-9. 
18. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of 
the Charlson comorbidity index predicted in-hospital mortality. Journal of Clinical Epidemiology 
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Search strategy for identification of studies (Appendix I) 
Prior to commencing the systematic review process, databases were searched to verify whether 
a systematic review on this subject had been previously conducted. The search was done in the 
following: The Cochrane Library, Joanna Briggs Institute Library of Systematic Reviews, MEDLINE 
and the Database of Abstracts and Reviews of Effects (DARE) were searched and no systematic 
reviews were found on this topic. 
It is considered prudent to approach the literature search using a step-wise method involving 
three steps. The first step involves an initial limited search of MEDLINE and Cancerlit to help 
identify relevant keywords contained in the title and abstract and subject descriptors. The second 
step will involve a comprehensive and exhaustive search using all identified keywords and index 
terms specific to each included database and internet search engines. Thirdly, the reference list 
of all included research papers will be searched for additional studies while relevant journals will 
also be hand searched. 
Databases to be searched will be: 
1. MEDLINE 
2. ISI Web of science 
3. CINAHL 
4. LILACS 
5. Ovid databases, e.g. Embase, BNI 
7. SCIelo 
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Methods  
Assessment of methodological quality 
This will be conducted using the Effective Public Health Practice Quality Assessment Tool for 
observational studies. All relevant articles of observational studies will be independently 
appraised by both the researcher and supervisor for methodological quality. If any 
disagreements are evident, the article in question will be discussed but if different opinions 
prevail it will be passed on to a third reviewer who is the researcher’s associate supervisor. 
Data extraction 
This will be done using a standard format adapted from a previously used data abstraction sheet. 
3 The information to be collected will include the following: 
 Ref number 
 First author + year; Title of article; Setting for the study 
 Cancer anatomic site and stage; ICD-10 codes 
 Data analysis methods  
  Measure of comorbidity/ socioeconomic status 
  Description of results 
Data synthesis 
Dependent on the outcomes of the studies, a meta-analysis will be attempted, but this will hinge 
on homogeneity of studies under review. Where a meta-analysis is not possible, a narrative 
summary of findings will be conducted. 
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A p p e n d i x  A 3  S e a r c h  S t r a t e g i e s  
Literature search strategies 
A3.1. MEDLINE Search 
1     exp "head and neck neoplasms"/ or exp facial neoplasms/ or exp mouth neoplasms/ or 
exp otorhinolaryngologic neoplasms/ or exp tracheal neoplasms/ (385001) 
2     exp "head and neck neoplasms"/ or facial neoplasms/ or mouth neoplasms/ or 
otorhinolaryngologic neoplasms/ or tracheal neoplasms/ (379228) 
3     (neck adj5 neoplasm).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(1605) 
4     (head adj5 neoplasm).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (775) 
5     (head and neck neoplas*).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(34011) 
6     (head and neck cancer).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(34652) 
7     (head adj5 cancer).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (38413) 
8     (head adj5 tum*r).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (18658) 
9     (head adj5 tum?r).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (17829) 
10     ((head or neck or oral cavity or pharyng* or hypopharyng*) adj5 cancer).mp. [mp=ps, rs, 
ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (44650) 
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11     ((head or neck or oral cavit* or pharyng* or hypopharyng*) adj5 cancer).mp. [mp=ps, rs, 
ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (44659) 
12     ((head or neck or oral cavit* or pharyng* or hypopharyng*) adj5 tum*r).mp. [mp=ps, rs, 
ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (26377) 
13     (gastrointestinal tract or mouth or pharynx or upper gastrointestinal tract).mp. [mp=ps, 
rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (386258) 
14     gastrointestinal tract/ or mouth/ or pharynx/ or upper gastrointestinal tract/ (107474) 
15     neoplasms/ (373192) 
16     14 and 15 (677) 
17     13 and 15 (4869) 
18     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 (396013) 
19     diseases/ or comorbidity/ or confounding factors/ (273632) 
20     diseases/ or comorbidity/ or confounding factors/ or effect modifiers/ (273632) 
21     diseases/ or comorbidity/ or confounding factors/ or effect modifiers/ (273632) 
22     exp Comorbidity/ (127790) 
23     comorbidity.mp. (145592) 
24     comorbid*.mp. (176866) 
25     additional morbidit*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (718) 
26     multiple morbidit*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (213) 
27     co-existing disease.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (138) 
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28     comorbidit* index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (2179) 
29     comorbidity index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (2167) 
30     charlson index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (821) 
31     kaplan feinstein index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (35) 
32     greenfield index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (7) 
33     cumulative illness rating scale.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, 
mf] (407) 
34     index of co existent disease.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, 
mf] (20) 
35     adult comorbidity evaluation.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, 
mf] (93) 
36     (cancer and comorbidity measure).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, 
dm, mf] (6) 
37     19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 (323692) 
38     exp Socioeconomic Factors/ (414680) 
39     socio economic factors.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(2531) 
40     socioeconomic factors.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(94555) 
41     socioeconomic.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (149702) 
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42     socioeconomic status.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(31915) 
43     socioeconomic inequalities.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, 
mf] (891) 
44     socioeconomic level.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(1940) 
45     social class.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (53416) 
46     exp Social Class/ (56749) 
47     exp Poverty Areas/ or exp Poverty/ (55622) 
48     poverty.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (57495) 
49     social disadvantag*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (968) 
50     (soc* adj5 disadvantag*).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(5061) 
51     (soc* adj5 depriv*).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (5754) 
52     material deprivation.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (445) 
53     material depriv*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (448) 
54     income inequalit*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (1056) 
55     health inequalit*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (4469) 
56     (health adj5 inequalit*).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(8521) 
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57     exp Health Status Indicators/ or exp Health Status/ or exp Health Status Disparities/ 
(422019) 
58     deprivation index.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (431) 
59     deprivation indices.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (145) 
60     38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 
or 54 or 55 or 56 or 57 or 58 or 59 (857870) 
61     exp Disease-Free Survival/ or exp Survival Analysis/ or exp Survival/ or exp Survival Rate/ 
(586685) 
62     survival.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (1254684) 
63     treatment outcome.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(978943) 
64     surviv* trends.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (336) 
65     (surviv* adj5 trends).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(1872) 
66     exp Prognosis/ (1103497) 
67     medical prognos*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (230) 
68     (recurrence adj2 surviv*).mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] 
(13252) 
69     exp Hospital Mortality/ or exp Mortality/ (675205) 
70     mortality.mp. (986983) 
71     exp Death/ or exp Death Certificates/ or death.mp. (1075099) 
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72     61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 (3939133) 
73     exp Cohort Studies/ (1143041) 
74     exp Prospective Studies/ (446709) 
75     exp Retrospective Studies/mt, st [Methods, Standards] (13) 
76     exp Retrospective Studies/ (584695) 
77     exp Longitudinal Studies/ (739420) 
78     exp Follow-Up Studies/ (908603) 
79     follow up stud*.mp. [mp=ps, rs, ti, ot, ab, nm, hw, ui, tx, kw, ct, sh, tn, dm, mf] (456160) 
80     73 or 74 or 75 or 76 or 77 or 78 or 79 (1971225) 
81     37 or 60 (1145725) 
82     18 and 72 and 80 and 81 (842) 
83     remove duplicates from 82 (772) 
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A3.2. CINAHL Search  
1. (MH”Comorbidity”) OR ”comorbidity” (25872) 
2. “comorbidity” (892) 
3. additional morbidity (108) 
4. competing causes of illness (0) 
5. coexisting disease (124) 
6. co-existing disease (33) 
7. comorbidity index (412) 
8. Charlson index (313) 
9. Kaplan Feinstein index (1) 
10. Greenfield index (2) 
11. Cumulative illness rating scale (67) 
12. ACE-27 co-morbidity index (3) 
13. Index of co-existent disease (5) 
14. adult comorbidity evaluation (6) 
15. cancer and comorbidity measure (8) 
16. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 (26644) 
17. “cancer” (130427) 
18. “neoplasms” (169778) 
19. 17 OR 18 (207691) 
20. (MH”Socioeconomic Factors+”) (162744) 
21. “social class” (6220) 
22. (MH”Social Class+”) (5555) 
23. “material deprivation” (98) 
24. “health inequality” (159) 
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25. (MM"Survival") OR (MM "Survival Rate") OR (MM "Survival Analysis") (3157) 
26. (MH”Survival Analysis+”) (32690) 
27. (MH”Prognosis+”) (156570) 
28. “outcomes” (229869) 
29. 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 (424761) 
30. 16 and 19 and 29 (840) 
31. (16 and 19 and 29 ) AND ( head and neck cancer ) (36) 
32. (16 and 19 and 29 ) AND pharyngeal cancer OR laryngeal cancer OR mouth cancer OR lip 
cancer OR nasopharyngeal cancer (583) 
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A3.3. Embase Search 
1. (head and neck neoplasms).mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
2. (head and neck cancer).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
3. 1 or 2 
4. exp comorbidity/ 
5. co-morbidity.mp. 
6. coexisting disease.mp. 
7. 4 or 5 or 6 
8. comorbidity index.mp. 
9. charlson index.mp. 
10. kaplan feinstein index.mp. 
11. greenfield index.mp. 
12. cumulative illness rating scale.mp. 
13. index of coexistent disease.mp. 
14. ACE-27.mp. 
15. adult comorbidity evaluation.mp. 
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16. (cancer and comorbidity measure).mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
17. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
18. socioeconomic factors.mp. or exp socioeconomics/ 
19. exp socioeconomics/ 
20. socioeconomic status.mp. or exp social status/ 
21. socioeconomic inequalities.mp. 
22. socioeconomic level.mp. 
23. social class.mp. or exp social class/ 
24. poverty areas.mp. or exp poverty/ 
25. poor areas.mp. 
26. poverty.mp. 
27. social disadvantage.mp. 
28. deprivation.mp. 
29. material deprivation.mp. 
30. income inequality.mp. 
31. income inequalities.mp. 
32. health inequality.mp. or health disparity/ 
33. postcode lottery.mp. 
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34. health status indicator.mp. or exp health survey/ 
35. deprivation index.mp. 
36. deprivation indices.mp. 
37. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 
38. exp cause specific survival/ or survival/ or exp survival time/ or survival.mp. or exp overall 
survival/ or exp cancer survival/ or exp survival rate/ or exp disease free survival/ 
39. (follow-up or prognos:tw).mp. or ep.fs. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
40. treatment outcome.mp. or exp treatment outcome/ 
41. survival trends.mp. 
42. prognosis.mp. or exp prognosis/ 
43. prognos:.tw. 
44. medical prognosis.mp. 
45. exp mortality/ or mortality.mp. 
46. exp death/ or death.mp. or "cause of death"/ or exp death certificate/ 
47. 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 
48. cohort studies.mp. or exp cohort analysis/ 
49. prospective studies.mp. or exp prospective study/ 
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50. retrospective studies.mp. or exp retrospective study/ 
51. longitudinal studies.mp. or exp longitudinal study/ 
52. follow-up studies.mp. or exp follow up/ 
53. exp epidemiology/ or epidemiological study.mp. 
54. 48 or 49 or 50 or 51 or 52 or 53 
55. 3 and 7 and 17 and 37 and 47 and 54 
314  
 
A3.4. SciELO Search   
1. Head and neck neoplasms OR head and neck cancer OR pharyngeal cancer OR laryngeal 
cancer OR mouth cancer OR lip cancer OR nasopharyngeal cancer AND 
2. Survival OR survival analysis OR survival rate OR prognosis OR outcome AND 
3. Socioeconomic status OR socioeconomic deprivation OR social class OR poverty OR 
health inequality AND 
4. Comorbidity OR co-morbidity OR coexisting illness OR co-existing illness OR competing 
causes of death AND 
5. site:http://www.scielo.cl OR site:http://www.scielo.org.pe OR 
site:http://www.scielo.org.ar OR site:http://www.scielo.br OR 
site:http://www.scielo.org.co OR site:http://scielo.sld.cu OR site:http://scielo.isciii.es OR 
site:http://www.scielo.oces.mctes.pt OR site:http://www.scielo.org.ve OR 
site:http://www.scielo.org.mx OR site:http://www.scielo.sa.cr OR 
site:http://scielo.iics.una.py OR site:http://caribbean.scielo.org OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.edu.uy OR 
site:http://www.scielosp.org OR site:http://socialsciences.scielo.org (3000+ results) 
Unable to search all these terms in Google as it limits search to 32 words also returned 3000 
results which was not a sensitive enough search strategy. Terms changed to  
1. “Head and neck neoplasms and prognosis” site:http://www.scielo.cl OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.org.ar OR 
site:http://www.scielo.br OR site:http://www.scielo.org.co OR site:http://scielo.sld.cu OR 
site:http://scielo.isciii.es OR site:http://www.scielo.oces.mctes.pt OR 
site:http://www.scielo.org.ve OR site:http://www.scielo.org.mx OR 
site:http://www.scielo.sa.cr OR site:http://scielo.iics.una.py OR 
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site:http://caribbean.scielo.org OR site:http://www.scielo.org.pe OR 
site:http://www.scielo.edu.uy OR site:http://www.scielosp.org OR 
site:http://socialsciences.scielo.org (0 results) 
2. Head and neck neoplasms and prognosis site:http://www.scielo.cl OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.org.ar OR 
site:http://www.scielo.br OR site:http://www.scielo.org.co OR site:http://scielo.sld.cu OR 
site:http://scielo.isciii.es OR site:http://www.scielo.oces.mctes.pt OR 
site:http://www.scielo.org.ve OR site:http://www.scielo.org.mx OR 
site:http://www.scielo.sa.cr OR site:http://scielo.iics.una.py OR 
site:http://caribbean.scielo.org OR site:http://www.scielo.org.pe OR 
site:http://www.scielo.edu.uy OR site:http://www.scielosp.org OR 
site:http://socialsciences.scielo.org (162 results) 
3. Head and neck cancer prognosis site:http://www.scielo.cl OR 
site:http://www.scielo.org.pe OR site:http://www.scielo.org.ar OR 
site:http://www.scielo.br OR site:http://www.scielo.org.co OR site:http://scielo.sld.cu OR 
site:http://scielo.isciii.es OR site:http://www.scielo.oces.mctes.pt OR 
site:http://www.scielo.org.ve OR site:http://www.scielo.org.mx OR 
site:http://www.scielo.sa.cr OR site:http://scielo.iics.una.py OR 
site:http://caribbean.scielo.org OR site:http://www.scielo.org.pe OR 
site:http://www.scielo.edu.uy OR site:http://www.scielosp.org OR 
site:http://socialsciences.scielo.org (160 results) 
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A3.5. LILACS Search   
1. Head and neck neoplasms 
2. Oropharyngeal neoplasms 
3. Pharyngeal neoplasms 
4. Laryngeal neoplasms 
5. Mouth neoplasms 
6. Hypopharyngeal neoplasms 
7. / OR 1-6 (1872 results) 
8. Comorbidity 
9. Co-morbidity 
10. Coexisting illness 
11. Competing causes of death 
12. Chronic disease 
13. 8 OR 9 OR 10 OR 11 (3958 results) 
14. Poverty 
15. socioeconomic deprivation 
16. social class 
17. material deprivation 
18. /OR 14-17 
19. 7 AND 13 AND 18 (12 results) 
20. Death 
21. Prognosis 
22. Outcome 
23. / OR 20-22 (2798 results) 
24. 7 AND 13 AND 18 AND 23 (0 results) 
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A p p e n d i x  5  
Methodological Quality Assessment Tool 
Adapted from Marx and Marx, (221) Altman, (202) University of Montreal, (217)and Thomas et 
al. (222) 
CITATION: 
 
ASSESSMENT QUESTIONS YES NO CAN’T 
TELL 
1. Were patients with the same disease included in this study?     
2.  Are the individuals selected to participate in the study likely to 
be representative of the target population? 
   
3. Was a definite end point indicated?    
4. If a definite end point was not given, is there indication of a 
surrogate end point? 
   
5. Were withdrawals and drop-outs reported in terms of numbers 
and/or reasons per group? 
   
6. Is there analysis of baseline severity (e.g. TNM staging)?    
7. Are the study subjects truly representative of the population of 
interest? 
   
8. Were the study subjects chosen at a common point in the disease 
course? 
   
9. Is there indication of baseline frequency for candidate predictors 
(e.g. age, sex)? 
   
10. Does the classification of predictors make them reproducible 
(e.g. elderly, hypertension)? 
   
11. Has multivariate analysis been used to control for confounding or 
effect modification? 
   
12. Has consideration been given to Identification of the variables' 
importance in multivariate analysis? 
   
13. Have the authors accounted for the effect of treatment on 
predictors? 
   
14. Has the number of patients censored together with the reason 
for censoring been reported, and have these censored patients 
been adequately considered in the analysis? 
   
TOTALS    
 
 
320  
 
GLOBAL RATING METHODS 
LEGEND:   YES (STRONG)  CAN’T TELL (MODERATE)  NO (WEAK) 
GLOBAL RATING FOR THIS PAPER (circle one):  
1  STRONG   (All STRONG ratings with no WEAK ratings)  
2  MODERATE   (Mostly STRONG ratings and one WEAK rating)  
3  WEAK    (two or more WEAK ratings)  
With both reviewers discussing the ratings:  
Is there a discrepancy between the two reviewers with respect to the component (1-14) 
ratings?  
No   Yes  
If yes, indicate the reason for the discrepancy  
1 Oversight  
2 Differences in interpretation of criteria  
3 Differences in interpretation of study  
Final decision of both reviewers (circle one):  
1   STRONG  
2   MODERATE  
3   WEAK 
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A p p e n d i x  A 6   
Modified Methodological Quality Assessment Tool for Survival Studies  
Adapted from Laupacis et al, (203) Altman, (202)Hayden et al (223) 
CITATION: 
ASSESSMENT QUESTIONS YES PARTLY CAN’T 
TELL 
NO TOTAL 
1. Was there a representative and well 
defined sample of patients? 
     
2. Were these patients at a similar time point 
in the course of the disease? 
     
3. Was follow up sufficiently long and 
complete? 
     
4. Is the prognostic factor of interest 
adequately measured in order to limit 
potential bias? 
     
5. Were objective and unbiased outcome 
criteria used? 
     
6. Was there adjustment for important 
prognostic factors? 
     
7. Is the statistical analysis appropriate for 
the design of the study? 
     
8. Have the authors accounted for effect of 
treatment on predictors? 
     
Total       
 
GLOBAL RATING METHODS 
LEGEND:   YES (3)  PARTLY (2) CAN’T TELL (1)  NO (0) 
GLOBAL RATING FOR THIS PAPER (circle one):  
1  STRONG   (score of 18-24)  
2  MODERATE   (score of 12-17)  
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3  WEAK    (score 11 or less)  
GUIDE TO ASSESSMENT QUESTIONS 
1. Was there a representative and well defined sample of patients? This asks how well 
defined the individuals in the study are and whether they are representative of the 
underlying population on key characteristics, hence limiting potential bias to the study 
results.  
2. Were these patients at a similar time point in the course of the disease? - This describes 
whether all patients were at a similar well defined point in the course of their disease. 
This calls for a clear description of the stage of disease at which patients joined the 
study, e.g. as duration of disease is associated with outcome, the authors should 
describe the duration of the illness for the sample patients. Ideally all patients should 
be at a similar stage such as newly diagnosed head and neck cancer (HNC). An example 
could be that of an HNC survival study where survival was reported at two different 
points in time, a) referral to oncologist and, b) the point at which HNC symptoms 
became apparent. The former is the more certain time point but suffers from the 
disadvantage that patients seek medical attention at different points of the disease 
course. The latter provides a more uniform starting point but is potentially imprecise 
because some HNCs develop insidiously and time of onset is identified retrospectively. 
Survival after presentation to primary healthcare services is more pertinent. 
3. Was follow up sufficiently long and complete? – Follow up is important because the 
greater the number of patients unavailable for follow up the less accurate the estimate 
regarding the risk of adverse outcome. Study attrition should be minimal to limit 
potential bias from outcome measurement. In particular censoring asks that 
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consideration is made of the relation between the proportion of patients who are 
unavailable and those that have suffered the adverse outcome of interest. The larger 
the number of patients whose fate is unknown relative to the number who have 
suffered the event, the greater the threat to validity of the study. If reasons for 
unavailability or loss to follow up are omitted, the strength of inference from the study 
results is weaker. 
4. Is the prognostic factor of interest adequately measured in order to limit potential bias? 
– A clear definition and description of the prognostic factor should be given. This may 
include information such as dose, level, duration of exposure, and clear specification of 
methods of measurement. Misclassification bias should be minimised by ensuring the 
prognostic factor measure and method are valid and reliable. An adequate proportion 
of the study sample should have complete data on the prognostic factor under study. 
The method and setting for measurement should be the same for all study participants 
and if data on the prognostic factor is missing, appropriate imputations should be used. 
5. Were objective and unbiased outcome criteria used? – Clear description of adverse 
outcomes should be given at the start of the study. These vary from those that are 
objective and easy to measure (e.g. death) or those that need considerable judgement 
and are difficult to measure (e.g. quality of life or disability). To minimise bias, blinding 
to prognostic factor status is needed but this is not always possible. 
6. Was there adjustment for important prognostic factors? – When comparing the 
prognosis of two groups of patients, investigators should consider whether similarities 
in clinical characteristics are evident and adjust analysis for any differences found. Many 
prognostic studies split cohorts into distinct prognostic factor groups and comparison 
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of the pattern and frequencies of outcomes between these groups can determine the 
relative risk associated with the specific prognostic factor. 
7. Is the statistical analysis appropriate for the design of the study in limiting potential for 
presentation of invalid results? – There must be sufficient presentation of data to allow 
adequate review of the analysis methods used. Evidence must be available that 
demonstrates that the strategy for model building is appropriate (i.e. inclusion of 
variables) and that it is based on a conceptual model or framework. There should not 
be any selective reporting of results, while the selected model clearly demonstrates 
adequacy based on the study design. 
8. Have the authors accounted for effect of treatment on predictors? – Since treatments 
can alter patient outcomes, these should be taken into account when analysing 
prognostic factors. Investigators should adjust for treatment differences in the analysis 
despite the acknowledgement that treatment is not a prognostic factor. 
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A p p e n d i x  A 7   
REJECTED STUDIES 
This table details the reasons for rejection of the potential studies that had full text retrieval 
before exclusion with corresponding reasons. Studies were included in this review and meta-
analysis if they addressed comorbidity and socioeconomic status (deprivation) as prognostic 
factors for survival outcomes measurements. 
DOES NOT FOCUS ON SURVIVAL 
1. De Boer MF, Van den Borne B, Pruyn JF, Ryckman RM, Volovics L, Knegt PP, Meeuwis 
CA, Mesters I, Verwoerd CD. Psychosocial and physical correlates of survival and 
recurrence in patients with head and neck carcinoma: results of a 6-year longitudinal 
study. Cancer, 1998; 83(12):2567-2579. (313) 
2. Goeman JJ, Le Cessie S, de Jong RJB, van de Geer SA. Predicting survival using disease 
history: a model combining relative survival and frailty. Statistica Neerlandica. 2004; 
58(1):21-34. (251) 
3. Menvielle G, Luce D, Goldberg P, Leclerc A. Smoking, alcohol drinking, occupational 
exposures and social inequalities in hypopharyngeal and laryngeal cancer. International 
Journal of Epidemiology. 2004 Aug;33(4):799-806. (246) 
4. Patel RS, McCluskey SA, Goldstein DP, Minkovich L, Irish JC, Brown DH, et al. 
Clinicopathologic and therapeutic risk factors for perioperative complications and 
prolonged hospital stay in free flap reconstruction of the head and neck. Head and 
Neck-Journal for the Sciences and Specialties of the Head and Neck. 2010 
Oct;32(10):1345-53.(248) 
5. Vartanian JG, Carvalho AL, Toyota J, Giacometti Kowalski IS, Kowalski LP. 
Socioeconomic effects of and risk factors for disability in long-term survivors of head 
and neck cancer. Archives of Otolaryngology - Head and Neck Surgery, 2006 ; 132(1):32-
5. (574) 
6. Paleri V, Wight RG. A cross-comparison of retrospective notes extraction and combined 
notes extraction and patient interview in the completion of a comorbidity index (ACE-
27) in a cohort of United Kingdom patients with head and neck cancer. J Laryngol Otol. 
[Comparative Study 
7. Research Support, Non-U.S. Gov't]. 2002; 116(11):937-41.(299)  
8. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, et al. Validation of the 
Charlson comorbidity index in patients with head and neck cancer: a multi-institutional 
study. Laryngoscope, 1997; 107(11 Pt 1): 1469-75.(163) 
9. Piccirillo JF, Costas I. The impact of comorbidity on outcomes. ORL J Otorhinolaryngol 
Relat Spec. 2004; 66(4): 180-5.(148) 
10. Zabrodsky M, Calabrese L, Tosoni A, Ansarin M, Giugliano G, Bruschini R, et al. Major 
surgery in elderly head and neck cancer patients: immediate and long-term surgical 
results and complication rates. Surg Oncol, 2004; 13(4): 249-55.(287) 
11. Moore CE, Durden F. Head and neck cancer screening in homeless communities: HEAL 
(Health Education, Assessment, and Leadership). J Natl Med Assoc, 2010; 102(9): 811-
6.(284) 
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12. Sethi RA, Stamell EF, Price L, DeLacure M, Sanfilippo N. Head and neck radiotherapy 
compliance in an underserved patient population. Laryngoscope, 2010; 120(7): 1336-
41.(235) 
13. Woolley E, Magennis P, Shokar P, Lowe D, Edwards D, Rogers SN. The correlation 
between indices of deprivation and health-related quality of life in patients with oral 
and oropharyngeal squamous cell carcinoma. Br J Oral Maxillofac Surg. [Comparative 
Study]. 2006 Jun;44(3):177-86.(122) 
14. Borggreven PA, Kuik DJ, Quak JJ, de Bree R, Snow GB, Leemans CR. Comorbid 
condition as a prognostic factor for complications in major surgery of the oral cavity 
and oropharynx with microvascular soft tissue reconstruction. Head & Neck, 2003; 
25(10): 808-15.(15) 
15. Peters TTA, van der Laan B, Plaat BEC, Wedman J, Langendijk JA, Halmos GB. The 
impact of comorbidity on treatment-related side effects in older patients with laryngeal 
cancer. Oral Oncology. 2011 Jan;47(1):56-61.(18) 
16. Paleri V, Wight RG. Applicability of the adult comorbidity evaluation - 27 and the 
Charlson indexes to assess comorbidity by notes extraction in a cohort of United 
Kingdom patients with head and neck cancer: a retrospective study. J Laryngol Otol. 
[Validation Studies]. 2002 Mar;116(3):200-5.(575) 
17. Nobles J, Wold C, Fazekas-May M, Gilbert J, Friedlander PL. Prevalence and 
epidemiology of hepatitis C virus in patients with squamous cell carcinoma of the head 
and neck. Laryngoscope. 2004; 114(12): 2119-22.(247) 
18. Nagele P, Rao LK, Penta M, Kallogjeri D, Spitznagel EL, Cavallone LF, et al. 
Postoperative myocardial injury after major head and neck cancer surgery. Head and 
Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011; 33(8): 1085-
91.(286) 
19. Tong H, Isenring E, Yates P. The prevalence of nutrition impact symptoms and their 
relationship to quality of life and clinical outcomes in medical oncology patients. 
Supportive Care in Cancer. 2009;17(1):83-90.(296) 
20. Pytynia KB, Grant JR, Etzel CJ, Roberts D, Wei QY, Sturgis EM. Matched analysis of 
survival in patients with squamous cell carcinoma of the head and neck diagnosed 
before and after 40 years of age. Archives of Otolaryngology-Head & Neck Surgery. 
2004;130(7):869-73.(288) 
21. Rogers SN, Aziz A, Lowe D, Husband DJ. Feasibility study of the retrospective use of the 
Adult Comorbidity Evaluation index (ACE-27) in patients with cancer of the head and 
neck who had radiotherapy. Br J Oral Maxillofac Surg. 2006;44(4):283-8.(576) 
22. Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE. Cancer 
rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev 
Oncol Hematol. 2008;67(3):237-42.(259) 
23. Ferrier MB, Spuesens EB, Le Cessie S, De Jong RJB. Comorbidity as a major risk factor 
for mortality and complications in head and neck surgery. Archives of Otolaryngology-
Head & Neck Surgery. 2005;131(1):27-32.(258) 
24. Grandis JR, Snyderman CH, Johnson JT, Yu VL, D'Amico F. Postoperative wound 
infection. Cancer. 1992;70:2166-70.(257) 
25. Major SM, Bumpous JM, Flynn MB, Schill K. Quality of life after treatment for advanced 
laryngeal and hypopharyngeal cancer. The Laryngoscope. 2001;111:1379-82.(295) 
26. Piccirillo JF, Spitznagel Jr EL, Vermani N, Costas I, Schnitzler M. Comparison of 
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comorbidity indices for patients with head and neck cancer. Med Care. 2004 
May;42(5):482-6.(301) 
27. Antunes JLF, Borrell C, Perez G, Boing AF, Wunsch V. Inequalities in mortality of men by 
oral and pharyngeal cancer in Barcelona, Spain and Sao Paulo, Brazil, 1995-2003. 
International Journal for Equity in Health. 2008; 7.(271) 
28. Gourin CG, McAfee WJ, Neyman KM, Howington JW, Podolsky RH, Terris DJ. Effect of 
comorbidity on quality of life and treatment selection in patients with squamous cell 
carcinoma of the head and neck. Laryngoscope. [Comparative Study]. 2005; 115(8):1371-
5.(226) 
UNABLE TO OBTAIN FULL PAPER 
29. Cinamon U, Hier MP, Black MJ. Age as a prognostic factor for head and neck squamous 
cell carcinoma: should older patients be treated differently? J Otolaryngol. 2006; 
35(1):8-12.(272) 
NOT ENOUGH DATA AVAILABLE 
30. Cederblad L, Johansson S, Enblad G, Engstrom M, Blomquist E. Cancer of the parotid 
gland; long-term follow-up. A single centre experience on recurrence and survival. Acta 
Oncol. 2009; 48(4):549-55.(293) 
31. de Cassia Braga Ribeiro K, Kowalski LP, Latorre MdRDdO. Perioperative complications, 
comorbidities, and survival in oral or oropharyngeal cancer. Archives of Otolaryngology 
-- Head & Neck Surgery. 2003; 129(2):219-28.(253) 
IRRELEVANT, FAILED TO USE COMORBIDITY OR DEPRIVATION 
32. van der Schroeff MP, van de Schans SAM, Piccirillo JF, Langeveld TPM, de Jong RJB, 
Janssen-Heijnen MLG. Conditional relative survival in head and neck squamous cell 
carcinoma: permanent excess mortality risk for long-term survivors. Head and Neck-
Journal for the Sciences and Specialties of the Head and Neck. 2010; 32(12):1613-8.(270) 
33. El-Deiry MW, Futran ND, McDowell JA, Weymuller EA, Jr., Yueh B. Influences and 
predictors of long-term quality of life in head and neck cancer survivors. Archives of 
Otolaryngology -- Head & Neck Surgery. 2009;135(4):380-4.(268) 
34. Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of 
survival in patients with head and neck cancer. Head & Neck. 2001; 23(9):718-24.(267) 
35. Avery CM, Crank ST, Neal CP, Hayter JP, Elton C. The use of the pectoralis major flap for 
advanced and recurrent head and neck malignancy in the medically compromised 
patient. Oral Oncology. 2010; 46(11):829-33.(266) 
36. de Melo GM, Ribeiro KDB, Kowalski LP, Deheinzelin D. Risk factors for postoperative 
complications in oral cancer and their prognostic implications. Archives of 
Otolaryngology-Head & Neck Surgery. 2001 ; 127(7):828-33.(265) 
37. Lee MK, Nalliah RP, Kim MK, Elangovan S, Allareddy V, Kumar-Gajendrareddy P. 
Prevalence and impact of complications on outcomes in patients hospitalized for oral 
and oropharyngeal cancer treatment. Oral Surgery Oral Medicine Oral Pathology Oral 
Radiology and Endodontology. 2011; 112 (5): 581-91.(264) 
38. Hansen RP, Olesen F, Sorensen HT, Sokolowski I, Sondergaard J. Socioeconomic patient 
characteristics predict delay in cancer diagnosis: a Danish cohort study. Bmc Health 
Services Research. 2008;8:49-58.(289) 
39. Kruse AL, Bredell M, Luebbers HT, Grätz KW. Head and neck cancer in the elderly: a 
retrospective study over 10 years (1999 - 2008). Head Neck Oncol. 2010; 25-31.(262) 
40. Su C-C, Chung J-A, Hsu Y-Y, Huang S-J, Lian I-B. Age at diagnosis and prognosis of oral 
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cancer in relation to the patient's residential area: experience from a medical center in 
Taiwan. Oral Oncology. [Research Support, Non-U.S. Gov't]. 2008; 44(11):1032-8.(263) 
41. Jones AS, Beaseley N, Houghton D, Husband DJ. The effects of age on survival and 
other parameters in squamous cell carcinoma of the oral cavity, pharynx and larynx. 
Clin Otolaryngol. 1998; 23: 51-6.(577) 
42. Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head 
and neck squamous cell carcinoma. J Laryngol Otol. 2002;116:269-71.(260) 
43. Archer J, Hutchison I, Korszun A. Mood and malignancy: head and neck cancer and 
depression. J Oral Pathol Med. [Review]. 2008 ;37(5):255-70.(307) 
44. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, et al. Competing 
causes of death and second primary tumors in patients with locoregionally advanced 
head and neck cancer treated with chemoradiotherapy. Clin Cancer Res, 2004; 10(6): 
1956-62.(298) 
45. Rosenberg PS, Socie G, Alter BP, Gluckman E. Risk of head and neck squamous cell 
cancer and death in patients with Fanconi anemia who did and did not receive 
transplants. Blood. 2005 01 ;105(1):67-73.(308) 
46. Nouraei SAR, Al-Yaghchi C, Sandhu GS, Giussani DA, Doyle P, Clarke PM. Incidence and 
significance of myocardial injury after surgical treatment of head and neck cancer. 
Laryngoscope. 2007; 117(9):1581-7.(283) 
47. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ, et al. Survival 
following primary surgery for oral cancer. Oral Oncology, 2009; 45(3):201-11.(256) 
48. Zigon G, Berrino F, Gatta G, Sanchez MJ, van Dijk B, Van Eycken E, et al. Prognoses for 
head and neck cancers in Europe diagnosed in 1995-1999: a population-based study. 
Ann Oncol. 2011;22(1):165-74.(255) 
49. Sarini J, Fournier C, Lefebvre JL, Bonafos G, Van JT, Coche-Dequeant B. Head and neck 
squamous cell carcinoma in elderly patients - A long-term retrospective review of 273 
cases. Archives of Otolaryngology-Head & Neck Surgery. 2001; 127(9):1089-92.(164) 
50. Francis DO, Yueh B, Weymuller EA, Merati AL. Impact of Surveillance on Survival After 
Laryngeal Cancer in the Medicare Population. Laryngoscope. 2009 ;119(12):2337-
44.(297) 
51. Ahmad H, Jabar NA, Rahman NA, Rahman RA, Sha PP, Ramli R. Oral cavity squamous 
cell carcinomas in young patients in a selected Malaysian centre. Asia-Pacific Journal of 
Clinical Oncology. 2009 ;5(1):39-45.(254) 
52. Hall SF, Groome PA, Rothwell D. The impact of comorbidity on the survival of patients 
with squamous cell carcinoma of the head and neck. Head & Neck, 2000;22(4):317-
22.(294) 
53. Wutzl A, Ploder O, Kermer C, Millesi W, Ewers R, Klug C. Mortality and causes of death 
after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral 
Maxillofac Surg, 2007; 65(2):255-60.(250) 
54. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho OP, et al. Prognostic 
factors in tongue cancer - relative importance of demographic, clinical and 
histopathological factors. Br J Cancer. 2000; 83(5):614-9.(269) 
55. Antunes JL, Biazevic MG, de Araujo ME, Tomita NE, Chinellato LE, Narvai PC. Trends and 
spatial distribution of oral cancer mortality in Sao Paulo, Brazil, 1980-1998. Oral 
Oncology. 2001; 37(4):345-50.(252) 
RESTRICTED TO RACE ONLY 
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57. Shiboski CH, Schmidt BL, Jordan RCK. Racial disparity in stage at diagnosis and survival 
among adults with oral cancer in the US. Community Dent Oral Epidemiol. 2007;35:233-
40.(232) 
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patients in a university medical center setting. Are treatments provided and are 
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60. Moore SP, Green AC, Garvey G, Coory MD, Valery PC. A study of head and neck cancer 
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70. Jameson MJ, Karnell LH, Christensen AJ, Funk GF. First-year trends in self-reported 
general health predict survival in patients with head and neck cancer. Archives of 
Otolaryngology-Head & Neck Surgery, 2008; 134(9): 958-64.(292) 
71. Alho OP, Hannula K, Luokkala A, Teppo H, Koivunen P, Kantola S. Differential 
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A p p e n d i x  A 8  
Data Abstraction Tables 
COMORBIDITYAND/SOCIOECONOMIC STATUS (SES) STUDIES 
CITATION 
(FIRST 
AUTHOR, 
COUNTRY, 
YEAR,) 
 
NUMBER 
(N) 
TUMOUR 
SITE 
 
PROGNOSTIC FACTOR 
AND MEASUREMENT 
METHOD 
RECRUITMENT 
PERIOD 
SURVIVAL ANALYSIS REPORTED/ ENDPOINTS 
CONSIDERED 
 
ADJUSTMENT 
FOR 
CONFOUNDING 
 
QUALITY 
RATING 
 
Allareddy(341) 
USA 
2006 
24 803 
Head and 
neck 
cancer 
Comorbidity- No tool but 
comorbid disorders listed 
SES- Insurance status 
2000- 2003 
Multivariate OR for death 
Comorbidity 
Pulmonary circulation disorders OR=1.90 (CI 
0.99,3.64) 
Congestive heart failure OR= 2.17 (CI 1.79,2.63) 
p<.0001 
Neurological disorders OR=1.71 (CI 1.38,2.12) p<.0001 
Renal failure OR=1.49 (CI 1.02, 2.17) p0.03 
Liver disease OR=1.37 (CI 1.01,1.86) p0.03 
Coagulopathy OR=1.54 (CI 1.11,2.15) p.009 
Weight loss OR=1.16 (CI 0.98,1.38) p0.08 
Fluid & electrolyte disorders OR=1.73 (CI 1.51,1.98) 
p<.0001 
Deficiency aneamias OR=1.13 (CI 0.95,1.36) p<.0001 
Insurance  
Self pay/no charge/others OR=1.42 (CI 1.10,1.83) p.006 
Private Reference category 
Controlled for 
comorbid 
conditions, 
insurance status, 
complications of 
medical or 
surgical care 
hospital bed size, 
hospital location 
and hospital 
teaching status 
10/24 
Weak 
333  
 
Andersen(365) 
Denmark 
2008 
4857 
Mouth, 
pharynx 
and larynx 
cancer 
SES and Comorbidity- Social 
class and Charlson 
comorbidity index 
1994- 2003 
5yr RS Men vs. Women Social class 
Mouth and pharynx  
Creative core 39% (CI 28,35) vs. 49% (CI 37-64) 
Creative professional 43% (CI 37-,50) vs. 46% (CI34-62) 
Bohemian 27% (CI 13-55) vs. 0 
Service 32% (CI 28-36) vs. 45% (CI 40-50) 
Manual 32% (CI 29-35) vs. 43% (CI 32-57) 
Agricultural 38% (CI 25-56) vs. 0 
Unknown 26% (CI 20-34) vs. 35% (CI 29-43) 
CCI 0 35% (CI 33-38)vs. 46% (CI 42-51) 
CCI 1 27% (CI 22-32) vs. 36% (CI 28-46) 
CCI ≥2 27% (CI 20-35) vs. 29% (CI 19-43) 
Larynx Social class 
Creative core 83% (CI 70,97) vs. 59% (CI 59-59) 
Creative professional 63% (CI 56,72) vs. 82% (CI 59-114) 
Bohemian 19% (CI 7,48) vs. 0 
Service 53% (CI 41-60) vs. 55% (CI 47-64) 
Manual 52% (CI 48-56) vs. 49% (CI 34-69)  
Agricultural 55% (CI 41-73)vs. 101% 
Unknown 49% (CI 40,61)vs. 53% (CI43-66) 
CCI 0 56% CI 53-60) vs. 58% (52-66) 
CCI 1 56% (CI 49-63)vs. 44% (CI 32-61) 
CCI ≥2 38% (30-50) vs. 61% (CI  44-85) 
Not described 
16/24 
Moderate 
Gourin(340) 
USA 
2006 
1128 
Head and 
neck 
cancer 
Comorbidity- Modified 
Medical Comorbidity Index 
SES- Payer status (i.e. 
insurance, aid or none) 
January 1985-  
March 2002 
5yr DSS- Comorbidity  
0/1 All 43.8%, Black 30.3%, White 53.8% p<.0001 
2/3 All 34.5%, Black 17.8%, White 47.5% p<.0001 
5 yr DSS- Payer status 
Insurance- All 45.8%, Black 43.5%, White 46.9% p .5026 
Aid- All 43.9%, Black 28.0%, White 60.1% p<.0001 
None- All 41.6%, Black 29.5%, White 52.8% p.0004 
Stepwise variable 
selection 
adjusting for 
patient, tumour 
and treatment 
characteristics 
24/24 
Strong 
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COMORBIDITY STUDIES 
CITATION (FIRST 
AUTHOR, 
COUNTRY, YEAR,) 
 
NUMBER 
(N) 
TUMOUR SITE 
 
PROGNOSTIC 
FACTOR 
AND 
MEASUREMENT 
METHOD 
RECRUITMENT PERIOD SURVIVAL ANALYSIS 
REPORTED/ 
ENDPOINTS 
CONSIDERED 
 
ADJUSTMENT 
FOR 
CONFOUNDING 
 
QUALITY 
RATING 
 
Hathaway(428) 
USA 
2001 
330   Metastatic squamous cell 
carcinoma of the head and 
neck 
Comorbidity- 
Modified 
medical 
comorbidity 
index 
Not given DSS comorbidity 
adjusted risk ratio 
None  1 (reference) 
Mild  0.9 (CI 0.6-1.4) 
Moderate 1.4 (CI 0.9-
2.1) 
Severe 1.1 (CI 0.6-2.1) 
Comorbidity 
severity did not 
affect disease 
specific survival 
Adjusted for 
simultaneous 
impact 
treatment 
11/24 
Weak 
Powles(580) 
UK 
2004 
7  Head and neck cancer Comorbidity- 
HIV 
1986- 2001 Median OS 28 
months 
Not described 10/24 
Weak 
Paleri(494) 
England 
2003 
180 Laryngeal squamous cancer Comorbidity- 
ACE-27 index 
1 January 1993- 31 December 1997 Mortality rate  
Cardiovascular 27.4% 
Respiratory 32.1% 
Gastrointestinal 41.1% 
Endocrine 40% 
Neurological 70% 
Malignancy 46.6% 
Nil comorbidity 11.1% 
Not specified 10/24 
Weak 
Liu(352) 
China 
2006 
37 Nasopharyngeal cancer Comorbidity- 
Diabetes 
mellitus 
Not specified 4yr DFS Diabetics vs. 
Non-diabetics 
35.1% vs. 65.1% 
(Wilcox on p=.005) 
 
Not described 15/24 
Moderate 
Leitner(345) 
UK 
2001 
286 Oral cavity and oropharyngeal 
squamous cell carcinoma 
Comorbidity- 
Previous 
medical history 
1992- 1997 OS for patients with 
comorbidity 
(previous medical 
history) 
1year 87 (3%) 
3 year 69 (5%) 
Not described 13/24 
Moderate 
335  
 
5 year 56 (6%) 
Kutler(581) 
USA 
2003 
19  Head and neck squamous cell 
carcinoma 
Comorbidity- 
Fanconi’s 
anaemia 
1982- 2001 OS 26% 
2yr DSS 49% 
2yr OS 49% 
2 yr RFS 42% 
Not described 17/24 
Moderate 
Ramakrishnan(162) 
UK 
2007 
59 Nasopharyngeal cancer Comorbidity- 
ACE-27 index 
1989-2003 5yr DSS 41.2% 
Comorbidity present 
vs. Absent HR= 1.81 
(CI 0.92,3.57) 
p=0.083 
Adjusted for 
stage and age 
Moderate 
16/24 
De Cassia Braga 
Ribiero(140) 
Brazil 
2000 
110 Oral carcinoma Comorbidity- 
National cancer 
Institute (NCI) 
comorbidity 
score and 
Charlson 
Comorbidity 
Index (CCI) 
1 January 1990- 31 December 1994 5yr OS 
NCI Level 1 41.5% 
Level 2 22.2% p=0.04 
CCI 
Grade 0 30.8% 
Grade 1 36.2% 
Grade 2 33.3% p=0.72 
Adjusted for 
daily alcohol 
consumption, 
neck lump, 
dysphagia, 
hematocrit of 
0.35 or  lower, 
age over 50, 
NCI level 2, 
earache, and 
oral cavity 
bleeding 
Moderate 
15/24 
Woodard(351) 
USA 
2007 
143 Laryngeal cancer Comorbidity- 
No 
measurement 
tool described 
28 July 1994- 11 August 2005 Median survival  
Comorbidity 
≤2 51 months  
>2 16 months 
p=0.02 
Cardiovascular 
comorbidity 
Yes 22 months 
No 35 months 
P=0.04 
Controlled for 
cancer site, T 
stage, N stage, 
number of 
comorbidities, 
and 
cardiovascular 
comorbidity 
16/24 
Moderate 
Hall(138) 
Canada 
2002 
379 Head and neck cancer Comorbidity- 
CIRS, KFI, CCI, 
IECD, Chronic 
disease scale 
(CDS) 
1990-1996 Risk of death RR 
estimate 
CIRS Level 1(0-2) 1.0 
Level 2 (3-8) 1.66 
(1.06-2.56) 
Level 3(>8) 2.18 (1.31-
3.63) 
Controlled for 
age, sex, site 
and stage 
20/24 
Strong 
336  
 
KFI Level 1 (0,1) 1.00 
Level 2 (2) 1.38 (0.99-
1.93) 
Level 3 (3) 3.03 (2.12-
4.33) 
CCI Level 1(0,1) 1.00 
Level 2 (2) 1.70 (1.20-
2.42) 
Level 3 (>2) 2.82 
(1.77-4.48) 
IECD Level 1 (1) 1.00 
Level 2 (2&3) 1.37 
(0.96-1.95) 
Level 3 (4) 3.17 (2.13-
4.72) 
Hernandez 
Montero(187) 
Spain 
2008 
99   Hypopharyngeal and laryngeal 
cancer 
Comorbidity- 
WUHNCI 
1997- 2002 Odds of overall 
survival 
Comorbidity OR 
1.552 (1.088-2.214) 
p0.015 For each 
additional degree of 
comorbidity, the risk 
of death increases 
1.552 times 
Odds for specific 
overall survival 
Comorbidity OR 
1.446 (0.971-2.153) p 
0.070 
For each 
comorbidity stage, 
the original tumour 
death risk increases 
by 44.6% 
Controlled for 
response to 
neoadjuvant 
chemotherapy, 
staging and 
comorbidity 
23/24 
Strong 
Chen(161) 
USA 
2001 
182 Laryngeal squamous cell 
carcinoma 
Comorbidity- 
Modified 
medical 
comorbidity 
index 
1 January 1990- 31 December 1995 5yr Disease Specific 
Survival 
Comorbidity status 
OR 2.1 (1.3-3.5) 
p0.003 
Overall Survival  
Adjusted for 
age, gender, 
race, marital 
status, 
cigarette 
smoking, other 
19/24 
Strong 
337  
 
Comorbidity status 
OR 2.3 (CI 1.4-3.6) 
p0.0005 
tobacco use, 
and alcohol use 
Castro(427) 
Brazil 
2007 
90    Laryngeal squamous cell 
carcinoma 
Comorbidity- 
Cumulative 
illness rating 
scale (CIRS), 
Kaplan 
Feinstein index 
(KFI), Charlson 
index (CCI), 
Index of 
coexistent 
disease (IECD), 
Adult 
comorbidity 
evaluation 
(ACE-27) index, 
Alcohol-
tobacco-related 
comorbidities 
index (ATC) and 
the Washington 
university head 
and neck 
comorbidity 
index 
(WUHNCI) 
January 1996- December 2000 4yr OS 
CIRS Group ≤2  67.0% 
vs. Group >2 50.0% 
(p=0.006) 
KFI Group 0 81.8% vs. 
Group 1-2 64.9% vs. 
Group ≤3 47.6% 
(p=0.001) 
CCI Group 0 75.9% vs. 
Group  1 59.8% vs. 
Group ≤2 52.9% 
(p=0.019) 
IECD Group 0 80.2% 
vs. Group ≤1 57.3% 
(p=0.013) 
ACE-27 Grade 0 
88.2% vs. Grade 1 
59.0% vs. Grade≤2 
53.3% (p=0.010) 
ATC Group 0 80.8% 
vs. Group ≤1 56.5% 
(p=0.005) 
WUHNCI Group 0 
78.2% vs. Group ≤1 
55.5% (p=0.004) 
Not described Strong 20/24 
Borggreven(96) 
The Netherlands 
2004 
170   Oral and oropharyngeal cancer Comorbidity- 
ACE-27 index 
1 January 1995- 31 December 1998 5yr DSS  
ACE-27 grade ≤ 2 63% 
ACE-27 grade 3 31% 
5yr OS  
ACE-27 grade ≤ 2 64% 
ACE-27 grade 3 29% 
(p=0.039) 
No statistically 
significant 
relationship found in 
Cox 
Controlled for 
confounding by 
age, gender, 
tumour site, 
tumour stage, 
margin status, 
post operative 
radiotherapy 
and 
stratification 
for 
complications 
Strong 24/24 
338  
 
also carried out 
Datema(330) 
The Netherlands 
2009 
1371  Head and neck cancer Comorbidity- 
ACE-27 index 
1981- 1998 Impact on overall 
survival 
ACE-27 
Grade 0 HR= 1.00 
Grade 1 HR= 1.043 (CI 
0.88-1.24) 
Grade 2 HR= 1.379 
(CI 1.15- 1.65) 
Grade 3 HR= 2.229 
(CI 1.73-2.87) 
Analysis was 
adjusted for 
primary 
tumour site, 
age at 
diagnosis, sex, 
prior 
malignancies, 
comorbidity 
and TNM 
classification 
21/24 
Strong 
Yung(150) 
USA 
2008 
183   Squamous cell carcinoma of 
the oral cavity, oropharynx 
and larynx 
Comorbidity- 
ACE-27 index 
1 January 1997- 31 December 1998 Risk of death from 
baseline to outcome 
(HR) 
Mild 2.6 (CI 1.1-6.2) 
Moderate 2.8 (CI 1.2-
6.8) 
Severe 6.7 (2.7-16.7) 
Risk of death for 
worsened scores 
(adjHR) 
None to mild 1.4 (CI 
0.4-5.3) 
None to moderate 
1.7 (CI 0.4-6.7) 
None to severe 3.4 
(CI 1.1-10.1) 
Mild to moderate 2.7 
(CI 0.8-8.9) 
Mild to severe 2.9 (CI 
1.1-7.9) 
Moderate to severe 
3.3 (CI 1.3-8.6) 
Controlled for 
age, sex, race 
and stage of 
tumour 
19/24  
Strong 
Tanvetyanon(333) 
USA 
2009 
103  Head and neck cancer Comorbidity- 
Charlson 
comorbidity 
index and ACE-
27 index 
January 1998- 2008 2yr OS 40% (CI 
29.4,50.5) 
Multivariable 
survival 
CCI 0 HR 1.00  
Controlled for 
CCI, ACE-27, 
age, organ 
dysfunction, 
and recurrent T 
24/24 
Strong 
339  
 
CCI ≥ 1 HR 2.29 (CI 
1.34,3.91) 
Univariable p=0.002 
Multivariable 
p=0.016 
ACE-27 0 or 1 HR 1.00 
2 or more HR 2.68 
(1.51,4.78)   
Univariable p=0.001 
Multivariable 
p=0.032 
stage 
Soares(334) 
Brazil 
2009 
121  Head and neck cancer Comorbidity- 
ACE-27 index 
May 2000- December 2005 Univariate analysis 
OR risk of death 
Comorbidity none-
mild OR 1.00 
Moderate or severe 
OR 2.50 (CI 
1.04,6.00) p=0.040 
Adjusted for 
type of cancer, 
extensive 
disease, 
cancer, status, 
performance 
status, weight 
loss, moderate 
or severe 
comorbidity, 
sepsis, the 
need for 
mechanical 
ventilation 
(MV) and 
number of 
organ failures 
during ICU stay 
22/24 
Strong 
Liu(337) 
Taiwan 
2010 
214  Head and neck cancer Comorbidity- 
Charlson 
comorbidity 
index 
January 2000- December 2003 3yr OS 21.9% 
3yr DSS 24.4% 
Univariate 3yr OS 
CCI 0 25.9% 
CCI 1 21.8% 
CCI ≥2 3.5% 
P<.0001 
Univariate 3yr DSS 
CCI 0 26.9% 
CCI 1 28.3% 
CCI ≥2 7.5% 
Controlled for 
marital status, 
age, gender, 
smoking, betel 
quid chewing, 
education 
years, 
occupation 
status, tumour 
site, T stage, N 
stage, 
23/24 
Strong 
340  
 
P<.0001 
Multivariate survival  
OS CCI (0-1 vs. CCI 
≥2)  
HR 2.7 (CI 1.7,4.2) 
DSS CCI (0-1 vs. CCI 
≥2) 
HR 2.4 (CI 1.5,3.8) 
p<.001  
Karnofsky 
performance 
score, AJCC 
stage, 
treatment with 
2D technique, a 
radiotherapy 
alone dose 
<70Gy and no 
radiotherapy 
plus 
chemotherapy, 
Piccirillo(148) 
USA 
2004 
19 268  Head and neck cancer Comorbidity- 
ACE-27 index 
1 January 1995- 31 January 2001 OS  
No comorbidity 
HR=1.00 
Mild HR=1.03 (CI 
0.80,1.32) 
Moderate HR=1.92 
(CI 1.50,2.47)  
Severe HR=2.48 (CI 
1.77,3.47) p<.001 
Χ2/3 C statistic = 46.31 
Used partial 
likelihood ratio 
to test 
independent 
contribution of 
comorbidity 
20/24 
Strong 
Mell(339) 
USA 
2010 
479  Head and neck cancer Comorbidity- 
Charlson 
comorbidity 
index 
August 1993- November 2004 CCI competing 
mortality  
HR= 1.24 (CI 
1.05,1.47) p=0.012  
Adjusted for 
age, body mass 
index, female 
sex, and 
comorbidity 
status 
21/24 
Strong 
Terhaard(331) 
The Netherlands 
2008 
666  Salivary gland cancer Comorbidity- 
ACE-27 index 
1985- 1994 All cause mortality 
Grade 0 comorbidity 
vs. Grade 1 
comorbidity 
HR=1.5 (CI 1.1, 2.1) 
p<.007 
Grade 0 comorbidity 
vs. 
Grade 2 comorbidity 
HR= 1.7 (CI 1.2,2.5) 
p=.003 
Grade 0 comorbidity 
Adjusted for 
clinical AJCC 
2000 stage, 
pain, sex and 
age 
22/24 
Strong 
341  
 
vs. Grade 3 
comorbidity HR= 2.7 
(CI 1.5,4.7) p=.001 
Teppo(290) 
Finland 
2009 
221  Larynx, tongue and pharynx 
cancer 
Comorbidity- 
Charlson 
Comorbidity 
index 
January 1986- December 1996 OS 
Low comorbidity 
HR=1.0 
Modest HR=0.9 (CI 
0.4,2.2) 
High HR=5.6 (CI 
2.3,13.5) p<.001 
DSS 
Low comorbidity 
HR=1.0 
Modest HR=2.7 (CI 
0.9,8.6) 
High HR=5.0 
(CI1.3,19.2) p.019 
Adjustments 
made for 
patient and 
professional 
diagnostic 
delays, 
comorbidity 
status, sex, 
age, sub site of 
tumour and 
cancer stage 
21/24 
Strong 
Singh(163) 
USA 
1997 
88  Head and neck cancer Comorbidity- 
Charlson 
comorbidity 
index 
1 January 1983- 30 June1994 Charlson index grade 
(High vs. Low) RR 
2.35 (CI 1.23,4.46) 
p=0.009 
Controlled for 
cancer stage 
18/24 
Strong 
Kuo(582) 
Taiwan 
2011 
27 424  Head and neck cancer Comorbidity- 
Charlson 
comorbidity 
index 
1997- 2008 Radiotherapy group 
(RT) HR- 1.34 
p=0.0001 
Only surgical 
treatments or 
combination of 
surgical treatments 
and radiation (ORT) 
HR= 1.22 p=0.0065 
Only chemotherapy 
or combination of 
chemotherapy and 
radiation (CRT) HR= 
1.26 p=0.0014 
Adjusted for 
age, gender, 
area of living, 
occupation 
categories and 
disease sites 
22/24 
Strong 
Reid(335) 
USA 
2001 
9386 Head and neck cancer Comorbidity- 
Charlson 
Comorbidity 
index 
1985- 1993 Estimated relative 
hazards (RH) 
Charlson 
comorbidity index 
Grade 0 RH=1 
Regression and 
stratified 
analysis of age 
and date at 
diagnosis, 
Strong 22/24 
342  
 
Grade 1 RH=1.33 (CI 
1.21,1.47) 
Grade 2 RH=1.83 (CI 
1.64,2.05) p<0.00001 
RH for all cause 
mortality 
Charlson 
comorbidity Grade 0 
RH=1 
Grade 1+ RH=1.50 (CI 
1.43,1.68)  
marital status, 
gender, race, 
anatomic site, 
historic stage, 
education  
treatment, 
histological 
grade, marital 
status, and 
socioeconomic 
status 
Sabin(276) 
USA 
1999 
152  Laryngeal cancer Comorbidity- 
Charlson 
Comorbidity 
Index 
January 1984- February 1994 5yr DSS p=0.0002 
Low comorbidity 47% 
High comorbidity 
32% Overall 44% 
RR 
High comorbidity vs. 
Low 1.57 (CI 
1.18,2.08) p=0.002 
Adjusted for 
comorbidity, 
tumour stage 
and age 
19/24 
Strong 
Sanabria(155) 
Brazil  
2007 
310  Head and neck cancer Comorbidity- 
ACE-27 index  
1 January 1990- 31 December 2003 5yr DFS 63.1% 5yr OS 
42.8% 5yr DSS 55.8% 
DFS  
ACE-27  
Group 0 DFS 68.3% 
HR=1 
Group 1 57.0%  HR= 
1.45 (CI 0.87,2.42) 
Group 2  75.0% 
HR=0.92 (0.55,1.55) 
Group 3 60.7% 
HR=1.28 
(CI0.67,2.44) p=0.41 
OS  Group 0 56.9% 
HR=1 
Group 1 46.0% 
HR=1.83 (CI 1.24,2.71) 
Group 2 30.2% 
HR=1.97 (CI 1.42,2.71) 
Group 3 21.6% 
HR=2.08 (CI 1.38,3.11) 
Used a 
stepwise 
backward 
Univariate and 
multivariate 
analysis 
gender, age, 
clinical stage, 
tumour site, 
neck 
dissection, 
treatment 
type, ACE-27, 
and Karnofsky 
index 
Strong 21/24 
343  
 
P<.001 
CSS 
Group 0 64.5% 
Group1 58.0% 
HR=1.52 (CI 
0.95,2.42) 
Group 2 43.6% 
HR=1.71 (CI 1.15,2.56) 
Group 3 45.2% (CI 
0.91,2.62) 
P=.007 
Sanabria(346) 
Brazil 
2008 
477  Head and neck cancer Comorbidity- 
Washington 
University Head 
and Neck 
Comorbidity 
Index 
(WUHNCI) 
1 January 1993- 31 December 2003 5yr OS 42.3% 
5yr DSS 56.3% 
WUHNCI OS 
0 reference HR=1 
1 HR=1.85 (CI 
1.35,2.53) 
2 HR=1.33 (CI 
0.95,1.85) 
>=3 HR=1.65 (CI 
1.12,2.44) 
Adjusted for 
age, sex and 
clinical stage 
20/24 
Strong 
Deleyiannis(310) 
USA 
1996 
649  Head and neck cancer Comorbidity- 
Alcoholism 
1 September 1983- 28 February 1987 RR for death  
Alcoholism 2.06 (CI 
1.43,2.98)p<.001 
History of alcohol-
related health 
problems 
RR for death 2.76 (CI 
1.69,4.49) p<.0001 
Adjusted for 
age, site of 
cancer, 
histopathologic 
grade, 
anatomical 
stage, and 
antineoplastic 
treatment 
24/24 
Strong 
Ledeboer(332) 
The Netherlands 
2011 
262  Head and neck cancer Comorbidity- 
ACE-27 index 
November 2003- November 2006 ACE-27 multivariate 
analysis 
Grade 0 HR Referent 
Grade 1 HR 0.9 (CI 
0.6, 1.3) 
Grade 2 HR 0.7 (CI 
0.5, 1.1) 
Grade3 HR 1.8 (CI 1.1, 
3.1) 
Prognostic 
importance of 
variables on 
survival tested 
univariately 
followed by 
multivariate 
Cox regression. 
19/24 
Strong 
344  
 
Grignon(291) 
USA 
2007 
571 Head and neck cancer- oral 
cavity, oropharynx, larynx and 
hypopharynx 
Comorbidity- 
ACE-27 index 
and Medical 
outcomes study 
36 item short-
term health 
survey (SF-36) 
1 January 1995- 30 November 2004 5yr Observed 
survival 
No comorbidities 
67.2% 
Severe comorbidities 
42.0% 
5yr DSS  
Severe  
comorbidities 63.2% 
Moderate 
comorbidities 74.8% 
5yr Observed 
Survival (health 
measures only) 
ACE-27 Risk ratio 1.24 
p.002 
Physical component 
summary Risk ratio 
0.97 p<.001 
5yr observed survival 
(health measures 
and disease factors) 
ACE-27 Risk ratio 1.25 
p .003 
Physical component 
summary Risk ratio 
0.97 p<.001 
Adjusted for 
comorbidity 
rating, self 
reported 
health scores in 
multivariate 
analysis 
20/24 
Strong 
Van de 
Schans(350) 
The Netherlands 
2007 
Not 
specified 
Larynx cancer Comorbidity- 
Modified 
Charlson 
Comorbidity 
Index 
1995- 1 January 2006 HR for death 
Older patients with 
COPD vs. Older 
patients without  
Model A unadjHR 2.0 
(CI 1.5,2.7) p=.05 
Model B 1.8 
(CI1.4,2.5) p=.05 
Model C HR 2.0 (CI 
1.5,2.8) p=.05 
Model D HR 2.1. (CI 
1.5,2.9) p=.05 
Adjusted for 
gender, 
socioeconomic 
status, stage, 
treatment, and 
cardiovascular 
disease 
Strong 18/24 
345  
 
Singh(583) 
USA 
1998 
70  Head and neck squamous cell 
carcinoma 
Comorbidity- 
Kaplan 
Feinstein Index 
1 January 1983- 30 June 1994 Median DFS KFI 
Grade0-1 21.6 
months 
Grade 2/3 11.1 
months p.045 
Median survival 
Grade 0-1 57.6 
months 
Grade2/3 13.7 
months 
p.030 
DFS KFI Grades High 
vs. Low RR 2.29 (CI 
1.18, 4.41) p.01 
Tumour specific 
survival KFI Grades 
High vs. Low 
RR 2.37 (CI 1.12,5.05) 
p.01 
Adjusted for 
tumour stage 
and HIV 
infection in 
multivariate 
analyses 
21/24 
Strong 
Gimeno-
Hernandez(338) 
Spain 
2011 
 
231 Laryngeal cancer Comorbidity- 
Charlson 
Comorbidity 
Index 
1 January 1995-31 December 2006 Overall mortality 
Comorbidity Severe 
vs. Non severe adjHR 
3.81 (CI 1.36, 10.69) 
p<0.011 
Specific mortality 
Comorbidity Severe 
vs. Non severe adjHR 
1.85 (CI 1.07, 3.17) 
p=0.028 
Controlled for 
influence of 
tumour stage 
19/24 
Strong 
Pedruzzi(343) 
USA 
2008 
366 Oropharyngeal squamous cell 
carcinoma 
Comorbidity  1 January 1990- 31 December 2001 5yr OS Comorbidity 
None   26.3%  
1 8.3%  
2 18.9%  
3 11.8%  
5yr DFS 
None    23.4% 
1 8.1% 
2 15.5% 
3 11.8% 
Conducted 
univariate 
analysis using 
stepwise 
variable 
analysis factors 
used  
18/24 
Strong 
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Ghobadi(336) 
USA 
2009 
182 Head and neck cancer Comorbidity- 
Charlson 
Comorbidity 
Index (CCI) 
January 2000- June 2007 CCI HR 1.11 (CI 0.99, 
1.24) p=0.08 
Median OS 883 days 
Adjustment for 
CCI, age, race, 
alcohol use, 
primary site, 
treatment and 
stage 
22/24 
Strong 
Homma(160) 
Japan 
2009 
156 Carcinomas of the 
hypopharynx 
Comorbidity- 
ACE-27 
1995- 2005 OSR Comorbidity 
None-Mild 45.1% 
Moderate-Severe 
27.7% p=0.0073 
HR 
None-Mild 1.80 (CI 
1.21, 2.68) p=.0036 
Moderate-Severe 1 
Adjusted for 
age, stage and 
comorbidity 
20/24 
Strong 
Wu(347) 
Taiwan 
2010 
372 OSCC excluding salivary gland, 
tonsils, oropharynx and 
hypopharynx 
Comorbidity- 
Diabetes status 
Jan 2002- Dec 2005 HR for OS Diabetics 
vs. Non Diabetics  
2.22 (CI 1.27, 3.88) 
p=.008 
DFR 2.96 (CI 1.88, 
4.68) p<.001 
RFS HR 2.66 (CI 1.28, 
5.54) p=.009 
Adjustment for 
confounding 
but specific 
factors not 
identified 
20/24 
Strong  
Peters (213) 
Netherlands 
2011 
 Pharyngeal cancer Comorbidity – 
ACE-27 
1997-2007 OR for OS (p<0.001) 
None Reference 
category 
Mild 0.323 (CI 0.063-
1.686 
Moderate 0.748 (CI 
0.133-4.187) 
Severe 0.435 (CI 
0.041-4.614)  
Adjustment for 
age, sex and 
birth cohort 
21/24 
Strong 
Ramroth (214) 
2011 
Germany  
594 Laryngeal cancer Comorbidity- 
CCI 
1998-2004 5yr OS                                
5yr DFS  
None 73.4%                      
85.4% 
Mild 65.8%                       
82.4% 
Moderate 59.2%              
84.1% 
Severe 52.1%                     
Not described 18/24 
Strong 
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74.5% 
Crude HR 2.1 
AdjHR 1.4 
Sadat (215) 
2012 
Germany 
169 Squamous cell HNC Comorbidity- 
Karnofsky 
performance 
score 
1996-2004 OS 20% KPI 80-100%, 
OS 8% KPI ≤ 70% 
(p < 0.001). HR 0.13 
(p=0.48) 
Not described 16/24 
Moderate 
Zhang (349) 
2013 
China 
205 Laryngeal cancer Comorbidity- 
CCI 
Jan 2003-Nov 2008 HR 
CCI 1-2 2.00 
(1.05;3.81) p=0.036 
adjHR 2.69 
(1.38;5.24) p=0.004 
CCI≥3 2.68 (1.35;5.31) 
(p=0.005) adjHR 3.6 
(1.77;7.33) p<0.001 
Not described 20/24 
Strong 
Yang (348) 
2015 
Taiwan 
4095 Nasopharyngeal cancer Comorbidity- 
Age adjusted 
CCI and HNC CCI 
2007-2011 Age related CCI, 
Head and neck CCI 
and CCI Higher 
comorbidity equates 
to poor survival ROC 
p<0.001 
5yr OS 
CCI 0 = 77% 
CCI 1-5 = 63% 
CCI≥6 = 40% 
Not described 20/24 
Strong 
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SOCIOECONOMIC STATUS (SES) STUDIES 
CITATION (FIRST 
AUTHOR, 
COUNTRY, YEAR,) 
 
NUMBER 
(N) 
TUMOUR SITE 
 
PROGNOSTIC FACTOR 
AND MEASUREMENT 
METHOD 
RECRUITMENT 
PERIOD 
SURVIVAL ANALYSIS REPORTED/ 
ENDPOINTS CONSIDERED 
 
ADJUSTMENT FOR 
CONFOUNDING 
 
QUALIT
Y 
RATING 
 
Paterson(353) 
England 
2002 
20 131 
All head and neck 
cancers 
SES- Carstairs Index Not specified 
5 yr RSR Most affluent vs. Most 
Deprived= 49.9% (48.8, 51.0) p<.001 
(1yr) p<.01 (thereafter) 
Carstairs 1/ 2 vs. 3-5 Age 40-59 
59.5% (CI 55.4, 63.8) vs. 52.4% (CI 
50.1,54.9) p=.001 
Age 60-79 51.1% 9 (CI 48.4,53.9) vs. 
46.2% (CI 44.7,47.8) p=.001 
Corrected for social class 
differences in mortality 
in general population. 
Used life table method 
to assess probability of 
survival 
16/24 
Moderat
e 
 
Coleman(309) 
UK 
2001 
2 887690 
Head and neck 
cancer- larynx and 
oral cavity 
SES- Carstairs index 1971- 1995 
1 yr survival 
Men vs. Women 
Larynx 83% vs. 79% 
Oral cavity 72% vs. 74% 
5yr survival 
Men vs. Women 
Larynx 63% vs. 57% 
Oral cavity 43% vs. 52% 
5yr survival difference Affluent vs. 
Deprived 
Larynx 68.4% Gap-9.3% 
Oral cavity 53.9% Gap -11.6% 
Not described 
16/24 
Moderat
e 
Booth(426) 
Canada 
2010 
854 Laryngeal cancer 
SES- Community median 
household income 
1 January 2003- 31 
October 2007 
5yr OS (%) Q1=poorest 
Q1 59.0 (CI 53.3-64.2) 
Q2 54.0 (CI 47.8-59.8) 
Q3 60.4 (CI 53.4-66.7) 
Q4 56.8 (CI 48.5-64.4) 
Q5 60.0 (CI 52.2-66.9) 
P=0.045 
3yr CSS (%) 
Q1 73.3 (CI67.1-78.5) 
Q2 65.3 (CI 58.0-71.6) 
Q3 80.4 (CI 74.3-85.2) 
Q4 75.3 (CI 67.0-81.8) 
Q5 75.8 (CI 68.0-81.9) 
P=0.011 
Controlled for stage of 
disease at diagnosis and 
age 
17/24 
Moderat
e 
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Konski(368) 
USA 
2003 
1073 
Squamous cell 
carcinoma of the 
head and neck 
SES- Education Not specified 
Univariable 2 yr OS 
Education level (college/technical 
school vs. less than college) 61% vs. 
46%  p<0.0001 HR=1.46 
Multivariable OS 
Education level (college/technical 
school vs. less than college) HR= 1.30 
P=0.0056 
Adjustment for 
education level, N 
classification, T 
classification, Karnofsky 
Performance Score 
(KPS), anatomic site, and 
race 
16/24 
Moderat
e 
Puigpinos(369) 
Spain 
2009 
Exact 
numbers 
unknown
, part of a 
larger 
cohort 
Mouth, pharynx and 
larynx cancer 
SES- Education level 1992- 2003 
Relative index of inequality (RII)- ratio 
of death between death rates of the 
highest and lowest educational levels 
Larynx cancer 
Men vs. women 
1992-94 2.82 
1995-97 3.70 
1998-2000 4.17 
2001-03 3.23 
Mouth and pharynx 
Men vs. Women 
1992-94 3.37vs. 0.43 
1995-97 4.85 vs. 1.74 
1998-2000 2.24 vs. 1.43 
2001-03 2.98 vs. 0.50 
Not described 
14/24 
Moderat
e 
Menvielle(371) 
France 
2007 
259 905 
Upper aero-digestive 
tract cancer 
SES by occupational 
class- Erikson, 
Goldthorpe, and 
Portecarero (EPG Score) 
1968- 1974, 1975- 
1981, 1982- 1988, 
1990-1996 
RII 1968-74 
All men 4.04 (CI 2.35, 6.93) 
Men in labour force 2.88(CI 1.58, 5.25) 
1975-81 
All men 10.76 (CI 6.66,17.4) 
Labour force 8.93 (CI 5.26,15.18) 
1982-88 
All men 11.06 (CI 7.26,16.87) 
Labour force 7.18 (CI 4.47,11.55) 
1990-96 
All men 18.75 (CI 11.23,31.30) 
Labour force 8.51 (CI 4.81,15.07) 
Regression modelling of 
the 7 categories of EPG 
Score, and direct 
standardisation by age 
on mortality rates 
15/24 
Moderat
e 
Chu (360) 
Canada 
2011 
2622 
Oral cavity, 
oropharyngeal, 
larynx/hypopharynx 
and nasopharyngeal 
SES- post code matching 
to 2006 Canada census 
tracts 
2003- 2010 
DSS 
Post secondary education p16-OPC HR 
0.93 (CI 0.86, 0.99) p=0.03 
Unemployment NPC HR 3.71 (CI 1.50, 
9.51) p=0.01 
Used multiple variable 
analysis adjusting for 
rural location, median 
income, nativity, 
transportation to work 
17/24 
Moderat
e 
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Anandan(354) 
Scotland 
2008 
556 
Nasopharyngeal 
cancer 
SES- Carstairs 1975-2001 
Affluent vs. Deprived HR 0.57 (CI 
0.41,0.79) p=.001 Log rank 15.32 df=4 
p=.004 
Adjustment for age, 
histological verification 
status, period of 
diagnosis, deprivation 
quintile, anatomical sub 
site. 
13/24 
Moderat
e 
O’Hanlon(167) 
England 
1997 
Not 
specified 
Oral cancer (tongue 
and mouth) 
SES- Small area statistics 1975-1991 
ASM Most deprived vs. Most affluent 
1976-85 Tongue 
Males 134 vs. 69 
Females 
1986-1991 
Mouth 
Males 142 vs. 61 
Females 127 vs. 44 
Mean SMR Northern region vs. 
England & Wales 
Tongue 148 vs. 106 
Mouth 169 vs. 91 
Not specified 
13/24 
Moderat
e 
Edwards(355) 
England 
1999 
17 393 
Upper aero digestive 
tract cancers 
SES- Carstairs Index 1984-1993 
5yr crude survival Quintile 1 48.4 (CI 
47.7, 49.1) vs. Quintile 5 40.6 (CI 
40.4,40.8) 
RR 1.6 (1.07, 1.26) Quintile 2/3 vs. 1.24 
(CI 1.13,1.35) Quintile 4/5 
Multivariate analysis by 
extent of spread, site 
and sub site, (mouth and 
pharynx)age, and 
deprivation 
22/24 
Strong 
Groome(108) 
Canada 
2006 
661 
glottic 
495 
supraglot
tic 
Larynx, glottis, 
supraglottic and 
subglottic cancer 
SES- Area level 1982-1995 
RR affluent vs. Deprived 2.75 (CI 1.48, 
5.12) 
CSS 1.90 (CI 1.24,2.93) 
Adjusted for age,sex, 
rural residence, tumour 
stage, lymph node 
status, use of diagnostic 
imaging, treatment type 
23/24 
Strong 
Robertson(358) 
Scotland 
2010 
1909 
Head and neck 
cancer 
SES- 2001 Depcat score 
1 Sept 1999- 31 
Aug 2001 
Univariate HR (All cause mortality) 
Affluent 1.00 Intermediate 1.18 (CI 
0.95,1.45) [0.91 (CI 0.64,1.29)] 
Deprived 1.33 (CI 1.06,1.68) [1.16 (CI 
0.79, 1.70)] 
Multivariate HR Affluent 1.00 
Intermediate 0.88 (CI 0.63, 1.22) [0.64 
(CI 0.40, 1.00)] 
Deprived 0.93 (CI 0.64, 1.35) [0.82 (CI 
0.49, 1.36)] 
Adjusted stepwise for 
deprivation, WHO 
performance status, 
stage, site, age, smoking 
status, tumour 
differentiation, alcohol, 
sex. 
21/24 
Strong 
Wong(372) 
Taiwan 
1010 Oral cancer 
SES- socio-demographic 
factors (occupation) 
March 1995- 
December 2002 
5yr OS 63.24% 
5yr survival (%) 
Adjusted for stage, age, 
gender, marital status 
22/24 
Strong 
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2006 Occupation  log rank 10.74 p=0.005 
None 58.30 
Unskilled 70.57 
Professional/managerial 65.60 
 
and religious beliefs 
Warnakulasuriya(
357) 
England 
2007 
5319 Oral cancer 
SES- Indices of 
Deprivation 
1986- 2002 
OS- Univariate 
Age group 0-44yrs 
Affluent HR=1.00 
Group 2 HR=1.19 (CI 0.62,2.27) 
Group 3 HR=1.16 (CI 0.62,2.17) 
Group 4 HR=1.53 (0.87, 2.71) 
Deprived HR=2.12 (CI 1.23,3.66) p<.002 
Age group 45yrs and over 
Affluent HR=1.00 
Group 2 HR=1.98 (CI 1.75,2.25) 
Group 3 HR=1.50 (CI 1.33,1.71) 
Group 4 HR=2.96 (CI 2.57, 3.41) 
Deprived HR=1.85 (CI 1.67,2.05) p<.001 
OS multivariate 
Affluent HR= 1.00 
Group 2 HR=1.92 (CI 1.69,2.19) 
Group 3 HR=2.10 (CI 1.84,2.40) 
Group 4 HR=3.15 (CI 2.72, 3.64) 
Deprived HR=1.72 (CI 1.53,1.92) p<.001 
Factors adjusted were 
age, stage, year of 
diagnosis, type of 
surgery, any 
radiotherapy received, 
socioeconomic status 
and cancer network by 
residence 
22/24 
Strong 
Boffetta(356) 
Italy 
1997 
272 Laryngeal cancer SES- Occupation 
January 1979- 
December 1982 
Risk of death (HR) 
Unskilled worker 1.0 (reference) vs. 
Skilled worker professional 0.8 (CI 
0.6-1.2) 
Non significant better prognosis for 
skilled workers/professionals 
Models were adjusted 
for age, tumour site, T 
stage, N stage, 
education, birthplace, 
tobacco smoking and 
alcohol drinking 
20/24 
Strong 
Mackillop(359) 
Canada 
1997 
357 530 
but HNC 
cohort 
number 
not given 
All invasive cancers- 
head and neck 
cancer only 
SES- Linked census 
enumeration and postal 
code 
1982- 1991 Risk of death by income 
≤20k 1.47 (1.24-1.74) 
>20k≤30k 1.32 (1.14-1.53) 
>30k≤40k 1.22 (1.05-1.41) 
>40k≤50k 1.07 (0.92-1.26) 
>50k 1.0 (reference) 
Overall risk of death with decreasing 
income 1.1 (1.07-1.13) 
All cause mortality and by income 
group 
Controlled for age, sex, 
year of diagnosis, and 
cancer catchment area 
19/24 
Strong 
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≤20k 1.47 (1.12-1.72) 
>20k≤30k 1. 27 (1.06-1.53) 
>30k≤40k 1. 16 (0.96-1.39) 
>40k≤50k 1.01 (0.83-1.22) 
>50k 1.0 (reference) 
Disease specific mortality by income 
≤20k 1.38 (1.24-1.74) 
>20k≤30k 1.32 (1.14-1.53) 
>30k≤40k 1.22 (1.05-1.41) 
>40k≤50k 1.07 (0.92-1.26) 
>50k 1.0 (reference) 
 
Kwok(367) 
USA 
2010 
1231 Head and neck 
cancer 
SES- Health insurance 
status 
January 1998- 12 
October 2007 
OS all cause mortality adjHR 
Private 1.00 
Medicaid/Uninsured 1.50 (1.07-2.11) 
Medicare<65yrs 1.69 (1.16-2.48) 
Medicare >65yrs 1.22 (0.85-2.11) 
Relapse free survival 
adjHR 
Private 1.00 
Medicaid/Uninsured 0.93 (0.65-1.35) 
Medicare<65yrs 1.19 (0.80-1.77) 
Medicare >65yrs 0.95 (0.65-1.77) 
Controlled for age, 
gender, race, anatomic 
tumour site, treatment, 
stage at diagnosis, 
occupational prestige, 
alcohol and tobacco use 
23/24 
Strong 
Rosso(370) 
Italy 
1997 
294 Mouth and pharynx 
cancer (as part of a 
variety of other 
cancers) 
SES- Education level 1985- 1992 Case fatality ratio (CFR) 
Primary school 1.00(reference) 
Middle school 1.12 (0.78-1.62) 
High school 0.78 (0.39-1.55) 
University 0.70 (0.34-1.47) 
P=0.401 
Adjusted for age, sex, 
area of birth, and 
housing tenure 
18/24 
Strong 
Chu(364) 
USA 
2011 
53 544 Head and neck 
cancer 
SES- Neighbourhood 
level SES 
1 January 1988- 31 
December 2007 
Multivariable DSS 
Neighbourhood SES High SES (state-
wide quintile 4-5) vs. Low SES (state-
wide quintile 1-3) 
Oral 1.07 (CI 1.01-1.14) 
Oropharynx 1.34 (CI 1.25-1.43) 
Hypopharynx/Larynx 1.22 (CI 1.15-1.29) 
Nasopharynx 1.31 (CI 1.18-1.47) 
Asians and Pacific Islanders  High vs. 
Low SES 1.26 (CI 1.08-1.48) 
Controlled for age at 
diagnosis, sex, 
race/ethnicity, marital 
status, tumour stage, 
tumour histological 
grade, initial treatment 
modality, university 
teaching hospital 
23/24 
Strong 
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de Graeff(361) 
The Netherlands 
2001 
208 Head and neck 
cancer 
SES- Family income May 1994- June 
1996 
No statistically significant results 
found 
Controlled for sex, age, 
marital status, family 
income, occupation, 
number of cigarettes 
smoked, units of alcohol 
consumed, KPS, site, 
AJCC stage, grade of 
differentiation, 
treatment, and radicality 
22/24 
Strong 
Arbes(311) 
USA 
1999 
7503 Oral cancer SES-Median household 
income 
1988- 1993 Risk of death (unadjHR) 
≥50k 1.00 (reference) 
35-49k 1.1 (CI 1.0-1.3) 
25-34k 1.3 (CI 1.1-1.4) 
≤24k 1.6 (CI 1.4-1.8) 
Unknown  1.3 (CI 1.1-1.5) 
≥50k 1.00 (reference) 
35-49k 1.1 (CI 0.9-1.3) 
25-34k 1.2 (CI 1.0-1.4) 
≤24k 1.6 (CI 1.3-1.9) 
Unknown  1.4 (CI 1.1-1.7) 
Blacks vs. Whites (HR) 
(race, age, area and SES) 
All cause 1.4 (CI 1.2 - 1.5) 
Oral cancer 1.3 (CI 1.0-1.7) 
Adjusted models for age, 
geographic area, race, 
anatomic site, year of 
diagnosis, grade, marital 
status, SES, lymph node, 
tumour size, treatment, 
and stage 
23/24 
Strong 
McDonald(212) 
Canada 
2014 
Oropharynx 
7022 
Oral cavity 
8541 
Naso/hypo/lar
yngeal 14655 
Oropharyngeal, oral 
cavity, 
hypopharyngeal, 
laryngeal and 
nasopharyngeal 
cancer 
SES – Median household 
income 
1991, 1996, 2001 2 yr OS Highest quintile is reference 
category 
Oropharynx 
2nd OR 0.826 p=0.018 
3rd OR 0.785 p=0.000 
4th OR 0.691 p=0.000 
5th OR 0.620 P=0.000 
Oral cavity 
2nd OR 0.892 P=0.271 
3rd OR 0.885 p=0.137 
4th OR 0.793 p=0.007 
5th OR 0.675 p=0.000 
Naso/hypo/laryngeal 
2nd OR 0.863 p=0.008 
3rd OR 0.806 p=0.001 
4th OR 0.755 p=0.000 
Not described 22/24 
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5th OR 0.626 p=0.000 
Chang(210)  
Taiwan 
2013 
4691 Nasopharyngeal 
cancer 
SES – Individual and 
Neighbourhood  
2002-2007 5 yr OS Under 65 years 
Disadvantaged neighbourhood Low SES 
ref category 
Advantaged Low SES HR 0.91 
Disadvantaged Moderate SES HR 0.77 
Advantaged Moderate SES HR 0.71 
Disadvantaged High SES HR 0.72 
Advantaged High SES HR 0.54 
5 yr OS Over 65 years 
Disadvantaged neighbourhood Low SES 
= Reference category 
Adv Low SES HR 0.88 
Disadvantaged Moderate SES HR 0.81 
Advantaged Moderate SES HR 0.87 
Disadvantaged High SES HR 0.79 
Advantaged Low SES HR 0.71 
Adjusted for age, gender, 
geographic location, 
treatment modality, 
severity of disease, and 
monthly income 
19/24 
Lee (211)  
Taiwan  
2012 
3607 Oral cancer SES – Individual and 
Neighbourhood 
2004-2005 High SES HR= 1.46 
Low SES HR= 1.64 
Adjusted for age, gender, 
CCI, urbanization, and area 
of residence, tumor extent, 
treatment modalities 
(operation, adjuvant 
therapy), hospital 
characteristics (ownership, 
teaching level, caseload), 
and year of diagnosis 
20/24 
Reitzel (366) USA  
2012 
1784 Salivary gland, 
nasopharyngeal, or lip 
carcinoma, 
SES – Neighbourhood level 
economic deprivation 
February 1996-
November 2009 
Highly deprived relative to less deprived 
HR 1.59 (1.00–2.53) 
OS 2.91 (1.63–5.17), p=0.001 
DSS 2.55 (1.24–5.27), p=0.011 
DFS 1.95 (1.05–3.62) p=0.034 
Adjusted for age, sex, 
race/ethnicity, income, 
smoking status, cancer site, 
cancer stage, and 
treatment approach 
23/24 
DFS – Disease free survival OS – Overall survival   DSS- Disease specific survival   CSS- Cancer specific survival  
HR- Hazard ratio  RR- Relative risk   OR- Odds ratio    CI- 95% confidence interval  
unadjHR- Unadjusted hazard ratio     adjHR- Adjusted hazard ratio
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A p p e n d i x  A 1 0   
Data Analysis Plan 
Rationale: - This plan is intended to provide a comprehensive road map of the statistical methods 
that will be used to calculate the survival of HNC patients from datasets from 2006 onwards. The 
time period 2006 till present was chosen as this is the period from which records of all diagnosed 
cases of HNC in Fife and Tayside are available. These datasets will be assessed using comorbidity 
and SES as the explanatory variables for determining survival. 
Objectives 
- Primary 
To determine the likelihood of survival for patients diagnosed with HNC dependent on their level 
of comorbidity (none, mild or severe) and SES (affluent or deprived). 
- Secondary 
To assess the survival of low SES (deprived) patients with comorbidity; and those without 
comorbidity vs. high SES (affluent) patients with and without comorbidity. 
Outcome of interest 
Death which can be described as:-  
 All cause mortality 
 HNC specific mortality 
 Recurrence free survival 
Definition of HNC- will be restricted to squamous cell carcinomas as this is the predominant type 
of HNC. Dependent on sub types, sub group analyses will be done e.g. laryngeal vs. 
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oropharyngeal while tonsil and oropharynx sub types will be explored as it has been suggested 
that these forms of HNC have the worst survival. 
Hypothesis 
Low SES alongside severe comorbidity equates to poor survival, i.e. the risk of death is increased 
in the presence of deprivation and severe comorbidity. 
Factors to account for  
Consider all cause mortality: The reasoning behind this approach is that prognosis is determined 
by other causes of death not just HNC, as death is dependent on patient characteristics such as 
age, gender, comorbidity, income, education, tumour stage etc. 
Potential confounders: 
 treatment type,  
 duration of therapy (where applicable), 
 ethnicity, 
 tumour stage,  
 anatomical subsite,  
 age,  
 sex,  
 performance status,  
 alcohol use,  
 urban/rural residence, 
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 smoking status,  
 hospital location/ teaching hospital status 
 prior malignancies.  
Data analysis methods: HNC patient datasets from Tayside and Fife 
 SMR01- Morbidity records 
 GRO Death records 
 Scottish Cancer Registry data 
Descriptive statistics 
1. Frequencies of demographic information 
2. Age, SES and gender distributions of cohort 
3. Cross tabulations of comorbidity by age, HNC by diagnosis, cancer stage by comorbidity/ 
SES 
4. Chi-square test to measure differences between groups 
Survival analysis  
1. Kaplan Meier survival analysis 
2. Cox proportional hazards regression 
3. Missing data analysis and imputation methods will be attempted 
Explanatory variables of interest: The influence of comorbidity status and SES on survival will be 
examined using time to event data, i.e. survival analysis is the appropriate analysis. It is not 
limited to a date range therefore follow up of all patients should be possible. 
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Rationale: Model the underlying distribution of event times and to assess the dependence of the 
event time on other explanatory variables. 
Approach 
1. Construct Kaplan Meier survival curves to estimate distribution of survival times within 
the cohort. 
2. Use life tables to calculate the cumulative survival probability and 95% confidence 
intervals.  
3. Use Cox regression for assessing the relationship between survival times and the 
explanatory variables, comorbidity and SES (to model each variables contribution to the 
outcome of interest). 
4. Comparison of 2 survival distributions Affluent vs. Deprived. 
Presentation of analysis results 
This will be done in narrative form in combination with graphics. Tables and figures will be used 
to heighten reader interest in the analysis and also to simplify the complex data generated. 
